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ABSTRACT
This thesis describes the characterisation of the expression of tumour associated 
proteins in a wide range of breast and colorectal lesions and the application of these 
observations to some specific clinical problems. Immunohistochemistry was the 
method of choice for these studies. Ki67, a proliferation associated antigen was 
studied using the MEB1 antibody and Heat Shock protein 27 with the D5 antibody. ER 
and p53 proteins were assessed with their respective antibodies and three CD44 
proteins were studied using antibodies CD44H, CD44v3 and CD44v6. Optimal 
methods for staining and the assessment of the staining pattern for each antibody have 
been developed and are discussed.
Variations in the expression of these proteins between benign and malignant lesions 
and at different stages of tumour progression were determined. Clinical problems of 
differentiating between metastasising and non-metastasising low grade breast 
carcinomas and between recurring and nonrecurring colorectal carcinomas at both 
Dukes’ B and Dukes’ C stages of tumour progression are addressed.
MIB1 was found to be useful for the distinction between benign and malignant lesions 
in both breast and colorectal studies and D5 for breast carcinomas. Maximum CD44H 
levels of expression were found in benign lesions with a decrease in expression 
manifest at the metastatic stage of tumour progression. CD44H was found to be a 
useful antibody for the distinction between non-metastasising and metastasising 
lesions of Gradel breast carcinomas and between non-recurring Dukes’ B carcinomas 
and those that showed metastatic, but not local, recurrence. No differences in CD44H 
staining could be found between recurring and non-recurring Dukes’ C carcinomas 
but differences in p53 staining were found at this stage of tumour progression. The 
staining pattern of ER over the range of pathological lesions studied was complex, but 
its role as both a predictive and prognostic factor is discussed.
© Margaret Green 1999
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CHAPTER 1 INTRODUCTION
1.1 Cancer and its prognosis
Cancer is a word that is used to describe a collection of diseases that are characterised 
by uncontrolled tissue growth. This thesis describes features of two of these diseases, 
breast and colorectal cancer. Clinical problems are discussed and the projects are 
designed to evaluate some possible prognostic and predictive markers for these 
diseases and to investigate how they could be used in the solution of these clinical 
problems.
The prognosis of a cancer is a term used to describe its likely future behaviour. The 
assessment of prognosis is necessary to enable clinicians to follow the best course of 
treatment for an individual patient. A clinician must decide, for example, whether 
limited or radical surgery is necessary and whether adjuvant therapy would benefit the 
patient.
Many features of a cancer are used in the routine assessment of prognosis and are 
known as prognostic factors. They include clinical features such as tumour size or 
how far a tumour has spread. Histopathological features such as how closely the 
tumour resembles the normal tissue and the number of dividing cells that can be seen 
in a section of the tissue are also used in the characterisation of a tumour. 
Alternatively, prognostic factors can be biochemical markers of tumour behaviour 
referred to as tumour markers. It is the aim of this study to try to identify any markers 
of tumour behaviour, additional to those used routinely, which could help prognosis 
and to consider whether the data obtained could also contribute to the understanding 
of the biological processes involved in tumour progression.
A predictive marker is any factor that is able to give information useful in selection of 
patients likely to respond to a specific, presently available form or combination of 
systemic adjuvant therapy. Some of the antibodies investigated in these projects, in 
particular oestrogen receptors (see 3.4), could be regarded as predictive markers.
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1.1.1 Terminology
Terminology, when referring to cancer, can be confusing as many words are used 
interchangeably. It is therefore necessary to define some of the terms used in these 
studies.
Tumour (neoplasm)
A tumour (also called a neoplasm) can be defined as a lesion resulting from the 
autonomous or relatively autonomous abnormal growth of cells which persists after 
the initiating stimulus has been removed. Literally the word ‘tumour’ means an 
abnormal swelling and ‘neoplasia’ means new growth.
Benign tumours
Benign tumours remain localised and are typically well circumscribed. They are 
generally slow growing lesions that do not invade the surrounding tissues or spread to 
other sites in the body. Because it cannot invade, when a benign tumour arises in an 
epithelial or mucosal surface, such as the colon, it grows away from the surface, often 
forming a polyp. Histologically a benign tumour closely resembles the parent cell or 
tissue.
Malignant tumours
‘Cancer’ is a word used when referring to a malignant tumour. Malignant tumours are, 
by definition, invasive or potentially invasive. They tend to be poorly circumscribed, 
sometimes throwing out strands of neoplastic tissue into the adjacent normal 
structures. It is from the resemblance of the cut surface of these lesions to a crab 
(Latin; cancer) that the disease acquired its name. Histologically, cancers resemble the 
parent cell, or tissue to a lesser extent than do benign tumours. They destroy adjacent 
tissues, enabling them to penetrate the walls of blood vessels and lymphatic channels 
and thereby disseminate to other sites to form secondary tumours.
Metastasis
The process of dissemination of tumour cells to form secondary tumours is called 
metastasis and the resulting secondary tumours are referred to as metastases. Not all 
tumours that are categorized as malignant exhibit metastatic behaviour. An example is 
basal cell carcinoma of the skin which rarely metastasises but is still classified as 
malignant because it is highly invasive and destructive.
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Carcinomas
A malignant tumour of epithelial tissue, i.e. the covering of the internal and external 
surfaces of the body, is called a carcinoma and one of glandular epithelium, which 
includes the lining of the gut and the breast ducts, is called an adenocarcinoma.
1.1.2 Regulation of norma! tissue growth
1.1.2.1 Growth signals
Normal tissue growth rate depends upon a balance between the increase in cell 
numbers, due to cell proliferation, and the decrease in cell numbers due to cell death. 
Cells have the ability to respond to extracellular signals that can be from molecules 
produced locally either from the same cell (autocrine) or from a different cell 
(paracrine), or alternatively from molecules produced in endocrine glands and 
transported via the bloodstream. Local signalling can be from polypeptide growth 
factors or from proteins, either from the membranes of adjacent cells or the 
extracellular matrix. Endocrine control is by low molecular weight, lipid-soluble 
regulators such as steroid hormones. These signals can be either growth stimulatory or 
growth inhibitory. In the case of polypeptides and proteins, they are recognised by 
receptors on the cell membrane and conveyed to the nucleus by complex pathways 
(see 1.1.2.2). Steroid hormones readily traverse the cell membrane and bind to 
intracellular receptors that are gene transcription factors.
1.1.2.2 Cell proliferation
A stimulatory growth signal will initiate cell proliferation. In order to proliferate, a 
cell must first replicate its DNA and then divide, distributing that DNA equally to the 
daughter cells.
Cell proliferation can be described in the following steps:-
1. The binding of a growth factor to its specific receptor either at the cell surface 
or inside the cell. Most of the growth factors have receptors on the plasma 
membrane, but steroid receptors are intracellular, interacting with lipophilic 
ligands that cross the cell membrane to interact with the receptor in the nucleus 
or cytoplasm.
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2. Transient and limited activation of the growth factor receptor, which in turn 
activates several signal-transducing proteins of the inner leaflet of the plasma 
membrane. Most growth factor receptors are equipped with intrinsic protein 
tyrosine kinase activity, which is activated after ligand binding. Such receptor 
kinases have a large glycosylated extracellular ligand-binding domain, a single 
hydrophobic transmembrane region, and a cytoplasmic domain that contains 
the tyrosine kinase activity. Ligand binding induces a conformational 
alteration of the extracellular domain, which in turn induces dimerization of 
receptors. It is thought that this dimerization, by allowing interactions between 
adjacent cytoplasmic domains, leads to activation (phosphorylation) of the 
kinase (Schlessinger and Ullrich, 1992). Other transmembrane growth factor 
receptors that do not possess endogenous kinase activity recruit intracellular 
protein kinases to the cell periphery. The net result in either case is activation 
of a protein phosphorylation cascade, which stimulates quiescent cells to enter 
the growth cycle (Karin, 1992).
3. Transmission of the transduced signal across the cytosol to the nucleus via 
second messengers for which tyrosine kinases are essential (Lange-Carter et al.
1993). Phosphorylation of tyrosine residues on one or more target proteins is a 
critical event in the transfer of extracellular signals (Karin, 1992).
4. Induction and activation of nuclear regulatory factors that initiate DNA 
transcription and ultimately cell division (Lam and La Thangue, 1994). These 
processes are controlled by changes in the intracellular concentration and 
activity of a group of proteins called cyclins, which form a complex with a 
protein kinase (Koff and Giordano, 1992; Dulic et al. 1992) The cyclin-kinase 
complexes phosphorylate a number of substrate proteins involved in DNA 
replication, formation of mitotic spindle and other events of the cell cycle.
1.1.2.3 The Cell Cycle
The stages of progression of a cell through its cycle of replication are defined with 
reference to DNA synthesis and cellular division. Cell division involves nuclear 
division (mitosis) and cytoplasmic division (cytokinesis). The period during which 
cell division takes place is referred to as the M phase and rest of the cycle is referred 
to as the interphase.
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Fig 1.1 Diagram to show the stages of the cell cycle
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The synthesis of most cellular constituents occurs throughout the interphase period 
between cell divisions, but DNA synthesis only takes place during a limited period of 
the interphase, called the S phase of the cell cycle. Following the M phase, the cell 
enters the first gap (Gi) phase and via the S phase, the second gap (G2) phase before 
entering the M phase again (Murray, 1993).
Different cell types divide at very different rates (Murray, 1993). Cell cycle times 
range from as little as eight hours, in the case of gut epithelial cells, to 100 days o f 
more for hepatocytes in the normal adult liver. The principal difference between 
rapidly dividing cells and those that divide slowly is the time spent in the Gi phase of 
the cell cycle. Some cells remain in Gi for days or even years. In contrast, the time 
taken for a cell to progress through the S, G2 and M phases of the cell cycle is 
remarkably constant, and independent o f the rate of cell division. Some cells may 
leave the Gi phase by entering a Go resting phase which can be either temporary or 
permanent, by a process of terminal differentiation, with loss of potential for further 
division (Murray, 1993).
During the Gi phase the cells prepare for DNA synthesis and during G2 the chromatin 
is reorganized into chromosomes, prior to mitosis.
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Cells use three mechanisms to ensure the accurate transmission of their genetic 
information (Murray, 1992):-
1. Repair mechanisms correct spontaneous or environmentally induced errors in 
DNA replication and chromosome alignment.
2. Delay mechanisms detect the errors and arrest the cell cycle until repairs are 
complete.
3. Mechanisms induce the death of damaged cells as a way of preventing them 
from giving rise to mutant progeny (see 1.1.2.4).
The term ‘cellcycle checkpoint’ refers to the entire process of monitoring cell cycle 
events such as DNA replication and spindle assembly, generating signals in response 
to errors in these processes, and halting the cell cycle at a specific point.
Three main checkpoints, in the Gi, Gi and M phases, that are involved in regulating 
the cell cycle have been identified (Murray, 1994). Gi transition requires a critical 
level of regulatory macromolecules and growth stimuli such as hormones, growth 
factors and cell contacts that act via this checkpoint. The Gi regulation ensures 
accurate transmission of genetic information, as cells that sustain DNA damage in Gi 
cannot begin DNA replication. The G2 checkpoint ensures the elimination of damaged 
cells that may have escaped Gi control or which have not accurately duplicated their 
DNA. Cells that sustain damage in G2 cannot enter mitosis. The M phase checkpoint 
monitors accurate chromosome alignment and retraction into the two daughter cells.
Regulation at the Gi checkpoint involves three protein families -  cyclins, cyclin- 
dependent kinases and cyclin-dependent kinase (Cdk) inhibitors. Currently p21, a 
gene regulated by the tumour repressor protein p53, is the most studied Cdk inhibitor 
(Wade Harper et al. 1993). p53 is an important regulator of the cell cycle acting at 
this checkpoint and is one of the most commonly mutated genes in human cancer, 
pointing to the potential importance of p21 in negative growth control (El-Deiry et al. 
1993; Li et al. 1994; El-deiry et al. 1994). In normal cells p53 levels are low but, 
when DNA damage is detected, its transcription is increased and cycle progression is 
blocked until repair is completed (see 3.2.1).
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1.1.2.4 Apoptosis
The term apoptosis is used to define programmed cell death. It is a biochemically 
specific mode of cell death characterised by activation of non-lyosomal endogenous 
endonuclease, which digests nuclear DNA into smaller DNA fragments. 
Morphologically, apoptosis is recognised as death of scattered single cells which form 
rounded membrane-bound bodies. These are eventually phagocytosed and broken 
down by adjacent unaffected cells.
Apoptosis is readily distinguishable from necrosis, which is a pathological method of 
cell death. Membrane integrity is lost in necrosis, resulting in the release of cellular 
contents and is thus often accompanied in vivo by the development of inflammation. 
In contrast to necrosis, in apoptosis there is no
• breakdown in the mechanisms supplying cellular energy
• failure in the maintenance of normal cell volume
• rupture of plasma membranes
• acute inflammatory reaction elicited by the death 
The process is
• energy dependent
• involves protein synthesis
In conventional histological section, apoptosis is usually inconspicuous. This is 
because of the speedy nature of the changes and thus the short duration of the process 
as it affects a single cell (1-2 hours or less). Accurate assessment of the extent of 
apoptosis in tissue sections requires several thousand normal cells to be inspected as 
the proportion of recognisable apoptotic cells is less than 1%. Because the duration of 
time in which these cells can be recognised is so short, even a small proportion of 
apoptotic cells may be responsible for major reductions in the cell population of a 
given tissue. The morphological changes that take place are;
• The affected cell separates from its neighbours
• Characteristically the nuclear chromatin becomes condensed, and well-defined 
masses of chromatin form under the nuclear membrane (this chromatin
7
condensation is associated with chromatin cleavage, shown by the characteristic 
‘laddered’ pattern of the DNA on electrophoresis).
• The cell then breaks up into a number of membrane-bound, ultrastructurally well- 
preserved, fragments (apoptotic bodies)
• These fragments are then either shed from epithelium-lined surfaces or are 
phagocytosed by other cells (Woolf, 1998).
For normal tissue growth a balance between the increase in cell numbers, due to cell 
proliferation, and the decrease in cell numbers due to cell death must be achieved. 
Thus the regulation of apoptotic cell death as well as the regulation of mitosis is 
fundamental to the homeostatic maintenance of cell populations. In addition to the 
p53-mediated growth arrest in the G1 phase of the cell cycle, the tumour suppressor 
gene p53 (see 1.1.3.2 and 3.2.1.3) also plays a critical role in the induction of 
apoptosis following DNA damage (Morgan and Kastan, 1997). Induction of 
expression of the wild-type p53 protein in a human colorectal cancer cell line was 
shown to result in apoptosis (Shaw et al. 1992).
1.1.2.5 Abnormal tissue growth
Tissue growth in tumours has escaped from the normal regulatory mechanisms 
described above and one feature of cancer cells is that of unregulated proliferation 
(see 1.1.3 and 1.1.4). Tumour cells have a lower requirement for growth factors and 
do not respond to negative environmental stimuli such as contact with other cells. 
Growth advantage of a tumour cell over its adjacent cells is achieved by increasing the 
efficiency of the intracellular machinery directed at proliferation and by the 
production of secreted growth factors. The growth factors can modulate functions of 
both the producing cells and those in the immediate vicinity.
1.1.3 Carcinogenesis
Carcinogenesis, the word used to describe cancer progression, is a multistep process at 
both the phenotypic and genetic level. The phenotypic attributes of a malignant 
neoplasm, such as excessive growth, local invasiveness, and the ability to form distant 
metastases are acquired in a stepwise fashion and are dependent on a cascade of 
genetic alterations, each one essential, but not sufficient, to afford the tumour a growth 
advantage.
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The genetic changes that give rise to cancer affect several different properties of cells. 
The development of a normal cell into a tumour cell appears to depend in part on 
mutations in genes that normally control the cell cycle and cell death, thereby 
resulting in inappropriate proliferation and cellular survival. The tumours that these 
cells form remain benign until further genetic alterations occur. One type of alteration 
allows tumour cells to avoid destruction by components of the immune system that 
recognise and kill abnormal cells (Garrido et al. 1993; Smith, 1991; Jackson et al. 
1996). A second type enables solid tumours to produce factors that induce the 
formation of new blood vessels that invade the tumour, allowing it to grow. Until this 
change, known as angiogenesis, occurs, the tumour cannot grow beyond a certain 
point because the cells in its centre are starved of nutrients. Finally cells in solid 
tumours can acquire the ability to invade blood vessels, migrate through the body, and 
settle in new locations to give rise to secondary tumours. This process is known as 
metastasis (see 1.1.1).
The initiating step in carcinogenesis is genetic damage or mutation. Such genetic 
damage may be acquired by the action of environmental agents, such as chemicals, 
radiation, or viruses, or it may be inherited in the germline (see 1.2.2 and 1.3.3).
Two classes of normal regulatory genes, growth promoting proto-oncogenes and 
growth inhibiting tumour suppressor genes are the principal targets of genetic damage, 
together with the category of genes that control apoptosis (see 1.1.2.4). Oncogenes 
and tumour suppressor genes are of major importance in the process of 
carcinogenesis. A decrease in tumour-suppressor gene activity, an increase in 
oncogene activity or a combination of both can confer a growth advantage to cells. 
Further changes then result in the development of cell clones that have the capability 
to invade surrounding tissue, overcome immune surveillance and metastasise to other 
sites.
1.1.3.1 Oncogenes
Oncogenes are normal, regulatory genes for which genetic alteration causes their 
activity to be increased by either a quantitative or qualitative change in the protein 
product of that gene. Their effect is dominant as only one allele needs to be changed 
for a biological effect to take place. Oncogenes, or cancer-causing genes, are derived 
from proto-oncogenes, cellular genes that promote normal growth and differentiation.
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They encode proteins called oncoproteins which resemble the normal products of 
proto-oncogenes, with the exception that oncogenic versions are devoid of important 
regulatory elements and their production in the transformed cells does not depend on 
growth factors or other external signals.
Mechanisms that activate proto-oncogenes include point mutation (e.g.K-ras), gene 
amplification (e.g. c-myc) or chromosomal translocation (e.g. bcr/abl), all of which 
deregulate gene expression or create a chimeric protein with an abnormal function. 
Apart from K-ras (see 1.1.5.2), few oncogenes have been shown to be involved in the 
majority of colorectal cancers although a small percentage do display mutations in 
myc.
1.1.3.2 Tumour suppressor genes
Suppressor genes are important in cell cycle regulation, normally functioning as 
checks on cell growth. Mutated tumour-suppressor genes are thought to lose this 
regulatory function, potentially leading to malignant transformation. Their effect is 
recessive as both copies of a diploid cell must usually be lost before a biological effect 
is found. There are exceptions, as in the case of BRCA1 and p53 (see below), where 
an effect requires only one gene copy to be nonfunctional. The concept of a tumour 
suppressor gene arose from Knudson’s hypothesis of the development of 
retinoblastoma (Knudson, 1985). He proposed that two key events (hits) are 
responsible for the occurrence of this tumour. In the case of inherited mutations in a 
tumour suppressor gene, it appears that the germline mutation constitutes the “first 
hit” required for malignant transformation (Knudson, 1971) and the subsequent 
somatic loss of the non-mutant allele is the necessary “second hit”. Thus germline 
mutations create highly susceptible groups of individuals for whom only one somatic 
event is required to produce inactivation of tumour suppressor activity at a given locus 
(see 1.2.2 and 1.3.3).
One copy of a tumour suppressor gene is usually mutated by a point mutation or a 
small frameshift deletion or insertion. The second copy is usually mutated by deletion 
of a large chromosomal segment or even an entire chromosomal arm (Hansen and 
Cavenee, 1987).
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p53, a tumour suppressor gene selected for study in these projects, is an exception as 
the abnormal p53 protein produced by mutation in one allele inactivates the normal 
product of the other allele (see 3.2.1). p53 is a critical participant in a signal 
transduction pathway that mediates either a G1 arrest or apoptosis in response to DNA 
damage. In addition, p53 is believed to be involved in the mitotic spindle checkpoint, 
in the regulation of centrosome function (Morgan and Kastan, 1997) and in the 
regulation of two anti-angiogenesis factors GD-AIF and TSP-1 (Norrby, 1998). p53 
was selected for these studies as it is one of the most frequently mutated genes found 
in both breast and colorectal carcinomas (see also 3.2.1).
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1.2 Breast Cancer
1.2.1 Breast cancer evolution
Many steps are involved in the transformation from normal breast epithelium to 
metastatic breast cancer. Initially, genetic alterations are thought to confer a growth 
advantage to individual cells by decreasing tumour suppressor gene activity or 
increasing oncogene activity, or both. Further changes result in the development of 
cell clones that have the ability to invade adjacent tissue, establish metastatic deposits, 
and evade immune surveillance. Also at some stage in this process breast cancer cells 
lose the normal ability to respond to hormonal growth regulatory signals.
The evolution of breast cancer and morphological, cellular or molecular events, which 
unequivocally lead to invasive disease, are not yet completely understood.
A model for the evolution of ductal breast cancer, analogous to the one proposed for 
the evolution of colorectal cancer (see 1.3.2) is shown below (Allred et al. 1994).
Normal epithelium
4,
Hyperplasia (without dysplasia)
4-
Hyperplasia (with dysplasia)
i
In situ carcinoma
i
Invasive carcinoma
i
Metastatic carcinoma
In this model ductal breast cancer is hypothesised as evolving from normal epithelium 
through a series of increasingly abnormal cellular changes ranging from hyperplasia to 
atypical hyperplasia or dysplasia, to non-invasive carcinoma, to primary invasive 
carcinoma, and finally to metastatic carcinoma. The non-invasive elements of the 
model are hyperplasia, which would include any proliferative disease without atypia, 
and ductal carcinoma in situ (DCIS). Atypical ductal hyperplasia is often diagnosed as 
a separate entity and this would represent hyperplasia showing a degree of dysplasia. 
Each lesion is a non-obligatory precursor of the next, in the sense that some may 
pursue a stable natural history while others may progress to the next stage of the
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model and there is also the possibility that some lesions may arise de novo relative to 
their immediately preceding stage.
Epidemiological evidence supports this model. This model is generally consistent with 
autopsy studies showing that, in breasts of women dying from other causes, ductal 
hyperplasia is more frequent than atypical hyperplasia, ductal carcinoma in situ or 
invasive carcinoma (Bartow et al. 1987). There is also progressively increasing 
relative risk of later developing breast cancer in women with previously excised 
hyperplasia without atypia, hyperplasia with atypia and ductal carcinoma in situ 
(Dupont and Page, 1985; London et al. 1992; Palli et al. 1991). A retrospective study 
involving over 10,000 patients, showed that hyperplastic, atypical hyperplastic, and 
non-invasive neoplastic lesions were associated with 2-fold, 5-fold, and 10-fold 
increased relative risks, respectively, of eventually developing invasive carcinoma 
(Page et al. 1990b; Page and Dupont, 1990a). Other studies have found that 
hyperplastic lesions and non-invasive cancer are concurrently present in the large 
majority of breasts containing invasive cancer (Kintanar and Raju, 1991; Alpers and 
Wellings, 1985).
Current knowledge of genetic or biological abnormalities in potential precursors of 
invasive breast cancer is quite limited. Three of the most comprehensively studied 
areas in this context include the tumour suppressor gene p53, proliferation rate and 
hormone receptors. These areas are included in the following studies.
1.2.2 Tumour Suppressor genes in breast cancer
Loss of heterozygosity (LOH) at a specific chromosomal location in tumours is widely 
interpreted as being a marker for the absence of a functional tumour suppressor gene 
within the region of loss. As described earlier (see 1.1.3.2), tumour suppressor genes 
are believed to play a central role in the development of many cancers. A large 
number of LOH studies involving invasive breast cancer have demonstrated 
significant levels of LOH at many loci. Of particular interest are chromosomes 17p, 
the location of p53 (see 3.2.1), 17q the location of BRCA1 and 13q the location of 
BRCA2.
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p53
p53 is a tumour suppressor gene and is one of the tumour markers chosen for 
investigation in these projects. p53 appears to be one of the most frequently mutated 
genes in human breast tumours and homozygous loss of the p53 gene is found in 30 -  
50% of breast carcinomas (Bosari et al. 1992; Ostrowski et al. 1991; Allred et al. 
1993; Eriksson et al. 1994; Walker et al. 1991; Rosen et al. 1995; Aas et al. 1996; 
Harris, 1992) (see 3.2.1 and 4.2.3.2). A few studies have reported mutation or 
overexpression of p53 in up to 40% of comedo DCIS and 10% of non-comedo DCIS 
(Davidoff et al. 1991; Poller et al. 1993), but little is known about this gene in other 
precursor lesions.
BRCA1 and BRCA2
BRCA1 and BRCA2 are recently identified tumour suppressor genes that are 
associated with hereditary breast cancer but are not of particular interest for these 
projects as to date, they do not seem to be associated with sporadic breast cancer 
(Breast Cancer Linkage Consortium, 1997).
A gene responsible for the hereditary form of breast carcinoma has been identified on 
chromosome 17q and named BRCA1 (Hall et a l 1990; Miki et al. 1994). Germline 
mutations in BRCA1 confer a high risk of developing early onset breast cancer (Hall 
et al. 1990) and ovarian cancer (Narod et al. 1991), which is inherited in an 
autosomal dominant manner. Whether there is an increased risk of breast or ovarian 
cancer depends on where in the gene the mutation lies. Studies have shown that 
approximately half of all cases of inherited breast cancer are attributable to germline 
BRCA1 mutations (Easton et al. 1993) and that prostate and colon cancer risks are 
also increased in individuals harbouring germline BRCA1 mutations (Ford et al.
1994).
A second gene that predisposes to breast carcinoma. It has been localised to 
chromosome 13ql2-13 and named BCRA2 (Wooster et al. 1994). This gene is also 
associated with the development of male breast cancer in approximately 6% of 
carriers. Tumours with BCRA2 mutations have been shown to have multiple 
chromosomal abnormalities and p53 mutations have been found to be more frequent 
in BRCA2 mutation carriers (Gretarsdottir and Thotlacius, 1998).
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These two genes, BRCA1 and BRCA2, together probably account for about two thirds 
of familial breast carcinoma or roughly 5% of all cases of breast cancer.
1.2.3 Proliferation rate
The assessment of proliferation rate is an intrinsic part of the grading of ductal 
carcinomas of the breast (see 1.2.5.6a). Proliferation rate as assessed by the Ki67 
antibody has been shown to be significantly associated with diminished patient 
survival and disease-free interval in breast cancer (Locker et al. 1992). MEB1, one of 
the antibodies selected for investigation in these projects, also recognises the Ki67 
antigen (see 3.1.1.5).
1.2.4 Hormonal growth regulation
Some breast cancer cells express receptors for and are sensitive to a variety of steroid 
hormones, polypeptide hormones and growth factors. In relation to hormonal growth 
regulation of tumours, there are two different types of breast disease. Oestrogens have 
been shown to stimulate the growth of both normal mammary gland and breast cancer 
(Howell, 1989) when the tumour cells are ER+ve, that is when they consist of cells 
with a functioning oestrogen receptor. ER-ve disease on the other hand is not 
promoted by hormones but by growth factors such as EGF. Breast cancer cells are 
usually EGFR +ve or ER +ve, but rarely both and an inverse relationship has been 
found between EGFR and ER concentration (Oehler et al. 1997) (see also 3.4.1). A 
few immunohistochemical studies suggest that most hyperplastic and in situ 
carcinoma lesions express high levels of ER, while expression of these receptors 
appears to be rare in comedo (high-grade) DCIS (Jacquemier et al. 1990; Barnes and 
Masood, 1990). The assessment of the ER status of a tumour is used as a predictor of 
the likelihood of the response of a particular tumour to endocrine therapy (see 3.4.1). 
There is evidence of a multistep progression from an oestrogen-dependent growth to 
an autonomous growth in breast (see also 3.4.1).
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1.2.5 Breast Pathology
1.2.5.1 Normal breast Anatomy
The breast is a modified sweat gland covered by skin and subcutaneous tissue. The 
main function o f the breast is the production and expression of milk. The lobules are 
the secretory units o f the breast.
Each lobule consists o f a variable number o f acini, or glands, embedded within loose 
connective tissue and connecting to the intralobular duct. Each acinus is composed of 
two types of cells, epithelial and myoepithelial (see Fig 1.3).
Fig 1.2 Diagram to show the anatomy of a normal breast
Duct
Nipple
Skin
The epithelial cells are the secretory cells, synthesising milk during pregnancy, but 
also, continuously, a variety of glycoproteins which are secreted into the glandular 
lumens. The myoepithelial cells, which contain contractile proteins, have a 
mechanical function. The intralobular duct connects with the extralobular duct, which 
link together to form subsegmental ducts. These in turn drain into the lactiferous 
ducts. There are 15 -  20 lactiferous ducts in each breast. Epithelial cells, surrounded
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by myoepithelial cells, line the ducts. The connective tissue in which they lie is denser 
than that of the lobules, and they are surrounded by elastic tissue, which helps in the 
drainage function of the ducts.
Fig 1.3 Diagram to show the structure of a breast lobule and a section of a 
normal breast lobule
Epithelial
cells Basement
membrane
Lumen
Myoepithelial
cells
Acini
Intralobular 
connective tissue
V;f 'i. V
Breast tissue responds markedly to hormonal and other influences throughout life, and 
as a result, it may display a wide range of normal appearances and it is thus sometimes 
difficult to define normal in the context of the breast.
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1.2.5.2 Clinical Features of breast lesions
Most pathological lesions of the breast present as a lump or lumps, These can vary in 
their nature, depending on their cause; well circumscribed or ill-defined; single or 
multiple small nodules; soft or firm; mobile or attached to skin or underlying muscle. 
These features assist in the clinical distinction between benign breast lesions and 
carcinomas but they are relatively weak discriminators on their own.
1.2.5.3 Diagnostic methods
Several methods are currently used to investigate breast lesions. Fine needle aspiration 
cytology (FNA) is often used (Thomas and et.al., 1994; Corkill and Katz, 1993; 
Robinson et al. 1994). A needle is inserted into the areas of the breast lump and cells 
are aspirated which are smeared onto a slide and stained. It is well tolerated 
(Wilkinson and Hendricks, 1993), although some people do experience pain. A recent 
investigation of pain levels, using needles of two different sizes was carried out at the 
Royal Surrey County Hospital It was found that smaller needles (blue needles) caused 
less pain and made no difference in cellularity of the samples (Daltrey I. European 
Journal of Surgical Oncology, in press). Core biopsies are now being increasingly 
used. Other aids to diagnosis are mammography, and examination of frozen sections. 
These all play a part in an initial diagnosis, but paraffin wax histological sections are 
always used for the definitive diagnosis.
1.2.5.4 Benign proliferative breast disease
There are many complex and interrelated proliferative breast disorders, most of which 
are probably not true neoplasms but rather hormonally induced hyperplastic processes. 
Some, such as fibroadenoma, are generally recognised relatively easily but others 
raise the differential diagnosis of carcinoma at the clinical, gross or microscopic level 
and some of them are probably related to the development of malignancy but in a 
fashion that remains ill defined and highly controversial. A selection of benign 
proliferative lesions have been selected for this study so that their staining properties 
could be compared to that of malignant lesions.
1.2.5.4 a Intraductal papilloma
A papilloma is defined as a tumour with an arborescent, fibrovascular stroma (see Fig 
1.4) covered by epithelium generally arranged in an inner myoepithelial and outer
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epithelial layer. Duct papillomas arise as a solitary lesion within a large duct and 
consist of branching fibrovascular cores covered by epithelium, which is cytologically 
benign. Solitary duct papillomas are benign lesions that are curable by local excision 
and there is no increased risk of carcinoma, relative to the general population, in these 
patients.
l  t
1
Fig 1.4 H&E sections of an intraductal papilloma. Fig 1.4a is a magnification of 
x40 and Fig 1.4b is the same papilloma at a magnification of x200
Fig 1.4a
Stalk of papilloma 
to lining
duct
Fig 1.4b
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1.2.5.4 b Ductal and lobular hyperplasia
Epithelial hyperplasia is the proliferation of epithelial cells which occurs in the small 
interlobular ducts, the intralobular ducts and the acini, resulting in a solid or almost 
solid mass obliterating the lumen (see Fig 1.5).
Fig 1.5 H&E section of ductal hyperplasia
Hyperplastic 
epithelial cells 
filling the ducts
Stroma
The fundamental feature of epithelial hyperplasia is an increased number o f cells 
relative to that normally found above the basement membrane. The normal number in 
the breast is two and therefore three or more cells above the basement membrane 
define hyperplasia in the breast. There is a wide range in the degree of epithelial 
proliferation in breast lesions and it has been postulated that there is a correlation 
between the degree of this proliferation and the likelihood of subsequent development 
of invasive carcinoma.
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Fig 1.6 H&E section showing atypical hyperplasia
Cells showing 
cytological atypia
The terms atypical ductal hyperplasia and atypical lobular hyperplasia have been 
proposed for proliferative lesions in which some but not all o f the features of 
intraductal carcinoma or lobular carcinoma in situ, respectively, are present (Page et 
al. 1990b). These features include disordered orientation o f cells, nuclear 
pleomorphism and occasional mitotic figures (see Fig 1.6). Studies, however, have 
shown an unacceptably high level of observer variability in estimating the type and 
degree of epithelial hyperplasia (Screaton et al. 1992). The differential diagnosis 
between atypical hyperplasia and carcinoma in situ is a difficult problem. If a breast 
biopsy contains areas of atypical hyperplasia, then the patient has a risk of developing 
cancer 5 times higher than that of a patient with non-proliferative lesions (Page et al. 
1990b).
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1.2.5.4 c Radial scars
Radial scars have always been regarded as benign lesions but they are of special 
interest in this study as there has been a suspicion in recent years that lesions that have 
been diagnosed as radial scars may not always behave in a benign fashion. This has 
been an area of particular interest in the Royal Surrey County Hospital histopathology 
department. Malignancy may arise in the same area as the radial scar. It is possible 
that the growth pattern of some carcinomas may resemble radial scars and thus they 
may be underdiagnosed. It is also possible that there may be coincidence of radial 
scars with tubular carcinomas. The radial scar is generally 10mm or less in diameter. 
If it is greater than 10mm it is known as a complex sclerosing lesion. It consists of a 
central fibro-elastic zone (see 1.7) from which radiate out tubular structures, which 
may be two-layered or exhibit intra-luminal proliferation and changes such as 
papilloma formation may be imposed on the main lesion.
Fig 1.7 H&E section of a radial scar
Central sclerosing 
region from 
which tubular 
structures radiatemm-
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1.2.5.5 In situ carcinoma
The definition of in situ carcinoma is that the tumour cells are confined to ducts 
(intraduct) or acini (intralobular). It is defined as a proliferation of epithelial cells with 
cytological features of malignancy and is distinguished from invasive carcinoma by 
the absence of stromal invasion across the basement membrane.
1.2.5.5 a Ductal carcinoma in situ (Intraduct carcinoma)
Ductal carcinoma in situ (DCIS) can occur in both pre- and post-menopausal women 
and pure DCIS accounts for about 5% of breast carcinomas that present clinically. 
Bilateral disease is uncommon. Despite the name, most DCIS is generally considered 
to arise from the terminal duct lobular units. DCIS varies in cell type, growth pattern 
and extent of disease and may thus represent a group or spectrum of related in situ 
neoplastic processes. Lesions composed of cells of high nuclear grade are thought to 
be more aggressive. There is currently no generally accepted method of classifying 
DCIS issued by the NHS Breast Screening Programme, but distinction between 
histological subtypes is of value for correlating pathological and radiological 
appearances, improving diagnostic consistency, assessing the likelihood of invasion 
and determining the probability of recurrence after local excision.
At present there are several classifications of DCIS based of histological structure, 
nuclear grade, comedo-type necrosis, cytonuclear differentiation or various 
combinations of these factors.
Several methods of classifying DCIS have been published based on
• Differentiation, mainly based of nuclear morphology and cell polarisation 
(Holland and et.al., 1994).
• Nuclear grade and necrosis (Silverstein, 1998). This is referred to as the Van Nuys 
proposal.
• Architectural pattern and nuclear grade, with separate identification of special 
types (Scott et al. 1996).
High nuclear grade DCIS is composed of cells with pleomorphic, irregularly spaced 
and usually large nuclei exhibiting marked variation in size, irregular nuclear
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contours, coarse chromatin and prominent nucleoli. Mitoses are frequently present and 
abnormal forms may be seen. It may exhibit several different growth patterns. It is 
often solid with central comedo-type necrosis, sometimes a solid proliferation of 
malignant cells and sometimes it exhibits micropapillary and cribriform patterns.
Low grade DCIS is composed of monomorphic, evenly spaced cells with roughly 
spherical, centrally placed nuclei and inconspicuous nucleoli. The nuclei are usually, 
but not invariably small. Mitoses are few and there is rarely individual cell necrosis.
Some cases of DCIS cannot be assigned easily to the high or low nuclear grade 
categories as the nuclei show mild to moderate pleomorphism, less than that of high 
grade DCIS, but without the monotony of the small cell type. The nucleo-cytoplasmic 
ratio is often high and one or two nucleoli may be identified. This type of DCIS is 
classified as intermediate grade.
A proportion of cases of DCIS exhibit features of more than one histological subtype. 
Other histological types are encysted papillary carcinoma and DCIS of signet ring 
cell, pure apocrine cell, cystic hypersecretory and neuroendocrine types.
Although the specimens used in these projects were not graded, the Van Nuys 
classification of DCIS is now used at the Royal Surrey County Hospital and is shown 
below.
Van Nuys classification of DCIS
SCORE 1 2 3
Tumour size Less than 15mm 16-40 mm More than 41 mm
Margin width More than 10 mm 1-9 mm Less than 1 mm
Grade Grade 1 + 2 
No necrosis
Grade 1 + 2  
With necrosis
Grade 3 
+/- necrosis
Total Score
Good 3 + 4
Average 5,6 + 7
Poor 8 + 9
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Fig 1.8 H&E sections of intermediately differentiated DCIS with a 
micropapillary growth pattern. Fig 1.8a at a magnification of xlOO shows ductal 
morphology and Fig 1.8b, at a magnification of x400 shows cytological atypia.
Pleomorphic 
tumour cells
Fig 1.8b
DCIS can spread along the duct system or into the lobules. Most cases of DCIS have 
been treated by mastectomy, so it is difficult to know the fate of these lesions if  left. 
Estimates of residual carcinoma changing from non-invasive to invasive range from 
one-third to one-half, based on studies where only local excision has been performed.
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1.2.5.5 b Lobular carcinoma in situ
Lobular carcinoma in situ occurs predominantly in pre-menopausal women and 
accounts for about 6% of all breast carcinomas. If it is found after the menopause it is 
usually associated with an infiltrating tumour (Haagensen et al. 1983). It poses a 
problem clinically as it does not present as a palpable lump. It is often multicentric 
within one breast and frequently bilateral.
Fig 1.9 H&E section of lobular carcinoma in situ
Carcinoma cells 
filling the lobule
Histologically the changes are found in the acini although they may extend into the 
extralobular ducts. LCIS has small rounded uniform cells with clear cytoplasm that 
appear loose and non-cohesive. The cells have granular or hyperchromatic nuclei, 
inconspicuous nucleoli and high nucleo-cytoplasmic ratio. The characteristic uniform 
cells comprise the entire population of the lobular units with no residual lumina. The 
overall size of the acini increases, but the lobular shape is retained. About one quarter 
to one-third of all patients with intralobular carcinoma who are given no further 
treatment following biopsy will go on to develop an invasive carcinoma.
'*  V
11122
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1.2.5.6 Invasive carcinomas
An invasive tumour is one whose cells have broken through the basement membrane 
around the breast structure in which they have arisen and spread into the surrounding 
tissue. Different types of invasive carcinoma have been studied in this project.
According to the Royal College of Pathologists data set for reporting breast cancer 
invasive breast carcinomas may be classified as:
• Common types
‘Ductal’ no specific type (ductal-NST), lobular (including alveolar, solid, tubulo- 
lobular, pleomorphic and mixed variants), tubular, medullary and mucinous. There are 
also ‘Mixed’ carcinomas containing different component types.
• Other types
Atypical medullary, spindle cell, infiltrating papillary, argyrophil, secretory and 
apocrine.
Rarer types include squamous carcinoma, mammary carcinomas with endocrine 
features, small cell (oat cell) carcinoma, mammary carcinoma with osteoclast-like 
giant cells, metaplastic carcinoma, adenoid cystic carcinoma, secretory carcinoma and 
cribriform carcinoma (Rosen, 1997).
The more common types are described below.
1.2.5.6 a Invasive ductal carcinomas
Invasive ductal carcinomas exhibit great variation in appearance (see Fig 1.10) and are 
the most common carcinomas, accounting for up to 75% of carcinoma cases. 
Histologically, the tumour cells are arranged in groups, cords and gland-like 
structures. The degree of differentiation of the tumour is based on the extent to which 
it resembles non-tumorous breast; whether the cells are in a gland-like pattern or as 
solid sheets; the degree of nuclear pleomorphism; and the number of mitotic figures 
present. A well-differentiated infiltrating duct carcinoma tends to behave less 
aggressively than a poorly-differentiated tumour, which is composed of sheets of 
pleomorphic cells with large numbers of mitotic figures.
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Histological grade is an important prognostic variable in primary infiltrating ductal 
breast carcinoma. The histological grade is obtained by analysis of the following three 
features, each of which is given a score of 1-3:-
1. Tubule formation (many tubules score 1, no tubules score 3)
2. Nuclear pleomorphism (low pleomorphism scores 1, high pleomorphism 
scores 3)
3. Mitotic rate ( low number of mitoses score 1, many mitoses score 3)
The higher the total score the higher the grade of the tumour and this, together with 
the size of the tumour and the lymph node status, is used to assess the prognosis. A 
total score between 3 and 5 gives a low grade (Grade 1) tumour, a total score of 6 or 7 
gives an average grade (Grade 2) tumour and a total score of 8 or 9 gives a high grade 
(Grade 3) tumour (NHS Breast Screening Programme).
There is, however, a group of patients with grade 1 or 2 tumours who already have 
metastatic deposits in their axillary lymph nodes at the time of surgery and similarly a 
group of grade 3 patients who have no detectable lymph node metastases. It is also 
true that 20%-30% of lymph node-negative breast cancer patients will relapse with a 
recurrence or distant metastasis (McGuire, 1989), showing that grading alone does not 
give a complete answer as far as predicting tumour behaviour is concerned.
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Fig 1.10 H&E sections of ductal carcinomas Fig 1.10a shows a grade 1 
carcinoma, Fig 1.10b shows a grade 2 carcinoma and Fig 1.10c shows a grade 3 
carcinoma
Tubule
formation
Fig 1.10a
Fig 1.10b
Pleomorphic cells
Mitotic figure
Fig 1.10c
29
1.2.5.6 b Invasive lobular carcinoma
Fig 1.11 H&E section of a lobular carcinoma
Carcinoma 
cells in 
‘Indian’ files
Infiltrating lobular carcinoma is composed of small regular cells identical to those 
seen in the in situ form. The cells are dissociated from each other or form single files 
(Indian files) or targetoid patterns around uninvolved ducts. While LCIS usually 
occurs in premenopausal women, the infiltrating lesion can also occur in post­
menopausal women. It is often multicentric throughout the breast. The cells in some 
carcinomas may appear signet-ring in shape due to the accumulation of mucin within 
their cytoplasm, displacing the nucleus to one side.
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1.2.5.6 c Tubular carcinomas
These are well-differentiated carcinomas composed of cells arranged as tubules (see 
Fig 1.12). The cells show little pleomorphism or mitotic activity. Patients with tubular 
carcinomas do extremely well, better than those with well-differentiated infiltrating 
duct carcinomas.
Fig 1.12 H&E section of a tubular carcinoma
Tubules
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1.2.5.6 d Medullary carcinomas
These rare tumours are composed of syncytial interconnecting masses of large 
pleomorphic cells with vesicular nuclei and prominent nucleoli. The stroma may be 
sparse but always contains large numbers of lymphoid cells. The border of the tumour 
is well-defined (see Fig 1.13). The interest in these carcinomas is that despite the fact 
that the cytological appearance o f these carcinomas puts them into the ‘poorly 
differentiated5 category, the patients have a significantly better 10-year survival than 
women with invasive ductal carcinomas.
Fig 1.13 .H&E section of a medullary carcinoma
Syncytial sheet of 
tumour cells
Lymphocytes in 
the stroma
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1.2.5.6 e Mucinous carcinomas
These carcinomas have small nests and cords of tumour cells, which show little 
pleomorphism, embedded in large amounts o f mucin (see Fig 1.14). The mucin is 
composed of neutral or weakly acidic glycoproteins, which are secreted by the tumour 
cells. The survival of women with mucinous carcinomas is better than those having 
either infiltrating ductal or lobular carcinomas.
Fig 1.14 Sections of a mucinous carcinoma. Fig 1.14a is stained with 
haematoxylin and eosin and Fig 1.14b with alcian blue periodic acid stain which 
stains the pools of mucin.
Carcinoma cells
Mucin pools
Carcinoma cells
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Decisions have to be made, based mainly on the pathology of the tumour, as to 
whether a patient would benefit from hormone therapy and whether chemotherapy is 
suitable. Clearly grade, together with lymph node status are good prognostic factors, 
but additional information that could help to predict tumour behaviour would be very 
valuable.
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1.3 Colorectal Cancer
1.3.1 Adenoma -  carcinoma sequence
Colorectal carcinomas are believed to evolve through a series of morphologically 
identifiable stages: epithelial hyperplasia followed by formation of adenomas that 
progressively enlarge and ultimately undergo malignant transformation.
The great majority of adenomas do not undergo malignant change. If all adenomatous 
polyps became malignant, with their known frequency in the general population, the 
incidence of carcinoma should be at least twenty times higher than it actually is. The 
most important issue from a practical standpoint is the likelihood of an adenomatous 
polyp becoming malignant during a reasonable life span. The figure for the number of 
cases in which a focal carcinoma is found in a tubular adenomatous polyp on 
pathologic examination is given at less than 5%. For an adenoma with a villous 
pattern (see 1.3.4.3b), however, the malignancy rate rises to about 40%.
The adenomatous polyposis coli (APC) gene, located to chromosome 5q21-22, is a 
tumour suppressor gene involved in the pathogenesis of colorectal cancer (Groden et 
al. 1993). Inherited loss of one allele predisposes to the formation of multiple colonic 
polyps (see 1.3.3.1) but in addition to cancers arising in the setting of inherited 
disease, the majority of non-familial colorectal carcinomas and benign adenomas also 
contain a mutated APC gene (Powell et al. 1992). It has been proposed that the APC 
protein could serve as a molecular “gatekeeper” for the development of adenomas 
(Kinzler and Vogelstein, 1996). In sporadic adenomas inactivation of the second APC 
allele is associated with the development of villous change (Jass et al. 1992) but only 
30% of the sporadic tumours (adenomas and carcinomas) have homozygous loss of 
the APC gene, suggesting that inactivation of both alleles may not be essential for 
tumourigenesis.
Both germline and somatic APC gene mutations predominantly result in deletion of 
the carboxyl-terminal region of the APC protein, suggesting that important growth- 
suppressor activity resides in this region (Powell et al. 1992).
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Evidence for the adenoma-carcinoma sequence
There is much evidence that adenomas can develop into carcinomas:-
1. Adenomas are six times as common in surgical specimens of colorectal cancer 
than in length, age and sex matched colorectal specimens from patients 
without cancer (Eide, 1986).
2. Metachronous carcinomas are twice as likely to arise in patients with 
carcinoma and adenoma in the original specimen than in patients with 
carcinoma alone. This demonstrates the risk associated with the presence of 
multiple adenomas (Bussey et al. 1997).
3. In patients with synchronous carcinomas additional adenomas are found in 
75% of specimens (Heald and Lockhart-Mummery, 1972).
4. Focal carcinoma may be observed in adenomas (Fig 1.15), and conversely 
residual adenoma is often present in surgical specimens of colorectal cancer 
(Eide, 1983).
5. Adenomas occur at an earlier age than carcinomas (Bussey, 1968).
6. Adenomas are larger and more numerous in high risk populations for 
colorectal cancer (Clark et al. 1985).
7. A series of adenomas will show all grades of dysplasia. Examination of 
multiple adenomas will show a range of dysplastic changes. Most will have 
only low-grade dysplasia, some will have areas of high-grade dysplasia, and a 
smaller number will harbour invasive adenocarcinoma, something that might 
be called carcinoma in situ (Konishi and Morson, 1982). It is believed that 
these represent stages in a progressive series, although there are, of course, no 
longitudinal studies of individual adenomas documenting progression in a 
single lesion. Increasing dysplasia is accompanied by an increasing incidence 
of DNA aneuploidy (Goh and Jass, 1986), an important feature of neoplastic 
transformation.
8. Removal of adenomas greatly reduces the incidence of cancer (Gilbertson and 
Nelms, 1978).
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9. Molecular biology findings also support the progression model in that various 
genetic alterations are present more frequently in carcinoma and less 
frequently in adenoma (Fearon and Vogelstein, 1990).
Although this evidence is largely circumstantial there is little doubt that adenomas 
have an increased propensity for malignant invasion as compared to normal mucosa. 
A more controversial question concerns the actual proportion of carcinomas that arises 
within a pre-existing adenoma. The evidence suggests that the great majority of 
carcinomas do arise in adenomas. There may be exceptions but sometimes adenomas 
may be small and flat and some illustrations of carcinomas that are said to have arisen 
‘de novo ’ may just be early cancers that have destroyed a small adenoma. The figure 
below shows a small (7mm diameter) carcinoma. The appearance is of a carcinoma 
that has arisen "de novo ’ but close examination reveals that there is a small area of 
possible adenoma present and it is more probable that it is a fast growing cancer that 
has quickly overtaken the adenomatous region and ulcerated.
Fig 1.15 H&E section to show a carcinoma developing in an adenoma
The term “adenoma -  carcinoma” sequence is not synonymous with “polyp- 
carcinoma” sequence. “Dysplasia-carcinoma” sequence is probably a better term as it
Remains of 
adenomatous 
epithelium
Normal
epithelium
Carcinoma
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allows for the possibility that cells might acquire all genetic mutations necessary for 
malignant behaviour without ever forming a grossly visible adenomatous polyp. It is 
now thought therefore, that as well as the classical polypoid adenoma-carcinoma 
sequence there may also exist a flat-adenoma-carcinoma sequence and also de novo 
cancerisation (Kuramoto and Oohara, 1988). A separate group of adenomas named 
‘serrated adenomas’ has been identified, which has a malignant potential that exceeds 
that of typical adenomas (Longacre and Fenoglio-Preiser, 1990) and has infrequent K- 
ras mutations (Ajioka et al. 1998).
1.3.2 Genetic changes in colorectal tumourigenesis
The genetic changes associated with colorectal tumourigenesis may be summarised as
shown below.
Morphologic appearance molecular change
MMR
Deficiency
normal epithelium 
4,
dysplastic aberrant crypt 
foci
i
early adenoma 
4,
intermediate adenoma
4,
late adenoma 
carcinoma 
metastasis
APC gene mutation
K-ras mutation on 
chromosome 12
chromosome 18q21 
LOH (DCC 
mutation/DPC4/JV 18)
p53 mutation and 
chromosome 17p LOH
other alterations
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Each stage or the morphological progression is associated with an increase in the total 
number of genetic mutations (Vogelstein et al. 1988).
According to this model (Fearon and Vogelstein, 1990) inactivation of the APC 
tumour suppressor gene occurs first and initiates the neoplastic process, followed by 
activation of the ras oncogene. Ultimately there is loss of heterozygosity of 18q21 and 
inactivation of p53 (see 3.2) genes, resulting in tumour progression.
K-ras is an oncogene that requires only one genetic event for its activation. K-ras 
mutations are thought to occur as relatively early events in neoplastic progression 
(Vogelstein et al. 1988). The ras protein, which is a guanosine triphosphate (GTP) 
binding protein involved in signal transduction, is expressed in normal colonic 
epithelium and mutations of ras frequently occur in colonic tumours as they progress 
(Shibata et al. 1993; Shpitz et al. 1996). Mutant ras proteins bind GAP, but their 
GTPase activity fails to be augmented. Hence the mutant proteins are trapped in their 
excited GTP-bound form, causing in turn a pathologic activation of the mitogenic 
signalling pathway. These mutations do not, however, seem to lead to colorectal 
neoplasia (Baker et al. 1990). Hyperplastic cells containing mutant ras genes, unlike 
their dysplastic counterparts with mutant APC genes, have little or no potential to 
form clinically important tumours and may eventually regress through apoptosis 
(Gorham etal. 1996).
Chromosome 18q21 may contain several different tumour suppressor genes involved 
in colorectal neoplasia, with DCC, DPC4 and JV18-1 genes proposed as candidates. 
The DCC gene encodes a transmembrane protein that has structural similarity with 
cell adhesion molecules so that it is probable that the gene product is involved in 
transmission of negative signals responsible for phenomena such as contact inhibition, 
a property lost on malignant transformation. Homozygous loss of the DCC gene is 
seen in more than 70% of colorectal cancers and in large (precancerous) adenomas 
(Vogelstein et al. 1988).
In addition, mutation of the tumour suppressor gene p53 on 17p appears to be a late 
phenomenon in colorectal carcinogenesis (see 5.2.3.2). This mutation may allow the 
growing tumour with multiple genetic alterations to evade cell cycle arrest and 
apoptosis.
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The tumour suppressor gene p53 is genetically altered in more than 80% of colorectal 
cancers (Garber et al. 1991), but patients with germline mutations of p53 do not 
develop polyposis (see 1.3.3.1) and in fact are not even at high risk to develop 
colorectal cancer (Vogelstein et al. 1988). Therefore, although it is clear that p53 can 
play a role in colorectal tumourigenesis, it is equally clear that it cannot initiate the 
process in a fashion similar to APC. These studies suggest that it is not simply the 
accumulation of mutations but also their order that determines the propensity for 
neoplasia. A recent study showed, however, that K-ras and p53 mutations are 
independent events in which neither is a prerequisite for the other. Patients with both 
K-ras and p53 mutations had lower survival times, but the effect of p53 mutations on 
survival was greater than that of the presence of K-ras mutations (Hardingham et al. 
1998).
A variety of other genetic alterations have been described in a small fraction of 
advanced colorectal cancers. These may be responsible for the heterogeneity of 
biologic and clinical properties observed among different cases.
1.3.3 Hereditary cancers
In these cancers, errors in one allele are passed to the offspring through the germ cells. 
Loss of the second allele in the colonic epithelium cells invariably leads to cancer. 
There are two well-documented types of hereditary colorectal cancer for which the 
genes have been identified.
Patients with FAP (see 1.3.3.1) inherit a germline APC mutation and subsequent 
somatic mutation of the second APC allele facilitates the development of the 
malignant phenotype due to inactivation of both alleles of this tumour suppressor 
gene. The patients develop numerous dysplastic aberrant crypt foci, some of which 
progress as they acquire the other mutations indicated in 1.3.2.
The tumours from patients with HNPCC go through a similar though not identical 
series of mutations and Mis Match Repair (MMR) deficiency speeds up this process 
(see 1.3.3.2).
1.3.3.1 Familial adenomatous polyposis (FAP)
FAP affects about 1 in 7000 individuals. It is a condition where many hundreds and 
often thousands of adenomas are present throughout the colon. These adenomas
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develop during their second and third decades of life. Most of these adenomas remain 
small with a tubular morphology but they do show a limited but inevitable tendency to 
proceed to the development of colorectal cancer in untreated cases. The gene 
responsible is known as the APC gene and it has been localised to chromosome 5q21 
(Bodmer et al. 1987). It is inherited as an autosomal dominant condition and affects 
both sexes equally. The child of an affected parent therefore has a 50% chance of 
inheriting the disease. Patients with germline mutations of APC do not necessarily 
develop colorectal cancer; they simply are at much greater risk to do so than the 
general population. Additionally patients often develop extracolonic manifestations 
including duodenal and gastric polyps, brain tumours and endocrine abnormalities (De 
et al. 1994). In order for tumours to form, additional genetic alterations are apparently 
required. Thus, although FAP patients each develop numerous colorectal tumours, 
only about 1 of every 106 colorectal epithelial stem cells gives rise to such a tumour.
Fig 1.16 Photograph of a colon from a patient with FAP
Polyps
The adenomas begin to appear in the second or third decades of life, much earlier than 
the usual adenomatous polyp. The figure of 100 adenomas is taken as a convenient 
distinction between Familial Polyposis and multiple adenomas.
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One of the proteins that is functionally important for the maintenance of epithelial 
architecture is E-cadherin, which is expressed on the basolateral surfaces of the 
epithelial cells at points of cell-cell contact. The cytoplasmic domains of E-cadherin 
interact with groups of cytoplasmic proteins, called catenins, which are necessary for 
cadherin function in anchoring and organizing the cytoskeleton
The protein produced by the APC gene binds to p-catenin along with a serine 
threonine glycogen kinase, enabling degradation of free p-catenin. If p-catenin is not 
degraded the surplus can bind to other proteins, especially transcription factors that 
are transported to the nucleus, such as lymphocyte enhancing factor and T cell factor. 
(Jankowski and et al., 1997). The APC gene product is mutated early in many cancers 
leading to reduced p-catenin degradation and, hence, an increased risk of aggregating 
with transcription factors. Most germline mutations of the APC gene generate stop 
codons and a truncated protein is therefore produced. Amino acid substitutions and 
frameshifts have however, also been identified. Somatic cell mutations in the APC 
gene show a different pattern with a lower proportion of stop codons.
Although germline mutations of the APC gene cause FAP, this syndrome accounts for 
less than 1% of colorectal tumours. It has been found however, that somatic mutations 
of APC occur in the great majority of sporadic colorectal tumours (Powell et al. 1992; 
Jen et al. 1994). APC mutations occur in single colonic epithelial cells, resulting in 
truncations of the APC protein identical to those observed in FAP patients.
Complete APC inactivation has been found in the earliest neoplastic lesions that can 
be examined. Such lesions, called dysplastic aberrant ciypt foci are believed to be the 
precursors of adenomas. It appears that APC is the initiating mutation for colonic 
epithelial cell proliferation. Other genes involved in colorectal cancer do not seem to 
efficiently initiate the neoplastic process.
1.3.3.2 Hereditary non-polyposis colorectal cancer (HNPCC)
Hereditary non-polyposis colorectal cancer, also known as Lynch syndrome, results 
from an inherited defect in one of the genes responsible for the repair of errors that 
occur during DNA replication. It is in fact an inherited group of syndromes, since 
mutations at more than one locus seem to be associated with similar clinical findings. 
Several DNA mismatch repair genes (hMSH2 - chromosome 2p, hMLHl -
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chromosome 3p, hPMSl- chromosome 2q and hPMS2 - chromosome7q) have been 
identified.
Tumours with defective DNA mismatch repair can be identified by the presence of 
errors in short repeat sequences that produce microsatellite instability. Microsatellite 
loci are short units (one to five base pairs) of DNA that are repeated in tandem. 
Hundreds of thousands of these markers are present throughout the human genome 
and usually occur in intronic (non-protein coding) regions of DNA. 10 to 15% of 
sporadic tumours also display microsatellite instability and this is also known as the 
replication error positive (RER+) phenotype (Ionov et al. 1993). These are largely 
right-sided (proximal) cancers (Thibodeau et al. 1993). Although sporadic RER 
positive colorectal cancers are viewed as non-familial counterparts of HNPCC, only a 
subset of sporadic RER positive cancers shows somatic mutation of hMSH2, hMLHl, 
hPMSl and hPMS2. This suggests that a proportion of RER positive colorectal cancer 
is not necessarily an exact sporadic counterpart of HNPCC. It is possible that different 
mis-match repair genes are implicated or that the genes are switched off by altered 
methylation.
Carriers inherit a germline mutation in one of these genes, but their cells have normal 
mismatch repair activity due to the presence of the wild-type allele. If a second, 
acquired somatic mutation of the functioning allele occurs, cells without mismatch 
repair activity are created, leading to genomic instability. The relentless accumulation 
of genetic mutations in such cells presumably enhances their potential for malignant 
degeneration and affected individuals have high risk of cancers of the colon at a 
relatively young age (fifth decade) and certain extracolonic sites, such as the 
endometrium, ovary, stomach, small bowel and renal pelvis. The carcinomas of 
HNPCC are more likely to be poorly differentiated than those of sporadic cancers 
(Mecklin and Jarvinen, 1986; Miyoshi et al. 1992) and also have a tendency to 
produce extracellular mucin, both of which are poor prognostic factors. These 
features, including the tendency to form in the proximal colon, are features of sporadic 
RER positive carcinomas as well as HNPCC cancers (Jass et al. 1998).
It appears that HNPCC patients form adenomas at about the same rate as the general 
population and there is some circumstantial evidence that adenoma is the precursor to 
colorectal carcinoma in the syndrome. Two lines of evidence support this view, the
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retrospective review of resected colons and the prospective surveillance of at-risk 
patients. Several series have reported the prevalence of adenomas in carcinomatous 
colons for patients with HNPCC, with between 13 and 39% of such colons having 
synchronous adenomas at resection (Love, 1986; Mecklin and Jarvinen, 1986; Lynch 
et al. 1993). Surveillance studies have also found adenomas in HNPCC patients. One 
survey found adenomas in 7 of 19 HNPCC patients less than 50 years old. Compared 
with an autopsy control group, the HNPCC adenomas were larger, more often villous, 
and more likely to contain areas of high-grade dysplasia.
A proportion of the colon cancers in affected individuals has residual adenoma, 
supporting the theory that adenomas are precursors to malignancy in HNPCC. One 
series (Love, 1986) found residual adenoma in 12%, a number not dissimilar from that 
described in the general population.
For reasons not understood there is a preponderance of cancers proximal to the splenic 
flexure in HNPCC, but the anatomical distribution for adenomas in subjects with 
HNPCC is similar to that of the general population. This implies that adenoma 
initiation in HNPCC occurs on a sporadic basis but that some factor, especially 
represented in the proximal colon, must be present before there is full expression of 
the mutator phenotype.
As adenomas do not occur with greatly increased frequency in HNPCC, if adenoma is 
the precursor lesion for malignancy in this syndrome, it follows that HNPCC 
adenomas are more likely to progress to adenocarcinoma and do so more rapidly than 
those of the general population. It is evident from autopsy studies that in the general 
population, adenomas are uncommon before the age of 50, yet cancers in HNPCC 
usually present in the fifth decade and often earlier. It is now appreciated, however, 
that for every macroscopically visible adenoma, there are probably numerous 
microadenomas (Jass et al. 1994). It is possible that these begin to develop relatively 
early in life, only small numbers becoming visible macroscopically. HNPCC genes 
presumably accelerate the progression of these microadenomas.
It is hypothesised, by Lynch, that these microadenomas in HNPCC are initiated on a 
sporadic basis. The mutator phenotype then develops in a small number of these, 
producing a stepwise accumulation of mutations leading to adenoma progression and 
eventually malignant change. Thus, in HNPCC, there is accelerated progression from
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colonic adenoma to carcinoma, a process theoretically driven by the inability to repair
DNA mismatches, leading to an “Aggressive Adenoma” (Lynch et al. 1995). RER
%
positive cancers, whether sporadic or associated with HNPCC, appear to show a 
molecular genetic spectrum that is distinct from common colorectal cancer or that 
developing in FAP, as APC, p53, and K-ras mutations occur with reduced frequency 
in HNPCC (Konishi et al. 1996). In sporadic RER positive cancers, there is a reduced 
frequency of p53 immunostaining (Kim et al. 1994; Bocker et al. 1996).
Three classes of genes are thus involved in colorectal carcinogenesis:-
1. Oncogenes, e.g. K-ras
2. Tumour suppressor genes e.g. APC, DCC and p53
3. Mismatch repair genes e.g. hmSH2, hMLH 1, hPMS 1 and hPMS2
These genes are involved in two basic genetic pathways which have been described 
(Baba, 1997). The Loss of Heterozygosity pathway describes the classic adenoma- 
carcinomas sequence, initiated by the inactivation of the APC gene. There are 
however controversies about the development of de novo cancer and some early 
cancers have shown the p53 mutation without the APC mutation (Aoki et al. 1994). 
The second pathway is the Mismatch Repair Pathway in which inactivation of 
mismatch repair genes causes replication errors, termed microsatellite stability, but 
there might be overlap between these two pathways.
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1.3.4 Colorectal Pathology
1.3.4.1 Anatomy of the large bowel
The large bowel comprises the terminal 1 to 1.5m of the gastrointestinal tract and is 
divided into the following regions: caecum, ascending (right) colon, transverse colon, 
descending (left) colon, sigmoid colon and rectum.
Fig 1.17 Diagram to show the anatomy of the large bowel
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ColonAppendix
Rectum
The large bowel wall is composed of four layers: mucosa, submucosa, muscularis 
propria and serosa. A brief explanation of the structure of these layers is required for 
the understanding of Dukes’ staging as referred to in this project.
1.3.4.2 Normal mucosa
The colonic mucosa is composed of a single-cell layer of columnar epithelium 
covering the luminal surface and lining the crypts, along with the lamina propria and a
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thin, underlying muscle layer, the muscularis mucosa. Numerous crypts open on to the 
colonic surface. Sections cut perpendicular to the surface show a characteristic “row 
of test tubes” appearance created by crypts in parallel alignment (see Fig 1.18).
Fig 1.18 H&E section of normal colon
colonic crypt
lamina 
propria
epithelium
Sections cut horizontally across the surface of the epithelium gives a cross-section of 
these crypts showing rings of epithelial cells (see Fig 1.19).
Fig 1.19 H&E section of normal colon
Colonic crypt
Lamina
propria
Surface epithelium
The surface epithelium is composed of absorptive cells (with basally located nuclei) 
and goblet cells, which synthesize, store and secrete mucin granules. Lymphocytes
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and occasional eosinophils may be present between the surface epithelial cells, which 
rest on a continuous thin basement membrane composed of collagen and other 
proteins. The epithelium lining the crypts comprises a more heterogeneous population 
of cells than does the surface epithelium. In addition to mature absorptive cells and 
goblet cells, immature and undifferentiated precursor cells as well as specialised 
endocrine and Paneth cells are sometimes found in the crypts. An important function 
of the colonic crypts is to renew the surface epithelium, the cells of which have finite 
lifetimes and are exfoliating constantly into the lumen or are being lost through the 
process of programmed cell death known as apoptosis (see 1.1.2.4). The base of the 
crypts is thus a proliferative zone which is defined by mitotic figures within epithelial 
precursor cells that retain the ability to divide.
Lamina Propria
The lamina propria is a connective tissue framework in which the epithelial tubules 
are embedded. It contains a wide variety of cells arranged among loosely organised 
strands of collagen. Lymphocytes are found in the lamina propria, both diffusely 
distributed and organised into lymphoid follicles.
Muscularis mucosae
This is a thin layer of muscle, which separates the mucosa (epithelium and lamina 
propria) from the deeper submucosa.
Submucosa
This is composed of collagen and reticulin fibres, blood vessels, lymphatics and 
nerves as well as small groups of ganglion cells.
Muscularis propria
This is a circular muscle layer, divided into bands of smooth muscle cells separated by 
connective tissue, including collagen and elastic fibres.
Serosa
This is a thin sheet of connective tissue containing blood vessels and lymphatics and 
covered by the peritoneum.
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Vasculature
The ascending and transverse colon are supplied by three branches of the superior 
mesenteric artery, whereas the splenic flexure, descending colon and sigmoid are 
nourished by branches of the inferior mesenteric arteiy. The arteries are accompanied, 
as components of neurovascular bundles, by veins, lymphatics and nerves. Venous 
drainage from the right and transverse colon is directed into the superior mesenteric 
vein and the left colonic drainage is into the inferior mesenteric vein. Lymphatic 
channels in the colonic mucosa are confined to the lowermost portion of the lamina 
propria and within the muscularis mucosae. For this reason, carcinomas confined to 
the colonic mucosa have essentially no metastatic potential. Lymph nodes are located 
adjacent to the colonic wall as well as along the course of the major arteries and drain 
to the superior and inferior mesenteric nodes. The lymphatic drainage from the rectum 
is complex with flow to inferior mesenteric and internal iliac nodes (Gannon, 1995).
Nerve supply
The colon and rectum are supplied by the two arms of the autonomic nervous system. 
Parasympathetic fibres are derived from the vagus and sacral spinal nerves, and their 
preganglionic fibres terminate in the myenteric plexus that lies between the two layers 
of the muscularis propria. The sympathetic supply is derived from lower thoracic and 
lumbar spinal nerves, the preganglionic fibres terminating in the superior and inferior 
mesenteric ganglia. The postganglionic sympathetic fibres terminate in either the 
myenteric plexus, which is situated in the submucosa. These two complexes form a 
network of communicating ganglia, each ganglion showing the presence of nerve 
cells, glia and nerve processes. The two complexes may have either an excitatory or 
inhibitory effect on the smooth muscle of the gut and normal peristalsis depends on 
coordination of these (Woolf, 1998).
1.3.4.3 Adenomas
An adenoma may be defined as a circumscribed focus of dysplastic epithelium. It 
usually presents as a polyp, but a small percentage may be entirely flat (see 1.3.1). 
The transition with adjacent normal mucosa is always abrupt.
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Fig 1.20 H&E stained section of a polyp
Polyp
Stalk 
Normal colon
The adenoma is regarded as a benign neoplasm for several reasons:-
1. The adenoma shows a disturbance o f growth and differentiation.
2. A series of adenomas reveals a spectrum of changes ranging from a slight 
deviation from normal through to severe dysplasia of carcinoma in situ.
3. Adenomas have an increased potential for malignant change.
4. Adenomas are likely to be monoclonal (Fearon et al. 1987).
The classification o f adenomas may be either tubular, tubulo-villous or villous, based 
on the configuration.
1.3.4.3 a Tubular adenomas
Tubular adenomas are the commonest of the three types of adenoma and resemble a 
raspberry or a miniature cauliflower. They are generally small, most have a stalk 
(pedunculated) and a minority have a broad base (sessile). Histologically, they are 
seen to consist of numerous cross-sectioned crypt profiles lined by mucus-secreting 
epithelium showing varying degrees of dysplasia.
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Fig 1.21 H&E section of a tubular adenoma showing many tubules
Tubules
epithelium
lamina propria
1.3.4.3 b Villous adenomas
Villous adenomas are often large sessile (sitting flat) polyps but may also be 
pedunculated. Some extend over a wide area as a thick carpet-like growth. 
Histologically, they consist of elongated villi in a papillary growth pattern; the villi are 
again lined by columnar epithelium showing dysplasia. The propensity for malignant 
change is much greater in villous than in tubular adenomas.
Fig 1.22 H&E section of a villous adenoma showing fronds of tissue
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lamina
propria
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adenoma
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1.3.4.3 c Tubulo-villous adenomas
Tubulo-villous adenomas may be regarded as intermediate between the tubular and 
villous adenomas in terms of their architectural configuration, size and malignant 
potential.
Fig 1.23 H&E section of a tubulo-villous adenoma showing both tubules and 
fronds of tissue.
Villous
pattern
Tubular
pattern
1.3.4.4 Adenocarcinomas
Colorectal cancers can be classified according to two types of criteria - grade and 
stage.
Tumour grade is based on the cellular and architectural characteristics of the cancer 
whereas stage is concerned with the spread of the tumour.
1.3.4.4 a Grade (also referred to as differentiation) of colorectal tumours 
Low grade carcinomas
Low grade (well-differentiated) tumours are composed of regular tubules lined by 
columnar epithelium. Nuclei are uniform in size and shape and cellular polarity is 
usually discerned with ease.
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Fig 1.24 H&E section of a well-differentiated carcinoma showing marked
tubular architecture
tubules
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Average grade carcinomas
Average grade (moderately differentiated) cases are formed of regular or slightly 
irregular tubules and cellular polarity is only just discerned or lost
Fig 1.25 H&E section of a moderately differentiated adenocarcinoma showing 
irregular glandular architecture
Irregular
tubules
Most tumours are well to moderately differentiated and the tumour cells represent a 
combination of columnar and goblet cells. It is unclear whether grading makes an 
independent contribution to survival prediction.
High grade carcinomas
High grade (poorly differentiated) tumours have tubules that are highly irregular or 
absent altogether. In place of tubules are single cells, small clumps or larger sheets of 
undifferentiated cells.
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Fig 1.26 H&E section of a poorly differentiated adenocarcinoma showing very
little glandular architecture.
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Fig 1.27 H&E section of a very poorly differentiated adenocarcinoma showing 
no gland formation.
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1.3.4.4 b Staging of colorectal carcinomas
In 1937 Dukes proposed a staging system for rectal carcinomas that also can be 
applied to carcinomas of the colon. It is still widely used because o f its direct 
relationship to prognosis.
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The Dukes’ classification of staging of a tumour is as follows:- 
Fig 1.28 Diagram of a Dukes’ A carcinoma
Tumour 
- Muscle layer 
Lymph node
Dukes A - The tumour has spread through muscularis mucosae but not beyond the 
muscularis propria, and there are no lymph node metastases.
Fig 1.29 Diagram of a Dukes’ B carcinoma
Tumour 
Muscle layer
Lymph node
Dukes B - The tumour has spread beyond the muscularis propria but without forming 
lymphatic metastases.
Fig 1.30 Diagram of a Dukes’ C carcinoma
Tumour 
Muscle layer
Lymph node
Dukes C - The tumour has spread to the lymph nodes.
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Flat carcinomas have a greater tendency for deep stromal invasion with 
lymphovascular permeation than the more common polypoid types. The most 
common sites of metastatic involvement of colorectal carcinoma are regional lymph 
nodes and liver. Lymph node metastases are more common in the tumours showing 
poorly differentiated areas and a highly infiltrative pattern of growth.
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1.4 Treatment of Breast and Colorectal cancer
Breast cancer is the most common malignant disease among women in the UK, with 
over 20,000 cases each year. It shows great clinical and biological diversity and while 
some women can be cured, others die rapidly. Colorectal cancer is common in both 
men and women. It is second only to lung cancer as the most common malignant 
disease in the UK, accounting for about 26,000 new cases and 20,000 deaths each 
year. Radical surgery is possible in about 70-80% of newly-diagnosed colorectal 
cancer patients but nevertheless two-thirds subsequently develop incurable recurrent 
disease and five-year survival has not improved much over the last few decades.
The objective of current treatments is to maximise the effects on the cancer whilst 
minimising adverse side-effects on normal tissues. If the cancer is localised then the 
first line treatment for both breast and colorectal cancer is surgery. This may be 
followed by radiotherapy. Ionising radiations such as X-rays are widely used to kill 
cancer cells. Radiation treatment is often used in conjunction with surgery often at the 
surgical margins to ensure they are free of tumour cells.
Drug therapy
Most chemotherapeutic agents block DNA replication, damage DNA, or interfere with 
chromosome segregation (Murray, 1993). Some tumour types, such as lymphomas 
and germ cell cancers, respond to treatment better than breast and colon cancers. This 
is possibly because they have a better tendency to undergo DNA damage-induced 
apoptosis following chemotherapy or radiation therapy than carcinomas. 
Chemotherapeutic drugs are ones that have a broad cell specificity because they affect 
cell processes such as DNA synthesis and cell proliferation common to all cells and 
side effects are inevitable. The DNA-damaging property of many of these drugs 
means that they are mutagens and can actually cause cancers as well as cure them.
As they arise from steroid hormone-sensitive cells, breast cancers may also be treated 
hormonally. The differentiation properties of breast cells means that steroid 
hormones, oestrogen and progesterone are required for their growth. Blocking the 
receptors on the cells that respond to these hormones can provide effective treatment 
for hormonally responsive tumours but because most cells in the body do not have 
those receptors they are unaffected by the hormone antagonists used, generating fewer
58
side-effects than chemotherapy. Not all breast cancers can be treated hormonally as 
many are steroid hormone receptor negative (see 3.4.1.2).
Several features of the cell cycle are exploited in the treatment of cancers as the 
majority of drugs for treating cancer are based on preventing DNA synthesis or 
mitosis (see Fig 1.31)
Fig 1.31 Diagram to show the phases of the cell cycle that are involved in the 
action of some of the common drugs involved in the treatment of breast and 
colorectal cancer.
Cyclophosphamide
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CorticosteroidsCyclophosphamide
Methotrexate
5-Fluorouracil
Doxorubicin
Alkylating agents 
Cyclophosphamide
Cyclophosphamide is a widely used drug and is used in the treatment of breast cancer. 
It works as an alkylating agent forming an adduct with guanine bases in the DNA 
which interrupts DNA synthesis.
Cyclophosphamide is commonly used in conjunction with methotrexate and 5- 
Fluorouracil in the treatment of breast cancer (CMF). Unlike cyclophosphamide, 
Methotrexate and 5-Fluorouracil do not work as alkylating agents but as 
antimetabolites which antagonise metabolites needed for DNA synthesis.
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Antimetabolites
Methotrexate
Methotrexate is a derivative of folic acid and competitively inhibits the enzyme 
dihydrofolate reductase that is essential for purine and pyrimidine production and 
therefore DNA synthesis.
5-Fluorouracil
5-FU is used in the treatment of both breast and colorectal cancer. It is a derivative of 
uracil that can be phosphorylated and incorporated into RNA, which is thus not 
functional. Additionally, it produces 5-fluoro-dUMP that forms an inactive tertiary 
complex with the N5,N10-methylene-FH4 and thymidylate synthase and thereby 
inhibits DNA synthesis, (see also 3.2.1.4 and 5.4.1)
Hormone antagonists
Oestrodiol is the main oestrogen in humans and is mostly synthesised in the ovary. In 
postmenopausal women, ovarian oestrodiol synthesis stops but continues at a low 
level in extraglandular sites such as fat cells and breast cancer cells themselves. 
Antioestrogens bind to the oestrogen receptor but do not activate gene transcription. 
Receptor binding by the antagonist prevents oestrodiol binding and blocks its 
mitogenic effect.
Tamoxifen
The most widely used antioestrogen is tamoxifen, a derivative of the non-steroidal 
oestrogen, diethylstilboestrol (see 3.4.1.2). Its benefit has been shown to be greater in 
women over the age of 50 (Williams, 1996).
Arimidex
The primary source of oestrogen in postmenopausal women is the extraovarian 
conversion of adrenal androstenedione to oestrone. Aromatase, concentrated mainly in 
adipose tissue, muscle and liver is the major enzyme involved in this conversion. 
Arimidex acts by inhibiting aromatase.
Progestogens
Progestogens are used largely as second- or third-line therapy in breast cancer as they 
cancel the stimulatory effect of oestrogens. Megestrol Acetate (Megace) is frequently 
used.
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Other antineoplastic drugs include Taxanes
Paclitaxel (Taxol) acts by inhibiting tubulin, a protein involved in mitosis. Because of 
cost and toxicity it is used when standard therapy has failed (Wall, 1998).
Docetaxel (taxotere) is also used as an alternative to taxol.
Clinical trials are also underway to establish the capacity of a recombinant anti-HER2 
antibody (Herceptin) to enhance the antitumour activity of other antineoplastic drugs 
such as paclitaxel, doxorubicin and cisplatin (Pegram, 1998; Baselga, 1998).
The drugs mentioned above are used routinely in the treatment of breast and colorectal 
cancers. New forms of treatment are being developed where tumour cells are targeted 
with monoclonal antibodies. These methods are based on the differential specific 
surface antigens on tumour cells relative to those on normal cells. The antibodies can 
be used to deliver either an enzyme that will activate a prodrug or a cytotoxic drug to 
cells expressing the target antigens. These methods would have the advantage of 
targeting tumour cells specifically and thus reducing toxic side effects.
1.5 The requirement for prognostic information
1.5.1 Breast Lesions
There is a great deal more to learn about cancer-associated genes in potential 
precursor lesions of the breast. Comparing the phenotypes of precursors occurring 
alone to similar lesions associated with carcinoma may help to identify abnormalities 
associated with tumour progression. These abnormalities could be targets for future 
genetic intervention or prevention therapies.
Conventional clinical and histopathological tumour characteristics provide some guide 
to risk of relapse after surgery but there is a requirement for further prognostic and 
also predictive information (seel.l). Lymph node status, size of tumour, pathological 
grade and presence or absence of vascular invasion are features used to define 
prognosis and to select patients with the poorest outlook for the most aggressive
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therapy. Clinical evidence indicates that benefit from adjuvant cytotoxic 
chemotherapy is proportionately greater for patients at lower risk (lymph node 
negative) than for those at higher risk (lymph node positive) (Early Breast Cancer 
Trialists' Collaborative Group., 1992). Recent guidelines on use of tissue tumour 
markers in the management of patients with breast cancer recommended the 
measurement of only oestrogen receptors and progesterone receptors as useful 
markers. They were recommended to be used to identify patients most likely to benefit 
from endocrine forms of adjuvant therapy and therapy for metastatic disease, but not 
to be used alone to assign a patient to prognostic groupings (American Society of 
Clinical Oncology, 1998). ER is the target of most widely used treatments and 
measurement of ER has been clinical practice in many centres for over 20 years. 
Immunohistochemical measurement is a fairly recent option, however, and its value is 
still being assessed. Oestrogen is the most important mitogen for ER-positive breast 
carcinomas but of little or no significance for those in which ER is absent or non­
functional. Currently there are no proven criteria for selection of conventional 
chemotherapy regimens with tumour markers.
1.5.2 Colorectal lesions
There are clinical problems associated with the assessment of the potential 
aggressiveness of adenomas. There are at present no clear guidelines for follow up of 
patients who have presented with adenomas.
Prognosis of colorectal cancer correlates well with stage and grade. Many tumours, 
however, present at a late stage or high grade, and the patient’s prognosis is 
consequently poor. There is potential for more accurate prediction of prognosis and 
tailoring of treatment to an individual tumour. Recent guidelines, on use of tissue 
tumour markers in the management of patients with colorectal cancer, found 
insufficient evidence to recommend the use of any tumour marker for the prevention, 
screening, treatment or surveillance of colorectal cancer (American Society of Clinical 
Oncology, 1998).
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1.6 Aims of the Studies
1.6.1 Breast Studies
The aims of the three studies of breast cancer that are described in this thesis were:
Project 1 To provide baseline information on the patterns of 
immimostaining with the antibodies MIB1 (a marker of cell proliferation), 
CD44 (a marker of metastatic potential), ER (a marker of hormone 
sensitivity) and D5 (the ER related heat shock protein 27).
Project 2 To use the data obtained in the first project to investigate the 
biology of a number of breast lesions of clinical interest. The lesions 
studied ranged from benign papillomas and hyperplasias to fully invasive 
carcinomas and included lesions of doubtful prognosis such as radial scars.
Project 3 To use the data obtained to investigate a specific clinical 
problem found with grade 1 ductal carcinomas. Most of these types of 
tumour are lymph node negative but some of these carcinomas, even 
though they are low grade carcinomas, have already metastasised to lymph 
nodes in the axilla at time of surgery. Two groups of patients were studied, 
a lymph node negative group and a lymph node positive group. The 
staining characteristics of three antibodies, which were selected on the 
basis of data obtained in the previous studies, were investigated to see 
whether they could be related to the metastatic potential of these tumours.
1.6.2 Colorectal Studies
The aims of the three studies of colorectal carcinoma described in this thesis were:
Project 1 To characterise the staining of adenomas and carcinomas, with 
a range of antibodies, over a wide range of pathology, with respect to 
dysplasia in adenomas and grading and staging in carcinomas. The 
antibodies chosen were potential markers of cell proliferation (MIB1), 
tumour progression and possibly resistance to a particular 
chemotherapeutic regimen (p53) and metastatic potential (CD44).
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Project 2 To use the data obtained in the above study as a basis for the 
study of a specific clinical problem found with Dukes’ B carcinomas. As 
the recurrence of tumour in patients with this group of colorectal 
carcinomas is not always predictable, a study of two groups of patients, 
one with recurrence and the other with no recurrence of their tumours was 
made.
Project 3 To investigate a different, but similar, clinical problem which is 
found in patients with Dukes’ C carcinomas. Dukes’ C patients vary in 
their response to adjuvant therapy. Survival in some patients is surprisingly 
good; some have local recurrence and some distant recurrence of their 
tumour. Using the data on the staining pattern of the same three antibodies 
from the earlier projects, these three groups of patients were studied to see 
whether any differences in staining patterns between the groups existed 
and whether this could be related to the biological behaviour of the tumour.
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CHAPTER 2 MATERIALS AND METHODS
2.1 Selection of specimens
The availability of archive material, in the form of paraffin blocks, of both colorectal 
and breast tissue enabled a large number of cases to be investigated retrospectively in 
these projects. Relevant clinical information was obtained from the departments of 
breast and colorectal surgery.
2.2 Immunocytochemistry
Immunocytochemistry is the demonstration of antigens in tissue sections or smears by 
use of specific antigen-antibody interactions, the term immunohistochemistry being 
used specifically for tissue sections.
The reaction between an antibody and an epitope does not involve covalent forces; it 
involves weak forces of interaction such as electrostatic, hydrophobic, and Van der 
Waals forces. Consequently, for a significant interaction, the antibody combining site 
and the epitope require a close steric fit like a lock and key.
Immunohistochemical detection of an antigen will be influenced by many variables. 
These include absolute level of the antigen, affinity of the antibody, concentration of 
the antibody, duration of incubations, sensitivity of the detection system, and the 
consequences of fixation. The signal strength given in an immunohistological assay is 
not linear with the antibody concentration (nor with any other variable) and with a 
given set of conditions there will be a specific threshold below which no signal is 
obtained. If conditions are changed and the threshold for detection altered, such as by 
using antigen retrieval techniques or by changing the antibody concentration or 
incubation time, then relationships between staining intensity and neoplasia that had 
previously been observed could be lost. It is thus essential to ensure that assay 
conditions are consistent both within an individual laboratory and with comparative 
work from other groups of researchers.
There were many advantages of using immunocytochemistry as the method of choice 
when looking for prognostic markers in tumours. Alternative possible methods of 
looking for changes present in tumour cells include Enzyme Linked ImmunoSorbent
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Assays (ELISAs) for the detection of proteins or reverse transcription polymerase 
chain reaction (RT-PCR). ELISA is a solid-phase immunoassay in which an enzyme 
is linked to the anti-immunoglobulin. Quantification of enzyme-linked anti­
immunoglobulins is achieved by colourimetric evaluation, after the addition of a 
substrate, which changes colour on the action of the enzyme. RT-PCR is a very 
sensitive method of detecting changes in gene expression in tumour cells. It may be 
able to detect changes where immunocytochemistry is not sufficiently sensitive or 
where the antigen is masked, by fixation for example, and cannot be bound by the 
antibody, giving false negative results. For the study of surgical specimens the 
samples are solid pieces of tumour tissue rather than cultured cells. For this type of 
sample, neither the ELISA nor the RT-PCR methods are able to distinguish whether 
low expression of an antigen is due to low expression on the tumour cells or to the 
presence in the sample of low numbers of tumour cells. The marker in question may 
also be present in normal tissue present in the sample. Immunohistochemistry can 
clearly identify the morphology of the specimen and thus which cells are staining 
positively. Immunohistochemistry demonstrates real epitope in the cell, while RT- 
PCR can only detect mRNA transcripts with unknown translational effects within the 
cell. The most important reason for choosing this method of study, however, is that 
immunohistochemistry is the quicker and more reproducible method and is easier to 
handle with a large number of specimens. This would also make it the method of 
choice as a valuable clinical tool.
2.2.1 Monoclonal Antibodies
The production of antibodies by animal immunisation is well known and useful but 
the response by an individual animal is unpredictable. The antiserum raised is 
polyclonal because the immunising antigen, which usually has many epitopes, leads to 
production of antiserum that contains a mixture of antibodies with varying specificity 
for all the epitopes. Even antibodies to a single epitope are usually mixtures of 
immunoglobulins with different fine specificities, and therefore different affinities for 
the determinant. In 1975 the resolution and discriminating power of antibodies was 
provided by Milstein and Kohler (Kohler and Milstein, 1975) with the development of 
methods for the generation of monoclonal antibodies. Monoclonal antibodies are 
homogeneous populations of antibody molecules, derived from a single antibody-
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producing cell, in which all antibodies are identical and of the same precise specificity 
for a given epitope. Milstein and Kohler (Kohler and Milstein, 1975) took advantage 
of the properties of malignant plasma cells, which are “immortal” and can be 
maintained in culture for years. They selected a population of malignant plasma cells 
unable to secrete immunoglobulin and also deficient in the enzyme hypoxanthine 
guanine phosphoribosyl transferase (HGPRT) that would die unless HGPRT were 
introduced. The malignant cells were then fused with antibody-producing cells, which 
have HGPRT.
The fusion is generally accomplished by the use of polyethylene glycol or by 
inactivated Sendai virus. The nuclei of the hybrids also fuse, and the hybridoma cells 
then possess both the capacity to secrete immunoglobulins and the ability to survive in 
culture in a select medium such as that containing hypoxanthine, aminopterin, and 
thymidine (HAT). The enzyme deficiency of the malignant cell results in its death in 
this medium unless that deficiency is corrected by the acquisition of the enzyme- 
producing cell. Thus, the hybrids can be separated from the contaminating malignant 
cells, which do not survive, because they have not acquired the enzyme.
Those hybrid cells synthesising specific antibody are selected by some test for antigen 
reactivity and then cloned from single cells and propagated in tissue culture, each 
clone synthesising antibodies of a single specificity. These highly specific, 
monoclonal antibodies are used as reagents for immunocytochemistry. Occasionally, 
however, there is cross reactivity where an antibody raised against a given antigen can 
cross react with a partially related antigen that bears one or more identical or similar 
determinants. This results in unexpected binding to molecules which react poorly, if at 
all, with a specific antiserum directed to the original antigen. Polyclonal antibodies 
also bind determinants other than the specific antigen, which results in lower 
alternative specificity. Another problem encountered with monoclonal antibodies is 
that the antigen is often masked by formalin fixation of the tissue (see 2.2.4 for 
antigen retrieval techniques). It is also possible that the epitope recognised by an 
antibody could be altered in a defective protein expressed by a tumour cell so that the 
antibody may not always recognise this protein. The monoclonal antibodies used in 
these projects are discussed in chapter 3.
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2.2.2 Tissue sections
The advantages of using sections of paraffin wax embedded specimens are many:-
1. The morphology of the specimen is retained. This means that the tumour cells 
are more easily identified.
2. Different types of pathology can be seen and compared within one section.
3. Archive specimens can be used.
4. Serial sections can be used for different antibodies.
5. Serial sections can be used to duplicate staining procedures for control 
purposes.
6. Serial sections can be used as negative controls.
There are also a few disadvantages >
1. The fixation of the tissue in formalin, which is a necessary part of the method 
of processing the tissue, masks some antigens. As a result not all antibodies 
that give positive results on fresh tissue will give positive results on fixed 
tissue.
2. In general, it is not possible to obtain a specimen for diagnosis without 
intrusive surgery, although core biopsies of some tumours can be taken.
2.2.3 Preparation of paraffin sections.
2.2.3.1 Fixation
Fixation is necessary to prevent the decay of the tissue. It arrests the enzyme actions 
within the tissue which cause autolysis and stabilises labile elements so that they 
remain unaffected by organic solvents and wax embedding during processing. If tissue 
is autolysed (self-destroyed due to the proteolytic enzymes released from lysosomes), 
then no nuclei or structural detail of cells can be seen. Using an isotonic solution 
prevents shrinkage of the tissue. Formal saline is the fixative of choice and is made 
up as follows
Formalin (40% HCHO (formaldehyde) in solution) 100ml
Sodium Chloride 9gm
Tap water 900ml
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Formal saline forms additive compounds with proteins without precipitation of the 
proteins, thus preserving the morphology of the specimen. It is important that 
specimens are fixed quickly so thin slices of tumour must be used to allow rapid 
penetration of the fixative through the specimen. Following surgical resection, 
specimens are placed in 10% Formal Saline in a well sealed container and transported 
from theatre to the histopathology laboratory. The whole specimen is dissected by a 
medical officer and a sample of tumour is placed in a numbered cassette. The whole 
cassette is then placed in a pot of 10% formal saline to await processing.
It is also important that all tissues are well fixed before processing and it is often 
necessary, due to the large amount of fatty tissue present in both gut and breast tissue, 
to leave the specimen to fix for 24 hours before the next stage of processing. In 
practice fixation is difficult to control. The time taken before the specimens are placed 
in formal saline, following surgical resection in theatre, is variable. Also large fatty 
specimens, such as gut and breast will have the outside of the specimen covered in 
fixative but the inner part of the specimen will not be fixed until the specimen has 
been cut into smaller pieces. This is not done until the pathologist is ready to examine 
the macroscopic appearance of the specimen. Some antigens, in particular the 
oestrogen receptor, are unstable and their antigenicity is destroyed if the specimen is 
not promptly fixed.
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2 ,2 3 2  Tissue Processing
The blocks of tissue were routinely processed, after fixation, using a Leica TP 1050 
enclosed tissue processor. The programme is as follows >
Reagent Time Temp
Formal Saline 45min 40°C
Alcohol(IMS99) 30min 32°C
IMS99 45min 32°C
IMS99 lhr 32°C
IMS99 lhr 32°C
IMS99 lhr 32°C
IMS99 lhr 32°C
Xylene lhr 32°C
Xylene 45min 32°C
Xylene lhr 32°C
Wax 2hr 60°C
Wax lhr 15min 60°C
Wax lhr 30min 60°C
The tissue specimens are removed from the processor and embedded in paraffin wax. 
They are left to cool and 3 p. sections are cut using a microtome. The sections are 
floated on a water bath and picked up on APES slides. The slides on to which the 
sections are floated are dried either at 37°C overnight or at room temperature for 48 
hours. High drying temperatures can reduce the immunoreactivity of the antigens.
Some antigens, such as p53, seem to be stable once the specimen is embedded in 
paraffin wax, but once sections are cut and the slides stored before using for staining 
then antigenicity is lost (see also 3.2,4). A study on the loss of staining intensity for 
various tumour markers after storage of breast carcinoma slides at room temperature 
for 12 weeks showed considerable loss of staining for both p53 and ER over those 
stained at Day 0 (Shi et al. 1995).
2.2.3.3 Preparation of APES slides
Microwaving the tissue sections is a necessary part of the antigen retrieval process and 
sections that are picked up on ordinary slides tend to float away during this process.
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To prevent this occurring the slides are first coated with 3-aminopropyltriethoxysilane 
(APES) as follows
1. Dilute APES 1:50 in acetone.
2. Place clean slides in the diluted solution for 20 seconds.
3. Wash twice in acetone.
4. Wash twice in distilled water.
5. Dry slides at room temperature for 48 hours.
2.2.4 Antigen retrieval
As mentioned above, histology specimens are routinely fixed in formal saline 
solution, which results in the masking of the epitopes with which some of the 
antibodies bind. The restoration of immunoreactivity of tissue antigens can in some 
cases be restored by protease digestion (Cattoretti, 1993). This is consistent with the 
idea that aldehyde fixation reduces accessibility of antibodies to their epitopes by 
cross-linking proteins. It is thought to be due to the formation of methylene bridges 
between reactive sites on different portions of the same molecule or of adjacent 
proteins (Mason and O'Leary, 1991). Antigen retrieval, incorporating high- 
temperature microwave heating of tissue sections before immunostaining, is a 
technique that can unmask the antigens in formalin-fixed tissue sections, thus making 
them available for immunohistochemical staining (Cattoretti, 1993). For some 
antibodies, the threshold for detection of the antigen is lowered by antigen retrieval. 
One study found a fivefold increase in the number of epidermal cells that showed p53 
positivity after antigen retrieval (McKee et al. 1993).
Although high temperature is believed to be the primary mechanism in retrieval of 
antigens, a variety of chemical solutions have been tested to define an optimal antigen 
retrieval solution. For example, Shi et al. (1995) tested a range of antigen retrieval 
buffer solutions at a series of different pH values. They found that the nuclear antigens 
MEB1 and ER showed strong intensity of immunohistochemical staining at very low 
pH and at neutral to high pH, but found a dramatic decrease in the intensity of the 
staining at moderately acidic pH (pH 3-6).
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Several variations of methods of immersing the sections, of pH of the buffer solution 
and of length of time for microwaving were investigated. It was found to be essential, 
particularly for the ER antigen retrieval, to adjust the pH of the citrate buffer to 6.0 
immediately before use.
The method of retrieval which gave good results in our laboratory and was used 
throughout these projects was as follows:-
Stock solutions
A: 0.1M solution of citric acid -  21.01 gm CeHgCb.^O in 1000ml H2O 
B: 0.1M solution of sodium citrate -  29.41 gm C6Hs0 7 Na3 .2 H2 0  in 1000ml H2O
Working solution
9ml of A + 41ml of B, diluted to a total of 500ml.
The slides were immersed in this solution and then processed in the microwave for a 
total time of 25 minutes at 750W. They were checked after 15 minutes to make sure 
that they were still totally immersed in the solution as it important that they do not dry 
out during the microwaving process. To avoid bubble trapping between the slides, at 
least 4mm was left between the slides. The sections were then left to cool in the 
solution for at least 20 minutes.
2.2.5 Selection of Staining Methods
Many combinations of staining methods were possible and initially several methods of 
staining were investigated. The two-step indirect method was tried but the three-step 
avidin-biotin method was much more sensitive and became the method of choice. For 
these studies all the primary antibodies used were mouse monoclonal antibodies. As 
the secondary antibody must be directed against the primary antibody, the secondary 
antibody that was used was raised in rabbit, directed against mouse immunoglobulins. 
This antibody was also biotinylated so that it would react with the avidin-biotin 
complex. This then determined that the serum used for blocking non-specific reactions 
needed to be rabbit serum.
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Enzyme label
Two different enzyme labels were tested - alkaline phosphatase and horseradish 
peroxidase. Horseradish peroxidase was selected mainly so that DAB could be the 
chromogen used (see below). Peroxidase has an iron-containing heme group (hematin) 
as its active site. The hematin of peroxidase first forms a complex with hydrogen 
peroxide and then causes it to decompose resulting in water and atomic oxygen. There 
are several electron donors which, upon being oxidised, become coloured products 
and are therefore called chromogens. This, and the property of becoming insoluble 
upon oxidation, make such electron donors useful in immunohistochemistry.
Chromogen
The most widely used chromogen for the immunohistochemical methods utilising 
horseradish peroxidase is 3,3 'diaminobenzidine (DAB) which produces a brown 
reaction product. This reaction product is highly insoluble in alcohol and other organic 
solvents enabling the slides to be dehydrated in alcohol and cleared in xylene before 
mounting in DPX.
Another chromogen tested was 3-amino-9-ethylcarbazole (AEC). Upon oxidation 
AEC forms a rose-red end product. This product, however, is alcohol soluble. Thus 
specimens processed with AEC must not be immersed in alcohol and so an aqueous 
counterstain and mounting medium must be used. The colour also tends to fade with 
time. For specimens containing melanin where the DAB reaction product is not 
clearly distinguishable from the pigment this may be a useful chromogen.
The alkaline phosphate chromogen tested was New Fuchsin. The method, however, 
was laborious and the red end product did not show up very clearly. For these 
projects, which used breast and gut tissue, DAB was the chromogen of choice.
Some cells contain endogenous peroxidase. Similar to other enzymes, peroxidase 
activities can be inhibited by excess substrate. The complex formed between 
peroxidase and excess hydrogen peroxide is catalytically inactive and in the absence 
of an electron donor (e.g. a chromogenic substance) is reversibly inhibited. To 
suppress any endogenous peroxidase activity the sections are incubated in 3% H2O2 
for 10 minutes before the start of the staining procedure.
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Counterstain
A counterstain is necessary to stain the cell nuclei so that the morphology of the 
specimen can be defined. Mayer’s haemalum was selected as a counterstain as it stains 
the nuclei blue with good intra-nuclear detail, giving a good contrast with the brown 
DAB product. “Blueing” in alkaline tap water or Scott’s tapwater substitute, which is 
tap water with sodium bicarbonate and magnesium sulphate added to make it alkaline, 
is necessary to bring about the desired blue colour. The blue colour is stable in water, 
ethanol and xylene, making normal histological dehydrating, clearing and mounting 
procedures possible.
The overall method that was selected was the Dako Avidin-biotin /Horseradish 
peroxidase method, using DAB as chromogen and Mayer’s Haemalum as 
counterstain. This was a well-tried detection system and gave consistent results when 
staining procedures were repeated. Other more sensitive methods, such as methods 
using streptavidin were tested as they became available but the same detection system 
was used throughout these projects so that staining intensities could be compared with 
those from earlier projects.
Fig 2.1 Diagram to summarise the Dako Avidin-biotin /Horseradish peroxidase 
method of immunohistochemical staining.
Rabbit a  mouse 
secondary antibody
Mouse primary 
antibody
Peroxidase
enzyme
Avidin
Biotin
Antigen
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2.2.5.1 Preparation of solutions
Citrate buffer pH 6.0 was prepared as follows:- 
Stock Solutions:
A: 0.1M solution of citric acid (21.01gm C6H8O7.H2O in 1000ml distilled water).
B: 0.1 M solution of sodium citrate ( 29.41gm 0 ^ 5 0 7 ^ 3.2 H2O in 1000ml distilled 
water).
Working solution
9ml of A + 41ml of B, diluted to a total of 500ml.
It was adjusted to pH 6.0 before use.
Tris Buffered Saline pH 7.6 was prepared as follows:-
40.5 gm Sodium Chloride NaCl.
3.00gm Tris(hydroxy-methyl)methyl-amine NH2.C.(CH2.0H)3.
19ml IN Hydrochloric acid HC1.
5000ml distilled water.
It was adjusted to pH 7.6 before use.
Citrate buffer pH 6.4 was prepared as follows :- 
Stock Solutions:
A: 0.2 M solution of disodium hydrogen orthophosphate (14.15gm Na2HPC>4 in 
1000ml distilled water).
B: 0.1M solution of citric acid (10.5gm C6H8O7.H2O in 500ml distilled water). 
Working solution:
66ml A + 33ml B 
It was adjusted to pH 6.4 before use
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Avidin-biotin / Horseradish peroxidase complex was prepared from a Dako kit as 
follows:-
1 drop A
1 dropB
5ml Tris buffered saline pH7.6 
This was prepared at least 30mins before use and was then stable for three days.
2.2.5.2 Dewaxing slides
Slides were placed in a staining rack and were immersed in>
1. Citroclear (1) for 5 mins
2. Citroclear (2) for 5 mins
3. Alcohol (Industrial Methylated Spirit) (1) for approx. 1 min
4. Alcohol (Industrial Methylated Spirit) (2) for approx. 1 min
5. Alcohol (Industrial Methylated Spirit) (3) for approx. 1 min
They were rinsed in tap water and the rack was placed in a pot of distilled water.
2.2.5.3 Antigen Retrieval
The slides were placed in either a plastic slide rack or in plastic slide boxes leaving at 
least one space between slides to prevent trapping of air bubbles.
They were:-
1. immersed in citrate buffer pH 6.0 in microwave dish.
2. microwaved for lOmins on full power.
3. checked for air bubbles and topped up with hot distilled water to replace any 
that had evaporated.
4. microwaved for a further 8 minutes.
5. left to cool in the buffer for at least 30 minutes.
76
2.2.5.4 Blocking of endogenous peroxidase
The slides were placed back in the staining rack and rinsed in distilled water.
They were:
1. transferred to Tris buffer (pH 7.6) for 5 minutes.
2. rinsed in distilled water.
3. incubated for 5 minutes with 3% Hydrogen Peroxide in distilled water. (BDH 
H2O2 was diluted 1:10 - 270ml distilled water and 30ml H2O2 added).
4. rinsed with distilled water and placed in Tris buffer for 5 minutes.
2.2.5.5 Staining Procedure
1. The sections were incubated with normal rabbit serum diluted 1:5 in Tris 
buffer for 20 minutes to block nonspecific background.
2. The serum was drained off and the excess wiped away.
They were:-
1. incubated with a Mouse antibody optimally diluted in Tris buffer for 30 
minutes.
2. rinsed with Tris buffer and placed in Tris buffer bath for 5 minutes.
3. incubated with biotinylated rabbit anti-mouse immunoglobulin optimally 
diluted in Tris buffer for 30 minutes.
4. rinsed in Tris buffer and placed in Tris buffer bath for 5 minutes.
5. incubated with horse radish peroxidase labelled Avidin-Biotin complex for 30 
minutes.
6. rinsed with Tris buffer and place in Tris buffer bath for 5 minutes.
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2.2.5.6 Substrate-Chromogen Reagents
1. 36mg DAB was dissolved in 60 ml citrate buffer pH6.4.
2. 0.6ml 3% H2O2 (BDH H2O2 diluted linlO) was added.
3. The solution was placed in a coplin jar and the slides added.
4. They were incubated for 2-5 mins.
5. They were rinsed with distilled water.
Solutions were made up and used under a fume hood. Care was taken to wear gloves 
and not inhale dust. The fan was switched on after making up the solution.
2.2.5.7 Counterstain
The sections were then:-
1. counterstained in Mayer’s Haemalum for 1 -4 mins.
2. rinsed in tap water and “blued” in Scotts.
The sections were then:-
1. dehydrated with 3 alcohol rinses,
2. cleared with 2 citroclear rinses
3. mounted from xylene in DPX.
2.2.5.8 Antibodies
All the antibodies were supplied as concentrates and required dilution. All were 
diluted in Tris buffer pH 7.6 (see 2.2.5.1).
Prim ary antibodies
The primary antibodies used in these projects were obtained from a variety of sources.
Serial dilutions of all the primary antibodies were performed and tested for optimum 
concentration. If the antibody was too concentrated then there was too much 
background staining and if the concentration was too weak then the antigen could not
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be detected at all. The source of the primary antibodies used in these projects and the 
optimum dilutions that were determined for each antibody are shown below.
MIB1 (Supplied by Immunotech - 200pg/ml) 1 in 100
CD44H (Supplied by Cymbus Biotechnology -100 jug/ml) 1 in 200
CD44v3 (Donation from Dr D Simmons, Cell Adhesion 1 in 200
Laboratory, Institute of Molecular Medicine, Oxford - 
1 mg/ml)
CD44v6 (Donation from Dr D Simmons, Cell Adhesion 1 in 200
Laboratory, Institute of Molecular Medicine, Oxford -  
1 mg/ml)
p53 (PAbl801) (Donation from ICRF - 1360jag/ml) 1 in 1000
ER (ID5) (Supplied by Dako - 280jLig/ml) 1 in 50
D5 (HSP 27) (Donation from ICRF - 150pg/ml) 1 in 300
(see chapter 3 for detail about antibodies used).
Secondary antibody
The secondary antibody used was Biotinylated Rabbit Anti-Mouse Immunoglobulins 
(supplied by Dako -1100 pg/ml)
The dilution used was as per manufacturer’s recommendation 1 in 200
2.2.5.9 Control sections.
Positive control sections were included in each batch of staining for both p53 and ER 
staining. When control sections that had been cut several weeks previously were 
stained alongside freshly cut sections from the same block, it was found that staining 
intensity was weaker in the older sections and this was particularly true for p53 
controls (see 2.2.3.2). Control sections were therefore freshly cut at the same time as 
the sections of tumour being stained. As the sections were batch stained a number of 
sections showed positivity within each batch, providing further positive controls. Two 
positive controls, one which stained strongly and one which showed weak staining 
were always included. Sections of breast carcinomas which had been shown 
previously to stain positively for the appropriate antibody were included when breast 
lesions were stained and, likewise positive colon carcinoma for the staining of 
colorectal lesions. Negative controls, where Tris buffer alone, without the addition of 
the primary antibody that was used for the first incubation, were also included. The 
heterogeneity of the cells in the lesions studied meant that, even in sections that
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stained positively with a particular antibody, there were many cells that were negative 
for the immunostaining. This provided an internal negative control for each section, 
showing that the staining was not blanket artifactual staining across the section.
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2.3 Selection of Statistical Methods
2.3.1 Means, standard deviation and standard error
2.3.1.1 The Mean value
The mean is a measure of the average value of the data. It is found by taking the sum 
of the observations and dividing by their number.
2.3.1.2 The Standard Deviation
Apart from the mean a measure of the dispersion of the data is also required. If the 
data are widely scattered, many of the observations will be far from the mean and so 
many deviations (the difference between the value of a particular observation and the 
mean value of all the observations) will be large. If the data are narrowly scattered, 
very few observations will be far from the mean and so few deviations will be large. 
To measure the scatter, some kind of average deviation is needed. The standard 
deviation is used as a measure of the dispersion of the data.
2.3.1.3 The Standard Error
The samples of patients used in these studies were drawn from a much larger 
population of patients with breast or colorectal cancer. Data were collected from these 
samples so that we could learn about the population as a whole. If measurements had 
been obtained from an entire population, the results would have described the 
population exactly. In these projects information was obtained from a random sample 
and the results served as estimates of the unknown population values.
The sample mean is an estimate of the population mean. The means obtained from 
different samples taken from a given population would also show some variability and 
would themselves form a normal distribution. The standard deviation of this sampling 
distribution is called the standard error and it provides a measure of how far from the 
true value the estimate is likely to be.
The standard error of the mean depends on both the sample standard deviation and the 
sample size. For a fixed standard deviation, as the size of a sample increases, the 
standard error decreases. This is because the more data are gathered, the more 
confident you can be that the sample mean is not too far from the population mean.
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Also, as the standard deviation of the observations decreases, the standard error 
decreases as well. Small standard deviations occur when observations are fairly 
homogeneous.
Thus standard deviation is a measure of how much observations vary from the mean 
and the standard error of the mean is a measure of variability of the sample mean.
2.3.2 Statistical tests
As shown in the graphs showing the distribution of staining scores in chapters 4 and 5 
the data collected in these projects did not have a normal distribution so that non- 
parametric tests were used. Two methods were used to assess the variations in staining 
with the chosen antibodies over the range of pathology studied.
2.3.2.1 Mann-Whitney l/Test
The Mann-Whitney U Test is a non-parametric equivalent of the two-sample t test. 
The advantage over the t test is that the only assumption about the distribution of the 
data is that the observations can be ranked, whereas for the t test one must assume the 
data are from Normal Distributions with uniform variance. There are disadvantages. 
For data which are Normally distributed, the U test is less powerful than the t test, i.e. 
the t test, when valid, can detect smaller differences for given sample size. However 
the U test is almost as powerful for moderate and large sample sizes, and usually this 
difference is not important. The U  test gives no idea of the size of the difference. It is 
purely a test of significance.
The Mann-Whitney U is a measure of the rank order of the scores of the two groups 
that are being compared. If U  is very small then nearly all the scores from the first 
group are less than those from the second group. If U is very large then the scores 
from the second group are nearly all less than those from the first group. Moderate 
values of U mean that the rank orders of scores from the two groups are closely 
mixed. The null hypothesis states that the samples come from the same population and 
so the p (significance) value states with what probability these data could have arisen 
if there were no difference.
Conventionally it is said that differences are significant if the probability is less than
0.05.
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23 .2.2 Spearman Correlation Coefficient
Correlations measure the linear relationship between two quantitative variables. The 
correlation coefficient quantifies the strength of the linear relationship between two 
variables. The correlation coefficient rages in value from -1 to +1. A value of 0 
indicates no linear relationship between the two variables. A value of +1 indicates a 
perfect positive relationship (as the values of one variable increase, the values of the 
other also increase). A value of -1  indicates a perfect negative relationship (as the 
values of one variable increase, the values of the other decrease).
The Spearman Correlation Coefficient is a nonparametric measure that is useful when 
the distribution of the data is non-normal. It can be used with rank-order data (ordinal 
data with cases ranked from the lowest to the highest.
Using this test it is possible to assess whether loss or gain of one antigen (either 
nuclear, cytoplasmic or membranous) follows the same pattern of loss or gain as 
another antibody.
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CHAPTER 3 ANTIBODIES
3.1 MIB1
3.1.1 Background
Proliferation rate describes the speed at which cells are reproducing. In a histological 
section the cell population is static so that the term proliferation index would perhaps 
be more accurate. Cell proliferation is of interest since abnormal cell proliferation 
appears to be a precursor of tumourigenesis and also because the quantitative 
description of cell proliferation in tumours can be used to predict the biological 
behaviour of a particular neoplasia. Tumours with a high percentage of MIB1 positive 
tumour cells (>40%) have been shown to be correlated with tumour responsiveness to 
primary chemotherapy (MacGrogan et al. 1996).
3.1.1.1 Mitotic activity index.
One way of measuring proliferation is the mitotic rate, which is calculated as the 
number of mitoses per 1000 cells. The traditional way of measuring proliferative 
activity is the mitotic activity index. It is assessed microscopically as the number of 
mitotic figures per high power field, with the mean number of mitoses from 10 
consecutive high power fields in the most cellular area of the tumour being measured. 
This method does not take into account differences in cellularity or cell size from one 
tumour to another. Also delays in fixation of tissue and the type of fixative used 
affects the appearance of mitotic figures (Cross et al. 1990; Cooper et al. 1992).
3.1.1.2 Thymidine labelling index
A second method of measuring proliferative activity is the thymidine labelling index. 
The uptake of tritiated thymidine during DNA synthesis is measured. The 
disadvantage of this method, apart from it being slow and imprecise, is that a small 
and possibly unrepresentative piece of tissue is used that must be absolutely fresh 
(Lambert, 1986).
3.1.1.3 Bromodeoxyuridine labelling
Bromodeoxyuridine labelling can also be used instead of thymidine. BrdU is a 
thymidine analogue incorporated during the S phase of the cell cycle and antibodies
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against BrdU remove the need for autoradiography, but again only fresh tissue can be 
used (Meyer et al. 1989).
3.1.1.4 Immunohistochemical methods
KiSl
The KiSl antibody recognises a cell associated antigen which is expressed at 
increasing levels during DNA synthesis and reaches a peak in mitosis.
Ki67
The first immunohistochemical method of measuring proliferation used the Ki67 
antibody (Gerdes et al. 1983), but again fresh tissue was necessary. The function of 
this Ki67 antigen is unknown but reaction with this antibody serves as an indicator of 
the growth fraction, i.e. the number of cells undergoing active division. Enzymatic 
digestion experiments showed that this antigen is highly susceptible to protease 
treatment, and the antigen cannot be extracted by 0.1N HC1, indicating that Ki67 is a 
non-histone protein (Gerdes and Li, 1991). Ki67 antigen-specific antisense 
oligonucleotides were shown to inhibit the proliferation of IM-9 cell line cells, 
indicating that the Ki67 antigen may be an absolute requirement for maintaining cell 
proliferation (Schluter et al. 1993). The gene encoding the Ki67 protein has been 
cloned and sequenced. It is organised in 15 exons and is localised on chromosome 10 
(Duchrow et al. 1995; Duchrow et al. 1996).
MIB-1
MIB-1 recognises a 66 base pair repeat element in the Ki67 nuclear antigen expressed 
on all proliferating cells during late G l, S, M, and G2 phases of the cell cycle. This 
part of the Ki-67 antigen recognised by MIB1 survives the fixation process and this 
can be retrieved using the microwave antigen retrieval technique (Cattoretti et al.
1992) (see 2.2.4 and 3.1.2). This means that proliferation can be assessed on archive 
material, giving MIB1 a considerable advantage over other methods of assessing 
proliferative activity. MIB1 has been shown to correlate well with proliferative 
activity evaluated by BrdU in breast cancer, but not with PCNA (Moriki et al. 1996). 
It has also been shown to show a coincidental nuclear staining pattern with that of 
Ki67 on frozen tissue although the labelling index of MIB1 was higher than that of 
Ki67. This could have been due to better survival of the MIB1 epitope in freezing and 
acetone fixation or to differing accessibilities of the MIB1 and Ki67 epitopes during
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the cell cycle due to molecular conformational modifications. The MIB1 labelling 
index of the microwaved paraffin sections was strongly correlated to that of the MIB1 
labelling index of the frozen sections (Barbareschi et al. 1994). Another study, using 
colorectal biopsy specimens, showed a correlation between MIB1 and Ki67 staining 
but found that PCNA antibodies additionally stained cells outside the proliferative 
compartment so that a reliable assessment of cell proliferation was only possible after 
controlled paraformaldehyde or methacam fixation (Diebold et al. 1994). MIB-1 is 
now generally regarded as the best proliferation marker in conventional histological 
preparations (Bames, 1995; Rose et al. 1994).
Proliferating cell nuclear antigen
Proliferating cell nuclear antigen (PCNA) can be used on paraffin wax embedded 
material but conflicting data is found when measuring proliferation because PCNA is 
involved both in cell replication and DNA repair (McCormick and Hall, 1992). 
Expression of PCNA appears to correlate poorly with Ki67 expression in breast 
tumours and not with mitotic count (Sullivan et al. 1993) and therefore its usefulness 
as a marker of proliferative activity appears to be limited. PCNA can also be induced 
by growth factors in normal and benign cells that are in the vicinity of a malignant 
lesion (Gilett et al. 1993). Hence more cells are labelled than are actually 
proliferating.
3.1.2 Antigen retrieval
Antigen retrieval for the MIB1 antigen was as previously described (see 2.2.4), using 
the technique of microwaving at 750 watts for 25 minutes in pH 6.0 citrate buffer.
3.1.3 Antibody dilution
The relevance of antibody concentration to the immunohistological quantification of 
cell proliferation-associated antigens has been studied (McCormick et al. 1993). They 
found that with both PC 10 (anti-proliferating cell nuclear antigen -  PCNA) and Ki-Sl 
antibodies the number of stained cells increased with decreasing antibody dilution 
with no plateau being identified. In contrast, MIB1 showed a clear plateau. 
Immunocytological data indicate that PCNA and Ki-Sl antigen are present at low (but
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detectable) levels in at least some non-cycling cells and thus an artificial ‘cut-off has 
to be employed in assessing the number of proliferating cells with these antibodies. 
The superiority of MIB1 probably reflects the rapidity of catabolism of the Ki-67 
antigen at the end of M phase.
The manufacturer’s recommended dilution for the MIB1 concentrated antibody was 1 
in 50 but after serial dilutions were completed and the different antibody 
concentrations were tested for optimal staining, the plateau for optimal staining under 
our laboratory conditions was found to be 1 in 100. This dilution of antibody was used 
throughout the projects.
3.1.4 Assessment of staining
Heterogeneity within a tumour is a major problem when scoring the degree of staining 
in a histological section. In most sections of tumour there are some areas of high and 
other areas of low proliferative activity. This means that it is difficult to pick 
representative high power fields to count.
Several different methods were used to assess the positive staining in a section. 
Initially an attempt was made to measure staining intensity, but all shades of staining 
were found.
Some tumour nuclei were very large and showed granular staining and others were 
small and intensely stained (see Fig 3.1).
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Fig 3.1 MIB1 staining of two different grade 2 breast carcinomas. Fig 3.1a shows 
a tum our in which overall staining was assessed as 30% of the total cells showing 
some positive staining. Fig 3.1b shows a tumour in which overall staining was 
assessed as 25% of the total cells showing some positive staining
Nuclei showing pale 
granular staining
Fig 3.1a
Nuclei showing 
intense staining
Fig 3.1b
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Several methods of assessing MIB1 staining have been described. A semiquantitative 
method has been described (Other et al. 1996). Sections are scanned at low and 
intermediate magnification and immunoreactivity scored as
(-) - negative
(+) - positive staining in less than 10% of all tumour nuclei
(++) - positive staining in less than 10% of all tumour nuclei
(+++) - positive staining in more than 50% of all tumour nuclei
The same sections were assessed by quantitative image analysis and also by an 
accurate cell count at 400x magnification with an eye piece grid. They found that all 
three methods produced similar results.
Quantitative image analysis was not an option for these projects, but other methods 
were tried.
After experimenting with several methods of assessment it was decided that the most 
reproducible method was to scan the section on low power, select areas of average 
staining and assess the number of positive cells as a percentage of the total number of 
tumour cells present. Cells with any staining, whatever the intensity, were counted as 
positive.
Another group has recently compared a quantitative and semi-quantitative method. 
The quantitative method involved an accurate cell count, as above, in neighbouring 
fields (as compared to a random selection of fields in the previously described study). 
The semi-quantitative method used was similar to the method used for these projects. 
The entire tumour surface was scanned at low power, including areas of highest and 
lowest positivity and the percentage of positive nuclei assessed. They found that the 
semi-quantitative assessment of MIB1 positivity was a reliable method of assessing 
cellular proliferation that correlated with the S-phase fraction, as determined by flow 
cytometry. They also found, as in these studies, that the interobserver reproducibility 
was good using this method (MacGrogan et al. 1997).
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3.2 p53
3.2.1 Background
Wild-type p53 protein (see Fig 3.2) binds to and modulates the expression of genes 
important for DNA repair, cell division and cell death by apoptosis (Clarke et al. 
1993). Under normal conditions, it effects cell cycle arrest at the G1 and G2 
checkpoints in response to DNA damage, inhibiting cells from entering the S phase 
and because of this has come to be known as the "guardian of the genome". It is also 
involved in transcriptional induction of DNA damage inducible genes and regulation 
of apoptosis in response to y-irradiation (Yogelstein and Kinzler, 1992).
3.2.1.1 The p53 Gene
The p53 gene located on the short arm of chromosome 17 in the region 17pl3 encodes 
a 53kD nuclear phosphoprotein known as the p53 repressor protein.
There is much evidence for p53 being a tumour suppressor gene:-
Wild-type p53 arrests growth in most transformed cells into which it is introduced and 
reduces or eliminates the tumourigenic potential of a cell line (Hinds et al. 1989).
In many cancers both alleles of p53 have been inactivated, the commonest mechanism 
being loss of one allele (reduction to homozygosity or loss of heterozygosity) with 
inactivation of the second allele by point mutation (Ostrowski et al. 1991).
Transgenic mice have been bred in which the p53 gene has been completely ablated 
(Donehower et al. 1992). The progeny are completely normal, but tumours develop 
after 3 months or so, indicating that p53 is not an absolute requirement for cellular 
functioning or cell cycle control
So far, the p53 gene is the most often mutated gene found in cancer cells (Holstein, 
1996) with the majority of mutations being amino acid substitutions. Although in most 
instances p53 mutations are acquired in somatic cells, inherited forms of p53 
alterations have also been described. Rare patients with the Li-Fraumeni syndrome 
have inherited mutations in the p53 gene, and succumb to cancers arising at diverse 
sites, chief among which are carcinomas of the breast and adrenal cortex, sarcomas of 
bone and soft tissue, leukaemias and various central neuroepithelial neoplasms. More 
than 50 types of human tumours carry p53 mutations including about 70% of
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colorectal cancers and 40% of breast cancers. Changes in p53 may occur early or late 
in disease. Possession of a mutant p53 allele leads to functional inactivation of the 
other, since the protein functions as an oligomer and mutant protein inactivates the 
wild type form in a dominant negative manner (Milner et al. 1991).
3.2.1.2 The p53 protein
The p53 protein has three functional domains, one of which is involved in the 
regulation of transcription (transactivation), the second with binding to specific DNA 
sequences and the third in reacting with other p53 molecules (oligomerisation). The 
transactivation domain stimulates transcription indirectly by binding other nuclear 
proteins and recruiting them into the transcription complex.
Fig 3.2 Diagram to show the domain structure of the p53 protein and the 
PAbl801 antibody mapping site
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Fig 3.3 Diagrams to show conformational differences between wild-type and 
mutant p53 protein. Fig 3.3a shows wild-type and Fig 3.3b shows mutant p53.
N
Fig 3.3a
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Fig 3.3b
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3.2.1.3 Regulation of the cell cycle and apoptosis
Numerous DNA-damaging agents that trigger programmed cell death also induce p53 
expression. Regulation of p53 expression in response to DNA damage is not 
completely understood. p53 binds damaged DNA in a non-specific fashion via its C- 
terminal 75 amino acids (Bakalkin, 1994). This non-specific recognition of damaged 
DNA may be responsible for subsequent p53 activation, sequence-specific DNA 
binding and the induction of p21 (also known as WAF1 or CIP1) and GADD45 
(growth arrest on DNA damage) (Li et al. 1994; Smith et al. 1994). These two 
proteins interact with PCNA (proliferating cell nuclear antigen), an essential co-factor 
for replicative DNA synthesis. The p21 protein also inhibits growth by inactivating 
G1 cyclin-dependent kinases. This halts the cell cycle and gives the cell time to repair 
DNA before dividing. If the damage is not repairable the cell is then pushed into 
programmed cell death, called apoptosis. This response is lost in many tumour cells as 
they have either inactivated their p53 genes by mutation or blocked the activity of p53 
through the production of proteins that bind to and neutralise it. Abnormalities of p53 
are common in neoplasia (Bartek et al. 1991; Levine et al. 1991; Nigro et al. 1989). 
If p53 is not functioning normally then p21 (WAF1) induction in response to DNA 
damage does not occur and cells do not G1 or G2 arrest. Damaged DNA is not 
repaired via a p53-dependent pathway, the cell cycle remains unchecked, and the risk 
of tumour formation increases due to the accumulation of mutations. Apoptosis, 
however, can still occur by a p53-independent mechanism (Clarke et al. 1993). Cells 
lacking p53 have increased replicative potential but are not immortal. In human 
beings, each cell division shortens chromosome length by about 50-60 residues. When 
chromosomal shortening reaches a critical threshold value, apoptosis ensues, even in 
cells without p53. Unfortunately rare cells may withstand the crisis. The survivors re­
express the telomerase enzyme that prevents chromosome shortening, chromosomal 
length is restored and they can grow continuously (Bacchetti, 1996). Cells with 
normal p53 have a reduced probability of reaching the “telomere crisis” since 
senesence, terminal differentiation, or apoptosis will occur first.
3.2.1.4 Response to adjuvant therapy.
Most of the cytotoxic anticancer drugs in current use have been shown to induce 
apoptosis in susceptible cells (Hickman, 1998). Cells devoid of p53 do not easily die
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by apoptosis after DNA damage. Cancer treatment, therefore, may select for p53- 
deficient mutants, and loss of p53 may further increase the virulence of a tumour by 
causing chromosomal instability and aneuploidy.
Intrahepatic infusion therapy with 5-fluorouracil (see 1.4.1) for unresectable colorectal 
liver metastases may lead to improved overall survival for some patients but others 
fail to respond. One study on p53 mutations, using PCR showed that patients with 
mutated p53 tumours had short survival, whereas prolonged survival was associated 
with the presence of wild-type p53. This suggests that mutated p53 colorectal tumours 
had a weak response, or even no response, to chemotherapeutic treatment (Benhattar 
et al. 1996).
p53 is thus a negative prognostic marker in cancer because it interferes with apoptosis 
and because it is a marker for an unstable population that often contains invasive 
variants. This means that mutant p53 confers resistance to radiation and 
chemotherapy, making these cancers difficult to treat, with the result that tumours 
containing aberrant forms of the p53 protein are particularly likely to spread and to 
cause death quickly.
Evidence suggests that p53 may have a role in predicting prognosis (Barnes et al.
1993). The presence of p53 mutations or abnormalities of p53 expression has been 
shown to correlate with an increased likelihood of poor survival in a number of 
studies, but such studies have produced variable results. Much of the variability of 
results is probably due to the fact that several different antibodies have been used, 
different thresholds for positive staining have been applied and the staining has 
sometimes been carried out on frozen and sometimes on paraffin tissue with or 
without antigen retrieval. An analysis of 21 papers (Dowell and Hall, 1994) showed 
that 18 out of 21 papers reported that detection of p53 abnormalities could be of value 
in selecting patients with an increased likelihood of poor survival.
Thus, although changes in p53 are not a direct cause of cancer, cells lacking functional 
p53 have a defective DNA damage control response and an extended lifespan. These 
cells are at high risk for malignant transformation and tumours containing p53 
deficient cells may be resistant to treatment.
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3.2.1.5 Immimohistochemistry
Mutation is associated with conformational changes and altered protein stability (see 
Fig 3.3). The p53 protein does not normally accumulate in cells as it has a very short 
half-life and is undetectable in formalin-fixed, paraffin-embedded sections by 
immunohistochemical means. Missense mutations in the p53 gene significantly 
increase the stability, and thus the half-life of the p53 protein, due to conformational 
changes in the molecule, thereby leading to its accumulation in tumour cells. This 
accumulation is detectable by immunohistochemical analysis. Initially it was thought 
that all immunohistochemically detected protein was mutant p53 but mutation in the 
p53 gene is not the only mechanism for rendering the p53 protein non-functional and 
also increasing its stability. A cancer family has been described where there is high 
level expression of p53 in normal cells without evidence of p53 mutation (Barnes et 
al. 1992). The original identification of p53 was a direct consequence of the 
stabilisation of this protein by the large T antigen of SV40. SV40 and other viral 
genomes encode proteins whose action is to bind to and inactivate p53. In some 
situations this leads to direct stabilisation of the wild-type protein, although it 
becomes non-functional. Positive staining can also be due to an abnormal 
accumulation of normal p53 rendered non-functional by binding to other proteins such 
as GADD45 (Kastan et al. 1992) or mdm2 (Oliner et al. 1992). The mdm2 gene has 
been mapped to the long arm of chromosome 12. The product of this gene has been 
shown to form complexes with both mutant and wild-type p53 (Momand et al. 1992). 
p53 induces the expression of mdm2, which in turn binds to and inactivates p53. High 
concentrations of mdm2 prevent normal p53 protein from activating gene 
transcription. In this way the transforming action of the mdm2 oncogene can be 
explained by its ability to inactivate the product of the p53 tumour suppressor gene. 
Cancers have been described that are normal for p53 but in which mdm2 is 
overexpressed (Levine et al. 1991).
The p53 antibody used in this project is PAM801, which reacts with both wild-type 
and mutant p53. The epitope is located between amino acid residues 45 and 91. This 
particular antibody was selected because it was the fact that the p53 was non­
functional that was relevant to this study and by using this antibody both mutant and 
inactivated wild-type p53 are detected.
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3.2.2 Antigen retrieval
For a reliable staining technique, the antibody PAbl801 used in these projects 
required the antigen retrieval techniques previously described (see 2.2.4) to be used.
3.2.3 Antibody dilution
The antibody used in these projects was supplied at a concentration of 1360//g/ml. A 
range of serial dilutions showed that optimal staining required a dilution of this 
solution of 1 in 1000.
3.2.4 Assessment of staining
As with MIB1 staining heterogeneity within a tumour, resulting in patchy positive 
staining presented a problem when assessing the total percentage of positive cells in a 
tumour (see Fig 3.4).
There was also variation in staining intensity. Apart from the biological explanations 
for varying concentrations of p53 within a cell, there could be artifactual reasons for 
variations in staining intensity. The p53 antigen is affected by long storage of paraffin 
sections (Jacobs et al. 1996) (see 2.2.3.2) and it is also apparent that the method of 
fixation, including both the fixative solution and temperature affects the stability of 
p53 protein in breast carcinoma tissue (Fisher et al. 1994). Although staining 
conditions were as consistent as possible, after an initial attempt to score staining 
intensity as well as the number of positive cells it was decided that this had no 
absolute meaning as it was impossible to pick a consistent threshold for different 
levels of staining intensity. It was thus decided to assess only the percentage of 
positive tumour cells. Those with any staining were counted as positive, whatever the 
intensity.
96
Fig 3.4 p53 staining of a Dukes’C carcinoma showing patchy positivity
p53 negative 
tumour cell
p53 positive 
tumour cell
The proportion of over-expressing cells seems to be an important biological variable 
of real clinical significance (Hall and Lane, 1994). Several distinct patterns of 
overexpression can be found. In some tumours the majority o f cells and sometimes all, 
show p53 overexpression (see Fig 3.5), and this is often at a very high level giving 
very intense staining.
Fig 3.5 p53 staining of a Dukes’C carcinoma with almost all cells showing 
positive staining
p53 positive 
tumour cell
Stromal cell
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In contrast, other tumours show variable levels of expression and sometimes only very 
occasional cells stain.
Fig 3.6 p53 staining of a Dukes’B carcinoma with only a few p53 positive cells
Cells showing 
weak p53 
staining
Occasional cells 
showing strong 
p53 staining
These contrasting phenotypes may have a very different biological basis. For example, 
occurrence of just occasional strongly positive cells in a tumour does not seem to 
correlate with obvious molecular abnormality of p53. They may represent the normal 
working of the p53 system in which the wild-type protein accumulates in response to 
spontaneous genetic errors occurring at a higher frequency in the tumour than in the 
normal surrounding tissue. In contrast the presence of strong staining in the majority 
of cells is frequently associated with mutation (Baas et al. 1994). Whatever the 
chosen cut-off point between positive and negative staining, there is a consensus 
among investigators that it is the proportion of positively stained cells that is 
important, and that the presence of staining is generally associated with features 
indicative o f poor prognosis (Allred et al. 1993; Ostrowski et al. 1991; Thor et al. 
1992; Walker etal. 1991).
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False negatives could also occur where biological mechanisms could result in the loss 
of p53 activity without accumulation of p53 protein in the nucleus and be explained 
by any of the following possibilities: -
1. A nonsense mutation at codon 196 has been found in one study where the 
mutated protein did not contain the nuclear localisation zone which is at amino 
acids 316 -  325. Overexpression of p53 protein was negative in this tumour 
with all antibodies used (Rosai, 1991).
2. The underlying lesion may not be a missense point mutation but gross 
deletion, which abolishes all p53 protein product. This has been reported in 
some sarcomas (Oliner et al. 1992).
3. Some missense mutations in the p53 gene may not stabilise the protein.
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3.3 CD44
3.3.1 Background
CD44 is a broadly distributed cell surface glycoprotein which, as a result of messenger 
RNA alternative splicing, is expressed in different isoforms in various tissues and may 
be implicated in metastatic spread.
In humans a single gene on chromosome llp l3  (Goodfellow et al. 1982) encodes 
CD44. All known CD44 proteins are composed of the same extracellular N terminal 
sequence, transmembrane and cytoplasmic region. This standard or haemopoietic 
form of CD44 (commonly referred to as CD44H or CD44S), is synthesised as a 37kD 
core protein and is found predominantly on haemopoietic cells, fibroblasts, cells of 
neuroectodermal origin and some epithelial cells. The CD44 gene is composed of at 
least 20 exons, 12 of which can be alternatively spliced (Molino et al. 1997).
In addition to the exons 1-5 and 16-20 which encode the CD44H isoform, there are 
10 variant exons which can be alternatively spliced and assembled within the standard 
ones to generate larger “splice variants” (CD44vl-10) in more than a thousand 
combinations, and these can be further modified by post-translational glycosylation. 
By these mechanisms, this gene can produce a large variety of protein isoforms. The 
variants of CD44 contain additional amino acids derived from the variant exons, 
positioned in the extracellular portion close to the transmembrane domain. Epithelial 
cells produce a larger core protein form of CD44, CD44E, which is generated by 
alternative RNA splicing and contains the last 3 exon products of the variable region 
(CD44v8-10). The longest CD44 isoform expressing in tandem eight exons of the 
variable region (CDv3-10) is detected in keratinocytes. The reasons for the existence 
of so many CD44 isoforms are not known but this may account for the diversity of 
cellular functions attributed to the CD44 molecule. The recognised functions of CD44 
are thought to reside in the CD44H isoform; the physiological functions of the 
alternatively spliced exons are less clear, but different CD44 isoforms may bind 
different ligands or influence the binding of a particular ligand.
Antibody interference studies suggest that CD44 functions as a lymph node homing 
receptor on circulating lymphocytes, is involved in lymphocyte activation and 
lymphopoiesis, and is responsible for homotypic and heterotypic cell adhesion. Many
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of the steps involved in the metastatic cascade such as entrance into small vascular or 
lymphatic channels, survival during circulation, arrest at distant sites, and extravasion 
are comparable to the steps involved in the normal trafficking of lymphocytes in 
which CD44 is known to play a role (Haynes et al. 1989). The extra cellular domain 
of CD44 is known to bind extracellular matrix components, the principal ligand being 
hyaluronic acid. It is also known to bind certain proteoglycans, fibronectin and 
collagen types I and VI. The standard form, containing no variant regions, binds to 
hyaluronic acid, but there is some disagreement as to whether all CD44 isoforms have 
this binding capacity. Hyaluronic acid is known to cause cell aggregation of a number 
of different cell types and has been implicated in the stimulation of cell proliferation, 
cell migration, cell adhesion and angiogenesis. High levels of hyaluronic acid 
production and overexpression of hyaluronic acid receptors (e.g. CD44 isoforms) have 
been found to be closely associated with tumourigenesis. A transfection of CD44vlO 
into nontumourigenic human breast epithelial cells that contained endogenous CD44s 
indicated that coexpression of both forms altered important biological properties of 
these cells. There was a significant reduction in hyaluronic acid-mediated cell 
adhesion, an increased migration capability in collagen-matrix gel and the production 
of certain angiogenic factors suggesting that coexpression may trigger the onset of cell 
transformation required for breast cancer development (Iida and Bourgignon, 1997). 
Immunohistochemical studies have indicated that the lymphocytes in the follicular 
mantle, interfollicular zone and sinusoidal compartments of normal adult lymph nodes 
strongly express the standard form of CD44, but those in the germinal centres do so 
only weakly or not at all. Early pre-B cells (CD19+ve) express CD44 at low levels 
whilst more differentiated (CD20+ve) B cells express CD44 at very high levels 
(Kansas and Dailey, 1989).
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Fig 3.7 Diagram to show the structure of the CD44, showing the insertion point of 
the variant exons
Hyaluronate binding domain
Variant Exon domain
Insertion site  for 
variant exon s
P lasm a m em brane
Cytoplasm ic domain
COOH
Many studies have now demonstrated overexpression of the CD44 gene in various 
types of human malignant tumours, and this abnormality has emerged as an interesting 
candidate marker for early cancer diagnosis. An early study demonstrated that 
transformed cells and rapidly dividing cells expressed more CD44 proteins on their 
surface (Vogelstein and Kinzler, 1992). Expression of a variant containing exon v6 
was shown to promote metastatic behaviour in rat cell lines (Gunthert et al. 1991). In 
different human tumours, splice variants of CD44 have been correlated with advanced 
stages of tumour growth and metastatic potential. Certain types of gastric 
adenocarcinomas (Heider et al. 1993a) and breast cancers (Heider et al. 1993c) also 
express high levels of v6 and invasiveness of human bladder cancer has also been 
shown to correlate with CD44v6 expression (Namec et al. 1987), as does non- 
Hodgkin’s lymphoma (Horst et al. 1990). These early findings indicated an important
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role for CD44 in regulating tumour progression and observations suggested that the 
mechanism involved might be largely dependent on the ability of CD44 to mediate 
cell attachment to hyaluronic acid (Stamenkovic et al. 1991).
Early studies were performed on cell lines. Numerous analyses at the mRNA level 
have indicated tissue specific expression of CD44 variants, but few analyses had been 
performed at the protein level because of the limited availability of suitable 
monoclonal antibodies. The existence of mRNA of different transcript sizes is, 
however, no guarantee of the eventual presence of the appropriate protein. RTPCR on 
clinical material is not as unequivocal as when tissue culture lines are used. Infiltrating 
stromal cells, including lymphocytes, can contribute to the isoform pattern detected.
One study looked at the patterns of transcription (using Southern blot hybridization 
analysis of RTPCR) and of translation (using Western blot and 
immunohistochemistiy). Direct comparison of Southern and Western blots on 
matched tumour cell line extracts indicated that most of the diverse mRNA isoforms 
did not detectably translate into proteins. Immunohistochemistiy of normal and 
malignant breast and colon tissue specimens showed increased staining of CD44 
standard and variant proteins in the carcinoma cells, but they concluded that 
overexpression at the protein level involved only a minority of the aberrant RNA 
transcripts. The authors also concluded that inappropriate CD44 expression in 
neoplasia affects the assembly of both the standard and the variable exons of the gene 
and that these are translated into deranged expression of its protein isoforms 
(Woodman et al. 1996). There is, as yet, no evidence that aberrant expression of any 
individual exon is specifically associated with neoplasia. Disorder in the regulation of 
production, splicing, and processing of CD44 pre-mRNA in breast cancer tissues 
using not only probes for several exons but also for a noncoding region (intron 9) has 
been demonstrated. Results were similar with all the probes used, indicating a wide 
disorder of CD44 transcript processing rather than a defect in processing any 
individual portion of the gene (Bolodeoku et al. 1996).
Although there is still a possibility that some unusual combination of exons could 
result in malignancy or be cancer associated, it seems more likely that it is the 
deranged pattern of gene expression that is characteristic of neoplasia.
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The CD44H antibody used in these studies is CBL 154 (Cymbus Bioscience Limited) 
clone F I0-44-2, which is directed against the epitope encoded by CD44 exon 1,
3.3.2 Antigen retrieval
For a reliable staining technique, all the CD44 antibodies used in these projects 
required the antigen retrieval techniques previously described (see 2.2.4) to be used.
3.3.3 Antibody dilution
The CD44H antibody, supplied by Cymbus technology (lOOjug/ml), did not have a 
recommended manufacturer’s dilution. The CD44v3 and CD44v6 antibodies were 
supplied at a concentration of lmg/ml.
A range of serial dilutions showed that optimal staining required a dilution of this 
solution of 1 in 200 for all three of the antibodies used in these projects.
3.3.4 Assessment of staining
Staining with CD44 was generally heterogeneous. Attempts were made to assess the 
overall intensity of staining, but the most reproducible method was to look for cells 
with three different patterns of staining intensity as shown in Fig 3.8.
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Fig 3.8 Diagram to show how the three different intensities of CD44 staining are 
assessed.
Cell
membrane
CD44
staining
CD44 staining 
of low intensity
CD44 staining of 
medium intensity
CD44 staining of 
high intensity
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Fig 3.9 CD44H staining of a grade 2 breast carcinoma
High intensity 
Medium intensity 
Low intensity
Negative cell
The percentage o f cells that were totally negative was assessed and the proportion of 
the remainder that stained with the three different intensities assessed. Two different 
scores were then obtained. One of these was a simple total of the percentage of tumour 
cells with any staining, regardless of the intensity. This is referred to as the total 
percentage score. The other score was one that took into account the different levels o f 
staining intensity. It was calculated by first multiplying the number o f cells with low 
intensity of staining by one, the number of cells with medium intensity of staining by 
two and the number of cells with high intensity of staining by three. These three 
scores were then added together, give a maximum possible total of 300. This score 
then gave a value weighted for the staining intensity. This is referred to as the CD44H 
expression score. Both these methods of assessment could then be assessed separately.
Published results from other groups give little information on how the CD44 staining 
was quantified. An alternative method is to assess areas as negative (lack of staining) 
or positive (a group of cells unambiguously stained) (Fromont Hankard et al. 1998). 
One other group used a method of assessment that graded the intensity of staining 
from 0 - 3  (Joensuuet al. 1993).
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3.4 ER
3.4.1 Background
The link between ovarian hormones and human breast cancer is well known, and 
oestrogens clearly stimulate the proliferation of both normal mammary gland and 
established breast cancer cells (Santen, 1990; Howell, 1989). The influence of 
oestrogen and progestin on normal and transformed mammary epithelial cells, 
however, is still not clearly understood (King, 1993).
Oestrogen (ER) and progesterone receptors (PR) are members of a family of nuclear 
regulatory proteins, which modulate the activity of target genes. Oestrogen down 
regulates its own receptor, but normally induces progesterone receptor (PR) through 
ER. Another molecule that is regulated by ER is pS2-TFFl (trefoil factor 1) which is 
expressed in normal and neoplastic breast. Its expression is regulated by a 5’ 
oestrogen responsive element (Berry and et al., 1989) and it has been investigated as a 
potential prognostic factor reflecting oestrogen dependence. There is also a positive 
interaction between ER and IGF1R (insulin growth factor 1 receptor). IGF1R 
activation sensitises cells to oestrogen by inducing phosphorylation of the oestrogen 
receptor. IGF1R promotes the transcriptional activity of ER by MAP kinase 
dependent-ER phosphorylation (Kato and et al., 1999). IGF1R, like oestrogen, 
increases the expression of the proposed ER coactivator cyclin D1 (Sweeney and et 
al., 1996). Overexpression of IGFR by gene transfection sensitises cells to IGF1 and 
reduces oestrogen dependency (Guvakova and Surmacz, 1997) and steroidal 
antioestrogens inhibit the IGF 1-dependent growth of ER positive breast cancers and 
down-regulate IGF1R expression (de Cupis et al. 1995). The level of IGF1R activity 
is therefore a key modulator of cellular oestrogen sensitivity and it is likely that it 
influences the efficacy of antioestrogen therapy.
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3.4.1.1 Structure and function of the oestrogen receptor
The oestrogen receptor gene is located on chromosome 6q25.1, comprises more than 
140 kb and is composed of eight exons and eight introns.
The oestrogen receptor protein can be divided into six domains A -  F. These 
functional domains are responsible for transcriptional activation and repression, 
nuclear localisation, DNA binding, and hormone binding of the receptor (Fuqua et al. 
1993).
Fig 3.10 Diagram to show the functional domains of the Oestrogen Receptor. See 
text for description of the functional domains
Exon boundaries 1/2 2/3 3/4 4/5 5/6 6/7 7/8
nucleotide
sites 114
Functional 
domains
amino acids 38
540 789 906 1659 1785
A B C D E F
180 263 302 553 595
The locations of the six functional domains of the oestrogen receptor, the eight 
exon/intron borders and the amino acid and nucleotide sites of the six domains are 
shown in Fig 3,10.
1. The N-terminal A/B region contains a constitutive activation function (AF-1, 
also known as TAF-1) that activates transcription of oestrogen-responsive 
genes.
2. The next region, amino acid domain C, contains 20 invariant residues, 
including 9 cysteines, which fold into 2 zinc-finger DNA binding motifs. This 
DNA-binding domain is responsible for the recognition of specific enhancer 
sequences (hormone response elements) found in hormone responsive genes. 
Each receptor recognises its own response element, so that extracellular 
hormonal signals are transduced via the receptor to specific target genes. 
Discrimination between different hormone response elements is determined by 
three amino acids at the base of the first zinc finger, and single base pair
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substitutions can produce receptors that recognise different hormone response 
elements. Thus sequence mutations within this region could have important 
functional consequences. The C-terminal extremity of the DNA-binding 
domain to the ER also contains a nuclear localisation sequence important for 
the nuclear localisation of the receptor.
3. The D region is a hinge of variable length and amino acid composition.
4. The large hydrophobic E domain is a complex region containing the hormone 
binding site and a region required for stable dimerisation of the receptor. This 
region also contains a transcriptional activation function (AF-2) which is 
hormone inducible, and which synergises with the A/B region transactivating 
activity. AF-1 is a hormone-independent and AF-2 is a hormone-dependent 
transactivation site. Mutations in either of these two transactivation domains 
trigger important changes in inactivating, or alternatively by reducing or 
enhancing the receptor’s ability to bind hormone, to bind DNA, or to promote 
gene transcription. Region E also appears to be the site for binding by heat- 
shock proteins.
5. No specific function has yet been unambiguously assigned to region F of the 
ER.
It has been shown that approximately 10-15% of normal mammary epithelium cells 
express immunodetectable ER. Using double antibody immunofluorescense it was 
shown that 96% of steroid receptor +ve cells synthesise both ER and PR and that, 
using the Ki67 proliferation antigen, dividing cells are separate from those expressing 
the receptors (although they are often in close proximity). In contrast two-thirds of ER 
+ve breast tumours examined had a high proportion of dividing cells that were ER+ve, 
This would be consistent with the hypothesis that ER-ve cells in normal breast 
epithelium are controlled by paracrine factors (see 1.1.2.1) released from ER+ve cells 
under the influence of oestrodiol and that this organisation may be disrupted in some 
tumours (Clarke et al. 1997).
Studies on breast cancer cell lines have shown that the expression and stability of the 
oestrogen receptor is the result of a complex process that is modulated by oestrogens 
and antioestrogens. Oestrogen exposure can cause either a down-regulation or an
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increase in the steady-state level of ER mRNA in different cell lines (Pink and Jordan, 
1996).
3.4.1.2 Endocrine therapy
Breast cancer has been treated by interfering with the growth stimulatory actions of 
oestrogen for nearly 100 years. Oophorectomy blocks breast tumour growth by 
eliminating the oestrogens required to activate the ER and stimulate tumour growth.
Measurements of the oestrogen receptor (ER) and the oestrogen-induced progesterone 
receptor (PR) are used by most clinicians as indicators of both overall prognosis and 
likelihood of response to endocrine therapy. First-line endocrine therapy is usually 
oophorectomy in premenopausal and tamoxifen (see below) in postmenopausal 
patients. About 50-60% of patients with ER+ve tumours respond to endocrine therapy. 
Patients with ER+/PR+ tumours have the highest likelihood of response (70-80%), 
even though, unfortunately, most patients treated successfully with endocrine therapy 
eventually develop endocrine-resistant disease recurrence (Jordan et al. 1988).
Oestrogen receptors play a critical role in the development, progression and hormone- 
responsiveness of breast cancers but it remains unresolved why nearly 50% of 
tumours that are ER+ve are initially unresponsive to hormone manipulation and 
conversely why 10% of patients whose tumours are ER-ve respond to treatment with 
antioestrogens.
Tamoxifen
The most important therapeutic antioestrogen is currently tamoxifen which is used for 
the treatment of hormone-dependent breast cancer. Tamoxifen is a triphenylethylene 
compound and, at lpM, generally suppresses growth and PR in oestrogen target 
tissues that cany a normal ER. Initially it was thought to act simply as a competitive 
inhibitor for the ligand binding site in the ER, i.e. if an antioestrogen occupied the 
ligand binding site of an ER molecule oestrogen would be unable to bind and 
therefore be unable to induce ER-mediated responses such as cell growth. However, 
further research has shown that the biological actions of antioestrogenic compounds 
are much more complex than this simple model suggests.
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Although tamoxifen is able to inhibit the action of oestrodiol, it itself exhibits slight 
oestrogenic activity and acts as a partial agonist. The relative amounts of antagonistic 
and agonistic properties depend on the physiological response. It has been proposed 
that its antagonistic properties are derived from an inhibition of AF-2 and its agonism 
as a consequence of AF-1 activity (Berry et al. 1990) (see 3.4.1.1).
Resistance to endocrine therapy
There are several mechanisms whereby resistance to endocrine therapy could develop:
1. altered responses to oestrogens and antioestrogens
2. altered stability of the ligand-receptor complex
3. ligand-independent activity
4. no activity of its own, but the ability to interfere with the normal receptor 
activity by competing for ligand, DNA binding sequences or transcription 
factors.
Any one or a combination of these possible activities could lead to antihormone 
resistance or ligand-independent activity, and thus to an apparently hormone- 
independent phenotype.
The separation of ER+ve and ER-ve cases in one study revealed that in hyperplastic 
breast epithelium, the ER+ve cases had a higher proliferation rate than that of ER-ve 
cases. Conversely in ductal carcinomas, both in situ and invasive, ER-ve cases had 
higher rates of proliferation than those observed among the ER+ve cases. This fits 
with the concept of an initial hormone-dependent status in breast carcinogenesis 
where activation of ER by hormone increases the possibility that cells may undergo 
malignant transformation with successive steps of progression being paralleled by a 
progressive hormone independence (Schmitt, 1995). These results are discussed later 
(see 7.4).
Around 30 -  40% of metastases from hormone receptor-positive primary breast 
cancer do not respond to endocrine therapy. One study of breast tumour recurrences in 
patients who had not received any adjuvant therapy showed that hormone receptor 
status of the recurrent tumour differed from that of the primary tumour in 36% of 
cases. ER was lost in 12%, PR in 12%, and both receptors in 12% of cases. Receptor- 
negative primary tumours were always accompanied by receptor-negative recurrences.
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Only 1 of 8 patients (12.5%) with lost ER expression responded to tamoxifen therapy, 
whereas the response rate was 14 of 19 (74%) for patients whose recurrent tumours 
retained ER expression (Kuukasjarvi et al. 1996).
The absence of ER in some cases of breast cancer does not imply a true negativity 
since there is evidence that many human breast tumours produce defective forms of 
ER.
Several mutations in ER exons have recently been demonstrated that could influence 
protein structure and protein function and thus response to hormone therapy (Murphy, 
1990; McGuire etal. 1991).
One group found a number of ER variants in breast cancer tissues. They found base 
pair insertions, transitions and deletions of exons 3, 5 and 7. They discovered 
receptors with outlaw function consisting of both dominant positive receptors that 
were transcriptionally active in the absence of oestrogen and dominant negative 
receptors that were transcriptionally inactive themselves but prevented normal ER 
function (McGuire et al. 1992). A truncated receptor, lacking the majority of the 
hormone-binding domain because of the deletion of exon 5 has been shown to act as a 
dominant-positive receptor in the absence of hormones (Fuqua, 1994). This variant, 
although originally identified in ER-negative, progesterone receptor-positive tumours, 
has been found by one group to be coexpressed at variable levels with the wild-type 
receptor in a large number of ER-positive tumours. In in vitro functional assays it has 
been shown that the exon 5 deletion variant is constitutively active and capable of 
inducing the expression of specific genes such as PR in cells in which it is expressed. 
It also manifests increased anchorage-independent colony formation in the absence of 
oestrogen (Fuqua and Wolf, 1995). Thus the exon 5 ER deletion may be involved in 
clinical tamoxifen resistance and hormone independence. Another variant which has a 
point mutation in a conserved region of the hormone-binding domain is hyper­
sensitive and is functionally active in response to subphysiological concentrations of 
oestrogen. It is possible that both ER variants may form productive heterodimers with 
wild-type receptor to modify the normal function of ER in the breast (Lemieux and 
Fuqua, 1996). A study which looked at several ER variants found that each individual 
tumour often manifests multiple variants coexisting with corresponding wildtype ER. 
They found, however, that the presence of ER variants was not associated to
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clinicopathological variables, and equally frequent in tumours from patients having 
recurred or remained recurrence free during adjuvant tamoxifen therapy. Although 
this study provided no evidence for a direct role of these ER variants in tumour 
development and tamoxifen resistance, it remains possible that minor cell clones could 
exist within the tumour, undetected by analysis of tumour homogenates. These could 
display extreme differences in function, and be selected for during therapy or 
metastasis (Zhang et al. 1996).
The oestrogen-independent MCF-7.2A cell line, which has adapted to growth in 
oestrogen free media, expresses two forms of the ER, a wild-type and a mutant form 
(Pink et al. 1996). The duplication of exons 6 and 7 in the mutant form of the receptor 
has abolished ligand binding, which eliminates the effect of antioestrogens such as 
tamoxifen (see 3.4.3).
A study of the effects of tamoxifen on a cell line T47Dv found that a selected subset 
of cells had increased rather than decreased PR levels. It was suggested that the 
molecular heterogeneity of oestrogen receptors in breast tumour cells, characterised 
by the presence of mutant receptor forms, generates the lack of uniformity in response 
to tamoxifen. Rather than being “resistant” different subsets of cells can be inhibited 
or stimulated by tamoxifen and their suppression or outgrowth alters the phenotype of 
the tumour. If the biologic behaviour of this cell line mimics the pattern seen in 
patients with metastatic breast cancer who have an initial growth inhibitory response 
to tamoxifen and then relapse, it may be these emerging subpopulations that lead to 
later tumour progression (Horwitz, 1994).
Early detection of breast cancer, when the number of cell divisions is small would 
lower the likelihood that a clone of tumour cells will develop which is resistant to 
therapy.
In one study (MacGrogan et al. 1996) ER status of a tumour has also been shown to 
be an independent factor in predicting tumour chemosensitivity to epirubicin, a 
derivative of doxorubicin (see 1.1.3.1).
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3.4.1.3 Measurement of the oestrogen receptor 
Comparison of Immunohistochemistry and cytosolic methods
Historically, ER was measured on tumour tissue cytosols using a ligand-binding 
assay. The tissue had to be transported and stored at low temperature to prevent loss of 
binding activity. Other problems included the amount of tissue required, the length of 
time taken to complete the assay and the limited number of samples that could be 
measured at one time. Later anti-ER antibodies made it possible to develop a cytosol 
enzyme immunoassay (Nicholson et al. 1986; King et al. 1979) and the availability 
of anti-ER antibodies also created the opportunity for the development of 
immunohistochemical assays. The introduction of the antibody ER DD5, the antibody 
used in this project, which can be used on fixed, paraffin-embedded sections after 
heat-mediated antigen retrieval, means that assays can be carried out as part of the 
routine histopathological assessment. Several studies have shown generally good 
agreement between the overall findings of the immunohistochemical assays and the 
established ligand-binding assays (Happerfield et al. 1996). The prognostic role of 
both techniques was equally good and showed a common trend of association between 
low grade malignancy and a high expression of hormonal receptors (Lerma et al. 
1994; Ciatto et al. 1994). Immunocytochemical assays of ER on breast cancer 
aspirates has also been shown to be a predictor of clinical response to hormone 
therapy (Momand et al. 1992).
The advantages of immunocytochemical methods over biochemical assays may be 
summarised as:-
1. positive cells are directly visualised so that any tumour cell heterogeneity can 
be detected.
2. The presence of viable tumour tissue in the assessed sample can be confirmed.
3. Any stromal contribution can be discounted.
4. Receptors already occupied by the relatively high levels of sex steroids in 
premeopausal women can still be detected.
5. They can be applied to cytological material.
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6. Only a small quantity of tissue is required, which is an important factor given 
that screening programs and the awareness of women now lead to an early 
diagnosis and allow smaller cancers to be detected.
3.4.2 Antigen retrieval
For a reliable staining technique, the antibody 1D5 used in these projects required the 
antigen retrieval techniques previously described (see 2.2.4) to be used. It was 
particularly important when using this antibody that the pH of the antigen retrieval 
buffer was accurate.
3.4.3 Antibody dilution
The antibody 1D5 used in these projects was supplied by DAKO at a concentration of 
245pg/ml. The manufacturer’s recommended dilution was 1 in 50 but a range of serial 
dilutions showed that optimal staining was achieved at a dilution of 1 in 100.
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3.4.4 Assessment of staining
ER positivity is very variable in intensity. It can be a strong nuclear stain as shown in 
Fig 3.1 la
Fig 3.11 ER staining of two different breast carcinomas showing the range of 
staining intensity.
ER staining of a grade 3 
breast cancer showing 
weak positivity
Fig 3.11b
Alternatively the nuclear staining can be positive but weak, as shown in the high grade 
carcinoma in Fig 3.1 lb.
There is no general agreement about assessing ER staining. Several methods of 
scoring have been described:-
ER staining of a grade 2 
breast cancer showing 
strong positivity
Fig 3.11a
ER positive cells
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1. The Histo score was described by Kinsel. It is a similar method to that used for 
assessing CD44 staining in this project. The intensity of staining of different 
areas of the section was assessed and allocated a value of 0 (nil), 1 (weak), 2 
(distinct), or 3 (strong). The percentage of positive cells in each of the staining 
categories was also evaluated. The percentage of positive cells was then 
multiplied by the intensity value and the score of the products added together 
to give the H score, which thus has a maximum of 300. A cut-off point of 100 
was taken to differentiate between positive and negative.
2. Another method, known as the category score, is to judge the overall 
appearance at different powers of magnification, i.e. 0, none (no staining); 1, 
weak (only visible at high power magnification); 2, moderate (visible at low 
power magnification); 3, strong (striking even at low power magnification).
3. The total proportion of cells staining positively at any intensity was scored as 0 
(no cells staining), 1 (when 1-25% cells stained), 2 (when 26-50% cells 
stained), 3 (when 50-75% cells stained) or 4 (when > 75% cells stained).
4. Staining was recorded as negative, heterogeneous positive or homogeneous 
positive throughout a tumour.
5. The cases were subdivided into negative or positive. Negative tumours 
included those with either negative or only weak staining while positive 
tumours showed moderate or strong staining.
6. Any positive staining at any intensity was scored.
7. Methods 2 and 3 could also be combined by being multiplied together to give 
the immunoreactive score or added together to give the “quick score”(Reiner 
etal. 1990).
One of the problems with any method that assessed staining intensity is technical 
reproducibility, which seems to be difficult with oestrogen receptors. Even using the 
same positive control in each run it is difficult to be consistent from one assay to the 
next when deciding whether staining is weak, moderate or strong. A study which 
compared both cytosol and immunohistochemical methods and the various methods of 
scoring found that whatever scoring method was used, immunohistochemistry gave 
superior results to the cytosol assay. All the methods of scoring gave significant
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results and that there was little to choose between the different methods of scoring 
(Barnes et al. 1996). A “quickscore” method was also devised (Detre et al. 1995). 
Here the whole section was scanned at low power to gauge the general level of 
intensity throughout and this was given a score of 0 to 3. The percentage of malignant 
cells staining positively throughout the section was also assessed and assigned a score 
from 1 to 6 (1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 80- 
100%). These two scores were then added together and also multiplied together. There 
was no difference between the additive and the multiplicative quickscores and the 
correlation with the enzyme immunoassay results previously obtained was very 
similar to that of the H score.
The method to choose seems to be the one that gives the most consistent results. After 
trying several different scoring systems the one that gave the most reproducible results 
was the one that measured the percentage of positive cells, whatever the intensity of 
staining, as there was generally a gradation of staining within individual tumours.
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3.5 D5
3.5.1 Background
In the cell, as in vitro, the final conformation of a protein is determined by its amino- 
acid sequence. Whereas some isolated proteins can be denatured and refolded in vitro, 
in the absence of other macromolecular cellular components, folding and assembly of 
polypeptides in vivo involves other proteins. The correct tertiary and quaternary 
structure is an important determinant of efficient intracellular protein function. A 
family of proteins involved in the stabilising of partially folded intermediates during 
polypeptide folding are known as heat shock proteins because they were first 
recognised because of their specific induction during the cellular response of all 
organisms to heat shock. Nevertheless, the majority of the family members are 
expressed constitutively and abundantly in the absence of any stress. Many heat shock 
proteins are induced in cells when exposed to different environmental stressful 
conditions whose common denominator may be the accumulation of unfolded of 
malfolded proteins in cells. They are thought to be molecular chaperones involved in a 
wide spectrum of cellular functions involving protein - protein interactions such as 
secretion, intracellular movement and proliferation (Gething and Sambrook, 1992). 
Breast cancer cells sometimes express high levels of several heat shock proteins, 
which may both augment the aggressiveness of these tumours and make them more 
resistant to treatment.
D5 is an antibody to an important small 27KDa heat shock protein (HSP27) found in 
human cells, both normal and cancer cells. HSP27 is a widely distributed protein, 
although levels attained in breast cancers exceed those found in other cells.
The function of HSP27 is unknown but in normal mammary epithelium it correlates 
well with proliferative activity at different stages of the menstrual cycle (Fuqua, 1994) 
and is linked to short disease-free survival in breast cancer (McGuire et al. 1992). 
Good but not absolute correlation has been found between the presence of ER and 
high amounts of HSP27 and low amounts of HSP27 are present in many ER negative 
cells (Dunn et al. 1993; Takahashi et al. 1995). HSP27 positivity in ER negative 
tumours characterises a subgroup with a good prognosis (Hurlimann et al. 1993). 
Staining does not correlate with PR. High HSP27 has been linked with short disease-
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free survival in node-negative patients but with prolonged survival from first 
recurrence (Love and King, 1994).
There is evidence that overexpression of HSP27 may have an effect on drug 
sensitivity. Work on human testis tumour cells has shown that cells overexpressing 
HSP27 were more resistant to heat shock, cisplatin and doxorubicin (Richards et al. 
1996). HSP27 has been shown to increase specific resistance to doxorubicin in breast 
cancer cell lines (Fuqua et al. 1994; Oesterreich et al. 1993).
3.5.2 Antigen retrieval
The D5 antibody required antigen retrieval for use on paraffin embedded tissue. The 
method used was the microwave technique described previously (see 2.2.4).
3.5.3 Antibody dilution
The D5 antibody was supplied as a 150/ig/ml solution. Serial dilutions showed that a 
dilution of 1 in 300 gave the clearest staining.
3.5.4 Assessment of staining
Staining with the D5 antibody was cytoplasmic. The staining was often heterogeneous 
within a tumour with some cells negative, some cells staining strongly and some cells 
staining weakly as shown in Fig 3.12.
Initially an attempt was made to assess the cytoplasmic staining by allocating different 
scores for two levels of intensity of staining. It was, however, difficult to have an 
accurate cut-off point between the two intensities as the range of staining was a 
continuum and the nature of immunohistochemistry means that intensity of staining 
can vary slightly with laboratory conditions from day to day. It was decided that the 
most reproducible method of assessment was to count the number of cells that were 
positive, regardless of intensity of staining.
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Fig 3.12 D5 staining of a grade 3 breast carcinoma
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Cytoplasmic 
D5 staining
The score that was used for statistical purposes was a ranked score of the total 
percentage of tumour cells with any D5 staining.
Nuclear HSP27 could not be detected immunohistochemically. This could perhaps 
indicate a lack of biologically relevant interaction between the HSP27 and ER, as ER 
is localised in the nucleus. However HSP27 levels about a thousand times higher than 
ER levels have been demonstrated in studies on cell lines (Hayward et al. 1990) so 
subtle changes in levels of HSP27 could be missed.
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CHAPTER 4 BREAST STUDIES
4.1 Background to these studies
4.1.1 Epidemiology of breast cancer
In Northwest Europe, North America and Australia, breast cancer is the commonest 
type of malignancy in women. In the United Kingdom it accounts for 20% of all 
cancers, and is the commonest cause of death in the 35 -  55 age group. It is estimated, 
in the high-risk areas that any individual woman has a 1 in 14 chance of developing 
the disease in her lifetime. The risk factors identified to date are:-
1. Female sex. Less than 1% of all breast cancers occur in men, so being female 
is an important risk factor.
2. Long interval between menarche and menopause. Women with 40 or more 
years of active menstruation have twice the breast cancer risk of those with 
fewer than 30 years of menstrual activity.
3. Age at first full-term pregnancy. Nulliparous women have an increased risk of 
developing breast cancer. However, among parous women protection is related 
to early age for the first full-term pregnancy. If the first birth is delayed to the 
mid or late thirties, the woman is at a greater risk of developing breast cancer 
than is a nulliparous woman.
4. Obesity and high-fat diet. Women aged 60 or over whose weight is above 
average have an increased cancer risk and international breast cancer incidence 
rates correlate with the consumption of fat.
5. Family history of breast cancer. An increased risk of breast cancer has been 
found in first-degree relatives of breast cancer cases and the risk increases to 
nine-fold for first-degree relatives of pre-menopausal women with bilateral 
breast cancer. Up to five-fold increases in risk have been found for women 
with multiple first-degree relatives with breast cancer. There is now evidence 
of an autosomal dominant mode of inheritance. The gene responsible for the 
hereditary form of breast carcinoma has been identified on chromosome 17q 
and named BRCA1 (Miki et al. 1994). A second gene that predisposes to
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breast carcinoma has been localised to chromosome 13ql2-13 and named 
BCRA2 (Wooster et al. 1994) (see 1.2.2). These two genes together probably 
account for about two thirds of familial breast carcinoma or roughly 5% of all 
cases.
6. Geographic location. There is a marked variation in breast cancer rates 
between different countries. The highest rates are in Northwest Europe, North 
America, Australia and New Zealand, with the lowest in South-East Asia and 
Africa. Several factors probably contribute to this difference: age at menarche, 
age of full-term pregnancy, age at menopause and post-menopausal weight. 
The length of time between menarche and first pregnancy may be quite short 
in Asian and African countries.
7. Atypical hyperplasia. Women with atypical hyperplasia in a previous breast 
biopsy are at increased risk of developing breast cancer.
The association of breast cancer risk with menarche, menopause and full-term 
pregnancy indicates that hormones must have some role in the development of 
carcinomas, but it is likely that they are acting as promotors rather than initiators. 
Oestrogen activity appears to be important, with overexposure to oestrogens and 
underexposure to progesterone being significant. A high number of menstrual cycles 
will result in more repeated surges of oestrogen having a stimulatory effect on the 
breast epithelium. The beneficial effect of early full-term pregnancy could be due to 
the high concentrations of progesterone and/or prolactin protecting the breast cells 
against oestrogen in the long term. The risks associated with obesity may be partly 
due to the ability of fat cells to synthesise oestrogens, or to altered levels of sex 
hormone binding-protein levels.
Hormones only have an effect on cells after interacting with specific receptors present 
on or in their target cells. Oestrogen interacts with a receptor, which can be found in 
the nucleus of cells (see 3.4). Subsequent interaction with DNA results in the 
formation of differentiation- and proliferation-associated factors. Oestrogen receptors 
can be detected in varying amounts in about 70% of breast cancers. The progesterone 
receptor, which can normally only be formed when the oestrogen receptor is present 
and active, is present in about 35% of tumours. Women whose tumours contain both
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types of receptors are more likely to respond to some form of hormone manipulation 
therapy.
4.1.2 Problems of diagnosis and treatment of breast cancer
Despite modem therapy, one third to one half of patients who develop breast cancer 
will eventually die from the disease. Enormous resources have been spent to develop 
methods of treating breast cancer, with only modest improvements in overall survival. 
Preventing breast cancer will require a much better understanding of the biological 
abnormalities underlying its development and progression.
There are many morphologically complex and extremely common proliferative 
lesions of the breast, few of which are unequivocal precursors of breast cancer. 
Nonetheless, a handful of epidemiological studies have shown that certain subsets of 
these proliferative lesions are statistically associated with the later development of 
breast cancer, and provide a few clues to early breast cancer evolution, (see 1.2.1). 
While the vast majority of potential precursors never progress to invasive breast 
cancer, microscopically they are morphologically similar to those that may have 
already undergone initiating and transforming genetic events leading to breast cancer.
Many patients are diagnosed with hyperplastic breast disease and in situ carcinoma. 
Based on epidemiological data, these morphologically defined lesions may be 
categorised as
1. those with little malignant potential (e.g. typical hyperplasia or proliferative 
disease without atypia),
2. those with significant malignant potential which may already be “initiated” 
(e.g. atypical ductal hyperplasia) and
3. early “transformed” lesions which are malignant but not yet invasive (e.g. 
ductal carcinoma in situ).
As discussed previously (see 1.2.1), these lesions may represent sequential 
evolutionary stages in the development of invasive breast cancer, with each 
morphologically defined stage resulting from accumulating genetic changes 
culminating in a transformed clonal lineage capable of invasion and metastasis. For 
these lesions it is important to be able to define with accuracy which of the early
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stages of breast cancer progression they have reached so that the clinician has better 
guidelines for follow-up of the patient. For instance, it may be that a patient would 
benefit from further surgery or from endocrine therapy. As these procedures are 
unpleasant for the patient, any additional information, over that available from routine 
histological analysis, which would better define whether the patient is likely to benefit 
from a particular regime would be of great clinical value.
Tumours that are clearly malignant can still have prognostic problems. The grading of 
breast tumours divides patients into three groups, grade 1, grade 2 or grade 3 (see 
1.2.5.6a). All grade 3 patients are given chemotherapy, regardless of whether or not 
they have presented with lymph node metastases at the time of surgery. The decision 
about treatment of grade 1 and 2 patients is not so easily made. Currently at the Royal 
Surrey County Hospital, as a general guide, grade 1 or 2 patients who present with 4 
or more lymph node metastases are given adjuvant chemotherapy and those with less 
than four positive lymph nodes are given only neoadjuvant and adjuvant endocrine 
therapy. Patients with less than 4 lymph node metastases are expected to do well but a 
significant proportion of these patients will, however, have further local or distant 
recurrence of their tumour. It can be assumed that their tumours have in some way 
already progressed to the stage where they are capable of metastasising, even though 
this was not apparent in every case at the time of surgery.
4.1.3 Aims of the Breast Cancer studies.
There were two main areas of interest for these studies:-
1. The first area of interest was the changes that occur between the benign and 
malignant stages of tumourigenesis.
2. The second was any changes that occurred during the later stages of tumour 
progression and in particular between the non-metastasising and metastasising 
stages.
The aim of this study was firstly to collect data on the staining pattern of several 
antibodies for a wide variety of pathological lesions and to relate any changes in 
staining pattern to different biological features of these lesions. Secondly, these data 
were analysed to select antibodies to use for a project that targeted a specific clinical 
question, i.e. the heterogeneity of metastatic potential in low grade breast carcinomas.
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4.2 Breast Carcinoma Project 1
The characterisation of staining by the MIB1, p53, CD44H, CD44v3, CD44v6, ER 
and D5 antibodies in a variety of breast lesions
4.2.1 Aim of the project
The aim of this study was to stain a wide range of breast lesions with five different 
antibodies. The types of breast lesion and antibodies used are described in detail 
below (see 4.2.2 and 4.2.3). Analysis of this data could then provide a basis for the 
selection of a panel of antibodies that could be used to address specific clinical 
problems.
4.2.2 Selection of samples
In order to produce a base line for the staining characteristics of each antibody across 
a selection of specimens across a wide range of pathology was required.
The initial selection of 118 patients included samples which ranged from benign to 
high grade malignant lesions. Within each sample there was also a range of pathology, 
for example a section of a ductal carcinoma would often include an area of DCIS and 
in some cases lymph nodes from the same patient were studied. Each of the areas of 
separate pathology were scored separately, resulting in a total of 199 separate 
specimen scores as follows >
Pathology No. specimens
DCIS 34
Ductal carcinoma 86
LCIS 6
Lobular carcinoma 19
Lymph nodes 42
Hyperplasia 3
Radial scars 3
Medullary carcinoma 1
Tubular carcinoma 3
Mucinous carcinoma 2
Total 199
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Not all of these specimens were stained with every antibody. For example the lymph 
nodes were stained only with CD44. The total number of specimens stained with each 
antibody was as follows: -
As one of the two main areas of interest was that of the change from benign to 
malignant lesions, tubular carcinomas, which are low grade ductal carcinomas, were 
grouped separately for the initial assessment.
4.2.3 Selection of antibodies
4.2.3.1 MEB1
MIB1 was used as a measure of the proliferative activity of the tumours. Grading of 
breast tumours is partly based on mitotic count and thus MIB1 staining would be 
expected to correlate with tumour grade. Detection of mitoses, however, can vary with 
the fixation of the specimen. MEB1 also gives a much more reliable assessment of the 
number of proliferating cells as the Ki67 protein is present for a longer duration of the 
cell cycle than the mitotic phase and thus marks a greater number of cells that are 
proliferating (see 3.1.1.5).
4.2.3.2 p53
It has been demonstrated that using retrovirus-mediated gene transfer to restore wild- 
type p53 to breast cancer cell lines with known mutations in the p53 gene reduces the 
tumourgenicity of these cell lines in nude mice (Wang et al. 1993). There is also 
much evidence that the presence of p53 mutations in breast cancers may be an 
important indicator of poor prognosis (Elledge et al. 1993; Noguchi et al. 1997).
Antibody No. specimens
MIB1
p53
CD44H
CD44v3
CD44v6
D5
ER
158
158
199
194
195 
157 
157
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Published results, however, on the histochemical detection of p53 in breast cancers are 
not always consistent. The independent prognostic role of p53 accumulation has been 
observed in some studies on breast cancer (Silvestrini et al. 1993; Thor et al. 1992) 
but not in others (Bosari et al. 1992; Ostrowski et al. 1991), even when the same 
monoclonal antibody is used. Immunoreactivity of p53 has been shown to vary with 
length of fixation in formalin although microwave irradiation of specimens that had 
been fixed in formalin for 24 hours induced antigen retrieval with an immunostaining 
similar to that obtained after a short-term fixation (Silvestrini et al. 1995).
Expression of mutant p53 protein has been associated with high tumour proliferation 
rate, early disease recurrence and early death in node-negative breast cancer (Allred et 
al. 1993) and with resistance to doxorubicin (Aas et al. 1996). Other recent studies 
disagreed with these results and found that p53 did not predict disease-free or overall 
survival of patients with node negative breast cancer (Kristen et al. 1997; Rosen et al. 
1995). It has also been shown that p53 status was not significantly associated with 
response to tamoxifen and time to treatment failure, although patients with higher p53 
had a worse survival (Elledge et al. 1997).
The expression of p53 (antibody CM-1) during the transition from benign to 
malignant breast disease has been studied. No accumulation of p53 protein was 
observed before the carcinoma in situ phase. The highest levels of expression were 
found in invasive carcinomas and were closely associated with aneuploidy and poor 
differentiation. p53 overexpression did not increase further during the tumour spread 
to lymph nodes (Eriksson et al. 1994). A further study also showed that p53 staining 
was the same in paired primary carcinomas and metastatic lesions (Bartkova et al. 
1993). The expression of p53 was studied in infiltrating and in-situ carcinomas, using 
5 different antibodies directed against the whole or part of the p53 protein. It was 
found that those carcinomas with a high percentage of positive cells with all 
antibodies were more likely to have metastasised to nodes, be at an advanced stage, 
and be oestrogen receptor-negative/epidermal growth factor receptor-positive. They 
also found expression in 50% of the comedo ductal carcinomas in situ studied but 
either not at all or at a lower level in the cribriform type (Walker et al. 1991). 
Similarly another study (using antibody D07) also found that mutant p53 protein
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accumulation in preinvasive lesions was limited to comedo (high grade) DCIS 
(O'Malley etal. 1994).
A study using antibody Pabl801 found that 30% of cases had high levels of p53 in the 
nucleus of the cancer cells; 33% had a complete lack of detectable staining and a third 
group of tumours (37%) showed a pattern of cytoplasmic staining with nuclear 
sparing. It was suggested that some breast cancers that contain the wild-type form of 
p53 protein might inactivate its tumour-suppressing activity by sequestering this 
protein in the cytoplasm, away from its site of action in the cell nucleus. This would 
explain inactivation of p53 without mutation (Moll et al. 1992). Another study using 
this antibody found p53 accumulation in 29.8% of the cases and it was associated with 
ER negativity, PR negativity and high histological grade (Bhargava et al. 1994).
p53 was selected for this project because of its link with poor prognosis, assessing the 
presence of abnormal p53 over a wide range of pathology may help to clarify its 
prognostic importance for breast tumours.
4.2.3.3 CD44
Normal human breast tissue has been shown, using RT-PCR, to contain primarily the 
CD44 epithelial (CD44E) form and very little CD44 standard (CD44s, also referred to 
as CD44H) form. Metastatic breast carcinomas appeared to overexpress both the 
CD44E and CD44s forms and also display multiple new species of CD44 variant 
isoforms (Iida and Bourguignon, 1995).
Many studies using CD44 have been carried out, the majority using CD44 splice 
variants. CD44 expression in breast carcinomas has been related to poor 
differentiation (grade3), high mitotic count and oestrogen receptor negativity (Joensuu 
et al. 1993). A significant correlation between expression of CD44v3 and CD44v6 
and tumour grade was shown in one study but normal mammary epithelia as well as 
ductal hyperplasias were negative indicating that the expression of the CD44 variants 
is upregulated and is closely linked to tumour anaplasia (Sinn et al. 1995). The 
expression of CD44 isoforms in node-positive and node-negative cases of breast 
carcinoma was evaluated using immunohistochemistry. Disease-free survival and 
overall survival data did not indicate significant correlations with the expression of the 
analysed isoforms in univariate and multivariate analyses but carcinoma tissues with
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elevated ER and PR levels showed positive correlation with CD44v6. The conclusion 
was that in breast cancer CD44s, CD44v9 and CD44v6 are apparently markers for 
cellular differentiation but not for tumour progression (Freidrichs et al. 1995).
One study compared the predictive capacity and the applicability of 
immunohistochemistry and semi-quantitative RT-PCR for the screening of breast 
tumours. Immunohistochemistry revealed lack of expression of CD44v on normal 
ductal epithelial cells but strong expression on myoepithelial cells. RT-PCR however, 
detected splice variants in normal epithelium which was probably derived from RNA 
expressed in the myoepithelium (Dali et al. 1995).
Both CD44H and the CD44v3 and v6 variants were used for this project so that 
positivity could be assessed over a wide range of pathology. In particular the changes 
in staining patterns of hyperplastic lesions and those of metastasising carcinomas are 
of interest.
4.2.3.4ER
This project studied the expression of ER over a wide range of pathology.
In an early study using monoclonal antibodies to detect ER an immunocytochemical 
analysis of ER was performed on 150 samples including proliferative and non­
proliferative breast disease, atypical hyperplasia and non invasive in situ carcinoma as 
well as on 150 cases of breast cancer. It was found that normal breast structures 
generally displayed a higher proportion of negative cells, with positive cells showing a 
degree of staining intensity lower than neoplastic cells. In benign breast disease, ER 
expression was heterogeneous with low staining intensity. In contrast, in atypical 
hyperplasia and in situ carcinoma high ER expression was observed also displaying a 
homogenous distribution. Breast cancer exhibited high staining intensity in positive 
cells, although with a heterogeneous staining pattern, probably due to cancer clonal 
heterogeneity (Fabris, 1987). A recent study of ER expression in DCIS showed that 
positive ER staining was present in 72% of cases. Non-comedo types of DCIS were 
more frequently ER positive than comedocarcinoma, and the incidence of ER in pre­
menopausal and post-menopausal women was similar (Karayiannakis et al. 1996). 
Another study found a significant association between high grade DCIS and lack of 
ER (Leal etal. 1995).
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ER was chosen as an antibody for this project because of evidence of its significance 
as a prognostic indicator. Even though many tumours that contain ER are 
unresponsive to hormone therapy and a small percentage of tumours that do not 
contain ER do respond to antioestrogen therapy (see 3.4.1.2), clearly steroid hormone 
receptor immunocytochemistry provides important prognostic information.
A study of ER and PR on 426 primary breast carcinomas found that patients with 
either ER- or PR-positive carcinomas showed better overall survival, and patients with 
both negative ER and PR showed a poorer prognosis, than patients with only one 
negative receptor. A trend could also be found that patients whose carcinomas 
contained high numbers of receptor-positive tumour cells had a better survival, 
suggesting that the proportion of steroid receptor-positive tumour cells is of clinical 
importance (Reiner et aL 1990). This agrees with the results that a high rate of 
recurrence occurs in patients whose tumours contain high proportions of ER-negative 
tumour cells (Walker et al. 1988). Another study showed that the response to 
endocrine therapy was significantly higher in women with ER positive tumours, 
especially where the tumours contained more than 70% positive cells. Tumours that 
were apparently negative for ER expression rarely responded to endocrine therapy. 
The hormone sensitivity of ER positive breast cancer was also influenced by the rate 
of tumour cell proliferation, with these tumours expressing high levels of Ki67 
immunostaining rarely responding to therapy (Nicholson, 1991). Much of the 
confusing results of published studies can be explained by the fact that different 
groups have variable cut-off points ( e,g.>10% positive tumour cells ) at which they 
call a tumour ER positive. A recent study showed that tumours with any positively 
staining cells are significantly associated with increased survival compared to tumours 
that are totally ER negative (Clark et al. 1997). This is important as higher cut-off 
points would misclassify potentially endocrine-responsive tumours as ER-negative, 
resulting in inappropriate therapy.
This project will be looking at ER levels in conjunction with Ki67 (MIB1 antibody). 
4.2.3.5D5
The selection of specific chemotherapeutic agents for the treatment of patients with 
breast cancer is unfortunately a process of elimination. Unlike the selection of patients 
for hormonal therapies, where steroid receptor status is a predictor of endocrine
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response, there are few tests available, other than in vitro chemosensitivity assays, 
which can predict the likelihood to response to a particular chemotherapeutic agent. 
The most effective cytotoxic agents in breast cancer are doxorubicin (Adriamycin), 
taxol, cyclophosphamide, methotrexate, and 5-fluorouracil (see 1.1.3.1). Each of these 
agents if given alone can induce regression of metastatic breast cancer, and these 
drugs now constitute the core of most combination chemotherapy programs used in 
breast cancer. However, the effectiveness of all of these regimens is hindered both by 
intrinsic tumour drug resistance and by the development of drug-resistant tumour 
subpopulations. Determining the mechanisms involved in clinical drug resistance is 
critical to overcoming resistance and improving patient survival. There is now 
evidence that heat-shock proteins may be involved in drug resistance. It is now 
apparent from studies on cell lines that when heat shock proteins are induced prior to 
drug treatment then resistance to doxorubicin may be conferred (Ciocca et al. 1992). 
Cell lines which express high constitutive levels of hsp27, were transfected with 
antisense hsp27, and were thereby rendered more sensitive to doxorubicin 
(Oesterreich et al. 1993). As heat shock proteins are somehow involved in 
“protecting” the cell from various stress-induced alterations it is easy to propose that 
they might also enable the cell to recover from drug-induced damage.
There are thus two reasons for including hsp27 in this project. The first is its 
correlation with ER and the possibility that it may be an indicator of good prognosis in 
ER negative tumours and the second is its link with drug resistance.
4.2.4 Assessment of staining
The methods used for assessing the staining were as previously described in chapter 3.
4.2.4.1 MIB1
The score for MIB1 staining was expressed as the total number of stained nuclei of 
tumour cells expressed as a percentage of the total number of tumour nuclei present. 
The intensity of staining was not taken into consideration for reasons described 
previously (see 3.1.4). The percentage of stained nuclei were then ranked as follows:-
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0% -> = 0
1% —^ 4% = 1
5% -» 10% = 2
11% 20% = 3
21% —^ 50% = 4
51% —^ 100% = 5
42.4.2 p53
p53 staining was assessed in a similar manner to MCB1. Staining intensity was not 
assessed (see 3.2.2). The total number of tumour nuclei stained was expressed as a 
percentage of the total number of tumour nuclei present. The percentage score was 
then ranked as follows: -
0% —y = 0
1% —^ 10% = 1
11% -> 50% = 2
51% 100% -  3
4.2.43 CD44
CD44 staining was assessed as previously described (see 3.3.2). The total number of 
tumour cells expressing any membrane staining was expressed as a percentage of the 
total number of tumour cells present. Additionally, for this antibody tumour cells 
showing three different intensities of staining were assessed separately and a score 
was calculated which was weighted for intensity of staining. As the intensity was 
given a score of 1-3 the maximum total was 300 if all the cells were strongly positive. 
This score of CD44 expression was ranked as follows: -
0 = 0
1 —^ 50 = 1
51 —^ 100 = 2
101 -» 150 = 3
151 -> 200 = 4
201 300 = 5
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4.2.4.4 ER
ER staining was mainly nuclear and only nuclear staining was assessed. Again an 
attempt was made to score two different intensities of staining, but, as this was 
unreliable, a score of the total number of tumour cells showing positive staining 
expressed as a percentage of the total number of tumour cells present was used (see 
3.4.3). These scores were ranked as follows: -
0% —^ = 0
1% -» 10% = 1
11% -» 50% = 2
51% 100% = 3
4.2.4.5 D5
D5 staining was cytoplasmic. Initially an attempt was made to divide the staining into 
two different intensities of staining. It was impossible to find a cut-off point between 
the two intensities, as there was a gradation of staining, The only score assessed was 
that of the total number of tumour cells showing positive staining expressed as a 
percentage of the total number of tumour cells present (see 3.5.2).
This score was then ranked as follows: -
0% -> = 0
1% 10% = 1
11% — > 30% = 2
31% -» 50% = 3
51% -> 70% = 4
71% —^ 100% = 5
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4.2.5 Selection of statistical methods
Fig 4.1 Graphs to show distribution of data for the staining scores for MIB1, 
p53, CD44H, ER and D5. For explanation of ranked scores see 4.2.4
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It was demonstrated, as shown in Fig 4.1, that the data obtained did not have a normal 
distribution, therefore non-parametric statistical tests were used.
Most of the data were ranked scores and were thus ordered nominal scales.
The most appropriate test for this type of data was the Mann-Whitney U  test, which 
could be used to look for significant differences in staining pattern between two types 
of pathology (see 2.3.2.1).
Spearman correlations were also performed on the ranked scores for the various 
antibodies to look for either a positive or a negative relationship between the staining 
patterns and also with the grade of ductal carcinoma to look for a linear relationship 
between positivity and grade of tumour.
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4.2.6 Results.
Mean values, standard deviations and standard errors were calculated for the 
different pathological groups, and Mann-Whitney U tests were used to look for 
differences in staining pattern between the different pathological groups with the 
following antibodies:-
1. Hyperplasia and DCIS MIB1, p53, CD44H,
CD44v6, ER, D5
2. Hyperplasia and ductal carcinoma MIB1, p53, CD44H,
CD44v6, ER, D5
3. DCIS and ductal carcinoma MIB1, p53, CD44H,
CD44v6, ER, D5
4. LCIS and DCIS MIB1, p53, CD44H,
CD44v6, ER, D5
5. LCIS and lobular carcinoma MIB1, p53, CD44H,
CD44v6, D5, ER
6. Ductal carcinoma and lobular carcinoma MIB1, p53, CD44H,
CD44v6, ER, D5
7. Ductal carcinoma and lymph node metastases CD44H, CD44v3, CD44v6, D5,
ER
8. Ductal carcinoma and radial scars MDB1, p53, CD44H, CD44v3,
CD44v6, ER, D5
9. Ductal carcinoma and tubular carcinoma MIB1, p53, CD44H, CD44v3,
CD44v6, ER, D5
10. Ductal carcinoma and mucinous carcinoma MIB1, p53, CD44H, CD44v3,
CD44v6, ER. D5
Mean values for the staining values of all the antibodies tested for each pathological 
group, the Mann-Whitney U score and the significance values are shown in the tables 
(see appendix tables 1-29). Differences in staining characteristics of the antibodies 
between the different types of breast lesion studied are summarised below.
CD44v3,
CD44v3,
CD44v3,
CD44v3,
CD44v3,
CD44v3,
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4.2.6.1 Comparison of benign, in situ and invasive malignant lesions and lymph 
node metastases.
MIB1 antibody
Fig 4.2 Charts to show the change in mean values for degree of staining of MIB1 
for the range of pathology hyperplasia, DCIS and ductal carcinoma. Fig 4.2a 
shows mean values only and Fig 4.2b shows the standard errors of these means.
hyperplasia DCIS ductal carcinoma
Fig 4.2a
3.5
2.5
2.0
1.5
+ 1.0
hyperplasia DCS ductal carcinoma
Fig 4.2b
It can be seen from Fig 4.2 that MDB1 staining was higher in the malignant than the 
benign lesions.
It can be seen from Fig 4.2 that MIB1 staining of in situ and invasive ductal 
carcinomas was higher than that hyperplasia.
Mann-Whitney U tests (see appendix table 2) showed that:-
1. MIB1 staining was significantly higher in the DCIS group than in the 
hyperplasia group
2. MIB1 staining was significantly higher in the ductal carcinoma group than in 
the hyperplasia group
3. MIB1 staining was similar in DCIS and invasive ductal carcinoma group.
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p53 antibody
Fig 4.3 Charts to show the change in mean values for degree of staining of p53
for the range of pathology hyperplasia, DCIS and ductal carcinoma. Fig 4.3a
shows mean values only and Fig 4.3b shows the standard errors of these means.
hyperplasia DCIS ductal carcinoma
Fig 4.3a
hyperplasia DCIS ductal carcinoma
Fig 4.3b
It can be seen from Fig 4.3. that:-
1. No p53 staining was seen in the benign lesions.
2. p53 staining was slightly lower in ductal carcinoma than in the DCIS group.
Mann-Whitney U  tests (see appendix table 4) showed that there were no significant 
differences between the p53 scores for any of these groups.
CD44 antibodies
Below are charts to show the staining pattern of CD44, both the standard and the 
variant forms (CD44H, CD44v3 and CD44v6). As with the previous antibodies, the 
values are ranked scores of the values weighted for intensity of staining. Lymph 
nodes, associated with the ductal carcinomas, which contained tumour were also 
stained with the three CD44 antibodies and the results are summarised below.
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CD44H
Fig 4.4 Charts to show the change in mean values for degree of staining of 
CD44H for the range of pathology hyperplasia, DCIS and ductal carcinoma. Fig 
4.4a shows mean values only and Fig 4.4b shows the standard errors of these 
means
hyperplasia ductal carcinoma
Fig 4.4a
hyperplasia DOS ducta; carcinoma
Fig 4.4b
It can be seen from Fig 4.4 that:-
1. CD44H staining was higher in the benign lesions than either of the malignant 
lesions.
2. CD44H staining was slightly higher in DCIS than in ductal carcinoma.
Mann-Whitney U tests (see appendix table 8) showed that:-
1. CD44H staining was significantly higher in the hyperplasia group than in the 
ductal carcinoma group. The differences were significant for the ranked score 
of the total percentage of cells and also for the score taking intensity of 
expression into account.
2. There were no significant differences between the DCIS and the ductal 
carcinoma group or between the hyperplasia and DCIS groups.
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Fig 4.5 Charts to show the change in mean ranked expresson values for degree of 
staining of CD44H for the range of pathology hyperplasia, DCIS and ductal 
carcinoma and lymph node metastases. Fig 4.5a shows mean values only and Fig 
4.5b shows the standard errors of these means
©  1.5
hyperplasia ductal carcinoma
DCIS lymph nodes
Fig 4.5a
w 1.0
hyperplasia ductal carcinoma
DCIS lymph nodes
Fig 4.5b
It can be seen from Fig 4.5 that:-
1. CD44H staining was higher in the benign group than any of the malignant 
groups of lesions.
2. CD44H staining was similar in the metastatic lesions to that of the invasive 
ductal lesions.
Mann-Whitney U tests (see appendix table 8) showed that:-
1. CD44H staining was significantly higher in the hyperplasia group than in the 
ductal carcinoma group. The differences were significant for the ranked score 
of the total percentage of cells and also for the score taking intensity of 
expression into account.
2. CD44H staining was significantly higher in the hyperplasia group than in the 
lymph node metastasis group.
3. There were no significant differences between the DCIS and the ductal 
carcinoma group or between the hyperplasia and DCIS groups.
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CD44v3 antibody
Fig 4.6 Charts to show the change in mean ranked expression values for degree 
of staining of CD44v3 for the range of pathology hyperplasia, DCIS and ductal 
carcinoma and lymph node metastases. Fig 4.6a shows mean values only and Fig 
4.6b shows the standard errors of these means.
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DCIS lymph nodes
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Fig 4.6b
It can be seen from Fig 4.6 that:-
1. CD44v3 staining was similar in all the groups of malignant lesions.
2. CD44v3 staining was higher in the benign than in the malignant lesions.
Mann-Whitney U tests (see appendix table 12) showed that there were no significant 
differences between the CD44v3 scores for any of these groups.
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CD44v6 antibody
Fig 4.7 Charts to show the change in mean values for degree of staining of 
CD44v6 for the range of pathology hyperplasia, DCIS, ductal carcinoma and 
lymph node metastases. Fig 4.7a shows mean values only and Fig 4.7b shows the 
standard errors of these means.
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Fig 4.7b
It can be seen from Fig 4.7 that:-
1. CD44v6 staining was similar in all the groups of malignant lesions.
2. CD44v6 staining was higher in the benign than in the malignant lesions.
Mann-Whitney U tests (see appendix table 14) showed that there were no significant 
differences between the CD44v6 scores for any of these groups.
ER antibody
Fig 4.8 Charts to show the change in mean values for degree of staining of ER
for the range of pathology hyperplasia, DCIS and ductal carcinoma. Fig 4.8a
shows mean values only and Fig 4.8b shows the standard errors of these means
hyperplasia DCS ductal carcinoma
Fig 4.8a
hyperplasia DCS ductal carcinoma
Fig 4.8b
It can be seen from Fig 4.8 that:-
1. ER staining was lower in DCIS than in ductal carcinoma
2. ER staining was higher in the benign lesions than either of the groups of 
malignant lesions.
Mann-Whitney U tests (see appendix table 16) showed that there were no significant 
differences between the ER scores for any of these groups.
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D5 antibody
Fig 4.9 Charts to show the change in mean values for degree of staining of D5
for the range of pathology hyperplasia, DCIS and ductal carcinoma. Fig 4.9a
shows mean values only and Fig 4.9b shows the standard errors of these means.
hyperplasia ductal carcinoma
Fig 4.9a
+
c
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hyperplasia DCIS ductal carcinoma
Fig 4.9b
It can be seen from Fig 4.9 that:-
1. D5 staining was similar in both the DCIS and invasive ductal carcinoma group 
of lesions.
2. No D5 staining was present in the hyperplasia.
Mann-Whitney U tests (see appendix table 18) showed that:-
1. D5 staining of the DCIS group was significantly higher than that of the 
hyperplasia group.
2. D5 staining of the ductal carcinoma group was significantly higher than that of 
the hyperplasia group.
A summary of the differences in staining pattern between the hyperplasia, ductal 
carcinoma and lymph node metastasis groups is given below.
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Benign lesions (Hyperplasia)
Hyperplasia and DCIS
1. MIB1 staining was significantly higher in the DCIS group than in the 
hyperplasia group.
2. There was no significant difference in p53 staining between the two groups.
3. There was no significant difference in CD44H, CD44v3 or CD44v6 staining 
between the two groups.
4. There was no significant difference in ER staining between the two groups.
5. D5 staining was significantly higher in the DCIS group than in the hyperplasia 
group.
Hyperplasia and invasive ductal carcinoma
1. MIB1 staining was significantly higher in the invasive ductal carcinoma group 
than in the hyperplasia group.
2. There was no significant difference in p53 staining between the two groups.
3. There was no significant difference in CD44v3 or CD44v6 staining between 
the two groups but there was significantly less CD44H staining in the invasive 
ductal carcinomas than the hyperplasias.
4. There was no significant difference in ER staining between the two groups.
5. D5 staining was significantly higher in the invasive ductal carcinoma group 
than in the hyperplasia group.
Carcinoma in situ
Staining of the ductal in situ group of carcinomas was compared to invasive ductal 
carcinoma and the lobular in situ group of carcinomas was compared with the invasive 
lobular carcinomas.
There were no significant differences in staining between the DCIS and ductal 
carcinoma groups for any of the antibodies studied or between LCIS and invasive 
lobular carcinoma.
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Lymph node metastases
1. There was no significant difference in CD44H, CD44v3 or CD44v6 staining 
between the ductal carcinoma and lymph node metastasis group.
2. There was no significant difference in ER staining between the ‘ductal carcinoma 
and lymph node metastasis group’.
3. D5 staining was significantly lower in the group of lymph node metastases than in 
the ductal carcinomas group.
4.2.6.2 Comparison of the 3 grades of ductal carcinoma
The above results included those for a group of ductal carcinomas that consisted of a 
mixture of all three grades of ductal carcinoma. It was also possible to split the ductal 
carcinoma group into the three different grades of carcinoma and look for changes in 
antibody staining with increasing grade of carcinoma.
Changes in staining intensity of the antibodies MIB1, p53, CD44H, ER and D5
between the different grades of ductal carcinoma are shown in Fig 4.10.
Changes in staining intensity of the three CD44 antibodies CD44H, CD44v3 and
CD44v6 are shown in Fig 4.11.
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Fig 4.10 Charts to show the mean values of the ranked expression scores for the 
five antibodies tested. For CD44H, the score weighted for intensity of expression 
was used. Fig 4.10a shows the mean values only and Fig 4.10b shows the 
standard errors of the means.
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Fig 4.11 Charts to show staining pattern of the different isoforms of CD44 in
ductal carcinoma and the associated lymph nodes. Fig 4.11a shows the mean
values only and Fig 4.11b shows the standard errors of the means.
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It can be seen from Figs 4.10 and 4.11 that:-
1. MIB1 staining increased with increasing grade of ductal carcinoma.
2. p53 staining increased with increasing grade of ductal carcinoma.
3. CD44H decreased with increasing grade of ductal carcinoma
4. There were no differences between any of the grades of ductal carcinoma for 
either CD44v3 or CD44v6 staining.
5. ER staining decreased with increasing grade of ductal carcinoma.
6. D5 staining remained constant for all grades of ductal carcinoma
Tables for the mean values and the Mann Whitney test values are given in the
appendix (tables 19-30).
In summary
MIB1
1. MIB1 staining of grade 2 ductal carcinomas was significantly higher than that 
of grade 1 ductal carcinomas.
2. MIB1 staining of grade 3 ductal carcinomas was significantly higher than that 
of grade 1 ductal carcinomas.
3. MIB1 staining of grade 3 ductal carcinomas was significantly higher than that 
of grade 2 ductal carcinomas.
p53
1. p53 staining of grade 2 ductal carcinomas was significantly higher than that of 
grade 1 ductal carcinomas.
2. p53 staining of grade 3 ductal carcinomas was significantly higher than that of 
grade 1 ductal carcinomas.
3. p53 staining of grade 3 ductal carcinomas was significantly higher than that of 
grade 2 ductal carcinomas.
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CD44
1. CD44H staining of grade 3 ductal carcinomas was significantly lower than that 
of grade 1 ductal carcinomas, both for the total percentage score and for the 
score weighted for intensity of expression.
2. There were no significant differences in CD44H staining between grade 2 
ductal carcinomas and either grade 1 ductal carcinomas or grade 3 ductal 
carcinomas.
3. There were no significant differences between any of the grades of ductal 
carcinoma for either CD44v3 or CD44v6 staining.
Staining of lymph node metastases.
CD44H staining was significantly lower than in grade 1 ductal carcinomas and similar
to grade 2 and grade 3 ductal carcinomas.
ER
1. ER staining of grade 2 ductal carcinomas was significantly lower than that of 
grade 1 ductal carcinomas.
2. ER staining of grade 3 ductal carcinomas was significantly lower than that of 
grade 1 ductal carcinomas.
3. ER staining of grade 3 ductal carcinomas was significantly lower than that of 
grade 2 ductal carcinomas.
D5
There were no significant differences between any of the grades of ductal carcinoma
for D5 staining.
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4.2.6.3 Lobular carcinomas
Fig 4.12 Charts to show the comparison of the mean scores for the staining of 
LCIS, lobular carcinomas and ductal carcinomas, when grouped as a whole, 
using MIB1, p53, CD44H, ER and D5 antibodies. Fig 4.12a shows the mean 
values only and Fig 4.12b shows the standard errors of the means.
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It can be seen from Fig 4.12 that:-
1. MIB1 staining was higher in lobular carcinomas than in LCIS and higher in 
ductal carcinomas than in lobular carcinomas.
2. p53 staining was absent in LCIS, low in lobular carcinomas and highest in 
ductal carcinomas.
3. CD44H staining was slightly higher in lobular carcinomas than in LCIS or 
ductal carcinomas.
4. ER staining was higher in lobular carcinoma, both in situ and invasive than 
ductal carcinomas.
5. D5 staining was higher in lobular carcinomas than in LCIS and higher in 
ductal carcinomas than in lobular carcinomas
Using Mann-Whitney tests (see appendix table 2), the staining of in situ and invasive
lobular carcinomas were compared both to each other and to their ductal counterparts.
LCIS and DCIS
1. MIB1 staining was significantly higher in the DCIS group than in the LCIS 
group.
2. There were no significant differences in staining between the LCIS and DCIS 
groups for any of the other antibodies studied.
LCIS and lobular carcinoma
There were no significant differences in staining between the LCIS and lobular
carcinoma groups for any of the antibodies studied.
Ductal carcinoma and lobular carcinoma
1. MIB1 staining was significantly higher in the ductal carcinoma group than in 
the lobular carcinoma group.
2. p53 staining was higher in the ductal carcinoma group than in the lobular 
carcinoma group, but the difference did not quite reach significance.
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3. There was no significant difference in CD44H, CD44v3 or CD44v6 staining 
between the two groups.
4. ER staining was higher in the lobular carcinoma group than in the ductal 
carcinoma group, but only the ranked score reached significance.
5. There was no significant difference D5 staining between the two groups.
Invasive lobular carcinomas were then compared separately with the different grades 
of ductal carcinoma.
Fig 4.13 Charts to show the comparison of staining between the three grades of 
ductal carcinoma and lobular carcinoma using MIB1, p53, CD44H, ER and D5 
antibodies. Fig 4.13a shows the mean values only and Fig 4.13b shows the 
standard errors of the means.
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When the ductal carcinoma group is divided into groups of different grade of 
carcinoma then it can be seen, from Fig 4.13 that:
1. MIB1 staining of lobular carcinomas is similar to grade 1 ductal carcinomas.
2. p53 staining of lobular carcinomas is similar to grade 1 ductal carcinomas.
3. CD44H staining of lobular carcinomas is similar to grade 1 ductal carcinomas.
4. ER staining of lobular carcinomas is similar to grade 1 ductal carcinomas
5. D5 staining of lobular carcinomas is similar to all three grades of ductal 
carcinomas
Using Mann-Whitney tests (see appendix table 2):
1. There were no differences between lobular carcinomas and grade 1 ductal 
carcinomas for any of the antibodies tested.
2. MIB1 staining was significantly higher in grade 2 ductal carcinomas than in 
lobular carcinomas and ER staining was significantly lower in grade 2 ductal 
carcinomas than in lobular carcinomas. There were no significant differences 
between the groups for p53, CD44H or D5 staining.
3. MDB1 and p53 staining were significantly higher in grade 3 ductal carcinomas 
than in lobular carcinomas and ER staining was significantly lower in grade 3 
ductal carcinomas than in lobular carcinomas. There were no significant 
differences between the groups for CD44H or D5 staining.
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4.2.6.4 Radial scars
The staining of radial scars was compared to that of ductal carcinomas.
Fig 4.14 Charts to show the comparison of staining between radial scars and 
ductal carcinomas, when grouped as a whole, using MIB1, p53, CD44H, ER and 
D5 antibodies. Fig 4.14a shows the mean values only and Fig 4.14b shows the 
standard errors of the means.
_ J C D 4 4 H
LJM B1
radial scar ductal carcinoma
Fig 4.14a
5
4
3
2
1
0
•1
ductal carc  inomaradial scar
I
□  CD44H
I
a D5
I
a  er
I
□ MB1
I
□ P53
Fig 4.14b
156
It can be seen from Fig 4.14 that:-
1. MIB1 staining was lower in radial scars than in ductal carcinomas.
2. p53 staining was absent in any of the radial scar lesions tested.
3. CD44H staining was similar in radial scars to ductal carcinomas.
4. D5 staining was lower in radial scars than in ductal carcinomas.
5. ER staining was slightly higher in radial scars than in ductal carcinomas.
Using Mann-Whitney tests (see appendix table 2):
1. MIB1 staining of radial scars was significantly lower than that of ductal 
carcinomas.
2. D5 staining of radial scars was significantly lower than that of ductal 
carcinomas
3. There were no significant differences in staining between the radial scar group 
and ductal carcinoma group for any of the other antibodies studied.
157
4.2.6.5 Tubular carcinomas
The staining of tubular carcinomas was compared to that of ductal carcinomas.
Fig 4.15 Charts to show the comparison of staining between tubular carcinomas 
and ductal carcinomas when grouped as a whole, using MIB1, p53, CD44H, ER 
and D5 antibodies. Fig 4.15a shows the mean values only and Fig 4.15b shows the 
standard errors of the means.
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From Fig 4.15 it can be seen that:-
1. MIB1 staining of tubular carcinomas is lower than in ductal carcinomas.
2. p53 staining of tubular carcinomas is lower than in ductal carcinomas.
3. CD44H staining of tubular carcinomas is higher than in ductal carcinomas.
4. ER staining of tubular carcinomas is higher than in ductal carcinomas.
5. D5 staining of tubular carcinomas is lower than in ductal carcinomas.
Using Mann-Whitney tests (see appendix table 2):
1. MIB1 staining of tubular carcinomas was significantly lower than that of 
ductal carcinomas.
2. D5 staining of tubular carcinomas is significantly lower than in ductal 
carcinomas.
3. There were no significant differences between the groups for p53, CD44H or 
ER staining.
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4.2.6.6 Mucinous carcinoma
The staining of mucinous carcinomas was compared to that of ductal carcinomas.
Fig 4.16 Charts to show the comparison of staining between mucinous 
carcinomas and ductal carcinomas when grouped as a whole, using MIB1, p53, 
CD44H, ER and D5 antibodies. Fig 4.16a shows the mean values only and Fig 
4.16b shows the standard errors of the means.
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From Fig 4.16 it can be seen that the mean values for the scores for all the antibodies 
tested were lower in mucinous carcinomas than in the ductal carcinoma group as a 
whole.
Using Mann-Whitney tests (see appendix table 2 and table 31) none of the differences 
between the two groups were significant for any of the antibodies tested.
When mucinous carcinomas were compared with the three different grades of ductal 
carcinoma (see appendix table31)
1. MIB1 staining was lower than any of the grades of ductal carcinoma but only 
the difference between mucinous and grade 3 ductal was significant.
2. There was no significant difference in p53 staining between mucinous and any 
of the grades of ductal carcinomas.
3. There was no difference in CD44H staining between mucinous and any of the 
other groups of invasive ductal carcinomas.
4. There was no significant difference in staining by either of the CD44 variants 
between mucinous and any of the grades of ductal carcinomas.
5. There was no significant difference in ER staining between mucinous and any 
of the grades of ductal carcinomas.
6. There was no significant difference in D5 staining between mucinous and any 
of the grades of ductal carcinomas.
4.2.6.7 Spearman correlations
Tables for Spearman’s rho correlation coefficients and significance values can be 
found in the appendix (tables 32 and 33). Throughout the range of pathology studied:
1. CD44H correlated negatively with MIB1
2. CD44H correlated negatively with p53.
3. There was a significant positive correlation between CD44H and both of the 
variant isoforms
4. CD44H correlated negatively with grade of carcinoma.
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5. The variant forms of CD44 did not correlate negatively with grade of 
carcinoma.
6. ER correlated positively with the variant isoforms of CD44
7. ER did not correlate with CD44H.
8. ER correlated positively with D5
9. ER correlated negatively with grade of ductal carcinoma.
10. D5 did not correlate with grade of ductal carcinoma
11. ER correlated negatively with MIB1.
12. D5 correlated positively with MIB1.
13. MIB1 correlated positively with p53.
14. MTBl correlated positively with grade of carcinoma.
15. p53 correlated positively with grade of carcinoma.
4.2.6.8 Discussion
(See also Chapter 7 General Discussion)
There were two main areas of interest for this study. The first was the difference in 
expression of the various antigens between benign and malignant cells. The second 
was to assess any changes in staining pattern that could be detected as cells gained 
metastatic potential.
The intention behind this first project was to obtain data for the overall staining 
pattern of a variety of breast lesions, which included benign and malignant, non­
metastatic and metastatic lesions. An initial impression could be gained as to which 
antibodies would be of interest for further, more specific, projects. No clear picture 
emerged but it appeared that four antibodies could be of interest for detection of the 
change from benign to malignant state. These included MIB1 and D5, as there was an 
increase in staining pattern between hyperplasia and DCIS. CD44H was also of 
interest as there was higher staining in hyperplasia than ductal carcinoma. Increasing 
grade of ductal carcinoma appeared to be accompanied by a decrease in CD44H 
expression. It might have followed from the comparisons of hyperplasia and DCIS
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and of hyperplasia and ductal carcinoma that there would be a difference between the 
DCIS and ductal carcinoma groups or between the LCIS and lobular carcinoma 
groups in CD44H staining, but no difference could be detected. CD44H showed 
potential as a marker of metastatic potential as expression appeared to be lost in high 
grade carcinomas and further investigation was required.
ER also required further investigation as, although the staining pattern was difficult to 
interpret, it correlated with D5 staining which was of interest for a marker of 
malignant change.
There were very few cases of hyperplasia or low grade ductal carcinomas included in 
the selection. The statistical tests allow for a small number of cases included in a 
group, but it was decided, nevertheless, to add more cases of hyperplasia to the 
selection. It was also decided to extend this area of interest by adding other benign and 
low grade lesions to the study including papillomas, radial scars, atypical 
hyperplasias, DCIS, grade 1 ductal carcinomas and medullary carcinomas. These 
could then be stained with the four antibodies named above.
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4.3 Breast Carcinoma Project 2
A detailed investigation o f the staining characteristics of the antibodies MIB1, p53, 
CD44H, CD44v3, CD44v6, ER and D5 in benign and malignant breast lesions.
4.3.1 Aim of the project
As the number of benign and low grade samples were few in the initial selection 
(Breast Carcinoma Project 1), extra samples of these types were then selected and 
added to the overall numbers of specimens.
4.3.2 Selection of specimens.
As a baseline for the pattern of staining of benign lesions a selection of papillomas 
was included. Also included were extra examples of hyperplasia and low grade 
lesions, such as grade 1 ductal carcinomas and radial scars. Extra medullary 
carcinomas were also added as they are an area of particular interest.
The total number of separate pathology scores was then 315, the number of specimens 
of specific types of pathology being as follows
Pathology no. specimens
Papilloma 23
Hyperplasia 20
Atypical hyperplasia 6
DCIS 41
Grade 1 ductal 65
Grade 2 ductal 38
Grade 3 ductal 25
LCIS 6
Lobular 21
Lymph node 42
Radial Scar 22
Medullary 4
Mucinous 2
Total 315
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4.3.3 Selection of antibodies
A slightly different range of antibodies was used for these additional specimens.
The extra benign and low grade lesions that were added to the selection of specimens 
were stained with MIB1, CD44H, ER and D5. p53 was not used as very few of these 
types of lesions stained with p53 in breast project 1.
1. Papillomas, hyperplasias, radial scars, medullary carcinomas and mucinous 
carcinomas were stained with MIB1, CD44H, ER and D5.
2. Lymph node metastases were stained with CD44H, CD44v3 and CD44v6 
only.
3. All other lesions were stained with MDB1, p53, CD44H, CD44v3, CD44v6, 
ER, and D5.
4.3.4 Selection of statistical methods
The following graphs (Fig 4.17) show that the data obtained for the staining scores for 
each antibody in this project did not have a normal distribution, therefore non- 
parametric statistical tests were used for analysis of the data.
The most appropriate test was the Mann-Whitney U test, which is the non-parametric 
equivalent of the two sample t test, and which can be used to look for significant 
differences in staining pattern between two types of pathology.
Spearman correlations were also performed on the ranked scores for the various 
antibodies to look for either a positive or a negative relationship between the staining 
patterns and also with the grade of ductal carcinoma to look for a linear relationship 
between positivity and grade of tumour.
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Fig 4.17 Graphs to show the distribution of the staining scores for the antibodies
MEB1, p53, CD44H, ER and D5.
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Most of the data are presented as rank scores and are thus ordered nominal scales.
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4.3.5 Assessment of staining
The methods used for assessing the staining of the various antibodies were as 
previously described (see Chapter 3).
4.3.5.1 MIB1
The score for MIB1 staining was expressed as the total number of stained nuclei of 
tumour cells expressed as a percentage of the total number of tumour nuclei present. 
The percentage of stained nuclei were then ranked as follows:-
0% -» ==0
1% -> 4% = 1
5% — > 10% = 2
11% —^ 20% = 3
21% —^ 50% = 4
51% —^ 100% = 5
4.3.5.2 p53
p53 staining was assessed in a similar manner. The total number of tumour nuclei 
stained was expressed as a percentage of the total number of tumour nuclei present. 
The percentage score was then ranked as follows:-
0% —^ = 0
1% 10% = 1
11% 50% = 2
51% -> 100% = 3
4.3.5.3 CD44
CD44 staining was assessed as previously described (see 3.3.2). The total number of 
tumour cells expressing any membrane staining was expressed as a percentage of the 
total number of tumour cells present. Additionally tumour cells showing three 
different intensities of staining were assessed separately and a score was calculated 
which was weighted for intensity of staining. As the intensity was given a score of 1-3
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the maximum total was 300 if all the cells were strongly positive. This score of CD44 
expression was ranked as follows:*
0 -> = 0
1 -> 50 = 1
51 100 = 2
101 -> 150 = 3
151 -» 200 = 4
201 —^ 300 = 5
4.3.5.4 ER
ER staining was mainly nuclear and only nuclear staining was assessed. Again an 
attempt was made to score two different intensities of staining, but, as this was 
unreliable, a score of the total number of tumour cells showing positive staining 
expressed as a percentage of the total number of tumour cells present was used and 
ranked as follows >
0% =0  
1% 10% =1
11% -> 50% = 2
51% 100% = 3
4.3.5.5 D5
D5 staining was cytoplasmic. Initially an attempt was made to divide the staining into 
two different intensities of staining. It was impossible to find a cut-off point between 
the two intensities, as there was a gradation of staining, and so the only score assessed 
was that of the total number of tumour cells showing positive staining expressed as a 
percentage of the total number of tumour cells present.
This score was then ranked as follows
0% - >  = 0  
1% ->  10% =1
11% -» 50% = 2
51% 100% =3
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4.3.6 Results.
Breast project 1 showed that there was no difference in statistical results whether the 
absolute values or the ranked score was used. To simplify the results for this project 
only ranked scores were used in the statistical tests. The scores were ranked scores of 
the total number of cells staining for MIB1, D5, ER and p53 and ranked scores of the 
expression score for CD44.
For this second selection of patients, as with Project 1, mean values of the staining 
scores of each antibody for the different pathological groups were calculated and 
Mann-Whitney U tests were used to look for differences in staining pattern between a 
wide range of pathological lesions. (See appendix tables 32-42 for these results).
4.3.6.1 Comparison of benign and malignant lesions
The staining scores for the antibodies M3B1, CD44, ER and D5 were assessed for 
benign lesions, represented by papillomas and hyperplasias. These scores were 
compared with the scores for malignant lesions, represented by DCIS and invasive 
ductal carcinomas.
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MEB1 antibody
Fig 4.18 Charts to show the mean values for the scores for MIB1 staining of
benign and malignant lesions. Fig 4.18a, shows mean values only and Fig 4.18b
shows the standard errors of these means.
papilloma hyperplasia DCIS ductal carcinoma
Benign lesions Malignant lesions 
Fig 4.18a
papilorra hyperplasia DCS ductal carcinoma
Benign lesions Malignant lesions
Fig 4.18b
It can be seen from Fig 4.18 that:-
1. Papillomas had a higher proliferation rate, as assessed by MIB1 staining, than 
the hyperplasias
2. DCIS and invasive ductal carcinoma showed a similar staining pattern to each 
other for MIB1.
3. MIB1 staining was lower in either of the groups of benign lesions than it was 
in either of the malignant lesions.
Using Mann-Whitney tests (see appendix tables 35-37);
Papillomas
1. MIB1 staining of papillomas was significantly lower than that of DCIS.
2. MIB1 staining of papillomas was similar to that of grade 1 ductal carcinomas.
3. MIB1 staining of papillomas was significantly lower than grade 2 or 3 ductal
carcinomas.
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Hyperplasia
MIB1 staining of ductal hyperplasia was similar to that of atypical ductal hyperplasia 
and significantly lower that that of DCIS or invasive ductal carcinoma.
Atypical ductal hyperplasia
MIB1 staining of atypical ductal hyperplasia was significantly lower than in the DCIS 
or any of the ductal carcinoma groups.
CD44H antibody
Fig 4.19 Charts to show the mean values for the scores for CD44H staining of 
benign and malignant lesions. Fig 4.19a, shows mean values only and Fig 4.19b 
shows the standard errors of these means.
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Fig 4.19a
It can be seen from Fig 4.19 that:-
papiilomas hyperplasia D3S ductal carcinoma
Benign lesions Malignant lesions
Fig 4.19b
1. The mean CD44 scores of both papillomas and hyperplasias were very similar 
to each other.
2. The scores for the two malignant lesions, DCIS and ductal carcinoma were 
very similar to each other.
3. Both of the benign lesions had higher scores than either of the malignant 
lesions.
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Using the Mann-Whitney tests (see appendix 35-37):
Papillomas
1. CD44H staining of papillomas was similar to that of hyperplasias.
2. CD44H staining of papillomas was significantly higher than that of DCIS.
3. CD44H staining of papillomas was significantly higher than that of grade 1, 
grade 2, or grade 3 ductal carcinomas.
Hyperplasia
1. CD44H staining of the hyperplasia group was significantly higher than that of 
DCIS.
2. CD44H staining of the hyperplasia group was significantly higher than that of 
grade 2 or grade 3 carcinomas.
3. CD44H staining of the hyperplasia group was higher than that of atypical 
hyperplasia and grade 1 ductal carcinomas, but not significantly so (p = 0.065 
for grade 1 ductal carcinomas).
Atypical ductal hyperplasia
CD44H staining in the atypical hyperplasia group was similar to that of the DCIS 
group and the grade 1 and grade 2 ductal carcinoma groups. It was higher than in the 
grade 3 ductal carcinoma group but the difference was not quite significant (p =
0.051).
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ER antibody
Fig 4.20 Charts to show the mean values for the scores for ER staining of benign
and malignant lesions. Fig 4.20a, shows mean values only and Fig 4.20b shows
the standard errors of these means.
papilloma hyperplasia DCIS ductal carcinoma
Benign lesions Malignant lesions
Fig 4.20a
papillomas hyoerplasia
Benign lesions
DOS Ductal carc inoma
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Fig 4.20b
It can be seen from Fig 4.20 that:-
1. ER staining was higher in the ductal carcinoma group, taken as a whole, than 
either DCIS or either group of benign lesions.
2. The malignant lesions tended to have higher staining than the benign lesions, 
but there were no clear differences.
Using the Mann-Whitney tests (see appendix tables 35-37):
Papillomas
1. ER staining of the papilloma group was similar to the hyperplasia, DCIS and 
grade 2 ductal groups.
2. ER staining of papillomas was significantly lower than grade 1 ductal 
carcinomas.
3. ER staining of papillomas was significantly higher than grade 3 ductal 
carcinomas.
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Hyperplasia
1. ER staining of hyperplasias was significantly lower than in grade 1 ductal 
carcinomas.
2. ER staining of hyperplasias was higher than in grade 3 ductal carcinomas and 
the difference was almost significant.
Atypical ductal hyperplasia
1. There were no significant differences in staining with ER between atypical 
hyperplasia and either DCIS or ductal carcinoma.
2. ER staining of atypical hyperplasia was lower than in grade 1 carcinomas and 
the difference almost reached significance (p = 0.054).
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Fig 4.21 Charts to show the mean values for the scores for D5 staining of benign
and malignant lesions. Fig 4.21a, shows mean values only and Fig 4.21b shows
the standard errors of these means.
papilloma hyperplasia DCIS ductal carcinoma
Benign lesions Malignant lesions
Fig 4.21a
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Fig 4.21b
It can be seen from Fig 4.21 that:-
1. The staining scores for D5 of the benign lesions were similar to each other.
2. The staining scores for D5 of the malignant lesions were similar to each other.
3. The staining scores for D5 of the benign lesions was lower than that of the 
malignant lesions.
Using the Mann-Whitney tests (see appendix tables 35-37):-
Papillomas
1. D5 staining of papillomas was similar to that of the hyperplasia groups.
2. D5 staining of papillomas was significantly less than the DCIS or any of the 
ductal carcinoma groups.
Hyperplasia
1. D5 staining of hyperplasia was similar to the atypical hyperplasias.
2. D5 staining of hyperplasia was significantly lower than DCIS or any of the 
grades of invasive ductal carcinomas.
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Atypical ductal hyperplasia
1. D5 staining of atypical hyperplasia was significantly lower than in DCIS.
2. D5 staining of atypical hyperplasia was significantly lower than in grade 2 and 
grade 3 ductal carcinomas. It was also lower than in grade 1 ductal carcinomas 
but the difference did not quite reach significance.
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4.3.6.2 Comparison of in situ and invasive ductal carcinoma
When the mean values of the scores for each antibody for the three grades of ductal 
carcinoma were analysed, the results were very similar to those for breast project 1.
Fig 4.22 Charts to show how staining scores for the antibodies MIB1, p53, 
CD44H, ER, and D5 are related to grade of ductal carcinoma. Fig 4.22a shows 
mean values only and Fig 4.22b shows standard errors of these means.
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Fig 4.23 Charts to show the relationship between the staining of in situ  and 
invasive ductal carcinoma for the antibodies MIB1, p53, CD44H, ER, and D5. 
Fig 4.23a shows mean values only and Fig 4.23b shows standard errors of these 
means
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It can be seen from Figs 4.22 and 4.23 that:-
1. MIB1 staining increased with increasing grade of ductal carcinoma.
2. MIB1 staining of DCIS was similar to that of grade 2 ductal carcinoma.
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3. CD44H staining of DCIS was similar to that of grade 2 ductal carcinoma.
4. CD44H staining decreased with increasing grade of ductal carcinoma.
5. p53 staining increased with increasing grade of ductal carcinoma.
6. p53 staining of DCIS was slightly higher than that of grade 2 ductal 
carcinoma.
7. ER staining decreased with increasing grade of ductal carcinoma.
8. ER staining of DCIS was slightly less than that of grade 2 ductal carcinoma.
9. D5 staining was similar in DCIS and all grades of ductal carcinoma.
Using Mann-Whitney tests (see appendix tables 38 and 39):- 
DCIS
1. MIB1 staining was similar to staining in grade 2 ductal carcinomas, 
significantly higher than in grade 1 and significantly lower than in grade 3 
ductal carcinomas.
2. p53 staining was significantly higher in DCIS than in grade 1 ductal 
carcinomas but there was no significant difference between DCIS and grade 2 
or 3 carcinomas.
3. CD44H staining was significantly higher in DCIS than in grade 3 ductal 
carcinomas.
4. There were no significant differences in CD44H staining between DCIS and 
grade 1 or grade 2 carcinomas.
5. There were no significant differences in the staining, with either of the CD44 
variants, between DCIS and any of the grades of ductal carcinoma.
6. ER staining of DCIS was similar to staining in grade 2 ductal carcinomas, 
significantly lower than in grade 1 and significantly higher than in grade 3 
ductal carcinomas.
7. There was no difference in D5 staining between DCIS and any of the grades of 
ductal carcinoma.
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Invasive ductal carcinoma
1. MIB1 increased significantly with increasing grade of carcinoma.
2. p53 staining increased significantly with increasing grade of carcinoma.
3. CD44H staining was significantly higher in grade 1 than in grade 2 or grade 3 
carcinomas. It was higher in grade 2 than in grade 3 carcinomas but the 
difference was not significant.
4. There were no differences in staining, with either of the CD44 variants, 
between any of the grades of ductal carcinoma.
5. ER staining was significantly lower in grade 3 than in grade 1 or grade 2 
carcinomas. It was lower in grade 2 than in grade 1 carcinomas, but the 
difference was not significant.
6. D5 staining was similar in all grades of carcinoma.
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4.3.6.3 Lobular carcinomas
Comparison of LCIS and lobular carcinomas
Fig 4.24 Charts to show the relationship between the staining of in situ  and 
invasive lobular carcinoma for the antibodies MIB1, p53, CD44H, ER, and D5. 
Fig 4.24a shows mean values only and Fig 4.24b shows standard errors of these 
means.
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Comparison of lobular and ductal carcinomas
MIB1 antibody
Fig 4.25 Charts to compare the scores for MIB1 staining of lobular carcinomas 
with those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 4.25a shows 
mean values only and Fig 4.25b shows the standard errors of these means.
E0 2.0
Ductal g1 Ductallg2 Ductal g3
UJ 2.0
Ductal g1 Ductal g2 Ductal g3
Fig 4.25a Fig 4.25b
It can be seen from Figs 4.24 and 4.25 that:-
1. MEB1 staining of lobular carcinomas was higher than that of LCIS.
2. MIB1 staining of lobular carcinomas was slightly higher than that of grade 1 
ductal carcinomas.
Using the Mann-Whitney tests (see appendix table 40):-
MIB1 staining was significantly lower than grade 2 or grade 3 ductal carcinomas. No 
other group comparisons were significant.
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p53 antibody
Fig 4.26 Charts to compare the scores for p53 staining of lobular carcinomas
with those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 4.26a shows
mean values only and Fig 4.26b shows the standard errors of these means.
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It can be seen from Figs 4.24 and 4.26 that:-
1. There was no p53 staining in any of the LCIS lesions studied and p53 staining 
of lobular carcinomas was very low.
2. p53 staining of lobular carcinomas was slightly higher than grade 1 ductal 
carcinomas.
Using the Mann-Whitney tests (see appendix table 40)>
1. The difference between p53 staining between LCIS and lobular carcinomas 
was not significant.
2. p53 staining of lobular carcinomas was similar to that of grade 1 or 2 ductal 
carcinomas and significantly less than that of the grade 3 ductal carcinomas.
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CD44H antibody
Fig 4.27 Charts to compare the scores for CD44H staining of lobular carcinomas
with those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 4.27a shows
mean values only and Fig 4.27b shows the standard errors of these means.
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It can be seen from Figs 4.24 and 4.27 that:-
1. CD44H staining of lobular carcinomas was slightly higher than that of LCIS.
2. CD44H staining was not as high as grade 1 ductal carcinomas but greater than 
that of grade 2 and grade 3 ductal carcinomas.
Using the Mann-Whitney tests (see appendix table 40):-
1. The difference between CD44H staining for LCIS and lobular carcinomas was 
not significant.
2. CD44H staining was significantly lower than in grade 1 ductal carcinomas, but 
not significantly different from grade 2 and grade 3 ductal carcinomas.
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ER antibody
Fig 4.28 Charts to compare the scores for ER staining of lobular carcinomas
with those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 4.28a shows
mean values only and Fig 4.28b shows the standard errors of these means.
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It can be seen from Figs 4.24 and 4.28 that:-
1. ER staining of LCIS and lobular carcinomas was almost the same.
2. ER staining of lobular carcinomas was higher than that of any grade of ductal 
carcinomas.
Using the Mann-Whitney tests (see appendix table 40):-
1. The difference between ER staining for LCIS and lobular carcinomas was not 
significant.
2. The only significant difference in ER staining was that between lobular and 
grade 3 ductal carcinomas.
185
M
ea
n 
D5
 
ra
nk
ed
 
sc
or
e
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Fig 4.29 Charts to compare the scores for D5 staining of lobular carcinomas with
those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 4.29a shows mean
values only and Fig 4.29b shows the standard errors of these means
Ouctalgl Cuctalg2 Ductal g3 Ductal g1 Ductal g2 Ductal g3 Lobular
Fig 4.29a Fig 4.29b
It can be seen from Figs 4.24 and 4.29 that:-
1. D5 staining was almost the same in LCIS and lobular carcinomas.
2. D5 staining was slightly lower in lobular carcinomas than that of grade 2 and 
grade 3 ductal carcinomas.
Using the Mann-Whitney tests (see appendix table 40):
There was no significant difference in D5 staining between LCIS, lobular carcinoma 
and any of the grades of ductal carcinomas.
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4.3.6.4 Medullary Carcinomas
Comparison of medullary and ductal carcinomas
Medullary carcinomas were classified separately as their diagnosis and thus their 
prognosis is difficult. Medullary carcinomas look pathologically very similar to grade 
3 carcinomas but behave like low grade carcinomas. Medullary carcinomas were 
stained with MIB1, CD44H, ER and D5.
MIB1 antibody
Fig 4.30 Charts to compare the scores for MIB1 staining of medullary 
carcinomas with those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 
4.30a shows mean values only and Fig 4.30b shows the standard errors of these 
means.
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It can be seen from Fig 4.30 that:-
MIB1 staining of medullary carcinomas was higher than all three grades of ductal 
carcinoma.
Using Mann-Whitney tests (see appendix table 41):-
1. MIB1 staining of medullary carcinomas was significantly higher than grade 1 
and grade 2 ductal carcinomas.
2. The difference between medullary and grade 3 ductal carcinomas was not 
significant.
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CD44H antibody
Fig 4.31 Charts to compare the scores for CD44H staining of medullary 
carcinomas with those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 
4.31a shows mean values only and Fig 4.31b shows the standard errors of these 
means
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It can be seen from Fig 4.31 that:-
CD44H staining of medullary carcinomas was higher than grade 2 or grade 3 ductal 
carcinomas but slightly lower than that of grade 1 ductal carcinomas.
Using Mann-Whitney tests (table 41):-
No significant differences were found between medullary and any of the ductal 
carcinoma groups.
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ER antibody
Fig 4.32 Charts to compare the scores for ER staining of medullary carcinomas
with those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 4.32a shows
mean values only and Fig 4.32b shows the standard errors of these means.
Ductal g1 Ductal g2 Ductal g3 Medulary
3.0'
2.5'
2.0 -
1.5-
1 .0 -
a:
111
111(0
CM+ 0.0'
c
w
©S
Ductal g1 Ductal g2 Ductal g3 Medullary
Fig 4.32a Fig 4.32b
It can be seen from Fig 4.32 that:-
No ER staining was found in any of the medullary carcinomas studied.
Using Mann-Whitney test (see appendix table 41):-
1. ER staining was significantly lower than either of the grade 1 or grade 2 
groups of ductal carcinomas.
2. There was no significant difference between the staining of the medullary and 
grade 3 ductal carcinomas.
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D5 antibody
Fig 4.33 Charts to compare the scores for D5 staining of medullary carcinomas
with those of grade 1, grade 2, and grade 3 ductal carcinomas. Fig 4.33a shows
mean values only and Fig 4.33b shows the standard errors of these means.
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It can be seen from Fig 4.33 that:-
D5 staining of medullary carcinomas was lower than all three grades of ductal 
carcinoma.
Using Mann-Whitney tests (see appendix table 41):-
1. D5 staining was significantly lower than either of the grade 2 or grade 3 
groups of ductal carcinomas.
2. There was no significant difference between the staining of the medullary and 
grade 1 ductal carcinomas.
190
4.3.6.S Radial scars
Radial scars have always been regarded as benign lesions but they are of special 
interest in this study as there has been a suspicion in recent years that they may not 
always behave in a benign fashion. The staining pattern of radial scars was compared 
with that of the two groups of benign lesions and with DCIS, using the antibodies 
MIB1, CD44H, ER and D5.
MIB1 antibody
Fig 4.34 Charts to compare the scores for MIB1 staining of radial scars with 
those of benign lesions, papillomas and hyperplasias and also malignant lesions, 
represented by DCIS. Fig 4.34a shows mean values only and Fig 4.34b shows the 
standard errors of these means.
CD 1.0
F f e p iJ o m a
CD 1-5
M 1.0
Hyperplasia Radial Scar
Fig 4.34a Fig 4.34b
It can be seen from Fig 4.34 that the mean score for MDB1 staining of radial scars was 
similar to those of the two groups of benign lesions.
Using Mann-Whitney tests (see appendix table 42):-
1. MIB1 staining was significantly lower in the radial scar group than in DCIS.
2. There was no difference between the radial scar group and either group of 
benign lesions.
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CD44H antibody
Fig 4.35 Charts to compare the scores for CD44H staining of radial scars with 
those of benign lesions, papillomas and hyperplasias and also malignant lesions, 
represented by DCIS. Fig 4.35a shows mean values only and Fig 4.35b shows the 
standard errors of these means
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It can be seen from Fig 4.35 that CD44H staining of radial scars was lower than that 
of the benign lesions and higher than that of DCIS.
Using Mann-Whitney tests (see appendix table 42):-
1. CD44H staining was significantly lower in the radial scar group than in either 
of the two groups of benign lesions.
2. There was no significant difference was found between radial scars and DCIS.
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ER antibody
Fig 4.36 Charts to compare the scores for ER staining of radial scars with those 
of benign lesions, papillomas and hyperplasias and also malignant lesions, 
represented by DCIS. Fig 4.36a shows mean values only and Fig 4.36b shows the 
standard errors of these means.
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It can be seen from Fig 4.36 that ER staining of radial scars was slightly lower than 
that of either the benign lesions or of DCIS, but the scores were similar for all four 
groups of lesions.
Using Mann-Whitney tests (see appendix table 42):-
1. There were no significant differences in ER staining pattern between radial 
scars and DCIS.
2. There were no significant differences in ER staining pattern between radial 
scars and either of the two benign groups tested.
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D5 antibody
Fig 4.37 Charts to compare the scores for D5 staining of radial scars with those 
of benign lesions, papillomas and hyperplasias and also malignant lesions, 
represented by DCIS. Fig 4.37a shows mean values only and Fig 4.37b shows the 
standard errors of these means.
■* 1.0
Ffcpiltoma Hyperplasia Radial scar
in 10
Papilloma Hyperplasia Radial scar DCIS
Fig 4.37a Fig 4.37b
It can be seen from Fig 4.37 that D5 staining for radial scars was higher than that for 
the benign lesions and lower than that for DCIS.
Using Mann-Whitney tests (see appendix table 42):-
1. D5 staining was significantly higher in the radial scars than in either of the two 
groups of benign lesions.
2. D5 staining of radial scars was significantly lower than that of the DCIS group.
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43.6.6 Spearman Correlations.
For tables of Spearman’s rho correlation coefficients and significance values see 
appendix (tables 43-45).
M m i
1. MIBl staining correlated positively with grade of ductal carcinoma.
2. MEBl staining correlated positively with p53 staining.
3. A negative correlation was found between MEBl and all CD44 antibody 
staining.
p53
1. p53 staining correlated positively with grade of ductal carcinoma.
2. p53 staining correlated positively with MIB1 staining.
3. p53 staining correlated negatively with CD44H staining 
CD44H
1. CD44H expression correlated positively with both CD44v3 and CD44v6 
expression.
2. There was a negative correlation between CD44H staining and MIB 1,
3. There was a negative correlation between CD44H staining and D5.
4. There was a negative correlation between CD44H staining and p53 staining.
5. There was a negative correlation between CD44H staining and grade of ductal 
carcinoma.
ER
Over the whole range of pathological groups:-
1. ER correlated positively with D5.
2. ER correlated positively with the CD44 variants
3. There was no correlation with MIB 1, p53 or CD44H.
4. ER correlated negatively with grade of tumour.
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Although when the different pathological groups were investigated as a whole, there 
was no correlation between MIB1 and ER, when different pathological lesions were 
grouped separately, then:-
1. There was no significant correlation between ER and MIB 1 for the hyperplasia 
group
2. There was no significant correlation between ER and MDB1 for the DCIS 
group, although the negative correlation was close to significance for the DCIS 
group (p = 0.069).
3. There was a significant negative correlation between ER and MIB1 for the 
ductal carcinomas.
D5
1. D5 staining correlated positively with MIB 1 staining.
2. D5 staining correlated positively with ER staining.
3. D5 staining correlated negatively with CD44H staining.
4.3.6.7 Discussion
(See also Chapter 7 General Discussion)
The greater number of benign and low grade malignant lesions included in this project 
gave greater significance to the findings of the first project. The significant differences 
of higher MIB1 staining and lower CD44H staining of carcinomas, when compared to 
benign lesions, was of prognostic interest. The negative correlation of CD44H staining 
with grade of ductal carcinoma and significantly lower CD44H expression of grade 2 
or grade 3 carcinomas when compared to grade 1 carcinomas, required further 
investigation. It was decided to investigate grade 1 carcinomas for differences in 
CD44H staining in relation to the metastatic potential of these tumours.
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4.4 Breast Carcinoma Project 3
A study on the metastatic potential o f Grade 1 Ductal Carcinomas o f the Breast.
4.4.1 Aim of the project
Clinicians have, for some time, been concerned by the fact that many patients whose 
primary tumours have been diagnosed as grade 1 tumours also have tumour in their 
lymph nodes at the time of surgery. When assessing the need for adjuvant therapy a 
cut off level of four or more positive lymph nodes is taken as a base line. Patients with 
4 or more positive lymph nodes have been shown, statistically, to benefit from 
chemotherapy. Although, in general, the grade of a tumour does correlate with its 
metastatic potential, clearly there are other factors in the metastatic process that are 
not apparent from the grading of a breast tumour.
4.4.2 Selection of specimens
This project was designed to look for any differences between grade 1 tumours that 
have metastatic potential and those that do not. For this project patients with any 
positive lymph nodes were assumed to have tumours with metastatic potential. The 
most straightforward way to approach this problem was to select two groups of 
patients. One group contained patients with grade 1 tumours with no detectable lymph 
node metastases and the other contained patients, also with grade 1 tumours, but with 
tumour present in their lymph nodes at time of surgery. The number of positive lymph 
nodes in the lymph node positive group ranged between 1 and 18 nodes. It was then 
possible to look for differences in the staining pattern of antibodies of interest between 
the two groups of patients.
One problem encountered with the project was the small amount of tumour tissue 
present in many of the selected cases. Grade 1 tumours tend to be small in size and 
some tissue was often lost during the microwaving procedure required for antigen 
retrieval. The tissue that floated off the slides tended to be mainly fat and fibrous 
tissue, but in a few of the cases that were initially selected, the small amount of tissue 
left on the slide made assessment of staining unreliable and these cases had to be 
eliminated from the study. The cases eliminated did not have a tendency to be from 
either the lymph node positive or the lymph node negative group.
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The staining method used was the same as described previously (see chapter 2).
4.4.3 Selection of antibodies
Three antibodies were selected for use in this study:
4.4.3.1 MIB1
As grading of breast tumours depends partly on mitotic count and breast project 2 had 
shown that M1B1 staining increases with grade of tumour, this antibody was used in 
this project to see whether proliferation rate was related to metastatic potential.
4.4.3.2 p53
The results of breast projects 1 & 2 showed that p53 staining increased with grade of 
carcinoma and that very few low grade carcinomas showed p53 positivity. This 
antibody was selected for this project to investigate whether abnormalities of p53 
function in grade 1 tumours could be related to the metastatic potential found in a 
minority of grade 1 tumours.
4.4.3.3 CD44
The results obtained in breast projects 1 and 2 showed that changes in CD44 positivity 
could be detected for different grades of tumour with the high grade tumours showing 
loss of CD44 staining. This raised the possibility that loss of staining could also be 
related to metastatic potential.
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4.4.4 Selection of statistical methods
Fig 4.38 Graphs to demonstrate the distribution of MIB1, p53 and CD44H 
scores for the grade 1 breast specimens. The number of cases each with scores 
0,1,2,3,4 or 5 are shown to demonstrate that the data is not normally distributed.
MIB1
(0
8
8
O
©
•§3
C
MIB1 ranked score
CD44H
0)8
8
O
c
p53
(0
60
50
40 -
30
10
0
40 1 2
CD44 ranked score P53 ranked score
As shown in Fig 4.38 the data obtained did not have a normal distribution, therefore 
non-parametric statistical tests were used (see 2.3). Most of the data are presented as 
rank scores and are thus ordered nominal scales. As the aim of this project was to 
compare two independent groups of patients and to look for a tendency for one group 
to exceed members of the other, the most appropriate test was the Mann-Whitney U 
test (see 2.3.2.1).
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4.4.5 Assessment of staining
The methods used for assessing the staining for the three antibodies were as 
previously described (see chapter 2).
4.4.5.1 MIB1
The score for MIB1 staining was expressed as the total number of stained nuclei of 
tumour cells expressed as a percentage of the total number of tumour nuclei present 
(see 3.1.4). The percentage o f stained nuclei were then ranked as follows:-
0%  =  0 
1% -> 4% = 1
5% -> 10% = 2
11% 20% = 3
21% -> 50% = 4 
51% ->100%  = 5
Fig 4.39 MIB1 staining of a grade 1 ductal breast carcinoma. See also Fig 1.10 
for pathological details.
MIB1 positive 
tumour cells
MIB1 negative 
tum our cell
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4A.5.2 p53
p53 staining was assessed in a similar manner. The total number of tumour nuclei 
stained was expressed as a percentage of the total number of tumour nuclei present 
(see 3.2.2). The percentage score was then ranked as follows:-
0% = 0
1% = 1
2% —» 10% = 2
11% — > 50% = 3
51% —> 100% = 4
Fig 4.40 p53 staining of two grade 1 ductal breast carcinomas, the first showing 
weak p53 staining and the second showing strong p53 staining.
Grade 1 lymph node negative 
breast carcinoma with 20% of 
cells p53 positive
p53 positive cells
Grade 1 lymph node negative 
breast carcinoma with 90% of 
cells p53 positive
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4.45.3 CD44
CD44 staining was assessed as previously described (see 3.3.2). The total number of 
tumour cells expressing any membrane staining was expressed as a percentage of the 
total number of tumour cells present. Additionally tumour cells showing three 
different intensities of staining were assessed separately and a score was calculated 
which was weighted for intensity of staining. As the intensity was given a score of 1-3 
the maximum total was 300 if all the cells were strongly positive. This score of CD44 
expression was ranked as follows:-
0 = 0
1 -> 50 = 1
51 —^ 100 = 2
101 150 = 3
151 -> 200 = 4
201 -» 300 = 5
The total percentage of cells showing any staining, of any degree of intensity, was also 
ranked as follows:-
0 =0  
1 - >  20 =1
21 40 = 2
41 60 =3
61 -»  80 = 4
81 300 = 5
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Fig 4.41 CD44H staining of a grade 1 breast carcinoma from a patient with two
positive lymph nodes
Tubules with cells 
showing a small 
amount of low 
intensity staining
Fig 4.42 CD44H staining of a grade 1 breast carcinoma from a patient with no 
positive lymph nodes
Tubules with most 
cells showing 
CD44H staining
4.4.6 Results
Mean values within the lymph node positive and the lymph node negative group were 
calculated for both total percentage scores and ranked scores of each of the antibodies 
used. Mann -Whitney U  tests were used for each antibody, to compare the two groups 
of patients, one with and one without lymph node metastases
For tables of means and Mann-Whitney values see appendix (tables 46-48).
A summary of the mean scores are shown in Fig 4.43.
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Fig 4.43 Charts to show the mean scores of MIB1, p53 and CD44H staining for 
both the lymph node negative and the lymph node positive groups of grade 1 
breast tumours. The scores shown for CD44H are ranked scores of the scores 
weighted for intensity of expression of staining. Fig 4.43a shows mean scores 
only and Fig 4.43b shows standard errors of the means.
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4.4.6.1 MIB1 antibody
MEBl staining was variable within the selection of patients tested and ranged between 
0% and 40% of the total number of tumour cells staining.
It can be seen from Fig 4.43 that the mean MIB1 score for the lymph node positive 
group of patients was slightly higher than that of the lymph node negative group.
Using the Mann-Whitney tests this difference was not significant.
4.4.6.2 p53 antibody
Only 17% (11/65) tumours showed any positive nuclear p53 staining, the range being 
between 1% and 90% with only 5% (3/65) patients having greater than 10% of nuclei 
staining. 22/65 tumours showed cytoplasmic staining of the cells.
It can be seen from Fig 4.43 that the mean p53 score for the lymph node positive 
group of patients was slightly higher than that of the lymph node negative group
Using the Mann-Whitney tests no significant differences in p53 staining were found 
between the two groups of patients.
4.4.6.3 CD44 antibody
For CD44, there were several different scoring options to consider. Scores for the total 
percentage of tumour cells showing any CD44H expression at all regardless of the 
intensity of staining were assessed. These scores were ranked and the ranked scores 
were assessed. Also individual scores for percentage of cells staining with weak, 
moderate or strong intensity were available. A weighted score, taking into account 
intensity of expression was calculated, as previously described, which was 
additionally given a ranked score.
It can be seen from Fig 4.43 that the mean CD44H score, weighted for intensity of 
expression and also ranked (see 3.3.4 and 4.4.5.3), for the lymph node positive group 
of patients was lower than that of the lymph node negative group.
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Using the Mann-Whitney V  test
1. When the scores for the total number of cells showing staining of any kind, 
whatever the intensity, was used the difference in the scores was statistically 
significant.
2. When these scores were ranked as described the difference between the groups 
was also significant.
3. Using a weighted score, there was a significant difference between the two 
groups.
4. When this score was ranked, the mean scores also gave a significant difference 
between the two groups. The means of this weighted, ranked score are the 
values shown in Fig 4.43.
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Fig 4.44 Graphs to show the differences in the number of cells showing low, 
medium and high CD44H expression between the two groups of grade 1 breast 
tumours, those with and those without lymph node metastases. Fig 4.44a shows 
mean scores of the percentage of cells staining with the three different intensities 
and Fig 4.44b shows the standard errors of these means.
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The different staining intensities of CD44H (see Figs 3.8 & 3.9) were considered 
separately. The ranked scores for the percentage of cells staining at low, medium and 
high intensity are shown in Fig 4.44.
It can be seen from Fig 4.44 that scores for all three staining intensities were lower in 
the lymph node positive group.
Using the Mann-Whitney tests (see Apendix table 48):-
1. The difference in the mean value for the percentage of tumour cells staining at 
low intensity showed a significant difference between the two groups.
2. The difference in the mean value for the percentage of tumour cells staining at 
medium intensity showed a significant difference between the two groups.
3. There was no significant difference in the number of cells staining with high 
intensity although the tendency was for the lymph node positive group to have 
a lower score.
4.4.6.4 Discussion
(See also Chapter 7 General Discussion)
One problem with the design of this project was the assumption that all patients with 
negative lymph nodes had tumours that did not have metastatic potential. It is possible 
that a tumour that does not appear to have spread to the lymph nodes at the time of 
surgery, could still have gained metastatic potential. Micrometastases, which might 
have been undetectable histologically, could already have been present in the lymph 
nodes. Alternatively tumour cells could already have spread from the tumour but not 
have settled in the lymph nodes. These possibilities are, however, unlikely to have 
been manifest in many of the patients.
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CHAPTER 5 COLORECTAL STUDIES
5.1 Background to these studies
5.1.1 Epidemiology of colorectal cancer
Cancer of the colon and rectum is one of the most common forms of malignant 
disease. The anatomical distinction between colon and rectum can only be arbitrarily 
defined and many tumours arise at the rectosigmoid junction itself. In these projects, 
the colon and rectum are considered as a single organ as cancers of rectum and colon 
share similar precancerous lesions as well as histopathological appearances and modes 
of spread. They are referred to as colorectal carcinomas.
A striking variation in the frequency of colorectal cancer is seen in different 
geographical areas. It is especially common in North America, Northern Europe and 
Australasia and is rare in Asia and particularly uncommon in Africa. In the UK, the 
mortality rate is second only to lung cancer for males and breast cancer for females. 
The cause and pathogenesis of colorectal carcinoma are related to both environmental 
and genetic factors. The former is largely dietary, particularly in terms of fats and 
animal protein and the genetic factor manifests itself in a variety of ways. The most 
obvious is the high predisposition for colorectal carcinoma in patients with familial 
polyposis (nearly 100% by age 50) and in those with the hereditary nonpolyposis 
colorectal cancer syndrome (50% risk to a first-degree relative of an affected patient 
in the direct genetic lineage)(seel.3.3).
5.1.2 Problems of diagnosis and treatment
The standard therapy for colorectal carcinoma is surgical resection, the type of surgery 
depending on the site of the tumour. If there are no lymph node metastases present, 
then this alone may be a cure but local recurrence sometimes develops. The role of 
preoperative or postoperative irradiation and/or chemotherapy for operable carcinoma 
has been investigated. In one study, a slight improvement in survival was noted 
following postoperative irradiation in Dukes’ C but not in Dukes’ B tumours (Balslev 
et al. 1986). Some studies have shown that combined postoperative chemotherapy 
and radiation therapy to the pelvis decrease the likelihood of local recurrence and
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prolong survival in rectal carcinomas. Other studies have shown little or no beneficial 
effects of preoperative radiotherapy and trials are continuing.
The 5-year survival rate after curative resection for colorectal carcinoma ranges 
between 40% and 60% in most large series. The prognosis of colorectal carcinoma is 
related to a number of clinical and pathologic parameters. Those of significance 
include:
1. Age - tumours in very young and very old patients are associated with a poor 
prognosis.
2. Sex -  the prognosis is significantly better for females than males.
3. Microscopic type and grade -  There is a relationship between the microscopic 
grade of the tumour and its prognosis. Mucinous carcinoma, small cell 
carcinoma, and signet ring carcinoma have a worse prognosis than the ordinary 
type of adenocarcinoma.
4. Inflammatory infiltrate -  carcinomas that have an inflammatory infiltrate at the 
interphase between the tumour and the neighbouring tissue have a better 
prognosis.
5. Vascular and perineural invasion -  When vein invasion is present the 5-year 
survival decreases markedly. Lymph vessel invasion is less important, but still 
represents an adverse prognostic feature.
6. Lymph node involvement -  Location and extent of lymph node involvement 
are significant. The greater the number of lymph nodes involved, the worse the 
prognosis.
7. Dukes’ staging -  The 5-year survival rates are 90% or higher for Dukes’ A, 
50% to 65% for Dukes’ B and 15% to 25% for Dukes’ C.
Although the presence of detectable lymph node metastases is clearly a poor 
prognostic factor, not all Dukes’ C patients do badly and similarly many Dukes’ B 
patients go on to produce local recurrence of the tumour and distant metastases. This 
indicates both that there is a variation in response by different metastatic tumour cells 
to chemotherapy and that early stage cancers may already have metastasised at the 
time of surgery.
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5.2 Colorectal Carcinoma Project 1
The characterisation of MIB1, p53 and CD44H antibody staining in colorectal 
adenomas and carcinomas
5.2.1 Aim of the project
Before specific clinical problems could be addressed it was necessary to stain 
colorectal adenoma and carcinoma specimens covering a wide range of colorectal 
pathology with the chosen antibodies so that a baseline for the staining characteristics 
of the chosen antibodies could be obtained.
5.2.2 Selection of specimens
Specimens were selected from archive material to include a range of specimens 
including tubular, tubulovillous and villous adenomas and Dukes’ A, Dukes’ B and 
Dukes’ C carcinomas.
The number of specimens selected was as follows >
Pathology No. of Specimens
Tubular adenomas 
Tubulovillous adenomas
22
9
Villous adenomas 1
Dukes’ A carcinomas 10
Dukes’ B carcinomas 28
Dukes’ C carcinomas 30
Total No. of Specimens 101
212
5.2.3 Selection of antibodies
5.2.3.1 MIB1
Neither the grading nor staging of colorectal carcinomas takes into account the 
proliferation index of the tumour. This is partly due to the fact that mitoses are 
difficult to detect in colorectal tumours, but MIB1 gives a much clearer picture of the 
number of proliferating cells. MDB1 was thus selected as an antibody for this project 
to determine whether the proliferation rate of a tumour could give any additional 
prognostic information over that provided by routine histopathology.
5.2.3.2 p53
One of the most common genetic changes encountered in colorectal cancer concerns 
chromosome 17p where the p53 tumour suppressor gene is located. Point mutation of 
the p53 gene occurs in about 50% of colorectal adenocarcinomas, frequently with 
allelic loss of Chl7p. Point mutation of the p53 gene often leads to a protein with 
greater stability which is detectable immunohistochemically.
Allelic loss of chromosome 17p is infrequent in adenomas of any stage but occurs in 
up to 75% of colorectal carcinomas. This suggests that loss of p53 function is 
associated with the transition from adenomas to carcinomas, and such loss is 
associated with tumour dissemination (Khine et al. 1994). One study found that 
lymphatic dissemination was driven by the presence of mutated p53, whether or not 
the cell contained wild type p53. Mutation occurred in 43% of cases without lymph 
node involvement (Dukes’ A&B) and in 70% of cases with lymph node involvement 
(Dukes’ C). By contrast loss of heterozygosity of Chl7p (i.e. no functional wild-type 
p53 present) was strongly related to distant metastases at the time of surgery (Dukes’ 
D). This study also found DNA aneuploidy to be associated with point mutation of the 
p53gene and with loss of heterozygosity of Chl7p. Furthermore, DNA aneuploidy, 
which indicates a more aggressive tumour, was significantly associated with complete 
inactivation of p53 supporting the fact that p53 guards the genome (Goh et al. 1994).
Many immunohistochemical studies have been carried out on colorectal carcinomas 
and adenomas using a variety of antibodies to p53. p53 immunohistological staining
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has been demonstrated in 26% of colorectal adenomas, positive foci occurring in the 
most dysplastic areas. It was not significantly related to size or histological type of 
adenoma (Kaklamanis et al. 1993). One study found nuclear p53 protein in 62% of 
colorectal cancer patients and that patients with strong p53 expression appeared to die 
from their disease sooner than those with weak expression although this observation 
was not statistically significant (Nathanson et al. 1994). Three recent studies (Ofiier et 
al. 1995; Poller et al. 1997; Starzynska et al. 1997) disagreed with these findings and 
showed that there was no difference in overall survival or recurrence-free survival for 
those cases that showed p53 expression compared with those cases showing absence 
of p53. The second study (Starzynska et al. 1997) found, however, that patients with 
p53 overexpressing tumours showed a higher local recurrence rate than those having 
undetectable levels of p53. Another study found immunoreactivity in 61% of 
specimens but there was no significant correlation between the expression of p53 and 
the histologic grade, tumour size, serosal invasion, lymphatic invasion, venous 
invasion, lymph node metastases or liver metastases. However, patients with p53- 
positive tumours had a higher recurrence rate and a greater relative risk of death 
compared with those who had p53-negative tumours (Yamaguchi et al. 1992).
Although there is much conflicting evidence it seems that p53 inactivation may be 
involved in tumour progression, rather than transformation, and may in some way be 
related to patient survival.
5.2.3.3 CD44
CD44 is expressed primarily in the region of cell replication in the lower crypt 
epithelium of normal colorectal mucosa, suggesting that expression is linked to 
proliferation (see Fig 5.1)
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Fig 5.1 .CD44H staining of crypts of normal colonic epithelium. See also Figs 1.20 
and 1.21 for description of normal colonic epithelium.
Most interest in CD44 for prognostic factors in colorectal tumours has been in the v6 
variant of CD44. A high level of CD44v6 expression has been observed in human 
colorectal adenocarcinomas and correlated with the stage of tumour progression 
(Domagala et al. 1993; Mulder et al. 1995; Weilenga et al. 1993).
Attention was drawn to the possible prognostic importance of expression of exon-v6- 
containing CD44 molecules from a study of 68 patients with colorectal carcinoma 
Dukes’ B and C stages. A poor prognostic outlook was found for patients with 
CD44v6 expression in their tumours (Mulder et al. 1994). Other studies have since 
disagreed with these results and have found that recurrence-free survival in potentially 
curatively resected patients was not determined by the presence or absence of CD44v6 
(Koretzetal. 1995).
Adenomatous colorectal polyps have been shown to produce as strong an expression 
of epithelial and variant forms of CD44-mRNA as primary and metastatic tumour 
tissues, suggesting that variant forms of CD44-mRNA might be expressed in an early 
stage of colorectal carcinogenesis (Imazeki et al. 1996). A study of CD44, K-ras and
CD44H positive 
epithelial cells at 
base of crypt
Positively stained 
lymphocyte
CD44H negative 
epithelial cells
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p53 expression in 22 small colorectal adenomas showed CD44 expression in 9 of the 
adenomas of which only 1 contained a K-ras mutation. In contrast to the early 
expression of CD44 in the adenoma-carcinomas sequence, mutations of K-ras and p53 
were detected preferentially in large adenomas and late-stage adenomas containing 
carcinoma. It thus appears that CD44 expression is an early event in carcinogenesis 
(Kim et al. 1994). One study found that all samples of tumour and metastatic tissue 
showed complex overexpression of many alternatively spliced products of the CD44 
gene (Wong et al. 1997). Another study also found that CD44 variant proteins were 
present on all invasive carcinomas and carcinoma metastases. They also found focal 
expression in adenomatous polyps, expression being related to areas of dysplasia 
(Heider et al. 1993b), showing that the so-called ‘metastasis-related variant’ was 
already expressed at an early stage in colorectal carcinogenesis and was not an 
invariant consequence of malignant progression.
A recent study used both a variety of CD44 monoclonal antibodies directed against 
specific CD44 variant domains together with RTPCR analysis of CD44 variant 
mRNA expression in the same tissue specimens. They demonstrated that as well as 
being expressed in colonic tumour cells, the full range of CD44 variants, CD44v2- 
vlO, are widely expressed in normal colonic crypt epithelium, predominantly in the 
crypt base. CD44v6 the epitope which is most commonly associated with tumour 
progression and metastasis, was not only expressed by many benign colonic tumours, 
but was expressed as frequently in normal basal crypt epithelium as in malignant 
colonic tumour cells, and surprisingly, was even absent from some metastatic 
colorectal tumours. Expression of none of the CD44 variant epitopes was found to be 
positively correlated with tumour progression or with colorectal tumour metastasis to 
the liver, results that were inconsistent with a role for CD44 variants as indicators of 
colonic cancer progression (Gotley et al. 1996).
The antibody clone F10.44.2 (the antibody used in this project) does not distinguish 
between the variant and standard forms. Using this antibody, one study showed that 
CD44 expression in human adenomatous polyps, colorectal adenocarcinomas (both 
primary and metastatic deposits), as well as in adjacent normal tissue, is associated 
with cellular proliferation (assessed by Ki67 in serial frozen sections)(Abassi et al.
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1993). It seems possible therefore that CD44 could be involved in stimulating cell 
growth.
5.2.4 Assessment of staining
The methods used for assessing the staining of the three antibodies were as previously 
described (see chapter 3).
5.2.4.1 MEB1
MIB1 staining was expressed as the total number of stained nuclei of tumour cells 
expressed as a percentage of the total number of tumour nuclei present. The 
percentage of stained nuclei were then ranked as follows: -
0 % = 0  
1% -> 20% =  1 
21% -> 40% = 2  
41% -> 60% =3 
61% 80% = 4
81% ->100% = 5
5.2.4.2 p53
p53 staining was assessed in a similar manner. The total number of tumour nuclei 
stained was expressed as a percentage of the total number of tumour nuclei present. 
The percentage score was then ranked as follows:-
0% =0  
1%  ->  20% =  1 
21% 40% = 2
41% -> 60% = 3 
61% -> 80% = 4  
81% ->100% = 5
5.2.4.3 CD44H
CD44 staining was assessed as previously described (see 3.3.4). The total number of 
tumour cells expressing any membrane staining was expressed as a percentage of the 
total number of tumour cells present. Additionally tumour cells showing three 
different intensities of staining were assessed separately and a score was calculated 
which was weighted for intensity of staining. As the intensity was given a score of
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1 - 3 ,  the maximum total was 300 if all the cells were strongly positive. This score of 
CD44H expression was ranked as follows: -
0 =  0 
1 -> 50 = 1 
51->100 = 2  
101->150 = 3 
151->200 = 4  
200 -> 300 = 5
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5.2.5 Selection of statistical methods
Fig 5.2 Graphs to show the distribution of scores for MEB1, p53 and CD44H, 
demonstrating that the data is not normally distributed.
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The aim of this project was to look for changes in staining pattern in lesions of 
varying pathology. As shown in Fig 5.2, the data obtained did not have a normal 
distribution so non-parametric statistical tests were used.
Most of the data were presented as rank scores and were thus ordered nominal scales.
The most appropriate test was the Mann-Whitney U test (see 2.3.2.1), which was used 
to look for significant differences in staining pattern between two types of pathology.
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Spearman correlations (see 2.3.2.2) were also performed on the ranked scores for the 
various antibodies to look for either a positive or a negative relationship between the 
staining patterns and also with Dukes’ stage of carcinoma to look for a linear 
relationship between positivity and stage of tumour.
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5.2.6 Results
For tables of mean scores and Mann-Whitney values see appendix (tables 49-72).
5.2.6.1 Comparison of adenomas and carcinomas
All the carcinomas were first grouped together and the staining of this group 
compared with the staining of the adenoma group.
Fig 5.3 Graphs to compare mean scores of adenomas and carcinomas for the 
three antibodies MIB1, CD44H and p53. Fig 5.3a shows mean scores only and 
Fig 5.3b shows standard errors of these means.
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It can be seen from Fig 5.3 that when the carcinomas were grouped together and 
compared with the group of adenomas then:
1. MIB1 staining was higher in carcinomas than in adenomas.
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2. p53 staining was higher in carcinomas than in adenomas.
3. CD44H staining was lower in carcinomas than in adenomas.
Using Mann-Whitney tests (see appendix table 54):
1. There was a significant increase in the level of MIB1 staining in the 
carcinomas compared to the adenomas.
2. p53 staining was significantly higher in the carcinoma group than in the 
adenoma group of specimens.
3. The mean level of CD44H staining in the carcinomas was significantly lower 
than that in the adenomas.
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The different intensities of CD44H staining (see Fig 3.8) were then considered.
Fig 5.4 Graphs to show the difference in CD44H high, medium and low intensity 
staining between adenomas and carcinomas. Fig 5.4a shows mean scores only 
and Fig 5.4b shows standard errors of these means.
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As can be seen from Fig 5.4, scores for all intensities of staining were higher in 
adenomas than carcinomas.
Using Mann-Whitney tests (see appendix table 55), then
1. high and medium intensity staining was significantly higher in adenomas than 
in carcinomas
2. the difference in low intensity staining was almost significant (p = 0.053).
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5.2.6.2 Comparison of adenomas with Dukes’ A, Dukes’ B and Dukes’ C
carcinomas
Dukes’ A, Dukes B and Dukes’ C carcinomas were then considered as separate groups 
and compared with the adenoma group.
Fig 5.5 Graphs to compare mean scores of adenomas and Dukes’A, Dukes’B and 
Dukes’C carcinomas for MIB1, CD44H and p53 staining. Fig 5.5a shows mean 
scores only and Fig 5.5b shows standard errors of these means.
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MIB1 antibody
As can be seen from Figure 5.5, the mean MIB1 score was higher in all groups of 
carcinomas than in the adenoma group.
Using Mann-Whitney tests (see appendix table 61) then:
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1. There was a significant difference between the adenoma group and all three 
carcinoma groups.
2. There was no significant difference between any of the carcinoma groups. 
p53 antibody
The above graphs (Fig 5.5) show that the mean score for the Dukes’ A carcinomas 
was lower than that of the adenoma group, the Dukes’ B or the Dukes’ C carcinoma 
group.
Using Mann-Whitney tests (see appendix table 62) then:
1. There was no significant difference between the adenoma group and the 
Dukes’ A carcinoma group
2. There was no significant difference between the adenoma group and the 
Dukes’ B carcinoma group.
3. The Dukes’ C carcinoma group had significantly higher p53 staining than the 
adenoma group.
CD44H antibody
Fig 5.5 shows that CD44H staining was highest in adenomas and lowest in Dukes’ C 
carcinomas and that staining was slightly lower in Dukes’ A than in Dukes’ B 
carcinomas
Using Mann Whitney tests (see appendix tables 63 and 64):
1. There was a significant difference in CD44H staining between the adenoma 
group and any of the carcinoma groups for all methods of scoring the CD44H.
2. Staining of all the carcinoma groups was significantly lower than that of the 
adenoma group.
3. There was no significant difference between the Dukes’ A and Dukes’ B 
carcinoma groups or between the Dukes’ A and Dukes’C groups.
4. Staining in the Dukes’ B carcinoma group was significantly higher than that of 
the Dukes’ C carcinoma group for all methods of scoring the CD44H.
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The different intensities of CD44H staining (see Fig 3.8) were then considered.
Fig 5.6 Graphs to show the difference in CD44H high, medium and low intensity 
staining between adenomas Dukes’ A, Dukes’B and Dukes’C carcinomas. Fig 
5.6a shows mean scores only and Fig 5.6b shows standard errors of these means.
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Fig 5.6b
As Fig 5.6 demonstrates, when the different staining intensities of CD44H were 
considered, then the scores for all intensities of staining were higher in the adenoma 
group than any of the carcinoma groups.
227
Using Mann Whitney tests (see appendix table 65) then:
1. There was a significant difference in medium intensity staining between 
adenomas and Dukes’ A carcinomas but not for any other staining intensites 
between adenomas and either Dukes’ A or Dukes’ B carcinomas.
2. Dukes’B carcinomas showed higher medium intensity staining than Dukes’ A 
carcinomas.
3. Dukes’ C carcinomas showed significantly less staining than adenomas for all 
intensities of staining
4. Dukes’ C carcinomas showed significantly lower low and medium intensity 
staining than Dukes’ B carcinomas.
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5.2.6.3 Comparison of adenomas, Dukes’ A&B carcinomas, (grouped together as 
non-metastasising carcinomas), and Dukes’ C (metastasising) carcinomas.
As, by definition, Dukes’ A and Dukes’ B carcinomas have no observable metastases 
at the time of surgery they were then grouped together and compared both with 
adenomas and with Dukes’ C carcinomas which, by definition, have already 
metastasised at the time of surgery.
Fig 5.7 Graphs to compare mean scores of adenomas, non-metatasising 
carcinomas (Dukes’A&B) and metatasising (Dukes’C) carcinomas for MIB1, 
CD44H and p53 staining. Fig 5.7a shows mean scores only and Fig 5.7b shows 
standard errors of these means.
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MIB1 antibody
Fig 5.7 shows that the mean score for MIB1 staining for the Dukes’A&B carcinoma 
group was similar to that for the Dukes’C carcinoma group.
Using Mann Whitney tests (see appendix table 71) then, using either the score for the 
total percentage of cells staining or the ranked score:
1. MIB1 staining of adenomas was significantly lower than that of the non- 
metastasising (Dukes’A&B) group.
2. MIB1 staining of adenomas was significantly lower than that of the 
metastasising carcinoma (Dukes’C) group.
3. There was no difference between the the non-metastasising (Dukes’A&B) 
group and the metastasising carcinoma (Dukes’C) group.
p53 antibody
Fig 5.7 shows that the scores for p53 were greater in Dukes’ C carcinomas than in 
Dukes’ A&B carcinomas, which were in turn greater than in adenomas.
Using Mann-Whitney tests (see appendix table 72) then:
1. There was no significant difference between the non-metastasising
(Dukes’A&B) carcinoma group and the adenoma group.
2. Staining was significantly higher in the metastasising (Dukes’C) group than in 
the adenoma group.
3. There was no significant difference between the non-metastasising
(Dukes’A&B) carcinoma group and the metastasising (Dukes’C) group.
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CD44H antibody
From Fig 5.7 it can be seen that:
1. The mean score for CD44H in the metastasing (Dukes’C) carcinomas was 
lower than that of the mean score for CD44H for the non-metastasising 
(Dukes’A&B) carcinomas
2. The mean score for CD44H for the non-metastasising (Dukes’A&B) 
carcinomas was lower than that of the adenomas.
Using Mann Whitney tests (see appendix tables 73 and 74) then:
1. The scores for CD44H were significantly higher in adenomas than in the 
Dukes’ A&B carcinomas using either the score for the total percentage of cells 
staining or the score weighted for intensity of expression of the CD44H. The 
ranked scores also showed significant differences between the two groups.
2. Adenomas had significantly more CD44H staining than Dukes’ C carcinomas 
for all methods of scoring the staining.
3. Dukes’ A&B carcinomas also had significantly higher CD44H staining scores 
than Dukes’ C carcinomas.
The different staining intensities for CD44H (see Fig 3.8) were then considered 
separately.
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Fig 5.8 Graphs to show the difference in CD44H high, medium and low intensity 
staining between non-metastasising carcinomas (Dukes’A&B) and metastasising 
(Dukes’C) carcinomas. Fig 5.8a shows mean scores only and Fig 5.8b shows 
standard errors of these means.
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Fig 5.8 shows that:
1. The mean scores for all intensities of CD44H in the metastasing (Dukes’C) 
carcinomas are lower than those for the non-metastasising (Dukes’A&B) 
carcinomas.
2. The mean scores for all intensities of CD44H staining of the non-metastasising 
(Dukes’A&B) carcinomas are lower than those of the adenomas.
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Using Mann Whitney tests (see appendix table 75):
1. Medium intensity staining was significantly higher in adenomas than in non- 
metastasising (Dukes’A&B) carcinomas, but the difference in high intensity 
staining did not quite reach significance (p = 0.052). There was no significant 
difference in low intensity staining between these two groups.
2. Adenomas had significantly higher scores than Dukes’ C carcinomas for all 
intensities of CD44 staining.
3. The group of Dukes’ C carcinomas had significantly less low and medium 
intensity CD44 staining than the group of Dukes’ A&B carcinomas but there 
was no significant difference between these two groups for the high intensity 
staining
5.2.6.4 Spearman correlations
Spearman correlations give a slightly different approach from the analysis of the 
separate groups of tumours as the staining characteristics of individual tumours are 
assessed.
Tables giving the Spearman’s rho correlation coefficients and the significance values 
can be found in the appendix (tables 76-79).
Two of the parameters are called Dukes’ 1 and Dukes’ 2. Dukes’ 1 represents a 
grouping with Dukes’ A and Dukes’ B carcinomas grouped separately i.e. there are 
four stages, adenomas, Dukes’ A carcinomas, Dukes’ B carcinomas and Dukes’ C 
carcinomas. Dukes’ 2 represents a grouping with Dukes’ A and Dukes’ B carcinomas 
grouped together i.e. there are three stages, adenomas, Dukes’ A & B  carcinomas and 
Dukes’ C carcinomas.
A summary of the relationships between the staining scores for the three antibodies 
are given below.
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MIB1
No correlation was found between MIB1 and any other parameter. 
p53
1. There was a negative correlation with CD44H staining.
2. There was a positive correlation with degree of dysplasia of the adenomas.
3. There was a positive correlation with Dukes’ stage of carcinoma when the 
Dukes’ A and Dukes’ B carcinomas were grouped separately (Dukes’ 1).
CD44H
Apart from the negative correlation with p53 no relationship could be found between 
CD44H and any other parameter.
5.2.7 Discussion
(See also Chapter 7 General Discussion)
There were two options in grouping the carcinomas. One was to consider each Dukes’ 
stage individually and the second was to group the Dukes’ A and B carcinomas 
together. The reason for the second approach was that neither Dukes’ A or Dukes’ B 
carcinomas had known metastases at the time of surgery as compared to Dukes C 
carcinomas which were already known to have metastasised. Another advantage of 
this approach was that there were not a large number of Dukes’ A carcinomas so that 
including them in a larger group made a more powerful statistical analysis possible. 
When the Dukes’ A and Dukes’ B carcinomas were classed separately the small 
number of Dukes’ A carcinomas could have made the results unreliable. The main 
problem with this approach was the assumption that all the carcinomas in the 
combined Dukes’A&B group are non-metastasising. The definition of this group is 
that there are no detectable metastases at the time of surgery, but some of these 
tumours may already have produced micrometastases.
It was assumed, however, that if this were the case, then it would not be true for the 
majority of carcinomas in the group.
234
The results of this study indicated that all three antibodies could be important 
prognostic factors. A high level of 3VHB1 staining was shown to be indicative of 
malignant change and MEBl could be used as a marker of tumour progression in 
adenomas although it showed no benefit for assessing the progression of carcinomas. 
An increase in p53 positivity was evident at the Dukes’ B stage of carcinoma and also 
in the most dysplastic areas of adenomas. Thus p53 staining would be an indicator of 
late stage of tumour progression both for adenomas and carcinomas.
The change from normal to the premalignant or adenoma stage was accompanied by 
an increase in CD44H expression and the transition from Dukes’ B to Dukes’ C i.e. 
from non-metastasising to metastasising carcinoma seemed to be accompanied by a 
loss of CD44H.
It is probable that some of the individual tumour cells present in Dukes’ B tumours 
would have already gained metastatic potential and not all cells present in Dukes’ C 
tumours would be capable of metastasis. This means that the staining of either group 
of carcinoma would be expected to be heterogeneous. The general trend within the 
groups was to lower CD44H levels in Dukes’ C carcinomas. Thus CD44H could be an 
important marker of tumour progression at both early and late stages of tumour 
progression. It was decided that a more detailed approach to the heterogeneity within 
the Dukes’ B and Dukes’ C carcinomas would be valuable.
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5.3 Colorectal Carcinoma Project 2
A n investigation o f the heterogeneity ofprognosis fo r  D ukes’ B  colorectal 
carcinomas
5.3.1 Background
The definition of a Dukes’ B carcinoma is one where the tumour has spread beyond 
the muscularis propria but without forming lymphatic metastases. There is, however, a 
great deal of variation in the outcome of Dukes’ B patients. Many survive 5 years or 
more, but there is a group of patients who present with either local recurrence or 
distant metastases within that period.
The problem that the clinicians have to confront is whether or not to give these Dukes’ 
B patients adjuvant therapy. Patients who present with distant metastases at the time 
of surgery (Dukes’ C tumours) are given chemotherapy but, as there is also a group of 
Dukes’ B patients who could also possibly benefit, any extra prognostic factors that 
could help to select this group would be valuable.
5.3.2 Selection of patients from clinical data
A list of patients who had previously had surgery and diagnosed as having Dukes’ B 
carcinomas was supplied by the clinicians. A selection of patients was supplied that 
included patients who, within five years, had presented with distant metastases, ones 
that had had local recurrence of the tumour but no distant metastases, and ones who 
were free from any type of recurrence. Sixty-three specimens were examined. Of the 
32 cases where the patient had subsequently suffered recurrence, 21 had local 
recurrence and 18 metastatic disease (7 patients suffered both local and distant 
recurrence). The mean age of those who suffered recurrence was 67.9 years and those 
who remained disease free was 66.8 years. The distribution of males and females in 
each group was equal. All 31 patients who remained free of recurrent disease survived 
to the end of the period of study. 66% of those with local recurrence and 38% of those 
with metastatic disease survived. All 7 patients with both local and distant disease 
died.
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5.3.3 Selection of a panel of antibodies
Three antibodies were selected for this project.
5.3.3.1 MEB1
MIB1 was selected as it is a proliferation marker that would give an indication of how 
fast the tumour was growing. As previously stated (see 5.2.3.1), the staging and 
grading of colorectal tumours does not use proliferation as a factor so that is possible 
that MIB1 could be an independent prognostic factor within a group of tumours of the 
same histological grade.
5.3.3.2 p53
p53 was selected for this project as there is some evidence from these studies that p53 
positivity is related to patient survival even though results from various publications 
are conflicting. Our own results (colorectal project 1) had shown that p53 positivity is 
related to tumour progression and that p53 abnormalities become important at the 
transition from Dukes’ A to Dukes’ B stage of tumour progression i.e. at the stage of 
invasion beyond the muscularis propria.
5.3.3.3 CD44H
CD44H was selected mainly from our own evidence that expression of this antigen 
seemed to be lower in Dukes’ C than in Dukes’ B carcinomas. As discussed earlier 
there is evidence that its expression could be related to the metastatic potential of a 
cell (see 5.2.3.3)
5.3.4 Assessment and scoring of staining
The methods used for assessing the staining of the three antibodies were as previously 
described (see chapter 3).
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5.3.4.1 MIB1
The score for MIB1 staining was expressed as the total number of stained nuclei of 
tumour cells expressed as a percentage of the total number of tumour nuclei present. 
The percentage of stained nuclei were then ranked as follows:-
0% ->  20% =  1 
21% -* 40% ==2 
41% -> 60% = 3 
61% -> 80% = 4  
81% ->100% = 5
5.3.4.2 p53
p53 staining was assessed in a similar manner. The total number of tumour nuclei 
stained was expressed as a percentage of the total number of tumour nuclei present. 
The percentage score was then ranked as follows:-
0% =  0 
1% -> 20% = 1  
21%-> 40% = 2 
41%-> 60% = 3 
61%-> 80% = 4 
81%-> 100% = 5
5.3.4.3 CD44H
CD44 staining was assessed as previously described. The total number of tumour cells 
expressing any membrane staining was expressed as a percentage of the total number 
of tumour cells present. The total percentage of cells showing any staining, of any 
degree of intensity, was ranked as follows:-
0 =  0 
l->  2 0=1  
21 -> 40 = 2 
41-> 60 = 3 
61-> 80 = 4 
81->100 = 5
Additionally tumour cells showing three different intensities of staining were assessed 
separately and a score was calculated which was weighted for intensity of staining. As 
the intensity was given a score of 1 -3  the maximum total was 300 if all the cells were 
strongly positive. This score of CD44H expression was ranked as follows:-
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0 =  0 
l-> 50 = 1
50-» 100 = 2 
101 -> 200 = 3 
201 -> 300 = 4
5.3.5 Selection of statistical methods
Fig 5.9 Graphs to demonstrate the distribution of MIB1, p53 and CD44H scores 
for the Dukes’ B carcinomas. The number of cases each with scores 0,1,2,3,4 or 5 
are shown to demonstrate that the data is not normally distributed
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Fig 5.9 demonstrates that the data obtained did not have a normal distribution, 
therefore non-parametric statistical tests were used.
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Most of the data are presented as rank scores and are thus ordered nominal scales.
As the aim of this project was to compare two independent groups of patients and to 
look for a tendency for one group to exceed members of the other, the most 
appropriate test is the Mann-Whitney U test, which is the non-parametric equivalent 
of the two sample t test (see 2.3.2.1).
5.3.6 Results
1. Two groups of patients were compared, one with and one without any type of 
recurrence.
2. Those patients with no recurrence were compared both with those with local 
recurrence only, those with distant recurrence only and those with both local 
and distant recurrence.
3. Patients with both local and distant recurrence were added to the distant 
recurrence group (so that all patients with distant recurrence were included). 
This group was then compared to the group with no recurrence and to the 
group with local recurrence only.
4. Patients with both local and distant recurrence were added to the local 
recurrence group (so that all patients with local recurrence were included). 
This group was then compared to the group with no recurrence and to the 
group with distant recurrence only.
For CD44H, there were several different scoring options to consider. As well as scores 
for the total percentage of tumour cells showing any CD44H expression at all, this 
score was ranked and also individual scores for percentage of cells staining with weak, 
moderate or strong intensity were available. A weighted score was also calculated, as 
previously described, which was additionally given a ranked score.
Mean values for the scores of these groups were assessed and also Mann-Whitney 
tests were performed to compare the scores of these groups.
For tables of results see appendix Tables 80-101
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5.3.6.1 All recurrences grouped together
Fig 5.10 Graph to compare the mean CD44H, MIB1 and p53 scores for the 
recurrence and the no recurrence groups of Dukes’ B carcinomas. Fig 5.10a 
shows mean values only and Fig 5.10b shows standard errors of these means.
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MIB1
Fig 5.10 shows that MIB1 staining was similar in both the recurrence and non­
recurrence groups of patients.
Using the Mann-Whitney tests (see appendix table 84):
There were no significant differences between the recurrence and no recurrence 
groups forM IBl.
p53
Fig 5.10 shows that p53 staining was similar in both the recurrence and non­
recurrence groups of patients.
Using the Mann-Whitney tests (see appendix table 89):
There were no significant differences between the recurrence and no recurrence 
groups for p53.
CD44H
Fig 5.10 shows that the CD44H scores were higher for the no recurrence group than 
for the recurrence group when ranked CD44H expression scores were used.
Using the Mann-Whitney tests (see appendix tables 94 and 99):
The CD44H scores for the total number of positive cells, regardless of intensity of 
staining, and the scores for CD44H weighted for intensity of staining were 
significantly higher in the no recurrence group than in the recurrence group. This was 
true both for the total percentage scores and for the ranked scores.
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5.3.6.2 Local, distant and both local and distant recurrences as different groups
The tumours were then grouped differently so that local and distant recurrences were 
grouped separately, as were the patients with both local and distant recurrence.
Fig 5.11 Graphs to compare mean scores for the three antibodies of the local, 
distant and both local and distant recurrence groups with the no recurrence 
group of Dukes’ B carcinomas. Fig 5.11a shows mean values only and Fig 5.11b 
shows standard errors of these means.
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MEB1
As can be seen from Fig 5.11 scores for MIB1 staining were similar in all four groups
of tumours.
Using the Mann Whitney tests (see appendix table 84), when the different types of 
recurrence were grouped separately then there was no difference in MIB1 staining 
between any of the groups.
p53
As shown in Fig 5.11, the mean p53 scores were slightly higher in the tumours that 
showed local recurrence.
Using the Mann Whitney tests (see appendix table 89) there were no significant 
differences for p53 staining between any of the groups studied.
CD44H
For CD44H staining, a similar pattern emerged whether the scores for the percentage 
of cells staining, regardless of intensity, or the scores weighted for intensity of 
staining were used.
Fig 5.11 shows the ranked values for the scores weighted for intensity of staining and 
it can be seen that CD44H expression is lower in the groups that contain patients with 
distant recurrences of their tumours.
Using Mann-Whitney tests (see appendix tables 94 and 99), the scores for both total 
percentage of cells staining, regardless of intensity, and scores weighted for intensity 
of staining were significantly higher in the no recurrence group than either the group 
containing only distant recurrence or the group containing patients with both local and 
distant recurrence. There were no differences between the no recurrence group and the 
group with local recurrence only.
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5.3.6.3 All distant recurrences grouped together
The group with both local and distant recurrence was then added to the group with 
only distant recurrence so that all patients with distant recurrence were included in one 
group.
Fig 5.12 Graphs to compare mean scores for CD44H, MIBl and p53 of the no 
recurrence group with those of the groups containing local recurrence only and 
the group containing all patients with distant metastases. Fig 5.12a shows mean 
values only and Fig 5.12b shows standard errors of these means.
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MIB1
Fig 5.12 shows that, as with the previous grouping of the tumours, MIB1 expression 
was similar in all groups of tumours.
Using Mann-Whitney tests (see appendix table 84), no significant differences were 
found between any of the groups for MIB1 staining.
p53
Fig 5.12 shows that p53 expression was similar in all groups of tumours.
Using Mann Whitney tests (see appendix table 89) no significant differences were 
found between any of the groups for p53 staining.
CD44H
Fig 5.12 shows that the CD44H scores were lower in the group of tumours that 
contained any patients with distant recurrences of their tumours.
Using the Mann Whitney tests (see appendix tables 94 and 99), the difference between 
the no recurrence group and the group containing all patients with distant metastases 
was highly significant for either method of scoring the CD44H. When the method of 
scoring the percentage of cells staining regardless of intensity was used the results 
were the most significant (p = 0.001 for either the total percentage or the ranked 
score).
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S.3.6.4 All local recurrences grouped together
The group of patients with both local and distant recurrence was added to the group of 
patients with local recurrence only so that all patients with local recurrence were 
grouped together.
Fig 5.13 Graphs to compare mean scores for the three antibodies of the no 
recurrence group with those of the groups containing distant recurrence only 
and the group containing all patients with local recurrence. Fig 5.13a shows 
mean values only and Fig 5.13b shows standard errors of these means.
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M m i
Fig 5.13 shows that MIB1 expression was similar in all groups of tumours.
Using Mann-Whitney tests (see appendix table 84), no significant differences were 
found between any of the groups for MIB1 staining.
p53
Fig 5.13 shows that p53 expression was similar in all groups of tumours, being 
slightly higher in the group of tumours showing local recurrence.
Using Mann Whitney tests ( see appendix table 89) no significant differences were 
found between any of the groups for p53 staining.
CD44H
Fig 5.13 shows that the CD44H scores were lower in both the recurrence groups of 
tumours than in the group with no recurrence. The scores were lowest in the group 
containing tumours with distant recurrence only.
Using the Mann Whitney tests (see appendix tables 94 and 99) the group containing 
all patients with local recurrence (including those with both local and distant 
recurrence) was not significantly different from either the no recurrence group or the 
group with distant metastases only for CD44H expression.
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Differences in the expression of the different intensities of staining of CD44H (see Fig 
3.8) were then assessed separately for the groups that showed significant differences 
in CD44H staining.
Fig 5.14 Graphs to show the changes in the three different CD44H staining 
intensities between the no recurrence and the recurrence groupings of the of 
Dukes’ B carcinomas. Fig 5.14a shows mean values only and Fig 5.14b shows the 
standard errors of these means.
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Fig 5.15 Graphs to show the changes in the three different CD44H staining 
intensities between the no recurrence, local recurrence distant and both local and 
distant groupings of the of Dukes’ B carcinomas. Fig 5.15a shows mean values 
only and Fig 5.15b shows the standard errors of these means
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Fig 5.16 Graphs to show the changes in the three different CD44H staining 
intensities between the no recurrence, local recurrence and distant (together with 
both local and distant) groupings of the of Dukes’ B carcinomas. Fig 5.16a shows 
mean values only and Fig 5.16b shows the standard errors of these means.
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Fig 5.17 Graphs to show the changes in the three different CD44H staining 
intensities between the no recurrence, distant recurrence and local (together with 
both local and distant) groupings of the of Dukes’ B carcinomas. Fig 5.17a shows 
mean values only and Fig 5.17b shows the standard errors of these means
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The results were very different for high and low intensity of staining for different 
groupings of the tumours.
1. The group of patients with no recurrence was compared to:
2. The groups of patients with recurrence of any kind,
3. The groups of patients with distant recurrence only and
4. The groups of patients with distant recurrence which included patients with 
both local and distant recurrence
Using Mann-Whitney tests (see appendix table 101), for all three groupings of the 
tumours
1. There were no significant differences between the groups for high intensity 
staining scores.
2. There were no significant differences between the groups for medium intensity 
staining scores.
3. For the staining of low intensity there were significantly more positive cells in
the tumours of the no recurrence group than in either the group containing
patients with distant metastases only or the group containing all patients with 
distant metastases
5.3.7 Discussion
(See also Chapter 7 General Discussion)
5.4 Colorectal Carcinoma Project 3
An investigation o f the recurrence o f Dukes9 C Colorectal Carcinomas,
5.4.1 Background
The definition of a Dukes’ C carcinoma is one where the tumour has spread beyond 
the primary site into the lymph nodes. Although their prognosis is not good, some 
patients survive for a surprisingly long period and the variation in survival for these 
patients cannot be explained clinically.
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As a continuation of the Dukes’ B project it was decided to look at sections of Dukes’ 
C tumours with the same antibodies as had been assessed for the Dukes’ B tumours. 
There are two major differences in the groups of patients in these two projects. The 
first is that Dukes’ C tumours have, by definition, already metastasised to the lymph 
nodes but the Dukes’ B tumours do not have metastases that were detectable at the 
time of surgery. The other variable factor that may be relevant is that, in general, the 
Dukes’ B patients will have had radiotherapy but not chemotherapy, whereas 
generally the Dukes’ C patients will, following a curative operation, have been given a 
course of chemotherapy, usually 5-FU (see 1.4). Biomodulated 5-fluorouracil (5-FU) 
chemotherapy may limit disease progression in up to 50% of patients with metastatic 
or unresectable carcinoma. Its anticancer activity is due to its ability to induce DNA 
damage both by inhibition of thymidylate synthetase, a key enzyme in pyrimidine 
biosynthesis, and by direct fragmentation of DNA. The tumour cell may respond to 
DNA damage by undergoing cell cycle arrest or apoptosis. Cell proteins that are 
involved in cell cycle progression, such as p53 (see 3.2.1), may influence the response 
to treatment in some way as could the proliferation rate of the tumour, as measured by 
MEB1. Treatment is expensive and may be toxic and thus any predictors of response 
may be clinically and economically valuable.
5.4.2 Selection of patients from clinical data
A list of patients who had previously had surgery and diagnosed as having Dukes’ C 
carcinomas was supplied by the clinicians. They supplied a list of a balanced selection 
of patients that included patients who, within five years, had presented with recurrence 
of their tumour and ones that had remained free from recurrence. The recurrences 
included both local recurrences of the tumour and distant metastases. Included were 
33 patients with no recurrence, 5 patients with local recurrence and 24 patients with 
distant recurrence.
5.4.3 Selection of a panel of antibodies
Three antibodies were selected for this project.
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5.4.3.1 MIB1
MIB1 was selected as it is a proliferation marker that would give an indication of the 
aggressiveness of the tumour. It was used to investigate whether proliferation rate has 
any effect on response to chemotherapy.
5.4.3.2 p53
p53 was selected for this project as there is some evidence that p53 positivity is 
related to patient survival even though results from various publications are 
conflicting. Our own results had shown that p53 positivity is related to tumour 
progression and that p53 abnormalities become important at the transition from 
Dukes’ A to Dukes’ B stage of tumour progression. For this project interest is also 
focused on the response to chemotherapy for patients with different levels of abnormal 
p53.
5.4.3.3 CD44H
From our previous results (colorectal project 1) it would be expected that Dukes’ C 
carcinomas would have low CD44H levels. It was decided to investigate this further to 
see whether CD44H negativity has any effect in promoting metastasis further than that 
to the initial lymph node sites.
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5.4.4 Assessment and scoring of staining
5.4.4.1 MIB1
The methods used for assessing the staining were as previously described (see 3.1).
The score for MIB1 staining was expressed as the total number of stained nuclei of 
tumour cells expressed as a percentage of the total number of tumour nuclei present. 
The percentage of stained nuclei were then ranked as follows:-
0% -> 20% = 1
21% -> 40% = 2
41% —^ 60% = 3
61% — ^ 80% = 4
81% ->100% = 5
5.4.4.2 p53
p53 staining was assessed as described in 3.2.. The total number of tumour nuclei 
stained was expressed as a percentage of the total number of tumour nuclei present. 
The percentage score was then ranked as follows:-
0% =  0 
1% 20% =1 
21% -> 40% = 2 
41%-> 60% = 3 
61%-> 80% = 4 
81%-> 100% = 5
5.4.4.3 CD44H
CD44H staining was assessed as previously described (see 3.3). The total number of 
tumour cells expressing any membrane staining was expressed as a percentage of the 
total number of tumour cells present. Additionally tumour cells showing three 
different intensities of staining were assessed separately and a score was calculated 
which was weighted for intensity of staining. As the intensity was given a score of 1 -  
3 the maximum total was 300 if all the cells were positive. This score of CD44H 
expression was ranked as follows
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0 =  0 
l->  50 = 1 
51—> 100 = 2 
101-> 200 = 3 
201->300 = 4
The total percentage of cells showing any staining, of any degree of intensity, was also 
ranked as follows:-
0 =  0 
1 - >  20  =  1 
2 1 4 0  = 2 
41-> 60 = 3 
61 _> 80 = 4 
81 ->100 = 5
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5.4.5 Selection of statistical methods
Fig 5.18 Graphs to show the distribution of data of the staining scores for MIB1, 
p53 and CD44H in Dukes’ C carcinomas.
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As can be seen from Fig 5.18, the data obtained did not have a normal distribution 
therefore non-parametric statistical tests were used.
Most of the data are presented as rank scores and are thus ordered nominal scales.
As the aim of this project was to compare two independent groups of patients and to 
look for a tendency for one group to exceed members of the other, the most 
appropriate test is the Mann-Whitney U  test, which is the non-parametric equivalent 
of the two sample t test (see 2.3.2.1).
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5,4.6 Results
The tumours were grouped in two different ways for comparison of their staining 
characteristics. Firstly the tumours with any type of recurrence were grouped together 
and compared to the groups of tumours with no recurrence. Secondly the recurrence 
group was divided into those with local and those with distant recurrence and the 
separate groups were then compared with the no recurrence group.
Tables showing mean scores for the three groups of tumours and the Mann-Whitney 
values are shown in the appendix (tables 102-121).
259
5.4.6.1 No recurrence and recurrence groups
Fig 5.19 Graphs to show the mean values for MIB1, p53 and CD44H staining for 
the recurrence and no recurrence groups of Dukes’ C carcinomas. Fig 5.19a 
shows mean values only and Fig 5.19b shows standard errors of these means.
3 . 0 1
□  C D 4 4 H  
I I M I B 1
N o  r e c u r r e n c e  R e c u r r e n c e
Fig 5.19a
3 . 5
3 . 0
2 . 5
2.0
1 . 5
o  C D 4 4 H1.0
o  M I B 1
+ 3
c  
<0 
<D
5  0.0 □  P 5 3
N o  r e c u r r e n c e R e c u r r e n c e
Fig 5.19b
260
MIB1
As can be seen from Fig 5.19, MIB1 scores were slightly higher in the no recurrence
tumour group than the recurrence group.
Using the Mann-Whitney test (see appendix table 103), there was no significant 
difference between these two groups for MIB1 staining.
p53
As shown in Fig 5.19, p53 staining was lower in the recurrence group of tumours.
Using the Mann-Whitney test (see appendix table 105) there was a significant 
difference between these two groups for p53 staining, using both the total percentage 
score and the ranked score.
CD44H
As for the previous projects, there were several different scoring options to consider 
for CD44H. As well as scores for the total percentage of tumour cells showing any 
CD44H expression at all, this score was ranked and also individual scores for 
percentage of cells staining with weak, moderate or strong intensity were available. A 
weighted score was also calculated, as previously described (see 3.3.4), which was 
additionally given a ranked score.
As Fig 5.19 shows, the mean values for CD44H staining tended to be higher in the 
group with no recurrence.
Using the Mann-Whitney test (see appendix tables 107 and 109) there was no 
significant difference between these two groups for any method of scoring the 
staining. For the weighted CD44H score, where the staining intensity is taken into 
account, the difference between the two groups was almost significant (p = 0.072 for 
the ranked score).
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5.4.6.2 No recurrence, local recurrence and distant recurrence groups.
Fig 5.20 Graphs to show the differences in mean M IBl, p53 and CD44H staining 
scores between the group of Dukes’ C patients with no recurrence, the group of 
patients with local recurrence and the group of patients with distant recurrence 
of their tumours. Fig 5.20a shows mean values only and Fig 5.20b shows 
standard errors of these means.
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M IBl
As can be seen from Fig 5.20, the mean value for the group with local recurrence was 
higher than that both of the group with no recurrence and the group with distant 
recurrence.
Using the Mann-Whitney test (see appendix table 113) only the difference between 
the group with local recurrence and the group with distant recurrence was significant.
p53
As can be seen from Fig 5.20, the mean p53 score for the group of tumours with no 
recurrence was higher than either the group with local recurrence or the group with 
distant recurrence
Using the Mann-Whitney test (see appendix table 115) the difference between the 
group with local recurrence and the group with no recurrence was not quite significant 
(p = 0.056 for the ranked score. The difference between the group with no recurrence 
and the group with distant recurrence was also not quite significant (p = 0.061 for the 
ranked score).
There was also no significant difference between the group with local and the group 
with distant metastases.
CD44H
As Fig 5.20 shows the mean CD44H score for the group of tumours with no 
recurrence was higher than either the group with local or the group with distant 
recurrence.
Using the Mann-Whitney tests (see appendix tables 117, 119 and 121) non of the 
differences between the groups were significant either for CD44H staining as a whole 
or for any of the different intensities of staining.
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5.4.7 Discussion
(See also Chapter 7 General Discussion)
Although none of the results for CD44H reached significance mean scores for CD44H 
staining were lower for tumours with distant recurrence. MTR1 scores were 
significantly higher for tumours with local recurrence and p53 scores were 
significantly lower in tumours with recurrence (grouped together) than in tumours 
with no recurrence. All three of the antibodies require further investigation but show 
promise as prognostic factors for Dukes’ C carcinomas.
CHAPTER 6 SUMMARY
The antibodies studied in these projects have all been evaluated successfully and 
shown to have some clinical value in the prognosis of cancer. A summary of the 
evaluation of the results is given for each antibody individually.
6.1 MIBl antibody
6.1.1 Methodology
As described earlier, MIBl has now been shown to be a reliable marker of 
proliferation in many studies (Barnes, 1995; Rose et al. 1994). At the start of these 
projects, however, there was little published about this antibody and much preliminary 
work was necessary to achieve optimum staining conditions.
6.1.1.1 Antigen retrieval
After investigating several variations of method, MIBl antigen retrieval was best 
achieved using the technique previously described (see 2.2.4). Using this technique, 
staining was reliable. Although intensity of staining did vary from tumour to tumour 
(see 1.2) staining intensity for a particular tumour was reproducible.
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6.1.1.2 Assessment of staining
Heterogeneity was found in staining intensity and staining pattern in the majority of 
tumours studied (see 3.1.4). A major factor in this variation was the size of the nuclei, 
as large granular nuclei generally showed less intense staining than small nuclei. It 
was sometimes difficult to decide, in the case of weak staining, whether a cell was 
very weakly positive or totally negative, but not many cells fell into this category. 
When the cut off point for positivity was taken as the presence of any staining at all, 
this proved to be the most reproducible method. This method has now been used by 
other groups (Schmitt, 1995).
6.1.2 Breast Projects
6.1.2.1 Breast Carcinoma Project 1
The characterisation o f  staining by the M IBl, p53, CD44H, CD44v3, CD44v6, ER 
and D5 antibodies in a variety o f breast lesions.
The aim of this project was to collect data on the MIBl staining of a variety of breast 
lesions and the findings are summarised below:
1. MIBl staining in the ductal in situ group was similar to that in the ductal 
invasive group when all grades of carcinoma were grouped together.
2. MIBl staining in the lobular in situ group was similar to that in the lobular 
invasive group.
3. Tubular carcinomas had low MIB1 staining.
4. MIBl staining of lobular carcinomas was to be similar to grade 1 ductal 
carcinomas.
5. There was a difference in MIBl staining between the hyperplasia group and 
both the ductal in situ and ductal invasive carcinoma groups. No difference 
could be detected between the hyperplasia group and either the in situ lobular 
or the invasive lobular group of carcinomas. The number of cases included in 
these groups, however, was low.
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6.1.2.2 Breast Carcinoma Project 2
A detailed investigation o f  the staining characteristics o f the antibodies MIBl, p53, 
CD44H, CD44v3, CD44v6, ER and D5 in benign and malignant lesions.
This project was an extension of project 1 with many more benign and low grade 
lesions included (see 4.3.2).
The results for the second project verified the findings of project 1. The greater 
number of benign and low grade lesions used strengthened the statistics for some of 
the group comparisons. The findings were as follows:
Comparison of benign and malignant lesions
MIBl staining was significantly higher in DCIS and invasive malignant lesions than 
in benign lesions.
Comparison of in situ and invasive carcinomas
No difference in MIBl staining characteristics could be found between DCIS and 
invasive ductal carcinoma or between LCIS and invasive lobular carcinoma.
Grade of ductal carcinomas
MIBl was positively correlated to grade of ductal carcinoma.
Lobular carcinomas
MIBl staining of lobular carcinomas was similar to grade 1 ductal carcinomas and 
significantly lower than grade 2 or grade 3 ductal carcinomas.
Radial scars
MIBl staining of radial scars was similar to that of the benign lesions.
Mucinous carcinomas
MIBl staining of mucinous carcinomas was equivalent to a low or average grade 
ductal carcinoma.
Medullary carcinomas
In this study the mean MIBl staining was even higher in the medullary carcinomas 
than in grade 3 ductal carcinomas and significantly higher than grade 1 or grade 2 
ductal carcinomas.
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Spearman Correlations
Over the whole range of pathological lesions MIBl correlated positively with p53. It 
also showed a negative correlation with CD44H staining.
6.1.2.3 Breast Carcinoma Project 3
A study on the metastatic potential o f grade 1 ductal carcinomas o f  the breast.
This study looked specifically at grade 1 breast tumours that had already metastasised 
at the time of surgery and compared them with a group selected randomly from the 
majority of grade 1 carcinomas which were associated with lymph nodes shown to be 
negative for tumour metastases. MIBl staining was generally at a low level. There 
was no significant difference between the mean MIBl staining scores for the lymph 
node positive tumours and those of the lymph node negative tumours.
6.1.3 Colorectal Projects
6.1.3.1 Colorectal Carcinoma Project 1
The characterisation o f  MIBl, p53 and CD44H antibody staining in colorectal 
adenomas and carcinomas.
The aim of this project was to characterise the MIBl staining of adenomas and 
carcinomas to establish a baseline for staining that could be used in more clinically 
specific projects. The findings were as follows:
1. MIB1 staining was significantly higher in carcinomas than adenomas.
2. No differences in MIB 1 positivity could be detected between the various 
Dukes’ stages of carcinoma
Spearman correlations
There were no significant correlations between MIBl staining and any other 
parameter measured.
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6.1.3.2 Colorectal Carcinoma Project 2
An investigation o f the heterogeneity ofprognosis for Dukes * B colorectal 
carcinomas.
MIBl staining of groups of Dukes’ B patients, those with and those without 
recurrences of their tumour, were studied. No significant difference in MIBl staining 
between different categories was found however the patients were grouped in this 
project. It therefore appears that proliferation rate is not an important factor in 
metastatic potential of Dukes’ B carcinomas.
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6.1.3.3 Colorectal Carcinoma Project 3
An investigation o f the recurrence o f Dukes ’ C colorectal carcinomas.
This project investigated the MIBl staining of tumours of Dukes’ C patients. Two 
groups of patients were studied, those whose tumours responded well to adjuvant 
therapy and those who had either local or distant recurrence of their tumours. The 
findings were as follows:
1. When the patients were grouped simply as those with and those without 
recurrence then no significant difference was found in MIBl staining between 
the two groups.
2. When the local and distant recurrences were grouped separately, then the 
group with local recurrence had higher MIBl positivity than either the distant 
recurrence or the no recurrence groups. Only the group with distant metastases 
showed a significant difference from the local recurrence group as this group 
had slightly lower values than the no recurrence group.
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6.2 p53 antibody
6.2.1 Methodology
As discussed in section 3.2.2, long storage of paraffin sections affects the p53 antigen 
and it is also apparent that the method of fixation, including both the fixative solution 
and temperature affects the stability of p53 protein. p53 staining did not appear to be 
affected by long term storage of the tissue in paraffin blocks, as overall staining was 
similar in tissue cut from both recent and old blocks. It soon became apparent, by 
looking at control sections that had been cut a few weeks earlier, that the intensity of 
staining gradually declined with time from when the section was cut. Sections, 
including the positive control sections, which were included with each batch of 
staining, needed to be freshly cut. A recent publication supports these findings (Jacobs 
et al. 1996). Another important parameter was the drying of the sections after cutting. 
They were dried in at 37°C as drying at high temperature also affected the intensity of 
staining (see 2.2.3.2 and 2.2.5.9).
6.2.1.1 Antigen retrieval
p53 staining of paraffin sections was shown to be consistent when the antigen retrieval 
technique described previously (see 2.2.4) was used. Some earlier published studies 
had used the same antibody PAbl801 without antigen retrieval and this may explain 
some of the variation in findings (see 4.2.3.2 and 5.2.3.2). These studies showed that 
this antibody, in conjunction with antigen retrieval gave consistent, reproducible 
results.
6.2.1.2 Assessment of staining
Staining was mainly nuclear and as p53 is normally located in the nucleus, nuclear 
p53 only was scored in these projects. Cytoplasmic staining was also observed in 
some sections, however, and this cytoplasmic staining has been observed in other 
studies. This may be a wild-type form of p53 which lacks tumour suppressor activity 
because it is sequestered in the cytoplasm, away from its site of action in the nucleus 
(Moll et al. 1992). It is also possible, however, that cytoplasmic staining could be
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artifactual, perhaps due to fixation problems. Because of this uncertainty it was 
decided to ignore any cytoplasmic staining.
Intensity of staining was variable and initially attempts were made to score cells with 
different intensities of staining. It was impossible to have a cut off point for staining of 
different intensities and when the presence of any staining at all was counted as 
positive then scoring was the most reproducible. Difficulties in scoring were 
encountered when the staining was patchy and this could only be estimated as a score 
representing the percentage of positive cells in the tumour as a whole. A carcinoma 
was assumed to be p53 positive if  more than 10% of the tumour cells were stained as 
the occasional cell staining could be attributed to the normal p53 response of a cell. 
This cut off point has been used by other groups (Rosen et al. 1995; Pereira et al. 
1997).
6.2.2 Breast Projects
22% of the ductal carcinoma lesions were p53 +ve. These figures are consistent with 
those of another study (Rosen et al. 1995), which used the same cut-off score of 10% 
positive cells, where 23% of infiltrating ductal carcinomas were found to be p53 +ve.
6.2.2.1 Breast Carcinoma Project 1
The characterisation o f staining by the MIBl, p53, CD44H, CD44v3, CD44v6, ER 
and D5 antibodies in a variety o f breast lesions.
This project investigated p53 staining in a wide range of breast lesions. There were no 
significant differences between any of the groups studied for p53 expression. p53 
staining of lobular carcinomas was lower than that of ductal carcinomas and the 
difference almost reached significance.
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6.2.22 Breast Carcinoma Project 2
A detailed investigation o f the staining characteristics o f the antibodies MIBl, p53, 
CD44H, CD44v3, CD44v6, ER and D5 in benign and malignant lesions.
p53 staining was very infrequent in benign and low grade malignant lesions in project 
1 and so it was not used for the much larger number of benign and low grade lesions 
added in the second project as the main aim of this project was to look at this type of 
lesion. Grade of ductal carcinoma was assessed separately in this project.
p53 expression increased significantly with grade of ductal carcinoma.
When the grades of ductal carcinoma were grouped separately then lobular 
carcinomas showed a similar p53 staining pattern to grade 1 ductal carcinomas. 
Lobular carcinomas had significantly lower p53 expression than grade 3 ductal 
carcinomas.
6.2.2.3 Breast Carcinoma Project 3
A study on the metastatic potential ofgrade 1 ductal carcinomas o f  the breast.
p53 was used for this Grade 1 breast project as the aim of this project was to look for a 
difference in staining that could be related to the unexpected characteristic of one of 
the groups of tumours to metastasise.
No significant difference in p53 staining could be found between the two groups.
6.2.3 Colorectal Projects
The percentage of colorectal carcinomas that were positive for p53 (more than 10% of 
cells showing positive staining) was 57%. This value is similar to that found in 
various other studies (Mulder et al. 1995; Nathanson et al. 1994; Yamaguchi et al. 
1992; Ofner et al. 1995). p53 positivity greater than 10% was seen in 3/32 adenomas. 
This compares with results of one study (Dunn et al. 1993) where 2/38 sporadic 
adenomas were found to overexpress p53 and another where only 3% were p53 
positive (Kikuchi et al. 1997).
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6.2.3.1 Colorectal Carcinoma Project 1
The characterisation o f  MIBl, p53 and CD44H antibody staining in colorectal 
adenomas and carcinomas.
This project investigated p53 staining in a range of adenomas and carcinomas with the 
following results:
1. The first project showed that p53 staining was lowest in adenomas and highest 
in Dukes’ C carcinomas.
2. p53 staining was significantly higher in the carcinoma group, when studied as 
a whole, than in the adenoma group.
3. p53 staining was significantly higher in the Dukes’ C group’ than in the 
adenoma group.
When the Dukes’ A and B carcinomas were grouped together:
1. There was no significant difference in p53 staining between the combined 
Dukes’ A and B group and the adenoma group.
2. There was no significant difference in p53 staining between the combined 
Dukes’ A and B group and the Dukes’ C group.
Spearman correlations showed that there was a positive correlation between degree of 
dysplasia of adenomas and also with Dukes’ stage of carcinomas.
6.2.3.2 Colorectal Carcinoma Project 2
An investigation o f  the heterogeneity ofprognosis fo r Dukes ’ B colorectal 
carcinomas.
p53 was selected for this project as colorectal project 1 had shown that although there 
was not a significant difference in p53 staining between Dukes’ B carcinomas and 
adenomas there was a significant difference between Dukes’ C carcinomas and 
adenomas.
There was no significant difference in p53 staining between any of the recurrence and 
no recurrence groups studied in this project.
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6.233  Colorectal Carcinoma Project 3
An investigation o f the recurrence o f Dukes 'C colorectal carcinomas.
This project investigated p53 staining in Dukes’C tumours, both those that responded 
well and those that responded badly to adjuvant therapy, with the following results:
The no recurrence group showed significantly higher p53 staining than the recurrence 
group as a whole.
The no recurrence group showed higher p53 staining than the group with local 
recurrence but the difference did not quite reach significance (p = .056).
The no recurrence group showed higher p53 staining than the group with distant 
recurrence but again the difference did not quite reach significance (p = .061).
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6.3 CD44 antibodies
6.3.1 Methodology
At the start of these projects the CD44 antibodies were new and were only 
recommended for frozen sections. Many studies were performed with varying 
dilutions of antibody and antigen retrieval.
6.3.1.1 Antigen retrieval
The initial studies with CD44H were performed on frozen sections.
As antigen retrieval was being performed on MIBl, which was being tested at the 
same time, the same technique was tried with the CD44H antibody and found to be 
successful (This technique is now recommended by the distributors of the CD44H 
antibody). The method used was that described in 2.2.4. The same method was used 
for CD44v3 and CD44v6.
6.3.1.2 Assessment of staining
Although initially the scoring technique for CD44, using three different intensities of 
staining, seemed to be complicated it proved to be highly reproducible between 
several different observers. The intensities of staining were an estimate of the 
proportion of the cell membrane that expressed CD44 (see 3.3.2) rather than an 
estimate of a cut-off point within a continuum of colour depth as is necessary if 
different intensities of staining are scored with nuclear or cytoplasmic stains. This was 
easier to estimate consistently than intensity of staining that involved depth of colour 
and it also did not vary from one batch of staining to another, as was inevitable with 
intensity of colour.
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6.3.2 Breast Projects
6.3.2.1 Breast Carcinoma Project 1
The characterisation o f  staining by the M IBl, p53, CD44H, CD44v3, CD44v6, ER 
and D5 antibodies in a variety o f  breast lesions.
This project investigated the staining characteristics of three CD44 antibodies, CD44H 
in a wide variety of breast lesions and CD44v3 and CD44v6 in a more limited 
selection. The findings were as follows:
CD44v3 and CD44v6
A limited number of lesions were stained with CD44v3 and CD44v6. No significant 
differences were found for the staining of either antibody between any of the groups 
of lesions studied.
CD44H
There was a significant difference between the hyperplasia group and the ductal 
carcinoma group for CD44H staining when either the score for CD44H weighted for 
intensity of expression or the ranked total percentage score was used.
No other significant differences between pathological groups were found.
6.3.2.2 Breast Carcinoma Project 2
A detailed investigation o f  the staining characteristics o f  the antibodies M IBl, p53, 
CD44H, CD44v3, CD44v6, ER and D5 in benign and malignant lesions.
Many more benign and low grade lesions were included in this project (see 4.3.2).
The results for the second project verified the findings of project 1. The greater 
number of benign and low grade lesions used meant that the statistical tests used were 
more powerful. Benign, malignant and metastatic lesions and also breast lesions of 
particular clinical interest were investigated individually with the following findings:
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Comparison of benign and malignant lesions
1. The CD44H staining of the hyperplasia group was significantly higher than the 
DCIS group.
2. Staining of hyperplasia group was almost significantly higher than the grade 1 
ductal carcinoma group (p = 0.065).
3. CD44H staining of the hyperplasia group was significantly higher than that of 
both the grade 2 and grade 3 ductal carcinomas.
4. CD44H staining of the papilloma group was significantly higher than the 
DCIS group.
5. Staining of the papilloma group was significantly higher than all grades of 
ductal carcinoma.
Comparison of in situ and invasive carcinomas
1. DCIS staining with CD44H was lower than in grade 1 ductal carcinoma and 
higher than in grade 2 ductal carcinoma, but neither of these differences was 
significant. It was significantly higher than in grade 3 ductal carcinoma.
2. No difference in CD44H staining was found between LCIS and invasive 
lobular carcinoma.
Grade of ductal carcinomas.
1. Grade 1 ductal carcinomas showed significantly higher levels of CD44H 
staining than grade 2 or grade 3 ductal carcinomas.
2. There was a significant negative correlation between grade of ductal 
carcinoma and CD44H expression.
Lobular carcinomas
Lobular carcinomas showed significantly lower staining than grade 1 ductal and
similar levels as grade 2 and 3 ductal carcinomas.
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Radial Scars
Radial scars showed significantly lower staining than either of the groups of benign 
lesions and were similar to the staining of the DCIS group.
Mucinous carcinomas
There was no significant difference in CD44H staining between mucinous and other 
ductal carcinomas, implying that CD44H expression is not an important factor in the 
prognosis of mucinous carcinomas.
Medullary carcinomas
Results for medullary carcinomas showed that they were not significantly different 
from any grade of ductal carcinoma for CD44H expression.
Spearman correlations
There was a negative correlation of CD44H staining with grade of ductal carcinoma 
and also with MIBl, p53 and D5 staining.
6.3.2.3 Breast Carcinoma Project 3
A study on the metastatic potential ofgrade 1 ductal carcinomas o f  the breast.
This project studied the CD44H staining of grade 1 ductal carcinomas. Two groups of 
tumours, one with and one without lymph node metastases at the time of surgery were 
investigated with the following results:
Using any method of scoring the CD44H staining i.e. total percentage of cells staining 
or a score weighted for intensity of staining (see 3.3.2), there were significantly lower 
levels of CD44H staining in the group of tumours that had metastasised than those that 
had not.
When the different staining intensities were considered separately, the difference in 
the mean value for the percentage of tumour cells staining at low intensity showed a 
significant difference between the two groups. The same was true for the value for 
cells staining with medium intensity, but there was no significant difference in the 
number of cells staining with high intensity.
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6.3.3 Colorectal Projects
6.3.3.1 Colorectal Carcinoma Project 1
The characterisation o f  MIBl, p53 and CD44H antibody staining in colorectal 
adenomas and carcinomas.
This project investigated CD44H staining in adenomas and carcinomas with the 
following conclusions:
1. Adenomas showed significantly higher staining than carcinomas when 
grouped together as a whole.
2. Adenomas showed significantly higher staining than Dukes’ A, Dukes’ B or 
Dukes’ C groups of carcinomas when they were considered separately.
3. The staining levels were lower in the metastasising (Dukes’ C) group than in 
the non-metastasising (combined Dukes’ A and B) group.
When the three levels of CD44H staining intensity were considered separately:
1. Adenomas showed significantly higher staining than Dukes’ C carcinomas at 
all intensities.
2. There was a significant decrease in the scores for medium and high intensity 
staining between the adenomas and Dukes A&B (non-metastasising) 
carcinomas.
3. There was a significant difference in low and medium intensity CD44H 
staining between the Dukes’ A&B (non-metastasising) and the Dukes’ C 
(metastasising) carcinomas, but the high intensity staining was not 
significantly different.
Spearman correlations
The only significant correlation was a negative relationship between CD44H and p53 
staining.
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6.3.3.2 Colorectal Carcinoma Project 2
An investigation o f the heterogeneity ofprognosis for Dukes ’ B colorectal 
carcinomas.
CD44 staining of Dukes’ B carcinomas was investigated separately for this project. 
These tumours were divided into groups, those without recurrence, those with local 
recurrence, those with distant recurrence and those with both types of recurrence. The 
CD44H staining for these groups, and alternative combinations of these groups, was 
compared with the following results:
Expression of CD44H, which was weighted for intensity, showed significant 
differences between the group with distant metastases and either the group with no 
recurrence or local recurrence only.
When the score for total number of cells staining, regardless of intensity, was assessed 
the difference between the two groups was even more strongly significant.
CD44H staining was significantly different between the no recurrence group and any 
of the groups that contained tumours that had given rise to distant metastases for low 
staining intensity scores.
6.3.3.3 Colorectal Carcinoma Project 3
An investigation o f the recurrence o f Dukes ’ C colorectal carcinomas.
Dukes’ C carcinomas were studied in this project. The CD44H scores for these 
tumours were generally low, which was expected as project 1 had shown that there 
was less CD44H staining in Dukes’ C carcinomas than in Dukes’ A and B 
carcinomas.
For all methods of grouping the recurrences and all methods of assessing the CD44H 
positivity i.e. total percentage score, expression score or scores for different intensities 
of staining, the scores for the recurrence groups (see 3.3.2) were lower than the scores 
for the no recurrence group. None of the differences were statistically significant.
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6.4 ER antibody
6.4.1 Methodology
These studies of the oestrogen receptor expression on breast tumours highlighted 
many difficulties in consistent assessment. One factor that could not be completely 
controlled was the initial fixation of the specimens (see discussion section 7.4) as 
there was no way of allowing for this in these retrospective studies.
6.4.1.1 Antigen retrieval
After many studies on staining technique, consistent results were obtained using the 
antigen retrieval method described previously (see 2.2.4) but particular care was taken 
to ensure that the pH of the citrate buffer was accurate for this antibody.
6.4.1.2 Assessment of staining
Heterogeneity of staining was a problem with this antibody, as it was for MIBl and 
p53. A well-established method of scoring ER is the H-score (see 3.4.4.2) which is 
similar to the method used for scoring CD44 (see 3.3.2). Other methods of scoring 
have also been published (see 3.4.4.2) and different percentages of positive cells taken 
as the cut-off point for ER positivity. Many methods were tested initially but there 
were two problems with any method that required a subjective assessment of intensity 
of staining. One of these was consistency in staining intensity from one batch of 
staining to the next and even using the same positive control to give a guideline each 
time, it was still difficult to be consistent in assessment of staining intensity. The other 
problem was in the scoring of the cells. It was impossible to assess cells individually 
and to consistently put them in the correct staining intensity group. As discussed in 
3.4.3, it has been shown that there is little to choose between the various methods for 
significant results. For these projects it was decided that the only method of scoring 
that was reproducible was just to count any staining in a nucleus as positive and to 
score the total percentage of positive cells.
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6.4.2 Breast Carcinoma Project 1
The characterisation o f staining by the MIBl, p53, CD44H, CD44v3, CD44v6, ER 
and D5 antibodies in a variety o f  breast lesions.
The first project showed results that were consistent with those of many previously 
published studies.
1. ER staining decreased significantly with increasing grade of ductal carcinoma.
2. There was no significant difference in ER staining between hyperplasia, in situ 
and invasive lesions.
3. Staining was higher in lobular than in ductal carcinomas but only the ranked score 
was significant.
6.4.3 Breast Carcinoma Project 2
A detailed investigation o f  the staining characteristics o f  the antibodies MIBl, p53, 
CD44H, CD44v3, CD44v6, ER and D5 in benign and malignant lesions.
This second project included many more benign and low grade lesions.
Comparison of benign and malignant lesions
1. ER staining of benign lesions was lower than that of grade 1 ductal 
carcinomas.
2. Staining was similar to grade 2 ductal carcinomas.
3. Staining was higher than grade 3 ductal carcinomas.
Comparison of the in situ and invasive carcinomas
1. ER staining of DCIS was similar to that of the benign lesions.
2. ER staining of DCIS was similar to that of grade 1 and 2 ductal carcinomas
and significantly higher than that of grade 3 ductal carcinomas.
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3. No difference in ER staining could be found between LCIS and invasive 
lobular carcinoma.
Grade of ductal carcinomas
1. ER expression was significantly higher in grade 1 than in grade 2 ductal 
carcinomas.
2. ER expression was significantly higher in grade 2 than in grade 3 ductal 
carcinomas.
Lobular carcinomas
1. Staining of lobular carcinomas was similar to grade 1 ductal carcinomas.
2. Staining of lobular carcinomas was significantly higher than grade 3 ductal 
carcinomas.
Radial scars
1. No significant differences in ER staining were found between radial scars and 
either of the benign lesions.
r
2. No significant differences in ER staining were found between radial scars and 
DCIS.
Mucinous carcinomas
There was no significant difference in ER expression between mucinous and any of
the ductal carcinoma groups in this project.
Medullary carcinomas
ER staining for medullary carcinomas was significantly lower than ER staining of
either grade 1 or grade 2 ductal carcinomas.
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Spearman correlations
1. ER correlated positively with the CD44 variant isoforms CD44v3 and CD44v6.
2. ER did not correlate with CD44H.
3. ER staining correlated positively with D5 expression.
4. ER staining correlated negatively with grade of ductal carcinoma.
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6.5 D5 antibody
6.5.1 Methodology
Staining of paraffin sections with this antibody was relatively new at the start of these 
projects and preliminary work was necessary to establish a reliable staining method.
6.5.1.1 Antigen retrieval
Antigen retrieval using the method previously described (see 3.5) gave clear 
reproducible staining with this antibody.
6.5.1.2 Assessment of staining
There were no particular problems in assessing D5 staining. Initially, as with the 
nuclear staining of MDBl, p53 and ER an attempt was made to score different 
intensities of the cytoplasmic staining, but the range of intensity was a continuum and 
it was difficult to find a consistent cut off point for different staining intensities. The 
method selected as being the most reproducible was the one where any staining was 
counted as positive for that cell.
6.5.2 Breast Carcinoma Project 1
The characterisation o f staining by the M B1, p53, CD44H, CD44v3, CD44v6, ER 
and D5 antibodies in a variety o f breast lesions.
The first project indicated that:
1. There was a significant difference in Heat Shock Protein 27 expression, as 
indicated by D5 staining, between the hyperplasia and DCIS groups of lesions.
2. Staining characteristics of all grades of ductal and also of lobular carcinomas 
were similar to one another.
3. Tubular carcinomas showed lower expression than other ductal carcinomas.
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6.5.3 Breast Carcinoma Project 2
A detailed investigation o f  the staining characteristics o f  the antibodies MIB1, p53, 
CD44H, CD44v3, CD44v6, ER and D5 in benign and malignant lesions.
Comparison of benign and malignant lesions
1. The benign lesions, papillomas and hyperplasias, showed a similar staining 
pattern to each other.
2. The benign lesions had significantly lower scores than the malignant lesions. 
Comparison of in situ and invasive carcinomas
There was no significant difference in D5 staining between DCIS and invasive ductal 
carcinoma or between LCIS and invasive lobular carcinoma.
Grade of ductal carcinoma
There were no significant differences in D5 staining between any grade of ductal 
carcinoma.
Lobular carcinomas
There was no significant difference between lobular and ductal carcinoma for D5 
staining.
Radial scars
1. D5 staining of radial scars was significantly higher than that of the benign 
lesions.
2. D5 staining of radial scars was significantly lower than that of DCIS.
Mucinous carcinomas
D5 staining of the few mucinous carcinomas studied was similar to that of other ductal 
carcinomas.
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Medullary carcinomas
D5 staining of medullary carcinomas was significantly lower than grade 2 or grade 3 
ductal carcinoma.
Spearman correlations
1. Over the whole range of pathology D5 correlated strongly with ER but when
the grades of ductal carcinoma were assessed separately then D5 did not
decrease with grade as did ER.
2. ER staining correlated positively overall with MIB1 staining.
3. ER staining correlated negatively with CD44H staining.
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CHAPTER 7 GENERAL DISCUSSION
In discussion of the breast lesions, papillomas and hyperplasias are used as a base line 
for benign cell staining levels. Both groups of lesions showed similar patterns of 
staining to each other, the only slight difference being in MIB1 staining, where 
papillomas had a slightly higher proliferation rate. These projects have addressed the 
problems of distinguishing between benign and early neoplastic proliferative breast 
lesions and also the separation and stratification of different forms of DCIS and 
invasive ductal carcinoma.
For colorectal lesions distinctions between benign and neoplastic colorectal lesions 
and also the heterogeneity of invasive lesions in respect of tumour recurrence have 
been investigated.
Each of the antibodies used is discussed individually with respect to the findings of 
these studies.
7.1 MIB1 antibody
7.1.1 Breast lesions
The distribution of MIB1 staining across the range of lesions studied showed two 
peaks. The first peak, representing a low MD31 score, was more pronounced in the 
second breast project. The most likely explanation is that the first peak largely 
represents the benign lesions, which in general have a lower proliferation rate than 
malignant lesions, represented by the second peak. The increase in numbers with a 
lower proliferation rate in the second project would then be explained by the fact that 
the second project contained many more benign and low grade lesions than the first 
project.
Malignancy appeared to be accompanied by an increase in MIB1 staining as 
evidenced by the significant increase in MIB1 staining between the benign and 
malignant lesions. As higher levels of MIB1 staining were found in both DCIS and 
invasive malignant lesions than in benign lesions, this could be an important factor in
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distinguishing between hyperplasia and DCIS as this is sometimes difficult using 
routine histopathology.
The positive correlation with grade of ductal carcinoma was to be expected as 
proliferation, as identified by the number of mitotic figures seen, is one of the 
parameters of the breast grading system (see. 1.2.5.6 a). For the same reasons, the low 
MIB1 staining, shown by tubular carcinomas, was anticipated as they are classified as 
very low grade ductal carcinomas). Another study supports these findings as staining 
of the Ki67 protein, to which the MEB1 antibody binds (see 3.1), was shown to be 
significantly related to grade (Sullivan et al. 1993). MIB1 could be useful as a 
prognostic factor in the grading of ductal carcinomas as it gives a much quicker and 
more reliable assessment of the proliferation factor of the grading system than the 
present method of counting mitotic figures.
DCIS is a major clinical problem and now accounts for about 20% of 
mammographically detected tumours. As MIB1 staining of DCIS was similar to that 
of invasive cancer, this supports the idea that DCIS should be classified as a malignant 
rather than as a benign lesion for patient prognosis.
When the DCIS and the different grades of ductal carcinoma were compared, the 
DCIS pattern of staining was similar to that of the average (grade 2) carcinoma. As 
MIB1 staining was greater in the DCIS group than in the grade 1 carcinoma group and 
lower than that in the grade 3 carcinoma group, this implies that DCIS staining pattern 
is the same as the average ductal carcinoma. This could be explained by the fact that 
the tumour cells in DCIS have largely similar MIB1 staining properties to those in 
invasive carcinoma. The DCIS group could therefore have been broken down into a 
similar grading system as that used for the invasive ductal lesions. Presently DCIS is 
often called high, intermediate or low grade but this grading is not as specific as the 
grading of invasive ductal carcinoma. It is graded according to the cytological features 
of the tumour cells, which include nuclear pleomorphism and number of mitotic 
figures. The high grade DCIS is considered more likely to become invasive but 
mitoses are difficult to assess in routine pathology and it is possible that MIB1 could 
help the grading of DCIS, predicting the potential aggressiveness of a particular DCIS 
lesion and thus its potential to become invasive. A recent study supports these findings 
(Imamura et al. 1997). It was shown that MIB1-determined proliferative activity of
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intraductal components was an independent predictor of survival and was the most 
important predictor in non-comedo DCIS.
Radial scars are traditionally regarded as benign lesions but are of particular interest in 
our laboratory as there has, for some time, been a suspicion that they do not always 
behave as such. MIB1 staining did not provide any new indication, however, as the 
proliferation rate appeared similar to that of the benign lesions, being intermediate 
between the hyperplasia and papilloma groups and thus supporting the idea that radial 
scars should be regarded as benign lesions (see also 7.5).
The few mucinous carcinomas stained indicated that the proliferation rate was lower 
than that of an average grade ductal carcinoma which would fit with their better than 
average prognosis.
The results for medullary carcinomas were interesting. Medullary carcinomas are 
difficult to distinguish pathologically from high grade ductal carcinomas. It is now 
thought that there is a relationship between medullary carcinomas and the BRCA1 
mutation (see 1.2.2). One study (Lakhani and et al., 1998) studied cancers associated 
with BRCA1 or BRCA2 mutations and concluded that cancers associated with 
BRCA2 mutations exhibited a higher score for tubule formation (fewer tubules), a 
higher proportion of the tumour perimeter with a continuous pushing margin and a 
lower mitotic count. Cancers associated with BRCA1 mutations exhibited higher 
mitotic counts, a greater proportion of the tumour with a continuous pushing margin 
and more lymphocytic infiltration than sporadic cancers. They have also been shown 
to be poorly differentiated and show a very pleomorphic nuclear pattern (Breast 
Cancer Linkage Consortium, 1997). In addition high frequencies of p53 alterations 
and oestrogen receptor negativity (Eisinger and et al., 1997; Johannson and et al.,
1997) are observed in these tumours. Although these parameters are indicators of a 
poor outlook, the overall survival is equivalent to or even better than sporadic cases 
(Marcus and et al., 1996). This apparent discrepancy is reminiscent of what is 
observed for the medullary carcinoma (see 1.2.5.6.d). One group found that 19% of 
BRCA1 breast cancers were of the typical medullary type, compared to 0 out of 200 
controls (sporadic breast cancers). They also found that of 18 typical medullary 
carcinomas studied, two nonsense mutations were found, which corresponds to almost 
7 times the contribution of BRCA1 mutations in the general population. These results
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suggest that, although typical medullary carcinomas and BRCA1 breast carcinomas 
are not strictly coincidental, an important connection between the two populations 
does exist. In this study the mean MIB1 staining of medullary carcinomas was higher 
than any group of ductal carcinomas implying that proliferation rate is not an 
important factor in the good long term prognosis of medullary carcinomas. As the 
proliferation rate of these tumours is so high, it is possible that their good prognosis 
could be explained by a high apoptotic rate compensating for the high proliferation 
rate.
The low level of MD31 staining was expected for the grade 1 carcinomas (see above). 
Although the mean MIB1 staining scores for the lymph node positive tumours were 
higher those of the lymph node negative tumours, the difference was not significant. 
This suggests that proliferation rate, in itself, is not a factor that influences the 
metastasis of grade 1 tumours and thus is not particularly useful in prognosis other 
than in the initial grading of these tumours.
A complicated relationship between M3B1 and ER expression was demonstrated and 
this is discussed in 7.4.
7.1.2 Colorectal lesions
This project showed that colorectal carcinomas had a higher proliferation rate than 
adenomas and thus MIB1 could be useful in assessing the aggressiveness of adenomas 
as far as proliferation rate is concerned. There was, however, no correlation between 
MIB1 staining and degree of dysplasia of the adenomas, implying that proliferation 
rate itself is not directly related to the progression of an adenoma
Similarly to the findings by another group (Ofner et al. 1996), who showed that, 
whatever method of evaluation was used, there was no statistical correlation of MEB1 
with the clinical outcome of the respective patients, no differences in MIB 1 positivity 
could be detected between the various Dukes’ stages of carcinoma. Proliferation rate 
does not therefore seem to be an important factor in the staging of colorectal 
carcinomas.
The MIB1 scores had a wide distribution over the whole range of Dukes’ B 
carcinomas. The mean scores for MIB1 were very similar in all groups of Dukes’ B
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patients assessed. Thus MIB1 did not have any prognostic significance for this group 
of patients, suggesting that proliferation rate does not seem to be an important factor 
for recurrence of Dukes’ B carcinomas either for local or for distant recurrence.
For the Dukes’ C tumours, the results were slightly different. When the local and 
distant recurrences were grouped separately, then the group with local recurrence had 
higher MIB1 positivity than either the distant recurrence or the no recurrence groups, 
although only the group with distant metastases showed a significant difference. These 
results imply that proliferation rate could be an important factor in the control of local 
recurrence of advanced tumours and that Dukes’ C patients with high MIB1 positivity 
may benefit from wider excision of their tumours than those with low MIB1 
positivity. The number of patients studied that had local recurrence alone was small (n 
= 5), however, and a larger sample would be needed before any firm conclusions 
could be drawn from these results. The similarity in scores between the distant 
recurrence and no recurrence groups implies that proliferation rate is not important for 
metastatic recurrence.
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7.2 P53 antibody
7.2.1 Breast lesions.
Although in the first breast study there were no significant differences between the 
hyperplasia and DCIS groups, no p53 staining was found in any of the hyperplasia 
lesions but 35% of DCIS lesions showed positive p53 staining (>10%+ve cells). DCIS 
and invasive ductal carcinomas showed similar p53 staining patterns, p53 staining was 
higher in DCIS and ductal carcinomas than it was in any of the other lesions, but the 
differences were not significant. The statistics could have been unreliable, however, 
due to the small numbers in many of the benign and low grade carcinoma groups. A 
recent study showed that in 27 samples analysed for p53 mutations the same p53 
mutation was found in the DCIS as was present in the invasive carcinoma. In contrast 
no mutations were identified in adjacent non-invasive epithelial lesions (Donehower, 
1998).
p53 staining in DCIS was equivalent to that in invasive grade 2 ductal carcinoma. The 
grade of DCIS has been shown in a recent study to be related to p53 staining although 
the results did not quite reach significance (Mack et al. 1997). This means that p53 
could be used, in conjunction with MH31, in assessing the potential aggressiveness of 
DCIS and also supports the idea that, prognostically, DCIS should be regarded as a 
malignant lesion.
When grade of ductal carcinoma was considered separately, there was a significant 
increase in p53 staining with increasing grade of ductal carcinoma as shown both by 
Spearman correlations and Mann-Whitney tests to compare scores for groups of the 
three different grades of ductal carcinoma. These results support previous work (see 
4.2.3.2) showing that p53 staining is related to poorly differentiated and poor 
prognosis tumours.
Similar to the findings of another group (Rosen et al. 1995) no p53 staining was 
found in any of the tubular carcinomas and p53 staining of lobular carcinomas was 
lower than that of ductal carcinomas. When the grades of ductal carcinoma were 
grouped separately then lobular carcinomas showed a similar p53 staining pattern to 
grade 1 ductal carcinomas. This followed the pattern of MIB1 staining of the lobular
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carcinomas indicating the relationship between mutant p53 and proliferation rate in a 
cell (see 3.2.1.3).
p53 was not used for staining the additional benign and low grade lesions as the 
number of p53 positive tumours in these categories was very low in the preliminary 
study. For the project investigating the heterogeneity of grade 1 breast tumours, 
however, it was considered possible that the relatively unusual metastatic potential of 
some grade 1 carcinomas could be related to p53 expression. The results showed 
however, that there was little staining in either group of tumours and although the 
lymph node positive group did show higher staining the difference was not significant. 
It does not therefore appear that non-functional p53 is an important feature in 
assessing the likelihood of metastatic behaviour of low-grade breast tumours.
As p53 is involved in the regulation of the cell cycle (see 1.1.2.3) and thus of 
proliferation then it could be expected that inactive p53 would be associated with a 
higher proliferation rate. This was confirmed by the positive correlation of p53 
staining with MLB 1 staining.
7.2.2 Colorectal lesions
When the Dukes’ carcinoma stages were grouped separately, the increase in p53 
staining seemed to be at the Dukes’ B stage of tumour progression (see Fig 5.5) 
although the difference between adenomas and Dukes’ B carcinomas was not 
significant when Mann Whitney tests were used. The degree of staining was lower in 
the Dukes’ A carcinomas than in the adenomas, but the small number of Dukes’ A 
carcinomas available probably made these results unreliable.
The positive correlation of p53 staining with degree of dysplasia of adenomas and also 
with Dukes’ stage of carcinomas supports the evidence that the p53 mutation is a late 
step in carcinoma progression as discussed in section 1.3.2. The low staining in 
adenomas and the highest staining in Dukes’ C carcinomas also supports the findings 
of other studies (Khine et al. 1994; Goh et al. 1994). Unlike the results for the breast 
lesions, no correlation could be found between MIB1 and p53 staining for the 
colorectal lesions. This was surprising because, although MLB 1 correlated with grade 
of breast carcinoma and not with Dukes’ staging of colorectal carcinomas, the two 
parameters of grading and staging are not equivalent and it might have been
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anticipated that the relationship between overexpression of p53 and proliferation rate 
would be the same in both types of adenocarcinoma.
When p53 staining was investigated in the Dukes’ B carcinoma project, as with MIB1 
the p53 scores had a wide distribution. p53 expression appeared not to be related to 
recurrence of the tumour, either when patients with local and distant recurrence were 
grouped together or separately. There was a slightly higher score for patients with 
local recurrence, but the difference was not significant. A recent study (Starzynska et 
al. 1997) also found that patients with overexpression of p53 in their tumours showed 
a higher local recurrence rate than did those with undetectable levels of p53 (23% and 
9% respectively).
An earlier study (Yamaguchi et al. 1992) using the same p53 antibody (Pabl801) 
found that there was no significant correlation between the expression of p53 and the 
histologic grade, tumour size, serosal invasion, lymphatic invasion, lymph node 
metastasis, or liver metastasis. They did find, however, that p53 positive tumours had 
a greater relative risk of death compared with those with p53 negative tumours. They 
suggested that poor survival of those with p53-positive tumours may have been 
associated with a high cell proliferation. The tumours in Yamaguchi’s study were a 
mixture of varying Dukes’ stage, but the results on these Dukes’ B patients did not 
support these findings as Spearman correlations showed that there was no significant 
correlation between p53 and MIB1 staining. A recent study, that examined Dukes’ A 
and B colorectal tumours, also found no prognostic significance for p53 staining in 
these node-negative tumours (Pereira et al. 1997). As there was no significant 
difference in p53 staining between any of the recurrence and no recurrence groups 
studied, these results suggest that although p53 is related to tumour progression it is 
not a significant factor for change in metastatic potential of a cell.
For the Dukes’ C carcinomas a different picture emerged when further recurrence, 
after treatment with 5-FU, was considered. Here the relationship with p53 staining 
was a negative one. Only the difference between the no recurrence group and the 
recurrence group was significant, although the differences between the no recurrence 
group and both the local and distant recurrence groups were almost significant. This 
discrepancy was probably due to the fact that even though the scoring for the tumours 
in the local recurrence group was lower than the tumours in the any recurrence group,
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the number of local recurrences included was low. Because of this the difference 
between the two groups would have to have been much larger to be statistically 
significant.
The lower score for the group of patients with recurrence was surprising as p53 is 
regarded as a poor prognostic factor when colorectal cancers are considered as a 
whole (see 5.232). The groups, which have recorded these results, tended to have 
used a combination of carcinomas of different Dukes’ stage in their studies and very 
variable results have been obtained. Another study on Dukes’ B and C carcinomas 
concluded that p53 nuclear overexpression did not seem to influence the prognosis of 
these patients (Fante et al. 1996).
It appeared, from the results of colorectal project 1 (see 5.2.8.2), that lymph node 
invasion, which, by definition, has occurred in all Dukes’ C carcinomas was positively 
related to the presence of p53 staining as p53 scores rose with tumour progression, the 
highest values being in Dukes' C carcinomas.
A recent study of original primary tumour and resected metastases found that p53 
overexpression was associated with a lower rate of response to 5-FU (assessed 
radiologically by CAT scan) but did not predict survival from start of treatment (Brett 
et al. 1996). Also, as discussed earlier (see 3.2.1), another recent study showed that 
Dukes’C patients with p53 mutations have been shown to have shorter survival times 
after 5-FU treatment than patients in which only wild type p53 could be detected 
(Benhattar et al. 1996). There was no difference in survival with or without 5-FU for 
patients with mutated p53 tumours, but a 4-fold increase in survival times for patients 
with non-mutated p53 tumours treated with 5-FU.
The results of this project show that a different picture emerges when further 
recurrence, either local or distant, is considered. Here the relationship with p53 
staining is shown to be a negative one. An explanation of this could be complete loss 
of both p53 alleles i.e. total lack of any functional wild-type p53 in the cells of these 
highly advanced tumours.
One study (Goh et al. 1994) found that loss of heterozygosity, i.e. no functional wild- 
type p53, was related to distant metastases, whereas lymphatic metastases were 
associated with point mutation. Mutation occurred in 43% of cases without lymph
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node involvement (Dukes’ A and B) and in 70% of cases with lymph node 
involvement (Dukes’ C). By contrast loss of heterozygosity of Chl7p (i.e. no 
functional wild-type p53 present) was strongly related to distant metastases at the time 
of surgery (Dukes’ D).
The antibody used in this project, PAbl801, targets both wild-type and mutated p53. 
The staining in the no recurrence group would have been a combination of any mutant 
p53 present and also any wild-type p53 which had been stabilised by the formation of 
oligomers with mutant p53, which has been described previously (Milner et al. 1991).
It is also possible that some of the p53 that was stained by the antibody was not non­
functional but rather functional p53 that had also been stabilised by phosphorylation. 
All Dukes’ C tumours have, by definition, associated lymphatic invasion so that, in 
this study, a relationship with mutated p53 would not be expected. If, however, further 
recurrence i.e. lack of response to chemotherapy, were associated with loss of 
heterozygosity then the lower p53 staining in the recurrence group could be explained 
by loss of staining associated with wild-type p53. In the event of a deletion of Chl7p 
(see 3.2.4), no p53 protein at all would be produced, in which case there would be no 
wild type p53 present to be stabilised in the cells and thus lower levels of staining 
would be observed. Alternatively, some p53 mutations resulting in loss of 
heterozygosity, could produce a protein that did not stain with the PAM801 antibody.
As discussed previously (see 1.4.1) 5-Fluorouracil, the usual treatment for Dukes’ C 
carcinomas, is a cell cycle-specific cytotoxic agent which induces DNA damage both 
by inhibition of thymidylate synthetase, a key enzyme in pyrimidine biosynthesis, and 
by direct fragmentation of DNA. The tumour cell may respond to DNA damage by 
undergoing cell cycle arrest or apoptosis, processes that may rely on a functioning p53 
gene and protein. Lack of response to 5-FU treatment could therefore be due to loss of 
any wild-type p53 and thus loss of any cell-cycle regulation or initiation of apoptosis.
These results could be of importance if p53 were used as a prognostic factor for 
Dukes’ C carcinomas as high staining with PAM801 could have the opposite meaning 
for prognosis than it would have for colorectal carcinomas as a whole.
Further work using an antibody that recognises only mutant p53 would be interesting, 
as a different relationship could then be possible.
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7.3 CD44 antibodies
7.3.1 Breast lesions
Although no significant differences between any of the groups were found for 
CD44v3 and CD44v6 staining, it was noted that the small number of hyperplasias 
stained showed much higher values than the other groups of lesions stained. The 
number of hyperplasia specimens was probably too low for the results to be of 
significance. The staining levels of both of these antibodies were consistently higher, 
when assessed by the same method (see 3.3.4), than the levels of CD44H in the same 
lesion.
The highest values for CD44H staining were in the benign lesions, being significantly 
higher than those in either the in situ or the invasive carcinoma groups. When the 
grades of ductal carcinoma were compared there was a decrease in CD44H expression 
with increasing grade. Loss of CD44H in high grade tumours was unexpected as other 
studies had shown an increase in CD44 levels with tumour progression (see 4.2.3.3). 
Most of the published results by other groups had, however, been for studies of the 
variant isoforms and conclusions were varied. CD44H expression was therefore 
expressed at its highest level in hyperplastic tissue and decreased with increasing 
grade of carcinoma.
Using the Mann-Whitney tests there was no significant difference in CD44 staining 
between the group of DCIS cases and the group of ductal carcinomas, when they were 
all included in one group. When the group of ductal carcinomas were separated into 
separate grades then the CD44H staining in the DCIS group was the same as in the 
grade 1 and 2 carcinomas but significantly higher than that of the grade 3 carcinomas. 
The staining pattern of DCIS for CD44H is thus different from the MIB1 staining 
pattern. A combination of MIB1 and CD44H staining could be useful in the grading of 
DCIS as a combination of high MIB1 and low CD44H staining could be an indication 
of DCIS with a high tendency to invade.
The finding that CD44H staining of DCIS was equivalent to that of an average ductal 
carcinoma and that CD44H staining of LCIS was equivalent to that of invasive lobular 
carcinoma again supports the idea that in situ carcinomas should be regarded as 
malignant rather than benign lesions. The reason for the association between invasive
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carcinoma of the breast and LCIS remains undefined and the natural history of LCIS 
is still unknown. The nature of LCIS is controversial. It is considered to be either a 
premalignant lesion or a benign marker for the development of carcinoma analogous 
to atypical ductal hyperplasia (Goldschmidt and Victor, 1996). The coexistence of 
LCIS with invasive lobular carcinoma led to the idea that LCIS represents a neoplastic 
cellular proliferation that can evolve into an invasive carcinoma. The findings of this 
project also support this idea. The majority of the LCIS lesions studied were 
associated with invasive carcinoma and the biological molecules studied showed 
similar expression in LCIS as in invasive lobular carcinoma supporting the idea that 
LCIS is a premalignant lesion.
These results for the CD44H staining of lobular carcinomas showed levels equivalent 
to those of grade 2 or 3 ductal carcinomas. These comparisons were at variance with 
those for the staining of lobular carcinomas with MIB1 and p53, where they showed 
levels of staining equivalent to low grade ductal tumours. This combination of results 
implies that the proliferation rate of lobular carcinomas could be that of a low grade 
tumour, but that they would have a greater risk of spread to distant sites than a low 
grade ductal carcinoma. Lobular carcinomas do have an increased propensity for 
contralateral disease and also a different pattern of metastatic spread from that of 
ductal carcinomas. After the initial spread to the lymph nodes, they have a tendency to 
spread to different sites from those to which ductal carcinomas spread. Another 
cellular adhesion molecule, E-cadherin on chromosome 16q22 has been shown to be 
involved in the development of lobular carcinoma. E-cadherin is involved in cell-cell 
adhesion. Using immunohistochemistry, 50 per cent of invasive ductal carcinomas 
have been shown to exhibit positive staining, while most invasive lobular carcinomas 
are negative (Lakhani, 1999). Protein truncation mutations were identified in 4/7 
invasive lobular carcinomas but none were identified in any of 42 invasive ductal 
carcinomas (Berx, 1995). E-cadherin staining has also been identified in DCIS and the 
molecule is expressed in normal epithelium, but staining is rarely seen in LCIS 
(Gamallo, 1993). The same truncating mutation in the E-cadherin gene has been 
shown in LCIS as in the adjacent invasive lobular carcinoma (Vos, 1997), providing 
strong evidence for the role of the E-cadherin gene in the pathogenesis of lobular 
lesions, as well as supporting the hypothesis for a precursor role for LCIS.
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The low CD44H staining scores for radial scars were interesting. The results for MEB1 
staining showed the radial scars to be the same as the benign lesions, but these CD44H 
results do show a tendency for these lesions to show the characteristics of the 
malignant groups of lesions (see discussion in section7.5).
The staining of the lymph node metastases was in general similar to their 
corresponding primary tumour for CD44H, CD44v3 and CD44v6.
Medullary carcinomas are generally considered to carry a prognosis superior to grade 
2 or grade 3 ductal carcinomas when strict histopathological criteria are used (Ridolfi 
and et al., 1977; Pedersen and et al., 1991), as were used for the tumours assessed in 
this study. As the better prognosis of typical medullary carcinomas over that of high 
grade ductal carcinomas cannot be explained by proliferation rate (see 7.1.1) or 
Oestrogen Receptor status (see 7.4) it might be expected that the better prognosis 
could be explained by a difference in adhesion molecules such as CD44. The results 
for this study of CD44 expression in medullary carcinomas were inconclusive and 
many more cases would need to be investigated. Of the four cases studied, although 
all four showed high MEB1, low ER and low D5 staining (see 7.5), the CD44 staining 
was inconsistent with three of the cases showing negative staining and one case 
showing highly positive staining (accounting for the large standard error). The study 
of further cases of medullary carcinoma for CD44 expression as well as for expression 
of other adhesion molecules would be of interest to see whether the better prognosis 
could be accounted for differences in the potential to invade.
There was a significant negative correlation of CD44H staining with MIB1, p53 and 
D5 staining. If, as these studies suggest, MIB1, p53 and D5 are related to breast 
carcinoma progression, it appears from the Spearman correlations that CD44H is 
inversely related to the expression of these antibodies and thus inversely related to 
tumour progression. The relationship with ER expression is discussed in 7.4.
The results of the breast project 3 which investigated the metastatic potential of grade 
1 breast tumours produced interesting results. Using any method of scoring the 
CD44H staining there was a significant difference between the two groups of tumours. 
The only variable that did not show a significant difference between the two groups
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was that of the high intensity staining and even there the mean value for the lymph 
node positive group was lower than that of the lymph node negative group. As shown 
in the previous breast study CD44H staining is highest in hyperplastic cells and 
decreases with increasing grade of tumour. Thus the cells that were showing the 
highest intensity of staining were probably ones that were at an early stage of tumour 
progression and thus not important in metastatic change within the cell. It appears 
from these results that loss of any CD44H staining from the cells could be important 
in the metastatic change within a cell. As discussed earlier (see 4.4.6.4) some of the 
cells from the lymph node negative tumours may already have gained metastatic 
potential, which would account for heterogeneity of staining.
An alternative explanation to the loss of CD44 expression is that the carcinomas with 
low CD44H expression were, in fact, not dedifferentiated but a distinct phenotype 
with a low CD44 expression. There is now evidence that high grade breast carcinomas 
may have molecular origins distinct from those of low grade carcinomas as distinct 
genetic differences between grade I and grade III tumours have been found (Roylance 
et al. Cancer Res. 1999 in press).
A recent study of the gains and losses of expression of the different isoforms of CD44 
during breast carcinogenesis and tumour progression was also conducted on a range of 
benign and malignant lesions that included papillomas, hyperplasias, DCIS and 
invasive ductal carcinomas. They found both qualitative and quantitative changes of 
CD44 expression in early stages of breast carcinogenesis and also found a marked loss 
of CD44s in high grade DCIS, which agreed with the findings of this study. They 
found, however, marked heterogeneity of staining of all the CD44 antigens in invasive 
breast carcinomas with loss of some variants and gain of others as the tumours became 
less differentiated. If anything a slight increase in CD44S was found in less 
differentiated tumours (Bankfalvi et al. 1998).
From the results obtained in these studies it appears that in both benign and malignant 
breast lesions there is a significant increase in the expression of CD44H, CD44v3 and 
CD44v6 compared to normal breast epithelium. A cell with a more malignant 
phenotype shows low CD44 expression, either because it has lost expression or 
because the phenotype was one that showed low CD44H expression, although no 
significant loss or gain of CD44v3 or CD44v6 is evident. CD44H is therefore a useful
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marker of both the initial stages of benign breast disease and also of the metastatic 
potential of malignant breast lesions, with high CD44H staining being then an 
indicator of good prognosis.
7.3.2 Colorectal lesions
When the Dukes’ A and B carcinomas were grouped together then CD44H staining 
showed a decrease in both non-metastasising (Dukes’ A and B) and metastasising 
(Dukes’ C) groups of carcinomas when compared to the levels in adenomas. The 
staining levels were also lower in the metastasising group than in the non- 
metastasising) group, suggesting that CD44H staining peaks in adenomas and is then 
lost during tumour progression.
When the three levels of CD44H staining intensity were considered separately then an 
interesting picture emerged. Whilst adenomas showed significantly higher staining 
than Dukes’ C carcinomas at all intensities it was the medium and high intensity 
staining cells that were reduced in number between the adenoma and non- 
metastasising carcinoma stage. Conversely the difference in low and medium intensity 
staining was significant between non-metastasising and metastasising carcinomas, but 
the high intensity staining was not significantly different. It thus appears that not only 
more adenoma cells than carcinoma cells stain with CD44 but the intensity of staining 
is also greater. The difference between non-metastasising and metastasising cells, 
however, seems to involve a change from cells with low intensity CD44 staining to 
more cells with no CD44 staining.
These results, as was also evidenced from the staining of the grade 1 breast tumours, 
implied that metastasis was related to loss of low intensity staining and that it was 
possibly the total loss of any CD44H expression on a cell that was related to the 
metastatic process. The difference between adenoma and carcinoma cells was 
significantly greater for the high intensity expression cells, implying that differences 
in the number of high intensity staining cells is related to malignant change.
The negative correlation between CD44H and p53 implies that, if  p53 is a marker of 
colorectal carcinoma progression as discussed in 1.3.2, then CD44H is inversely 
related to tumour progression in colorectal carcinomas. The negative correlation with
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MIB1 staining that was found for breast carcinomas was not found for colorectal 
carcinomas. It was also interesting to note that CD44H expression showed a 
significant negative correlation with degree of differentiation of the carcinomas. In 
contrast, MQ31 staining showed no correlation with degree of differentiation but p53 
showed an almost significant positive correlation. This implies that both CD44H and 
p53 expression are related to the degree of dedifferentiation of the carcinoma. As far 
as adenomas were concerned the same pattern evolved. CD44H expression showed a 
negative correlation with degree of dysplasia of the adenomas, p53 showed a positive 
correlation with degree of dysplasia and MIB 1 showed no correlation at all (see7.1 
and 7.2). This could imply a progression from adenoma to carcinoma or alternatively 
the cells that are expressing lower levels of CD44H in adenomas could be the cells 
that have the potential to progress to poorly differentiated i.e. high grade carcinoma 
cells. For either explanation the proliferation rate does not seem to be related to 
progression of the lesion.
The results for CD44H staining of Dukes’ B carcinomas were of particular interest, as 
it appeared that CD44H was important in metastatic spread of tumour cells to distant 
sites. The most significant results were obtained when all distant metastases were 
grouped together. The results indicated that loss of CD44H staining occurred when 
tumours metastasised but was not important in local spread of the tumour.
The score for the expression of CD44H, showed significant differences between 
groups where distant metastases were compared either to groups with no recurrence or 
local recurrence only. It was noted, however, that the differences in low intensity 
staining between the two groups were the significant ones. Staining of high intensity 
did not seem to be related to metastasis. It seems therefore that it is the complete loss 
of CD44H staining of a cell that is related to its metastatic potential.
In the previous study on the staining of adenomas and carcinomas, the most intensely 
stained cells were in adenomas and early carcinomas with CD44H being lost in 
Dukes’ C carcinomas. These, by definition, are those carcinomas that have produced 
cells that are capable of metastasis. This would mean that the high staining intensity of 
some cells was related to the early progression of the tumour, but that it is total loss of 
CD44H in cells that is significant for the gain of metastatic potential. Thus it appears 
that Dukes’ B carcinomas with cells that are not expressing CD44H could be the
303
carcinomas that are capable of metastasising and thus reducing the survival time for 
that patient. It is possible that the loss of CD44H expression occurs after the cell has 
gained its metastatic potential or that it is loss of CD44H that facilitates metastasis. It 
seems that there are changes of expression of the many CD44H variants during 
carcinoma progression. The antibody used in this project recognises all forms of 
CD44H so it appears that it is overall loss of any CD44H that could be important for 
metastatic potential. Although these observations do not help the understanding of the 
cellular pathways involved, for the purpose of this project, that is extra information 
that could guide the clinicians in the prognosis and thus treatment for the patient, then 
the histological information itself is valuable.
It is thus possible that CD44H could serve as an independent prognostic marker in 
Dukes’ stage B colorectal cancer for occult metastatic disease. It could help to identify 
patients with poor prognosis and designate them for intensive adjuvant therapy and 
clinical observation after curative surgical tumour treatment.
When Dukes’ C carcinomas were investigated the CD44H scores for these tumours 
were generally low, which was expected as project 1 had shown that there was less 
CD44H staining in Dukes’ C carcinomas than in Dukes’ A and B carcinomas. Again, 
as with p53, the differences were closer to being statistically significant when the 
tumours with any type of recurrence were grouped together and thus the number in the 
group was larger. Although none of the differences between the groups was 
significant the lower CD44H scores for the recurrence groups implies that low CD44H 
positivity could encourage further metastatic spread even after the initial spread to the 
lymph nodes.
These results were at variance with some earlier studies that used the CD44v6 
antibody as they found an increase in all CD44 staining with tumour progression 
(Domagala et al. 1993; Weilenga et al. 1993; Mulder et al. 1995).
A paper published after this work had been analysed disagreed with previous 
publications and, agreeing with our findings for CD44v6 (both for the breast studies 
and for a preliminary look at colorectal carcinomas), stated that that there was up- 
regulation of this CD44 variant isoform in adenomas. They also investigated 35 
metastases from colorectal cancer and showed that CD44v6 was substantially 
downregulated in metastatic lesions (Mulder et al. 1995). The antibody used in this
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study does not distinguish between the haemopoietic and variant forms of CD44 and 
thus it seems from our results that the same pattern of expression is true for any form 
of CD44. This is supported by the strong correlation in the breast studies (Chapter 4) 
between the haemopoietic and variant forms of CD44.
A recent study used in situ hybridisation to look at both standard and variant CD44 
mRNA and also immunohistochemistry to look at the CD44 protein. They 
investigated both the standard form, using the same antibody as in this project, 
directed against exon 1, and variant forms directed against exons 5, 7 and 11. They 
found that both CD44s and CD44v transcripts were both strikingly increased in 
colorectal carcinomas compared with corresponding normal mucosa and that the 
abundant CD44v transcripts in tumour tissues were localised exclusively in the cancer 
cells. In contrast CD44s transcripts were present in cancer, inflammatory and stromal 
cells, but the relative amount in carcinoma cells was greater. They found that, with a 
few discrepancies, immunohistochemical staining broadly paralleled these results 
(Gorham etal. 1996).
CD44 as a marker of tumour progression
Downregulation of adhesion molecules by tumour cells may free tumour cells from a 
tumour mass and allow migration and dissemination of the tumour cells. Therefore, 
downregulation of CD44 may be beneficial for the growth or metastasis of tumour 
cells. Early results in studies of CD44 led to optimism that CD44 isoform expression 
could be a marker for human cancers. Results obtained from numerous tumours of 
several organs has, however, lead to the conclusion that there is no specific pattern of 
expression of any individual exon nor of any combination of exons which is 
characteristic of malignant neoplasia. More recent studies, including this one, have 
shown that regulation of CD44 expression is complex. CD44 in tumour cells can be 
regulated quantitatively by increasing the expression of one particular CD44 isoform 
or by altering the expression of multiple isoforms. Most tumour cells express multiple 
CD44 isoforms and the predominant isoform is CD44H that is always expressed 
alongside the variant isoforms. A review of the role of CD44 in human tumour 
progression came to the conclusion that that there was some evidence for upregulation 
of CD44v6 in colorectal carcinomas, but that no correlation of CD44 expression with
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survival or any other prognostic marker had been established in breast carcinoma 
(Gunthert et al. 1995). The antibody used in these projects detected any isoforms of 
CD44 and so it was total CD44 expression that was studied.
It remains unknown at present whether the observed disturbances in CD44 gene 
expression are causally involved in cancer pathogenesis, or are a consequence of this 
disease process. It is clearly of considerable biological interest to resolve this 
uncertainty but the issue does not affect the promising implications of these findings 
for clinical cancer prognosis. The data obtained in these studies does help to 
illuminate the pathogenesis of aggressive neoplastic behaviour and it may be possible 
to convert the information obtained into practical advances in the early diagnosis and 
treatment of malignancy.
The finding, throughout these projects, that there was a down-regulation of CD44H 
expression in late stage cancers was at variance with most published results. 
Progressive loss of CD44 gene expression, however, has recently been shown in 
invasive bladder cancer (Sugino et al. 1996). The results indicated that initially there 
is a striking increase in CD44 gene expression in early bladder carcinomas, relative to 
normal urothelium, but that this diminishes as the tumours acquire a more aggressive 
phenotype. These observations agree with those described in this thesis, for both 
breast and colorectal carcinoma, and also for those described for melanoma (see 7.3.3 
and publication). A recent review also refers to unpublished data that show that cells 
in late stage colonic cancers, which have reached the boundaries of the organ or 
penetrated surrounding tissues, show little or no expression of any isoform (Goodison,
1998).
7.3.3 A parallel study on melanocytic lesions.
A project that was carried out in collaboration with Dr Catherine Harwood, a registrar 
in Dermatology, ran parallel to the projects described in this thesis and is relevant to 
the results obtained for CD44H in breast and colorectal tumours. The expression of 
CD44H in a range of melanocytic lesions was studied and the results of this project 
were published in a paper entitled ‘CD44 expression in melanocytic lesions: A marker 
of malignant progression?’ in the British Journal of Dermatology 1996; vol. 135 pages
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876-882. Skin biopsies of 106 lesions from 100 patients were assessed and included 
benign and dysplastic naevi, melanoma in situ, malignant melanomas in horizontal 
and vertical growth phase an also cutaneous and lymph node metastases. The 
particular interest of this project was to establish whether any differences in 
expression existed between horizontal and vertical growth phase melanomas as 
vertical rather than horizontal growth phase lesions are those considered to have 
metastatic potential (Clark et al. 1989). CD44H was highly expressed in benign and 
dysplastic naevi and in melanoma in situ. However expression within melanomas 
diminished with increasing invasiveness and the pattern of expression observed 
reflected the growth phase of the lesion rather than the Breslow thickness, which is a 
measure of the vertical thickness of invasive melanomas. CD44 splice variants v3, 
v4/5, v6 and v8/9 were also studied but no detection of expression occurred in any 
lesion type. These results suggest that downregulation of CD44H may be involved in 
modulating the biological behaviour of melanoma in a similar manner to its 
involvement in metastatic spread of breast and colorectal carcinomas.
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7.4 ER antibody
This project addressed many of the problems with assessment of the ER status of a 
tumour, including that of the initial fixation of the specimens. This factor was shown 
to be important in a project that was running alongside the projects described in this 
thesis. This project involved the MIB1, ER and PR staining of breast Fine Needle 
Aspirates (FNAs) as well as the complementary histology specimen. In some cases the 
cytological specimen showed strong positivity for oestrogen receptors but the 
histological specimen was only very weakly staining or even negative. This was 
explained by the fact that the FNAs were taken both from the patient preoperatively at 
clinic and also from the fresh specimen in theatre. There was sometimes a delay at this 
point before the specimen was fixed and also, particularly in the case of large fatty 
specimens, there were problems with the infiltration of fixative throughout the 
specimen. This showed that this would be an important factor to control when using 
the ER antibody diagnostically (see 2.2.3.1).
As ER expression decreased with increasing grade of carcinoma this supported 
previously published results that showed a poorer prognosis for tumours that were ER 
negative, as discussed in 4.2.3.4.
The pattern of ER expression throughout the range of pathology studied was complex. 
ER staining was the same in DCIS as in either of the two groups of benign lesions. 
When ductal carcinomas were assessed as a single group, using the Mann-Whitney 
test, then there was no difference between the benign lesions and the invasive ductal 
lesions but when the grades of ductal carcinoma were considered separately then a 
different picture emerged. The ER staining was significantly higher in grade 1 
carcinomas than in the papillomas and almost significantly higher (p = 0.051) than for 
the hyperplasia group. There was no difference between grade 2 carcinomas and either 
group of benign lesions, and ER staining was significantly lower in the grade 3 
carcinoma group than in the benign lesions. Results were similar for DCIS. Although 
not quite statistically significant (p = 0.054) grade 1 carcinomas had greater ER 
expression than the DCIS lesions and grade 3 carcinomas had significantly lower 
expression than the DCIS group. ER staining of LCIS was also similar to that of 
invasive lobular carcinoma. These results again support the idea that in situ carcinoma 
cells are similar, at least in their expression of tumour markers, to those of the
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invasive carcinoma cells. As the expression of ER in DCIS was similar to that of 
ductal carcinoma taken as a single group, which was also similar to the expression in 
benign lesions, changes in ER expression were only evident between grades of ductal 
carcinoma.
The ER status of the lobular carcinomas was higher than that of the ductal carcinomas 
taken as a group and was very similar to that of grade 1 ductal carcinomas. These 
results support the findings of another study that found that lobular carcinomas were 
more frequently ER positive than nonlobular carcinomas (Sastre-Garau and Jouve, 
1996).
As radial scars showed a similar pattern of staining to both benign and DCIS lesions, 
ER would not be helpful as a prognostic indicator for these lesions.
As there was no difference in ER expression between mucinous and other ductal 
carcinomas groups in this project, this implies that the better than expected prognosis 
of mucinous breast carcinomas is not related to ER expression.
Although only the differences between the medullary carcinoma cases and grade 1 and 
grade 2 ductal carcinomas were significant all the medullary carcinomas investigated 
were totally negative for ER expression. The lack of significance for grade 3 ductal 
carcinomas was probably due to the small number of cases of medullary carcinoma 
studied. It is surprising, however, that these types of carcinoma which are reported to 
have a good prognosis should be so negative for ER expression because, as with the 
MIBl expression, the results are even more extreme than those of grade 3 ductal 
carcinomas. These results, which agree with other recent findings (Jensen et al. 
1996), mean that, for a doubtful diagnosis, a positive oestrogen receptor staining 
makes the diagnosis of a medullary cancer less likely, particularly the diagnosis of 
typical medullary carcinoma. As discussed in 7.1.1, it is now thought that there is a 
connection between these medullary type carcinomas and the BRCA1 mutation. Low 
ER staining is a characteristic of both these types of tumour but, as found in this study, 
it is also a characteristic of high grade ductal carcinoma. As such ER positivity would 
neither be of use for distinguishing between high grade ductal and medullary 
carcinoma nor therefore as a prognostic factor for a patient with this type of tumour.
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Only a few lymph node metastases were stained with ER, but the results were much 
the same as for the primary tumours. This compares with other published results 
where the ER status of the primary tumour was found to be identical with that of a 
regional lymph node metastasis in 91% of cases (Andersen, 1994).
Over the range of benign and malignant lesions studied in these projects a complicated 
relationship between ER expression and the expression of both CD44 and MIB1 was 
demonstrated.
Spearman correlations between ER and CD44.
ER correlated positively with CD44v3 and CD44v6. This supports the work of 
Friedrichs et. al.(Freidrichs et al. 1995) who found that carcinoma tissues with 
elevated oestrogen and progesterone receptor levels showed a significant positive 
correlation of ER status with CD44v6 and suggested that CD44 isoforms are markers 
for cellular differentiation rather than tumour progression.
Another recent study assessed CD44 standard form, and CD44v7 and vlO variant 
mRNA using RT-PCR in a group of ER positive and a group of ER negative tumours. 
The levels of CD44s showed no correlation with ER status, but the pattern of 
expression of the variant forms was significantly different between ER positive and 
ER negative tumours (Hole et al. 1997). CD44 expression in breast cancer could 
therefore reflect cellular differentiation as indicated by the ER phenotype.
CD44H was unrelated to ER expression in these projects even though there was a 
positive correlation between CD44H and both the CD44 variants and also a positive 
correlation between ER and the CD44 variants. One explanation for the apparent 
discrepancy could be that lesions of a wider range of pathology i.e. papillomas and 
atypical hyperplasias, were stained with CD44H and ER than were stained with the 
CD44 variants.
Spearman correlations between ER and MEB1.
These results were difficult to interpret and the relationship between ER and MIB1 is 
considered separately for hyperplasia, DCIS and invasive ductal carcinoma lesions.
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Hyperplasia
When the group of hyperplastic lesions was considered separately then no correlation 
was found between ER and MIB1 staining. This study looked at the correlation 
between scores for individual tumours. These results could be compared to those of 
another study that compared MIB1 staining in ER positive and ER negative groups. 
They grouped the cases on the assumption that an H score of less than 20 was ER 
negative (see 3.4.3) and found that when hyperplastic lesions were considered then the 
mean MIB1 value for the ER positive group was significantly higher than that of the 
ER negative group (Schmitt, 1995).
DCIS
There was a negative relationship between ER and MIB1 for the DCIS lesions but the 
correlation did not quite reach significance (p = 0.069). The study mentioned above 
found that for the DCIS lesions the ER negative lesions had a significantly higher 
mean MIB1 score than the ER positive lesions (Schmitt, 1995).
Invasive Ductal Carcinoma
There was a statistically significant negative correlation between ER and MIB1 
staining for the group of ductal carcinomas. The study mentioned previously (Schmitt,
1995), found that the ER negative lesions had a significantly higher mean MIB1 score 
than the ER positive lesions for ductal carcinomas.
It thus appears from these results that proliferation rate corresponds with ER 
negativity in ductal carcinomas, both invasive and non-invasive. Although a positive 
relationship between ER positivity of benign lesions had been found previously the 
results of the Spearman correlations for this project did not support these findings.
As discussed in 3.4.3, ER status of a tumour gives the clearest indication as to the 
likely response to endocrine therapy. ER negativity of tumour cells has been shown to 
be correlated with tumour responsiveness to primary chemotherapy (MacGrogan et al.
1996). ER is thus important as a predictive (see 1.1) as well as a prognostic factor in 
conjunction with MIB1 and CD44H, when assessing the potential aggressiveness of 
DCIS lesions as well as the response to adjuvant therapy.
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7.5 D5 antibody
D5 staining increased between the benign and both the in situ and invasive malignant 
state as evidenced by the highly significant differences between either group of benign 
lesions and either the DCIS or invasive ductal carcinoma groups. There was no 
difference in staining pattern between the DCIS and ductal carcinoma groups. Thus it 
appears that HSP27 expression became evident during the change from benign to 
malignant state and then remained at a constant level throughout the levels of tumour 
progression of DCIS and invasive carcinoma. There was also no difference between 
LCIS and invasive lobular carcinoma. This again, as with all the other antibodies 
investigated in these projects, supports the idea that in situ lesions should be classified 
similarly to invasive malignant lesions.
Significant correlations with MIB1, CD44H and ER and lack of correlation with p53 
can be explained by assuming that differences in expression of D5 are between the 
benign and malignant cell phenotype, where there are also changes in oestrogen 
receptor expression and in proliferation rate. The D5 levels appear to remain constant 
throughout the grades of carcinoma, where changes in levels of p53 expression are 
significant. This does not, however explain the strong positive correlation between D5 
and ER staining when there was no correlation of D5 staining with grade of ductal 
carcinoma and a strong negative correlation of ER staining with grade of ductal 
carcinoma. It was also interesting that, even though there was a strong correlation 
between D5 and both ER and MIB1 staining over the whole range of pathological 
lesions investigated, when benign or in situ lesions were considered alone then no 
correlations could be found between either D5 and either ER or MIB1 staining. Also 
when invasive ductal carcinomas were considered alone then the relationship with 
MIB1 staining did not exist, even though the positive relationship with ER expression 
was retained. This implies that HSP27 expression remains linked to ER expression, 
but that a link to proliferation in an invasive carcinoma is lost during tumour 
progression.
As lobular carcinomas were similar in D5 staining pattern to all grades of ductal 
carcinomas it appeared that HSP27 expression was no different for lobular carcinomas 
from that for ductal carcinomas.
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There was a significant difference in D5 staining between the tubular carcinoma and 
the average ductal carcinoma groups. This implies that the very low grade tubular 
carcinomas are similar to benign lesions for HSP27 expression.
Staining of radial scars was intermediate between benign and both the in situ and 
invasive malignant lesions, being significantly higher than the benign and 
significantly lower than the in situ and invasive groups of tumours. These results 
imply that radial scars do not have totally benign characteristics and may, as 
suspected, have a tendency in some cases to become malignant.
As stated previously, there has for some time been a debate about whether lesions that 
have been diagnosed as radial scars or complex sclerosing lesions are pre-neoplastic.
Evidence for this comes from three main sources.
1. They may sometimes contain foci of carcinoma, giving them a pre-neoplastic 
status.
2. The incidence of radial scars in cancer-bearing and non-cancer-bearing breasts. 
Radial scars have been shown to occur more frequently in breasts which also 
contain carcinoma (Wellings and Alpers, 1984; Sloane and Mayers, 1993). The 
study examined 83 breasts obtained at random autopsy, presumed to be from 
patients at low risk of developing cancer, and 107 breasts either containing cancer 
or contralateral to cancer-bearing breasts. A significantly higher proportion of 
breasts in the cancer-associated series contained radial scars.
3. Follow-up studies of patients in whom uncomplicated radial scars have been 
identified. Very few such studies have been published and none have shown a 
clear relationship to carcinoma development (Andersen and Gram, 1984).
One study (Sloane and Mayers, 1993) reviewed lesions derived from routine surgical 
service that were diagnosed as radial scars or complex sclerosing lesions. They found 
that 9.5% of the specimens contained foci of in situ carcinoma, 1.4% foci of invasive 
carcinoma and 10.8% atypical ductal hyperplasia (these lesions may now be classified 
by many pathologists as in situ carcinoma). They found a clear relationship between 
the presence of carcinoma and atypical hyperplasia and size of the lesion with 6-7 mm 
being the cut-off point below which carcinoma was very uncommon. They also found 
that foci carcinoma was more common in radial scars from women over 50. This is the
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age when the incidence of breast cancer increases generally and it is possible that the 
epithelium of the radial scar was already predisposed to malignant transformation.
The lower staining levels found with CD44 in radial scars, when compared to the 
benign lesions (see 7.3.1), and the relatively high D5 levels, compared to benign 
lesions, could both be an indication of either an intrinsic neoplastic lesion or merely a 
reflection of normal breast proliferative capability. The scores analysed were totals for 
all epithelial cells present in radial scars, which varied in appearance, including areas 
such epithelial hyperplasia, blunt duct adenosis and apocrine metaplasia. It is possible 
that lesions exhibiting D5 staining of any component would benefit from closer 
examination to exclude a pre-neoplastic state in any epithelial lesions.
There was a difference in D5 staining between the medullary carcinoma group and the 
ductal carcinoma group. Medullary carcinomas showed lower staining than any grade 
of ductal carcinoma although the difference was significant for grades 2 and 3 only.
In this respect D5 was the most interesting of the antibodies used to stain medullary 
carcinomas as it was the only one which showed consistently different staining from 
that which would have been expected from a high grade ductal carcinoma. This means 
that D5 could possibly be an antibody that was useful as a prognostic marker in 
helping to establish whether a tumour is a medullary or a high grade ductal carcinoma 
but many more cases would need to be studied.
There was a significant difference between ductal carcinomas and associated lymph 
node metastases for D5 staining but the number of lymph nodes stained was too low 
to draw any conclusions from these results.
The potential of HSP 27 expression, demonstrated by staining with the D5 antibody, 
as a prognostic marker is thus as an aid in the assessment of whether a lesion is benign 
or malignant.
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CHAPTER 8 CONCLUSIONS
All the antibodies studied have been shown to have some prognostic value in relation 
to the clinical problems of breast and colorectal pathology investigated in these 
projects. Their potential contribution to solving these problems is summarised below.
8.1 Breast Lesions
8.1.1 The distinction between benign and malignant lesions
There was a marked increase in proliferation, as shown by MIB1 staining of both 
DCIS and invasive malignant lesions when compared to the benign lesions. In situ and 
invasive malignant lesions were also characterised by higher p53 and D5 staining and 
lower CD44H staining, but no overall difference in ER staining was found between 
benign, in situ or invasive malignant lesions. Thus a panel of antibodies using MIB1, 
p53, D5 and CD44H could be useful additional prognostic indicators when assessing 
the potential malignancy of a benign lesion.
8.1.2 In situ carcinoma
There was a lower proliferation rate for the lobular in situ carcinomas when compared 
to the ductal in situ carcinomas as measured by MIB1 staining. Ductal and lobular in 
situ carcinomas were similar to each other in all but MIB1 staining.
If a breast lesion presents as DCIS alone then an indication of the likelihood of that 
lesion becoming, or even having already become in a small area, an invasive cancer 
would be clinically useful. This would aid decisions on further treatment. It was hoped 
that some differences in staining characteristics between in situ and invasive cancer 
would be evident. Where in situ and invasive carcinoma, either ductal or lobular, 
were present together on the same section then the staining was similar in both types 
of lesion, with any of the antibodies used.
Thus, for the antibodies tested, then there was no difference between the two types of 
lesion. Differences in staining characteristics were, however, evident between DCIS 
and the benign lesions (see 8.1.1). The results gave support to the idea that in situ
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carcinoma should regarded as a malignant rather than as a benign lesion and that it 
could also be graded in a similar manner to the invasive ductal carcinomas.
8.1.3 Invasive ductal carcinoma
Throughout these projects, MIB1 staining of ductal carcinomas was much as 
anticipated, in that these lesions had already been graded using proliferation, as 
assessed by mitotic count, as one of the factors of the grading system (see 1.2.5.6 a). 
P53 staining increased and CD44H and ER decreased significantly with increase in 
grade of carcinoma. D5 staining did not change with increase in grade. A panel of 
antibodies using MIB1, p53 CD44H and ER would therefore be useful prognostic 
indicators when assessing tumour progression of invasive ductal carcinomas, but D5 
would be useful only as an indicator of malignant change.
8.1.4 Lobular carcinomas
Staining characteristics of lobular carcinomas were similar to low grade ductal 
carcinomas for MIB1, p53 and ER, supporting other work which has found that 
lobular carcinomas are more frequently grade 1 than nonlobular carcinomas (Sastre- 
Garau and Jouve, 1996). For CD44H staining however they were similar to high grade 
ductal carcinomas. The lower CD44H expression could be related to the dissociation 
of the cells in lobular carcinoma, compared to ductal carcinoma and also to the greater 
tendency to involve the contralateral breast.
8.1.5 Radial scars
Radial scars are often lesions of mixed pathology, which may account for the variation 
in staining characteristics found in these studies. The proliferation rate, as measured 
by MIB1 staining, was similar to the other benign lesions, papillomas and 
hyperplasias. Both the CD44H and D5 antibodies, however, showed staining 
characteristics that were different from the benign lesions. CD44H staining scores 
were similar to those of DCIS and D5 scores were intermediate between those of the 
benign lesions and those of DCIS. These results imply that although radial scars are
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largely regarded as benign lesions, they may have some biological features more akin 
to those of malignant lesions. It is thus possible that CD44H and D5 could be useful 
prognostic factors for follow up of patients with radial scars.
8.1.6 Mucinous carcinomas
Too few mucinous carcinomas were studied to draw any firm conclusions, but it 
appeared that their staining characteristics could not be differentiated from those of 
other ductal carcinomas for any of the antibodies studied, although MIB1 staining was 
equivalent to that of a low grade ductal carcinoma. This may partly explain its 
relatively good prognosis.
8.1.7 Medullary carcinomas
Medullary carcinomas were variable in their staining characteristics, in some ways 
being similar to high grade ductal lesions and in others more like low grade lesions. 
MIB1 staining of medullary carcinomas was even higher and ER staining even lower 
than grade 3 ductal carcinomas. In these respects they had features of very high grade 
carcinomas. CD44H staining, however, was slightly lower than that of grade 1 ductal 
carcinomas and D5 staining was lower than any ductal carcinoma group. High CD44H 
staining and low D5 staining scores could in this way help to distinguish medullary 
from high grade ductal carcinomas.
8.1.8 Grade 1 breast carcinomas
MIB1 and p53 did not appear to have any prognostic value for the metastatic potential 
of these carcinomas. CD44H showed promise as a prognostic indicator as CD44H 
expression was significantly lower in tumours that had metastasised to the lymph 
nodes than those that had no evidence of having done so at the time of surgery.
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8.1.9 Further studies
The results for project 3, which studied grade 1 breast tumours, indicated that loss of 
CD44H expression could be related to the metastatic process. A study which 
investigated grade 3 ductal carcinomas in the same manner, one group that were 
lymph node positive and the other group that were lymph node negative, would be 
interesting. This would demonstrate whether the same CD44H effects are found for 
high grade carcinomas as low grade carcinomas, with respect to lymph node 
positivity.
The combination of ER expression and D5 expression in medullary carcinomas was 
interesting. To ascertain whether low ER and D5 staining is a universal characteristic 
of these tumours more cases are needed. If verified then the low D5 staining could be 
a factor that would help to distinguish these carcinomas from grade 3 ductal 
carcinomas. The other feature that merits further investigation is the relatively high 
CD44H staining of medullary carcinomas when compared to ductal carcinomas. The 
main problem for such a study would be collection of specimens as tumours are very 
rarely diagnosed as medullary. As discussed in 7.1.1 there is now thought to be a link 
between the BRCA1 mutations and medullary type carcinomas and staining of these 
hereditary carcinomas with these three antibodies could be investigated.
Another interesting project would be the study of lobular carcinomas to establish 
whether low CD44H staining in the primary tumour was related to either contralateral 
disease or to metastatic spread.
A recent study has shown that p53 overexpression was a predictor of response to 5-FU 
and radiation given preoperatively (Formenti and Dunnington, 1997). A retrospective 
study of p53 levels in either FNAs or core biopsies taken prior to neoadjuvant therapy 
and also the response of patients with advanced tumours to postoperative 
chemotherapy with respect to p53 levels of their primary tumours would be useful.
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8.2 Colorectal Lesions
8.2.1 Adenomas
MIBl was shown to be a possible prognostic indicator for adenomas as staining was 
significantly higher in carcinomas than adenomas, although no correlation of MIBl 
staining with degree of dysplasia of adenomas was found. As documented in previous 
publications p53 staining was found to be low in adenomas, but it did correlate with 
degree of dysplasia of the adenomas. CD44H staining was not present in normal 
epithelium, except for some positivity on proliferating cells at the base of the crypts 
but was apparent in adenomas with high intensity CD44H staining being particularly 
pronounced. There was an almost significant correlation (p = .067) between high 
intensity CD44H staining and degree of dysplasia of the adenomas when rated from 
mild to severe dysplasia.
8.2.2 Carcinomas
No differences in MIBl staining could be found between any of the Dukes’ stages of 
carcinoma. p53 was at its highest in Dukes’ C carcinomas agreeing with studies that 
have shown p53 mutation to be a late step in colorectal tumour progression and thus a 
poor prognostic factor. Both the number of cells showing any CD44H expression and 
also the intensity of expression decreased with increasing tumour progression, as 
measured by Dukes’ staging. Dukes’ C carcinomas, which are tumours that have 
already been shown to have associated lymphatic invasion at the time of surgery, were 
characterised by low CD44H expression.
8.2.3 Heterogeneity of metastatic potential of Dukes’ B carcinomas
When studied as a separate group in relation to their metastatic potential then it was 
shown that neither MIBl nor p53 had any prognostic value. It was shown, however 
that CD44H could be of prognostic value for this heterogeneous group of tumours as 
the group of tumours that showed recurrence had significantly fewer cells showing 
CD44H expression than the group of tumours that remained recurrence free over a 
period of five years.
319
8.2.4 Dukes’ C carcinomas
Neither MIBl nor CD44H showed prognostic significance for this group of tumours, 
although CD44H staining was lower in the recurrence group and the difference was 
almost significant.
The results for p53 staining of Dukes’C carcinomas were interesting as p53 staining 
was lower in the recurrence group of tumours than in the groups with no recurrence. It 
appeared from the results obtained that, when using PAbl801 on Dukes’ C 
carcinomas, the prognostic indications would in fact be the opposite from colorectal 
carcinomas taken as a whole.
8.2.5 Further studies
p53 expression, although not often found in adenomas correlated with degree of 
dysplasia. Different expression of p53 in depressed (as opposed to polypoid 
adenomas) has been found in one study (Yao et al. 1996). p53 positive cells were 
more frequently found in the deep mucosal areas than in superficial areas of some 
non-polypoid adenomas. The authors suggested the existence of another type of 
carcinogenesis other than the sequence discussed for polypoid adenomas. Depressed 
adenomas would thus be considered to have a high potential risk of carcinoma and 
further studies on p53 staining with different adenoma groups would be of interest.
A further study of p53 staining of Dukes’ C carcinomas with respect to response to 
chemotherapy would be of value. Two p53 antibodies, one staining wild-type and 
mutant and the other staining mutant only, used at the same time would add useful 
information. If different results were obtained with the two antibodies this could mean 
that loss of heterozygosity, a possible advancement in the tumour progression, was 
indicated. Further studies using PAb240, an antibody that recognises only mutant p53 
(see 3.2.1) are planned. PCR studies on this group of patients would also show 
whether the tumours in the recurrence group are indeed characterised by loss of 
heterozygosity for p53.
A study that assessed MIBl and CD44H staining of epithelium, which had normal 
histological appearance, around the site of an adenoma, would be of interest. It is
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possible that early signs of CD44H expression or greater than normal MIBl positivity 
could be detected in epithelium that had the potential to form an adenoma.
These projects have therefore been completed successfully and have produced much 
useful information on the use of these tumour markers as prognostic indicators in both 
breast and colorectal lesions.
Many parallels were found in changes of staining characteristics of the antibodies 
studied for breast and colorectal carcinomas. Most noticeably, for both types of 
carcinoma the difference between normal epithelium and that of a benign tumour was 
characterised by an increase in CD44 staining. The difference between benign and 
neoplastic lesions was characterised by an increase in MIBl staining and the 
progression of a carcinoma to one with metastatic potential was characterised by a 
loss of CD44H staining for both breast and colorectal carcinomas.
Clinically the most useful indicators of prognosis in breast and colorectal cancer as 
indicated by these studies are:
• The differentiation between the benign and malignant phenotype in both breast 
and colorectal cancer is indicated by an increase in MIBl, p53 and D5 staining 
and by a decrease in CD44H staining. This panel of antibodies could thus be used 
in the prognosis of lesions where there is some doubt as to potential malignancy.
• The potential aggressiveness of in situ breast carcinoma could be assessed using 
high MIBl and p53 and low CD44H and ER staining as markers of poor 
prognosis.
• MIB1 could aid the clarification of the current breast grading system with high 
p53 and low CD44H staining as additional markers of a high grade tumour and 
thus of poor prognosis.
• A combination of high D5 and low ER could help to distinguish good prognosis 
medullary from the poor prognosis high grade ductal breast cancers.
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• High D5 and low CD44H staining could be related to poor prognosis for radial 
scars.
• p53 could be used as a prognostic indicator of recurrence for colorectal 
carcinomas but possibly high p53 staining with the PAbl801 antibody could have 
the opposite prognosis for Dukes’ C as for Dukes’ B carcinomas.
• The most striking indicator of prognosis for both breast and colorectal carcinoma 
was the loss of CD44H staining that accompanied tumours that had gained 
metastatic potential. This was true for both ductal breast carcinomas and invasive 
colorectal carcinomas as a group, where the advanced stage showed lower CD44H 
staining than the earlier stage. The effect was particularly marked for the low 
grade breast carcinomas and Dukes’ B colorectal carcinomas and thus CD44H 
would be a valuable marker of prognosis for both cancers.
GLOSSARY
Adenocarcinoma: carcinoma of glandular epithelium (see 1.1.1.5).
Adenoma: a benign epithelial tumour.
Adjuvant therapy: Treatment given in addition to surgery.
Allelle: gene on one chromosome that has a homologue on the other chromosome of 
a diploid cell.
Anaplastic: showing lack of any differentiated features.
Aneuploid: inexact multiple of normal DNA (chromosome) content.
Antigen: molecule capable of generating an immune response.
Apoptosis: active cell death that requires nucleic acid and protein synthesis (see 
1.1.2.4).
Atypia: not corresponding to a standard type.
Autocrine: secretion of regulatory molecules that function on the producing cell. 
Autosome: chromosome that is not one of the sex chromosomes.
Benign: non-invasive (see 1.1.1.2).
Cadherin: an adhesion molecule, responsible for intercellular interaction. 
Carcinogenesis: process involved in the formation of a cancer (see 1.1.3). 
Carcinoma: malignant tumour of epithelial tissue (seel. 1.1.5).
Carcinoma in situ: early stage of cancer that has not invaded into surrounding tissue. 
Cell cycle: cycle of events required for cell multiplication.
Centrosome: a cytoplasmic organelle near the geometric centre of the cell which 
divides into two parts during mitosis.
Chromatin: nuclear DNA plus its attached proteins.
Chromosome: structural unit that contains genetic material.
Clone: single cell that can produce identical cells.
Codon: three-base sequence in DNA that codes for one amino acid.
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Comedo: a type of ductal carcinoma in situ whose central cells are degenerated.
Differentiation: development of specialist function by a cell.
Diploid: normal DNA content of cells with a double complement of each
chromosome.
Domain: region of a protein that serves a specific function.
Dominant: mutation that overcomes the influence of the other allele in a diploid cell. 
Dysplasia: abnormal development of tissue.
Endocrine: chemical signals carried to the target cells by the blood stream.
Epithelium: the covering of internal and external surfaces of the body, including the 
lining of vessels.
Epitope: region of an antigen that is recognised by an antibody.
Exon: transcribed regions of a gene that are translated into protein.
Gene: DNA containing regulatory and coding sequences for one protein.
Genotoxic: agent that damages DNA.
Germ cell: sperm or egg whose genetic complement can be inherited.
Growth factor: secreted polypeptide that regulates growth.
Heterozygous: two allelles of a gene are different.
Homozygous: two allelles of a gene are the same.
Hyperplasia: an increase in the number of cells.
Immunocytochemistry: the demonstration of antigens in tissue sections or smears 
by use of specific antigen-antibody interactions
Immunohistochemistry: immunocytochemistry applied specifically to tissue 
sections.
Interphase: period of the cell cycle between mitoses.
Invasion: spread into adjacent tissue.
Intron: gene sequences that are transcribed into RNA but removed before translation.
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Ligand: agent that binds to a receptor.
Loss of heterozygosity: loss of the second allelle of a gene.
Malignant: invasive or potentially invasive (see 1.1.1.3).
Metastasis: process of dissemination of tumour cells to form secondary tumours 
(1.1.1.4).
Mitosis: the division of a cell to produce two daughter cells.
Mitotic index: percentage of cells in mitosis.
Mutation: a change in one or more bases in DNA.
Necrosis: pathological method of cell death with membrane disruption and release of 
lytic enzymes that does not require RNA and protein synthesis.
Neoplasia: new growth (see 1.1.1.1).
Neoadjuvant therapy: adjuvant therapy given prior to surgery.
Oestrogen:, any one of the female sex hormones.
Oligomers: multiple sub units.
Oncogene: a gene whose protein product contributes to carcinogenesis (see 1.1.3.1).
Paracrine: secretion of growth factors by one cell type that influences a nearby cell 
of a different type.
Phenotype: characteristics of a cell.
Progesterone: a female sex hormone that prepares the uterus for the fertilised ovum 
and maintains pregnancy.
Progestin:.any hormone concerned with changes before pregnancy.
Progestogen: any of a range of hormones of the progesterone type.
Prognosis: forecast of the future outlook for a patient.
Prognostic factor: a factor that helps define prognosis.
Progression: changes that result in increased aggressiveness (dedifferentiation) of a 
cancer.
Promotion: stage of carcinogenesis after initiation.
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Promoter: 1. agent that promotes carcinogenesis. 2. regulatory region of a gene that 
initiates transcription.
Protein kinase: An enzyme that transfers phosphate groups from ATP to a particular 
amino acid in the target protein.
Proto-oncogene: a gene that, as a result of a mutation, can become an oncogene.
Somatic cell: not a germ cell so genetic complement cannot be inherited.
Suppressor (repressor) gene: gene whose function inhibits a cell function.
Syncytial: forming a multinucleate mass of protoplasm produced by the merging of 
cells.
Transcription factor: protein that regulates transcription.
Transcription: RNA synthesis from DNA.
Translation: protein synthesis from RNA.
Tumour suppressor gene: gene whose protein product inhibits the formation of a 
tumour.
Tumour: abnormal swelling (see 1.1.1.1).
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Breast Carcinoma Project 1
The characterisation o f staining by the MJB1, p53, CD44H, CD44v.3, CD44v6, ER 
and D5 antibodies in a variety o f breast lesions
MIB1
Table 1 - Mean values
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
DCIS 34 22.38 20.93 3.59 3.03 1.27 0.22
Ductal 86 25.19 23.86 2.57 3.03 1.37 0.15
LCIS 6 5.50 12.01 4.90 1.17 1.47 0.60
Lobular 19 9.74 11.06 2.54 1.84 1.26 0.29
Hyperplasia 3 1.00 0.00 0.00 1.00 0.00 0.00
Radial Scar 3 1.33 0.58 0.33 1.33 0.58 0.33
Tubular 3 2.33 2.31 1.33 1.33 0.58 0.33
Mucinous 2 3.00 2.83 2.00 1.50 0.71 0.50
Table 2 - Mann-Whitney values
Group
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Hyperplasia v DCIS 6.000 0.006 6.000 0.006
Hyperplasia v ductal carcinoma 21.000 0.007 21.000 0.007
DCIS v ductal carcinoma 1390.000 0.673 1444.500 0.916
DCIS v LCIS 32.000 0.006 32.000 0.006
LCIS v lobular carcinoma 37.500 0.221 37.500 0.221
Ductal v lobular carcinoma 459.500 0.003 434.000 0.001
G1 Ductal v lobular carcinoma 230.000 0.761 238.000 0.904
G2 Ductal v lobular carcinoma 218.000 0.028 205.000 0.013
G3 Ductal v lobular carcinoma 29.500 0.000 32,000 0.000
Ductal v radial scar 26.500 0.013 36.000 0,030
Ductal v tubular carcinoma 35.500 0.028 36.000 0.030
Ductal v mucinous carcinoma 28.500 0.118 29.000 0.125
A - l
p53
Table 3 - Mean values
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
DCIS 34 26.03 39.08 6.70 0.97 1.34 0.23
Ductal 86 16.55 33.63 3.63 0.68 1.15 0.12
LCIS 6 0.00 0.00 0.00 0.00 0.00 0.00
Lobular 19 1.05 3.15 0.72 0.11 0.32 0.07
Hyperplasia 3 0.00 0.00 0.00 0.00 0.00 0.00
Radial Scar 3 0.00 0.00 0.00 0.00 0.00 0.00
Tubular 3 0.33 0.58 0.33 0.33 0.58 0.33
Mucinous 2 0.50 0.71 0.50 0.50 0.71 0.50
Table 4 - Mann-Whitney values
Group
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Hyperplasia v DCIS 31.500 0.293 31.5 0.293
Hyperplasia v ductal carcinoma 90.000 0.399 88.500 0.388
DCIS v ductal carcinoma 1321.500 0.325 1304.500 0.319
DCIS v LCIS 63.000 0.148 63.000 0.148
LCIS v lobular carcinoma 51.000 0.733 51.000 0.733
Ductal v lobular carcinoma 644.000 0.064 627.500 0.052
G1 Ductal v lobular carcinoma 232.000 0.606 234.000 0.672
G2 Ductal v lobular carcinoma 272.000 0.106 257.000 0.074
G3 Ductal v lobular carcinoma 112.000 0.002 111.000 0.002
Ductal v radial scar 90.000 0.399 88.500 0.388
Ductal v tubular carcinoma 120.500 0.856 122.000 0.914
Ductal v mucinous 81.500 0.900 77.500 0.834
CD44H
Mean values
Table 5 - Total percentage of cells staining, regardless of intensity of staining.
Group No. o f  
Cases
Total % score Ranked score
Mean SD. SE Mean SD SE
DCIS 34 21.76 32.47 5.57 1.29 1.71 0.29
Ductal 86 16.76 31.23 3.37 1.00 1.62 0.17
LCIS 6 16.67 36.01 14.70 1.17 1.94 0.79
Lobular 19 23.95 35.53 8.15 1.37 1.83 0.42
LN 42 16.43 34.36 5.30 0.93 1.72 0.26
Hyperplasia 3 45.00 13.23 7.64 2.67 0.58 0.33
Radial Scar 3 13.33 15.28 8.82 1.00 1.00 0.58
Tubular 3 28.33 36.86 21.28 1.67 2.08 1.20
Mucinous 2 5.00 7.07 5.00 0.50 0.71 0.50
A - 2
Table 6 - Expression score, taking into account intensity of staining.
Group Total expression score Ranked score
Mean SD SE Mean SD SE
DCIS 38.82 68.59 11.76 1.03 1.47 0.25
Ductal 29.97 61.51 6.63 0.84 1.36 0.15
LCIS 31.67 72.71 29.68 1.00 1.55 0.63
Lobular 42.63 66.21 15.19 1.05 1.43 0.33
LN 35.60 84.51 13.04 0.81 1.57 0.24
Hyperplasia 85.00 45.00 25.98 2.00 1.00 0.58
Radial Scar 13.33 15.28 8.82 0.67 0.58 0.33
Tubular 43.33 58.59 33.83 1.33 1.53 0.88
Mucinous 5.00 7.07 5.00 0.50 0.71 0.50
Mann-Whitney values
Table 7 - Total percentage of cells staining, regardless of intensity of staining.
Group
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Hyperplasia v DCIS 24.5 0.148 24.5 0.148
Hyperplasia v  ductal carcinoma 45.5 0.056 43.000 0.049
Hyperplasia v LN 20.000 0.050 21.500 0.057
DCIS v ductal carcinoma 1350.500 0.470 1336.000 0.412
DCIS v LCIS 99.000 0.926 100.5 0.956
LCIS v lobular carcinoma 50.000 0.687 53.000 0.828
Ductal v lobular carcinoma 695.500 0.262 704.500 0.296
G1 Ductal v lobular carcinoma 230.500 0.763 239,500 0.932
G2 Ductal v lobular carcinoma 278.000 0.213 276.500 0.200
G3 Ductal v lobular carcinoma 150.000 0.055 151.000 0.058
Ductal carcinoma v lymph nodes 1705.500 0.559 1695.500 0.519
Ductal v radial scar 99.500 0.522 102.500 0.566
Ductal v tubular carcinoma 91.00 0.412 946.000 0.480
Ductal v mucinous carcinoma 82.500 0.922 85.500 0.989
Table 8 - Expression score, taking into account intensity of staining.
Group
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Hyperplasia v DCIS 19.500 0.810 23.500 0.132
Hyperplasia v ductal carcinoma 38.000 0.035 47.500 0.063
DCIS v ductal carcinoma 1353.500 0.482 1343.500 0.440
DCIS v LCIS 99.000 0.926 101.500 0.985
LCIS v lobular carcinoma 51.000 0.733 57.000 1.000
Ductal v lobular carcinoma 701.000 0.284 748.000 0.519
G1 Ductal v lobular carcinoma 236.500 0.875 233.500 0.814
G2 Ductal v lobular carcinoma 277.500 0.209 299.000 0.395
G3 Ductal v lobular carcinoma 148.500 0.049 160.000 0.096
Ductal carcinoma v lymph nodes 1704.000 0.554 1669.500 0.423
Ductal v radial scar 102.000 0.566 110.500 0.691
Ductal v tubular carcinoma 91.000 0.412 95.000 0.466
Ductal v mucinous carcinoma 84.500 0.966 85.500 0.989
A - 3
CD44H Intensity scores (total percentage score)
Table 9 - Mean values
Group
No.
o f
Cases
CD44intl CD44int2 CD44int3
Mean SD SE Mean SD SE Mean SD SE
DC1S 34 10.00 16.79 2.88 6.47 10.98 1.88 5.29 16.00 2.74
Ductal 86 6.86 12.63 1.36 6.58 14.16 1.53 3.31 9.63 1.04
LCIS 6 1.67 2.58 1.05 15.00 36.74 15.00 0.00 0.00 0.00
Lobular 19 10.26 21.44 4.92 8.68 22.04 5.06 5.00 11.67 2.68
LN 42 5.12 13.23 2.04 3.45 11.61 1.79 7.86 24.92 3.84
Hyperplasia 3 16.67 15.28 8.82 16.67 5.77 3.33 11.67 16.07 9.28
Radial scar 3 13.33 15.28 8.82 0.00 0.00 0.00 0.00 0.00 0.00
Tubular 3 13.33 15.28 8.82 15.00 21.79 12.58 0.00 0.00 0.00
Mucinous 2 5.00 7.07 5.00 0.00 0.00 0.00 0.00 0.00 0.00
Table 10 - Mann-Whitney values
Group
CD44 low intensity CD44 medium 
intensity
CD44 high intensity
Mann-
Whitney
U
Sig.
Mann-
Whitney
U
Sig.
Mann-
Whitney
U
Sig.
Hyperplasia v DCIS 35.500 0.407 20.500 0.092 27.000 0.202
Hyperplasia v ductal 
carcinoma
76.500 0.246 43.000 0.049 65.500 0.157
DCIS v ductal 
carcinoma
1325.500 0.363 1409.500 0.691 1443.500 0.859
DCISvLCIS 80.000 0.425 94.000 0.782 87.000 0.592
LCIS v lobular 
carcinoma
47.000 0.555 51.000 0.733 45.000 0.475
Ductal v lobular 
carcinoma
767.000 0.631 769.500 0.607 760.000 0.448
Ductal carcinoma v 
lymph nodes
1610.500 0.234 1585.000 0.110 1788.500 0.883
Ductal v radial scar 85.000 0.339 97.500 0.494 111.000 0.707
Ductal v tubular 
carcinoma
85.000 0.339 77.000 0.255 111.000 0.707
Ductal v mucinous 
carcinoma
78.500 0.836 65.000 0.586 74.000 0.754
A - 4
CD44v3
Table 11 - Mean values
Group No. o f  
Cases
fotal % score Ranked score
Mean SD SE Mean SD SE
DCIS 34 46.47 39.84 6.83 2.59 1.81 0.31
Ductal 84 48.18 38.71 4.22 2.49 1.73 0.19
LCIS 6 55.00 44.61 18,21 2.67 1.97 0.80
Lobular 18 51.67 44.39 10.46 2.61 1.94 0.46
LN 40 50.76 44.47 7.03 2.47 2,03 0.32
Hyperplasia 3 80.00 20.00 11.55 4.00 1.00 0.58
Radial Scar 3 36.67 47.26 27.28 2.00 2.65 1.53
Tubular 3 48.33 38.19 22.05 2.33 1.53 0.88
Mucinous 2 45.00 35.36 25.00 2.50 2.12 1.50
Table 12 - Mann-Whitney values
Group
Total % score Ranked score
Mann- 
Whitney U
Sig. ’Mann- 
Whitney U
Sig.
Hyperplasia v DCIS 28.000 0.223 30.000 0.268
Hyperplasia v ductal carcinoma 70.500 0.208 64.500 0.161
DCIS v ductal carcinoma 1350.500 0.470 1340.000 0.428
DCISvLCIS 88.500 0.618 98.500 0.897
CIS v lobular carcinoma 52.000 0.923 53.500 0.974
Ductal v lobular carcinoma 709.500 0.680 720.000 0.748
Ductal carcinoma v lymph nodes 1637.500 0.818 1676.000 0.983
Ductal v radial scar 103.000 0.619 108.500 0.700
Ductal v tubular carcinoma 120.500 0.904 120.500 0.904
Ductal v mucinous carcinoma 80.500 0.920 83.000 0.988
CD44v6
Table 13 - Mean values
Group
No.
of
Cases
Total % score Ranked score
Mean SD. SE Mean SD. SE
DCIS 34 50.74 41.42 7.10 2.74 1.88 0.32
Ductal 83 50.31 40.81 4.48 2.59 1.85 0.20
LCIS 6 56.67 48.44 19.78 2.67 1.97 0.80
Lobular 18 57.78 43.46 10.24 2.94 2.04 0.48
LN 42 52.38 42.67 6.58 2.64 1.91 0.29
Hyperplasia 3 76.67 25.17 14.53 4.33 0.58 0.33
Radial Scar 3 40.00 52.92 30.55 2.00 2.65 1.53
Tubular 3 66.67 30.55 17.64 3.00 1.00 0.58
Mucinous 2 50.00 56.57 40.00 2.50 2.12 1.50
A - 5
Table 14 - Mann-Whitney values
Group
Total % score Ranked score
Mann- 
Whitney U
Sig, Mann- 
Whitney U
Sig.
Hyperplasia v DCIS 34.000 0.376 28.000 0.223
Hyperplasia v ductal carcinoma 81.000 0.327 58.000 0,126
DCIS v ductal carcinoma 1373.000 0.818 1328.000 0.611
DCISvLCIS 87.500 0.592 99.500 0.926
LCIS v lobular carcinoma 49.500 0.770 49.000 0.770
Ductal v lobular carcinoma 673.000 0.506 652.500 0.391
Ductal carcinoma v lymph nodes 1662.500 0.670 1691.500 0.783
Ductal v radial scar 111.500 0.773 108.500 0.722
Ductal v tubular carcinoma 93.000 0.485 116.000 0.859
Ductal v mucinous carcinoma 82.000 0,988 81.000 0.965
ER
Table 15 - Mean values
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
DCIS 32 34.84 41.84 7.40 1.31 1.40 0.25
Ductal 85 45.00 44.19 4.79 1.52 1.44 0.16
LCIS 6 63.33 38.30 15.63 2.17 1.17 0.48
Lobular 19 66.84 38.88 8.92 2.26 1.24 0.28
LN 3 33.33 57.74 33.33 1.00 1.73 1.00
Hyperplasia 3 40.00 40.00 23.09 1.67 1.53 0.88
Radial Scar 3 53.33 47.26 27.28 2.00 1.73 1.00
Tubular 3 86.67 11.55 6.67 3.00 0.00 0.00
Mucinous 2 30.00 42.43 30.00 1.50 2.12 1.50
Table 16 - Mann-Whitney values
Group
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Hyperplasia v DCIS 45.000 0.890 42.500 0.760
Hyperplasia v ductal carcinoma 115.500 0.795 125.500 0.966
DCIS v ductal carcinoma 1201.000 0.303 1256.500 0.486
DCIS v LCIS 59.500 0.147 66.500 0.245
LCIS v lobular carcinoma 52.500 0.780 49.500 0.642
Ductal v lobular carcinoma 602.000 0.071 585.500 0.039
G1 Ductal v lobular carcinoma 239.000 0.923 243.000 1.000
G2 Ductal v lobular carcinoma 228.500 0.054 230.500 0.042
G3 Ductal v lobular carcinoma 95.500 0.001 91.000 0.000
Ductal carcinoma v lymph nodes 113.000 0.761 105.500 0.631
Ductal v radial scar 125.500 0.966 102.500 0.585
Ductal v tubular carcinoma 71.000 0.209 55.500 0.101
Ductal v mucinous carcinoma 66.500 0.618 84.000 0.989
A - 6
D5
Table 17 - Mean values
Group
No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
DCIS 32 58.91 36.43 6.44 3.41 1.78 0.31
Ductal 84 63.82 36.36 3.97 3.63 1.68 0.18
LCIS 6 37.50 42.40 17.31 2.33 2.16 0.88
Lobular 19 56.32 43.17 9.90 3.11 2.13 0.49
LN 4 14.00 16.75 8.38 1.50 1.29 0.65
Hyperplasia 3 0.00 0.00 0.00 0.00 0.00 0.00
Radial Scar 3 11.67 16.07 9.28 1.00 LOO 0.58
Tubular 3 15.00 18.03 10.41 1.33 1.53 0.88
Mucinous 2 40.00 56.67 40.00 2.50 3.54 2.50
Table 18 - Mann-Whitney values
Group
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Hyperplasia v DCIS 4.500 0.003 4.500 0.003
Hyperplasia v ductal carcinoma 9.000 0.001 9.000 0.001
DCIS v ductal carcinoma 1223.000 0.447 1250.000 0.538
DCISvLCIS 66.500 0.245 68.500 0.279
LCIS v lobular carcinoma 45,500 0.475 47.500 0.555
Ductal v lobular carcinoma 715.500 0.474 710.000 0.425
G1 Ductal v lobular carcinoma 227.000 0.864 226.000 0.839
G2 Ductal v lobular carcinoma 323.000 0.855 320.500 0.812
G3 Ductal v lobular carcinoma 210.000 0.877 202.000 0.703
Ductal carcinoma v lymph nodes 46.000 0.010 56.500 0.021
Ductal v radial scar 31.000 0.021 30.500 0,020
Ductal v  tubular carcinoma 36.500 0.032 39.000 0.040
Ductal v mucinous carcinoma 47.500 0.328 66.500 0.633
A - 7
Grades of Ductal carcinoma
Mean values
Table 19 - Gradel
Antibody No. of 
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
MIB1 27 9.44 12.81 2.47 2.00 1.21 0.23
p53 27 0.07 0.27 0.05 0.07 0.27 0.05
CD44Htot% 27 20.22 31.89 6.14 1.33 1.71 0.33
CD44Hexp 27 36.37 65.42 12.59 1.11 1.42 0.27
CD44v3 27 50.22 38.24 7.36 2,63 1.71 0.33
CD44v6 26 58.46 39.49 7.74 2.85 1.80 0.35
D5 26 61.54 37.86 7.43 3.54 1.79 0.35
ER 27 68.89 39.74 7.65 2.30 1.27 0.24
Table 20 -Grade2
Antibody No. of 
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
MIB1 38 19.68 17.01 2.76 2.87 1.21 0.20
p53 38 11.00 28.04 4.55 0.57 0.99 0.16
CD44Htot% 38 17.76 33.89 5.50 1.00 1.72 0.28
CD44Hexp 38 32.89 68.24 11.07 0.87 1.51 0.24
CD44v3 36 53.33 39.06 6.51 2.64 1.79 0.30
CD44v6 36 54.06 41.21 6.87 2.78 1.85 0.31
D5 37 61.92 36.95 6.07 3.54 1.73 0.28
ER 37 46.76 42.04 6.91 1.62 1.40 0.23
Table 21 -Grade3
Antibody No. of 
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
MIB1 24 47.71 25.83 5.27 4.17 0.82 0.17
p53 24 37.71 42.68 8.71 1.42 1.41 0.29
CD44Htot% 24 12.29 26.78 5.47 0.67 1.34 0.27
CD44Hexp 24 18.96 42.68 8.71 0.50 0.98 0.20
CD44v3 24 36.50 37.42 7.64 2.00 1.62 0.33
CD44v6 24 37.50 39.20 8.00 2.04 1.78 0.36
D5 24 62.29 36.80 7.51 3.58 1.72 0.35
ER 24 23.13 39.56 8.07 0.79 1.28 0.26
A - 8
Mann-Whitney values
Table 22-M IB1
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Grade 1 v Grade 2 ductal carcinoma 288.000 0.002 318.000 0.007
Grade 2 v Grade 3 ductal carcinoma 168.500 0.000 186,000 0.000
Grade 1 v Grade 3 ductal carcinoma 53.000 0.000 53,000 0.000
Table 23 - p53
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Grade 1 v Grade 2 ductal carcinoma 378.000 0.012 318.000 0.007
Grade 2 v Grade 3 ductal carcinoma 314.500 0.021 309.500 0.025
Grade 1 v Grade 3 ductal carcinoma 159.500 0.000 160.500 0.000
Table 24 - CD44H (Total percentage of cells staining regardless of intensity)
Total % score Ranked score
Mann- 
Whitney U
Sig- Mann- 
Whitney U
Sig.
Grade 1 v Grade 2 ductal carcinoma 428.000 0.217 410.500 0.134
Grade 2 v Grade 3 ductal carcinoma 428.000 0.217 400.000 0.328
Grade 1 v Grade 3 ductal carcinoma 223.500 0.036 220.000 0.029
Table 25 - CD44H (Score for expression of weighted for intensity of staining)
Total exp. 
score
Ranked
score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig-
Grade 1 v Grade 2 ductal carcinoma 416.500 0.162 419.500 0.170
Grade 2 v Grade 3 ductal carcinoma 399.500 0.325 401.000 0.337
Grade 1 v Grade 3 ductal carcinoma 220.500 0.031 222.000 0,031
Table 26 - CD44v3
Total exp. score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig-
Grade 1 v Grade 2 ductal carcinoma 471.000 0.835 485.000 0.989
Grade 2 v Grade 3 ductal carcinoma 331.000 0.126 343.500 0.174
Grade 1 v Grade 3 ductal carcinoma 254.000 0.185 257.500 0.200
A - 9
Table 27 - CD44v6
Total exp. score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Grade 1 v Grade 2 ductal carcinoma 454.500 0.847 460.000 0.907
Grade 2 v Grade 3 ductal carcinoma 325.000 0.104 331.500 0.122
Grade 1 v Grade 3 ductal carcinoma 219.000 0.069 231.500 0.111
Table 28 - ER
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig-
Grade 1 v Grade 2 ductal carcinoma 348.500 0.035 356.000 0.028
Grade 2 v Grade 3 ductal carcinoma 308.500 0.031 308.500 0.026
Grade 1 v Grade 3 ductal carcinoma 155.500 0.001 149,000 0.000
Table 29 - D5
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Grade 1 v Grade 2 ductal carcinoma 475.500 0.938 479.500 0.982
Grade 2 v Grade 3 ductal carcinoma 440.000 0.952 433.000 0.863
Grade 1 v Grade 3 ductal carcinoma 305.000 0.890 433.000 0.863
Table 30 - Lymph nodes
CD44H CD44v3 CD44v6
Mann-W
U
Sig. Mann-W
U
Sig Mann-W
U
Sig
Lymph nodes v 
Grade 1 ductal 735.000 0.000 553.5 0.934 513.000 0.925
Lymph nodes v 
Grade 2 ductal 761.000 0.674 691.000 0.758 726.500 0.888
Lymph nodes v 
Grade 3 ductal 502.000 0.716 427.500 0.456 381.000 0.162
A - 10
Table 31 - Mucinous Carcinomas
CD44H MIB1 D5 ER
Mann- 
W U
Sig. Mann- 
W U
Sig Mann- 
W U
Sig Mann- 
W U
Sig
Mucinous v Grade 1 
ductal 33.500 0.285 52.500 0.701 29.000 0.721 29.000 0.762
Mucinous v Grade 2 
ductal 37.500 0.974 11.000 0.108 28.000 0.577 37.500 0.974
Mucinous v Grade 3 
ductal 22.000 0.821 3.000 0.034 19.500 0.627 18.000 0.570
p53 CD44v3 CD44v6
Mann- 
W U
Sig. Mann-
W  U
Sig Mann- 
W U
Sig
Mucinous v Grade 1 
ductal 35.500 0.444 27.500 0.966 23.500 0.825
Mucinous v Grade 2 
ductal 33.000 0.871 34.500 0.922 33.500 0.826
Mucinous v Grade 3 
ductal 14.000 0.554 20.000 0.745 20.500 0.745
Spearman Correlations
Table 32 - Spearman’s rho Correlation coefficients (Ranked scores)
No.
Cases
CD44H CD44v3 CD44v6 D5 ER Grade MIB1 p53
CD44H 199 0.546 0.532 0.016 0.112 -0.241 -0.265 -0.160
CD44v3 194 0.546 0.897 0.034 0.195 -0.133 -0.187 -0.190
CD44v6 195 0.532 0.897 0.044 0.232 -0.168 -0.214 -0.151
D5 157 0.016 0.034 0.044 0.217 0.016 0.162 -0.041
ER 157 0.112 0.095 0.232 0.217 -0.409 -0.250 -0.126
Grade 89 -0.241 -0.133 -0.168 0.016 -0.409 0.598 0.427
MIB1 158 -0.265 -0.187 -0.214 0.162 -0.250 0.598 0.409
P53 ....... .... . 157 -0.160 -0.190 -0.151 -0.041 -0.126 0.427 0,409
Table 33 - Significant correlations (p < 0.05) (Ranked scores)
CD44H CD44v3 CD44v6 D5 ER Grade MIB1 p53
CD44H 0.000 0,000 0.847 0.161 0.023 0.001 0.045
CD44v3 0.000 0.000 0.676 0.015 0.220 0.020 0.018
CD44v6 0.000 0.000 0.586 0.004 0.122 0,008 0.063
D5 0.847 0.676 0.586 0.006 0.886 0.044 0.613
ER 0.161 0.015 0.004 0.006 0.000 0.002 0.120
Grade 0.023 0.220 0.122 0.886 0.000 0.000 0.000
M3B1 0,001 0.020 0.008 0.044 0.002 0.000 0.000
p53 0.045 0.018 0.063 0.613 0.120 0.000 0.000
A -  11
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Table 34 - Mean values (Ranked scores)
Group
No.
o f
Cases
MIB1 D5 ER
Mean SD SE Mean SD SE Mean SD SE
Papilloma 23 1.70 1.06 0.22 0.74 0.69 0.14 1.22 1.09 0.23
Hyperplasia 20 1.18 0.95 0.23 0.68 0.82 0.19 1.21 0.98 0.22
Atyp. Hyperplasia 6 0.75 0.50 0.25 1.00 0.71 0.32 0.80 0.84 0.37
DCIS 41 2.90 1.29 0.21 2.31 0.95 0.15 1.38 1.39 0.22
Grade 1 ductal 63 1.89 1.19 0.15 2.03 1.12 0.19 2.03 1.29 0.22
Grade 2 ductal 38 2.97 1.17 0.19 2.34 0.97 0.16 1.63 1.38 0.22
Grade 3 ductal 23 3.88 1.17 0.23 2.20 1.08 0.22 0.68 1.25 0.25
LCIS 6 1.17 1.47 0.60 1.67 1.21 0.49 2.17 1.17 0.48
Lobular 21 2.24 1.26 0.28 2.19 1.12 0.25 2.19 1.29 0.28
Radial Scar 24 1.48 0.81 0.18 1.32 0.75 0.17 1.26 1.19 0.27
Medullary 4 4.25 0.50 0.25 1.00 0.00 0.00 0.00 0.00 0.00
Mucinous 2 1.50 0.71 0.50 1.50 , 2.12 1.50 1.50 2.12 1.50
Group
No.
o f
Cases
p53 CD44v3 CD44v6
Mean SD SE Mean SD SE Mean SD SE
Hyperplasia 20 0.00 0.00 0.00 3.00 2.16 1.08 3.25 2.22 1.11
DCIS 41 1.03 1.36 0.24 2.59 1.81 0.31 2.76 1.83 0.31
Grade 1 ductal 63 0.20 0.59 0.08 2.50 1.80 0.34 2.81 1.86 0.36
Grade 2 ductal 38 0.56 0.91 0.15 2.64 1.79 0.30 2.78 1.83 0.30
Grade 3 ductal 23 1.45 1.43 0.32 2.00 1.62 0.33 2.17 1.81 0.37
LCIS 6 0.00 0.00 0.00 2.67 1.97 0.80 2.67 1.97 0.80
Lobular 21 0.24 0.75 0.18 2.78 1.83 0.43 3.06 1.92 0.45
Lymph nodes 43 2.45 2.05 0.32 2.78 1.91 0.30
Radial Scar 24 3.00 2.83 2.00 3.00 2.83 2.00
Mucinous 2 0.50 0.71 0.50 2.50 2.12 1.50 2.50 2.12 1.50
Group No.
o f
Cases
CD44H
Mean SD SE
Papilloma 23 2.00 0.67 0.14
Hyperplasia 20 2.00 0.87 0.21
Atyp. Hyperplasia 6 1.50 0.58 0.29
DCIS 41 1.10 1.17 0.19
Grade 1 ductal 63 1.55 1.34 0.17
Grade 2 ductal 38 0.74 1.11 0.18
Grade 3 ductal 23 0.56 1.00 0.20
LCIS 6 0.83 1.17 0.48
Lobular 21 0.95 1.16 0.25
Lymph nodes 43 0.62 1.03 0.16
Radial Scar 24 1.35 0.67 0.15
Medullary 4 1.25 2.50 1.25
Mucinous 2 0.50 0.71 0.50
A -12
Mann -W hitney values
Table 35 - Papillomas
CD44H MIB1 D5 ER
Mann- 
W U
Sig. Mann-W
U
Sig Mann- 
W U
Sig Mann- 
W U
Sig
Papilloma v  
Hyperplasia 191.500 0.914 130.000 0.075 201.000 0.627 217.500 0.979
Papilloma v 
Atypical hyperplasia 26.00 0.191 19.000 0.069 45.500 0.483 45.500 0.483
Papilloma v 
DCIS 258.000 0.002 211.000 0.000 104.500 0.000 420.500 0.667
Papilloma v  
Grade 1 ductal 510.000 0.025 663.500 0.534 154.000 0.000 238.500 0.009
Papilloma v 
Grade 2 ductal 171.000 0.000 179.000 0.000 101.500 0,000 354.500 0.197
Papilloma v 
Grade 3 ductal 88.000 0.000 58.500 0.000 88.500 0000 200.000 0.045
Table 36 - Hyperplasia
CD44H MIB1 D5 ER
Mann-
W u Sig.
Mann- 
W U
Sig Mann- 
W U
Sig Mann- 
W U
Sig
Hyperplasia v 
Atypical Hyperplasia 21.000 0.275 25.500 0.462 34.000 0.367 36.000 0.462
Hyperplasia v 
DCIS 192.000 0.007 98.000 0.000 93.500 0.000 342.000 0.619
Hyperplasia v 
grade 1 ductal 390.000 0.065 337.000 0.015 127.500 0.000 183.500 0.007
Hyperplasia v 
grade 2 ductal 129.000 0.000 81,500 0.000 91.000 0.000 283.000 0.165
Hyperplasia v 
grade 3 ductal 67.000 0.000 28.000 0.000 76.000 0.000 163.500 0.051
Table 37 - Atypical hyperplasia
CD44H MIB1 D5 ER
Mann- 
W U
Sig. Mann- 
W U
Sig Mann- 
W U
Sig Mann- 
W U
Sig
Atypical hyperplasia 
v DCIS 59.000 0.417 11.000 0.002 28.500 0.007 78.500 0.494
Atypical hyperplasia 
v Grade 1 ductal 117.00 0.792 51.000 0.046 41.000 0.058 39.000 0.054
Atypical hyperplasia 
v Grade 2 ductal 37.000 0.100 8.000 0.001 27.500 0.007 63.500 0.241
Atypical hyperplasia 
v Grade 3 ductal 19.000 0.051 3.000 0.001 23.500 0.027 48.500 0.448
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Table 3 8 -DCIS
CD44H MIB1 D5 ER
Mann-W
U
Sig. Mann-W
U
Sig Mann-W
U
Sig Mann-W
U
Sig
DCIS v Grade 1 
ductal 1030.000 0.083 700.500 0.000 597.500 0.315 502.000 0.054
DCIS v Grade 2 
ductal 622.000 0.131 712.500 0.765 717.500 0.787 677.500 0.485
DCIS v Grade 3 
ductal 365.000 0,044 275.000 0.003 471.500 0.806 353.500 0.037
p53 CD44v3 CD44v6
Mann-W
U
Sig. Mann-W
U
Sig Mann-W
U
Sig
DCIS v 
Grade 1 ductal 598.000 0.001 458.000 0.794 439.500 0.970
DCIS v 
Grade 2 ductal 503.000 0.302 608.000 0.962 628.500 0.995
DCIS v 
Grade 3 ductal 270.500 0.300 334.000 0.231 326.000 0.187
Table 39 - Ductal Carcinomas
CD44H MIB1 D5 ER
Mann-
W U
Sig. Mann- 
W  U
Sig Mann- 
W U
Sig Mann- 
W U
Sig
Grade 1 ductal v 
Grade 2 ductal 740.000 0.001 619.000 0.000 565.000 0.224 543.500 0.208
Grade 1 ductal v 
Grade 3 ductal 415.000 0.000 206.500 0.000 400.000 0.542 220.000 0.001
Grade 2 ductal v  
Grade 3 ductal 433.000 0.481 268.000 0.003 445.500 0.640 311.000 0.010
p53 CD44v3 CD44v6
Mann- 
W U
Sig. Mann-
W U
Sig Mann-
W U
Sig
Grade 1 ductal v  
Grade 2 ductal 751.500 0.012 483.000 0.772 477.000 0.954
Grade 1 ductal v 
Grade 3 ductal 287.500 0.000 284.500 0.335 247.500 0.201
Grade 2 ductal v 
Grade 3 ductal 248.00 0.032 343.500 0.174 355.500 0.182
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Table 40 - Lobular carcinomas
CD44H MIB1 D5 ER
Mann-
W U
Sig- Mann- 
W U
Sig Mann- 
W U
Sig Mann- 
W U
Sig
LCIS v Lobular 60.000 0.887 35.000 0.110 46.500 0.345 56.500 0.712
Lobular v Grade 1 
ductal 486.000 0.048 544.000 0.211 335.500 0.556 324.500 0.520
Lobular v Grade 2 
ductal 346.000 0.348 271.500 0.037 376.500 0.687 303.500 0.096
Lobular v Grade 3 
ductal 203.500 0.137 87.000 0.000 261.500 0.980 123.500 0.001
p53 CD44v3 CD44v6
Mann- 
W  U
Sig. Mann-
W U
Sig Mann- 
W U
Sig
LCIS v Lobular 22.500 0.765
Lobular v Grade 1 
ductal 455.000 0.926 228.500 0.591 210.000 0.556
Lobular v Grade 2 
ductal 234.500 0.085 308.000 0.765 297.000 0.508
Lobular v Grade 3 
ductal 93.000 0.018 161.000 0.155 152.500 0.099
Table 41 - Medullary Carcinomas
CD44H MIB1 D5 ER
Mann- 
W U
Sig. Mann- 
W U
Sig Mann- 
W U
Sig Mann- 
W U
Sig
Medullary v Grade 
1 ductal 83.500 0.257 14.000 0.001 32.000 0.083 18.000 0.014
Medullary v Grade 
2 ductal 74.000 0.951 26.500 0.030 20.000 0.013 30.000 0.049
Medullary v Grade 
3 ductal 48.000 0.927 43.500 0.692 18.000 0.043 38.000 0.482
Table 42 - Radial Scars
CD44H MIB1 D5 ER
Mann- 
W U
Sig. Mann- 
W U
Sig Mann- 
W U
Sig Mann-
W U
Sig
Radial scar v 
Papilloma 118.000 0.002 202.000 0.310 131.000 0.016 215.000 0.927
Radial scar v 
hyperplasia 95.500 0.022 140.000 0.268 98.500 0.015 178.000 0.954
Radial scar v DCIS
327.500 0.236 151.500 0.000 153.000 0.000 357.000 0.812
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Spearman Correlations
Table 43 - Spearman’s rho Correlation coefficients (Ranked scores).
No. o f  
Cases
CD44
H
CD44
v3
CD44
v6
D5 ER Grade M IBl p53
CD44H 306 0.518 0.507 -0 .1 5 0 0.007 -0 .3 8 7 - 0.344 -0 .1 9 9
CD44v3 120 0.518 0.887 0.099 0.202 - 0.079 -0 .1 7 4 -0 .1 5 9
CD44v6 121 0.507 0.887 0.094 0.215 -0 .1 1 7 -0 .195 -0 .1 1 8
D5 239 -0 .1 5 0 0.099 0.094 0.249 0.127 0.283 -0 .0 1 5
ER 237 0.007 0.202 0.215 0.249 - 0.362 - 0.091 -0 .1 5 0
Grade 124 -0 .3 8 7 -0 .0 7 9 -0 .1 1 7 0.127 - 0.362 0.602 0.406
M IBl 264 - 0.344 -0 .1 7 4 -0 .195 0.283 - 0.091 0.602 0.420
P.53 ............ 171 -0 .1 9 9 -0 .1 5 9 -0 .1 1 8 -0 .015 -0 .1 5 0 0.406 0.420
Table 44 - Significant correlations (p < 0.05) (Ranked scores).
No. o f  
Cases
CD44
H
CD44
v3
CD44
v6
D5 ER Grade M IBl p53
CD44H 306 0.000 0.000 0.022 0.919 0.000 0.000 0.009
CD44v3 195 0.000 0.000 0.219 0.012 0.469 0.030 0.061
CD44v6 194 0.000 0.000 0.246 0.007 0.285 0.015 0.165
D5 239 0.022 0.219 0.246 0.000 0.223 0.000 0.860
ER 237 0.919 0.012 0.007 0.000 0.000 0.171 0.077
Grade 124 0.000 0.469 0.285 0.223 0.000 0.000 0.000
M IBl 264 0.000 0.030 0.015 0.000 0.171 0.000 0.000
p53 171 0.009 0.061 0.165 0.860 0.077 0.000 0.000
Correlation between ER and MIB1
Table 45 - Spearman’s rho correlation coefficients and Sig.
Pathology group No. o f  Cases Spearman’s rho Sig.
Hyperplasia 25 - .1 0 7 0.693
DCIS 42 -.2 9 8 0.069
Ductal carcinoma 125 - .214 0.038
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Breast Carcinoma Project 3
A study on the metastatic potential o f grade 1 ductal carcinomas o f the breast.
Table 46 - Mean values for LN-ve and LN+ve groups
No. o f  
Cases
Lymph node negative Lym ph node positive
Mean SD SE Mean SD SE
M IBl tot 51 5.39 5.21 0.94 9.63 10.64 1.88
M IBl (ranked) 51 1.45 0.72 0.13 1.91 1.03 0.18
p53tot 51 2.94 14.42 2.59 4.09 15.96 2.78
p53 (ranked) 51 0.23 0.80 0.14 0.45 0.90 0.16
CD44tot% 52 55.48 36.04 6.47 26.32 30.48 5.23
CD44% (ranked) 52 2.97 1.91 0.34 1.50 1.62 0.28
CD44exp 52 91.94 69.9 12.57 43.09 60.25 10.33
CD44exp (ranked) 52 2.10 1.51 0.27 1.18 1.36 0.23
CD44 low intensity 52 29.68 21.05 3.78 13.38 14.18 2.43
CD44 med intensity 52 17.74 13.83 2.48 8.82 13.60 2.33
CD44 high intensity 52 8.06 13.76 2.47 4.12 9.57 1.64
Mann-Whitney values
Table 47 - Lymph node negative v lymph node positive
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
M IBl 429.500 0.351 392.000 0.122
p53 424.500 0.086 425.500 0.089
CD44 total percentage score 304.000 0.003 304.500 0.003
CD44 expression score 327.000 0.008 344.000 0.014
Table 48 - CD44 staining intensity (total percentage score)
CD44 low intensity CD44 medium intensity CD44 high intensity
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
289.000 0.001 331.000 0.007 433.000 0.124
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Colorectal Carcinoma Project 1
The characterisation o f  MIBl, p53 and CD44H antibody staining in colorectal 
adenomas and carcinomas.
Carcinomas and Adenomas 
Mean values
Table 49 -M IBl
Group No. of 
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 38.31 25.40 4.49 2.31 1.20 0.21
Carcinomas 68 60.16 20.26 2.53 3.41 1.22 0.15
Table 50-p53
Group No. of 
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 6.66 20.69 3.66 0.97 1.03 0.18
Carcinomas 68 43.96 42.06 5.10 2.21 1.99 0.24
Table 51 - CD44H (Total number of cells with any staining)
Group No. of 
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 71.41 29.95 5.29 3.87 1.50 0.26
Carcinomas 68 38.48 34.59 4.26 2.21 1.77 0.22
Table 52 - CD44H (Expression score weighted for intensity of staining)
Group No. of 
Cases
Tota expression score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 126.72 72.22 12.77 2.84 1.32 0.23
Carcinomas 68 64.39 71.04 8.74 1.65 1.38 0.17
Table 53 - CD44H score for different staining intensities
Group No. of 
Cases
CD44H 
low intensity
CD44H 
medium intensity
CD44H 
high intensity
Mean SD SE Mean SD SE Mean SD SE
Adenomas 32 29.06 2.20 3.92 29.37 23.58 4.17 12.97 20.11 3.56
Carcinomas 68 19.62 18.63 2.29 11.82 13.80 1.70 7.05 17.93 2.21
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Table 54 - Mann-Whitney values
Total % score Ranked score
Mann-Whitney
U
Sig. Mann-Whitney
U
Sig.
M IBl 521.000 0.000 542.500 0.000
p53 805.500 0.033 806.000 0.032
CD44H Tot% 478.500 0.000 494.500 0.000
CD44H Exp 503.500 0.000 560.000 0.000
Table 55 - Mann-Whitney values for different intensities of CD44H
CD44 low intensity CD44 medium intensity CD44 high intensity
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
803.500 0.053 572.500 0.000 744.500 0.007
Colorectal adenomas, Dukes’ A, Dukes’ B (classed separately) and 
Dukes’ C carcinomas
Mean values
Table 56 - MIBl
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
Adenoma 32 38.31 25.40 4.49 2.31 1.20 0.21
Dukes’A 10 63.13 26.58 9.40 3.63 1.51 0.53
Dukes’B 28 57.41 20.77 4.00 3.33 1.39 0.27
Dukes’C 30 61.9 18.25 3.39 3.41 0.98 0.18
Table 57 - p53
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
Adenoma 32 6.66 20.69 3.66 0.97 1.03 0.18
Dukes’A 10 13.10 27.46 8.68 0.90 1.66 0.53
Dukes’B 28 46.14 43.09 8.14 2.25 2.03 0.38
Dukes’C 30 52.20 41.49 7.58 43.96 42.06 5.10
Table 58 - CD44H (Total number of cells with any staining)
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 71.41 29.95 5.29 3.87 1.50 0.26
Dukes’A 10 36.00 35.89 11.35 2.10 1.91 0.60
Dukes’B 28 49,63 35.16 6.19 2.78 1.60 0.31
Dukes’C 30 28.97 34.44 6.40 1.72 1.77 0.33
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Table 59 - CD44H (Expression score weighted for intensity of staining)
Group No. o f  
Cases
Total expression score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 126.72 72.22 12.77 2.84 1.32 0.23
Dukes’A 10 58.50 79.44 25.12 1.50 1.51 0.48
Dukes’B 28 81.85 62.94 12.11 2.04 1.19 0.23
Dukes’C 30 50.17 74.12 13.76 1.34 1.45 0.27
Table 60 - CD44H score for different staining intensities
Group No. o f CD44 low CD44 medium CD44 high
Cases intensity intensity intensity
Mean SD SE Mean SD SE Mean SD SE
Adenomas 32 29.06 22.20 3.92 29.37 23.58 4.17 12.97 20.11 3.56
Dukes’A 10 21.50 22.37 7.07 6.50 8.18 2.59 8.00 22.01 6.96
Dukes’B 28 24.44 17.56 3.38 18.15 12.87 2.48 7.04 13.46 2.59
Dukes’C 30 14.48 17.54 3.26 7.76 14.18 2.63 6.72 20.54 3.81
Mann-Whitney values
Table 61 - MIBl
Total % score Ranked score
Mann-Whitney U Sig. Mann-Whitney U Sig.
Adenomas v Dukes’ A 62.000 0.025 62.500 0.025
Adenomas v Dukes’ B 241.000 0.004 250.000 0.004
Adenomas v Dukes’ C 218.000 0.000 230.000 0.001
Dukes’A v Dukes’B 87.500 0.428 93.000 0.576
Dukes’B v Dukes’C 338.500 0.382 352.000 0.498
Table 62 - p53
Total % score Ranked score
Mann-Whitney U Sig. Mann-Whitney U Sig.
Adenomas v Dukes A 104.000 0.102 108.000 0.130
Adenomas v Dukes B 327.000 0.065 327.500 0.061
Adenomas v Dukes C 262.500 0.002 266.500 0.002
Dukes’A v Dukes’B 77.000 0.037 87.000 0.082
Dukes’A v Dukes’C 67.500 0.008 77.500 0.022
Dukes’B v Dukes’C 379.000 0.516 381.000 0.534
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Table 63 - CD44H
Total % score Ranked score
Mann-Whitney U Sig. Mann-Whitney U Sig.
Adenomas v Dukes’ A 72.000 0.008 70.000 0.007
Adenomas v Dukes’ B 242.500 0.004 251.500 0.004
Adenomas v Dukes’ C 164.000 0.000 173.000 0.000
Dukes’ A v  Dukes’ B 96.000 0.191 101.500 0.257
Dukes’ A  v Dukes’ C 131.000 0.669 131.500 0.669
Dukes’ B v Dukes’ C 237.500 0.011 251.500 0.019
Table 64 - CD44 (Expression score weighted for intensity of staining)
Total expression score Ranked score
Mann-Whitney U Sig. Mann-Whitney U Sig.
Adenomas v Dukes’ A 65.500 0.004 77.500 0.013
Adenomas v Dukes’ B 263.500 0.010 283.500 0.020
Adenomas v Dukes’ C 174.500 0.000 199.000 0.000
Dukes’ A v Dukes’ B 85.500 0.091 98.000 0.216
Dukes’ A v Dukes’ C 133.500 0.716 130.000 0.646
Dukes’ B v Dukes’ C 236.000 0.010 249.000 0.015
Table 65 - CD44 intensities score
CD44 low intensity CD44 medium 
intensity
CD44 high intensity
Mann- 
Whitney U Sig.
Mann- 
Whitney U Sig.
Mann- 
Whitney U Sig.
Adenoma v DukesA 130.500 0.390 65.500 0.004 105.500 0.108
Adenoma v Dukes B 396.500 0.584 308.500 0.057 340.00 0.130
Adenoma v Dukes C 276.500 0.006 198.500 0.000 299.000 0.007
Dukes A v Dukes B 114.500 0.489 64.000 0.014 112.000 0.448
Dukes A v Dukes C 121.000 0.456 135.000 0.764 145.000 1.000
Dukes B v Dukes C 240.500 0.012 200.500 0.001 320.000 0.149
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Colorectal adenomas, Dukes’ A and B, (classed together as non- 
metastasising carcinomas), and Dukes’ C carcinomas
Mean values
Table 66-M IBl
Group No. o f  
Cases
Tota expression score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 38.31 25.40 4.49 2.31 1.20 0.21
Dukes’A&B 38 58.71 21.94 3.71 3.40 1.40 0.24
Dukes’C 30 61.90 18.25 3.39 3.41 0.98 0.18
Table 67-p53
Group No. of 
Cases
Tota expression score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 6.66 20.69 3.66 0.97 1.03 0.18
Dukes’A&B 38 37.45 41.90 6.80 1.89 2.01 0.33
Dukes’C 30 52.20 41.49 7.58 2.60 1.92 0.35
Table 68 - CD44 (Total number of cells with any staining)
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
Adenomas 32 71.41 29.95 5.29 3.87 1.50 0.26
Dukes’A&B 38 45.95 33.27 5.47 2.59 1.69 0.28
Dukes’C 30 28.97 34.44 6.40 1.72 1.77 0.33
Table 69 - CD44 (Expression score weighted for intensity of staining)
Group No. of 
Cases
Tota expression score lanked score
Mean SD SE Mean SD SE
Adenomas 32 126.72 72.22 12.77 2.84 1.32 0.23
Dukes’A&B 38 75.54 67.45 11.09 1.89 1.29 0.21
Dukes’C 30 50.17 74.12 13.76 1.34 1.45 0.27
Table 70 - CD44 score for different staining intensities
Group No. o f  
Cases
CD44 low intensity CD44 medium 
intensity
CD44 high intensity
Mean SD SE Mean SD SE Mean SD SE
Adenomas 32 29.06 22.20 3.92 29.37 23.58 4.17 12.97 20.11 3.56
Dukes’A&B 38 23.65 18.70 3.07 15.00 12.80 2.10 7.30 15.88 2.61
Dukes’C 30 14.48 17.54 3.26 7.76 14.18 2.63 6.72 20.54 3.81
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Mann-Whitney values
Table 71 - MIBl
Total % score Ranked score
Mann-Whitney U .... Sig. Mann-Whitney U Sig.
Adenomas v Dukes’A&B 303.000 0.001 312.500 0.001
Adenomas v Dukes’C 218.000 0.000 230.000 0.001
Dukes’A&B v Dukes’C 468.500 0.597 480.500 0.706
Table 72 - p53
Total % score Ranked score
Mann-Whitney U Sig. Mann-Whitney U Sig.
Adenomas v Dukes’A&B 543.000 0.428 539.500 0.396
Adenomas v Dukes’C 262.500 0.002 266.500 0.002
Dukes’A&B v Dukes’C 446.500 0.117 458.500 0.155
Table 73 - CD44 (Total number of cells with any staining)
Total % score Ranked score
Mann-Whitney U Sig. Mann-Whitney U Sig.
Adenomas v Dukes’ A&B 314.500 0.001 321.500 0.001
Adenomas v Dukes’ C 164.000 0.000 173.000 0.000
Dukes’ A&B v Dukes’ C 368.500 0.029 383.000 0.043
Table 74 - (Expression score weighted for intensity of staining)
Total expression score Ranked score
Mann-Whitney U Sig. Mann-Whitney U Sig.
Adenomas v Dukes’ A&B 329.000 0.002 361.000 0.004
Adenomas v Dukes’ C 174.500 0.000 199.000 0.000
Dukes’ A&B v Dukes’ C 369.500 0.030 379.000 0.035
Table 75 - CD44 intensities scores
CD44 
low intensity
CD44 
medium intensity
CD44 
high intensity
Mann- 
Whitney U . ... s iS-
Mann- 
Whitney U Sig.
Mann- 
Whitney U Sig.
Adenoma v DukesA&B 527.000 0.428 374.000 0.008 445.500 0.052
Adenoma v DukesC 276.500 0.006 198.500 0.000 299.000 0.007
Dukes’A&B v DukesC 361.500 0.022 335.500 0.007 465.000 0.247
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Spearman Correlations
Carcinomas
In the following tables, Dukes’ 1 represents a grouping with Dukes’ A and Dukes’ B 
carcinomas grouped separately and Dukes’ 2 represents a grouping with Dukes’ A and 
Dukes’ B carcinomas grouped together (see 5.2.6.4 for fuller explanation).
Table 76 - Spearman’s rho Correlation coefficients (Ranked scores)
M IBl p53 CD44t CD44e CD441 CD44m CD44h Dukes 1 Dukes 2
M IBl 0.099 -0.186 -0.155 -0.125 -0.106 -0.059 0.014 0.048
P53 0.099 -0.239 -0.244 -0.245 -0.274 -0.220 0.242 0.174
CD44tot% -0.186 -0.239 0.941 0.596 0.825 0.646 -0.443 -0.471
CD44exp -0.155 -0.244 0.941 0.401 0.817 0.784 -0.402 -0.431
CD441ow -0.125 -0.245 0.596 0.401 0.452 0.075 -0.265 -0.284
CD44med -0.106 -0.274 0.825 0.817 0.452 0.578 -0.399 -0.445
CD44high -0.059 -0.220 0.646 0.784 0.075 0.578 -0.268 -0.289
Dukes’ 1 0.014 0.242 -0.443 -0.402 -0.265 -0.399 -0.268 0.982
Dukes’ 2 0.048 0.174 -0.471 -0.431 -0.284 -0.445 -0.289 0.982
Table 77 - Significant correlations (p < 0.05) (Ranked scores)
M IBl p53 CD44t CD44e CD441 CD44m CD44h Dukes 1 Dukes 2
M IBl 0.436 0.144 0.224 0.328 0.410 0.646 0.911 0.709
p53 0.436 0.053 0.049 0.048 0.026 0.076 0.047 0.156
CD44tot% 0.144 0.053 0.000 0.000 0.000 0.000 0.000 0.000
CD44exp 0.224 0.049 0.000 0.000 0.000 0.000 0.000 0.000
CD441ow 0.328 0.048 0.000 0.000 0.000 0.464 0.008 0.005
CD44med 0.410 0.026 0.000 0.000 0.000 0.000 0.000 0.000
CD44high 0.646 0.076 0.000 0.000 0.464 0.000 0.008 0.004
Dukes’ 1 0.911 0.047 0.000 0.000 0.008 0.000 0.008 0.000
Dukes’ 2 0.709 0.156 0.000 0.000 0.005 0.000 0.004 0.000
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Adenomas
Table 78 - Spearman’s rho Correlation coefficients
M IBl p53 CD44H CD441 CD44 m CD44 h Dysplasia
M IBl 0.128 -0.208 -0.049
p53 0.128 -0.286 0.437
CD44H -0.208 -0.286 -0.274
CD44 low 0.434
CD44 med -0.390
CD44 high -0.232
Dysplasia -0.049 0.437 -0.274 .434 -0.390 -0.232
Table 79 - Significant correlations (p < 0.05)
M IBl p53 CD44H CD441 CD44 m CD44 h Dysplasia
M IBl 0.214 0.043 0.791
p53 0.214 0.004 0.012
CD44H 0.043 0.004 0.129
CD44 low 0.107
CD44 med 0.147
CD44 high 0.067
Dysplasia 0.791 0.012 0.129 0.107 0.147 0.067
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Colorectal Project 2
An investigation o f the heterogeneity ofprognosis for Dukes ’ B colorectal 
carcinomas.
MIBl
Mean values
Table 80 - Recurrence v no recurrence
Group No. o f  
Cases
fatal % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 57.10 26.48 4.76 3.16 1.34 0.24
Recurrence 32 52.50 21.10 3.73 2.91 1.06 0.19
Table 81 - No recurrence v local recurrence v distant recurrence v both local and 
distant
Group
No.
of
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 57.10 26.48 4.76 3.16 1.34 0.24
Local only recurrence 14 52.86 18.58 0.96 2.86 0.86 0.23
Distant only recurrence 11 57.27 22.40 6.75 3.18 1.17 0.35
Local/Distant recurrence 7 44.29 24.40 9.22 2.57 1.27 0.48
Table 82 - No recurrence v local recurrence v distant/both recurrence
Group
No.
of
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 57.10 26.48 4.76 3.16 1.34 0.24
Local only recurrence 14 52.86 18.58 4.96 2.86 0.86 0.23
Distant/both recurrence 18 52.22 23.40 5.52 2.94 1.21 0.29
Table 83 - No recurrence v local/both recurrence v distant only recurrence
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 57.10 26.48 4.76 3.16 1.34 0.24
Local/both recurrence 21 50.00 20.49 4.47 2.76 1.00 0.22
Distant only recurrence 11 57.27 22.40 6.75 3.18 1.17 0.35
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Table 84 - Mann-Whitney values
Total % score Ranked score
Mann-
Whitney
U
Sig. Mann-
Whitney
U
Sig.
Recurrence v no recurrence 450.000 0.523 436.000 0.396
No recurrence v local recurrence 199.000 0.655 185.500 0.427
No recurrence v distant recurrence 168.500 0.954 170.000 1.000
No recurrence v both local and distant recurrence 78.500 0.265 80.500 0.299
Local recurrence v distant recurrence 70.500 0.727 68.500 0.647
Local recurrence v both local and distant recurrence 36.500 0.360 37.000 0.400
Distant recurrence v both local and distant recurrence 24.500 0.211 27.000 0.328
No recurrence v distant recurrence (including patients 
with local and distant recurrence) 251.000 0.558 250.500 0.544
Local recurrence v distant recurrence (including 
patients with local and distant recurrence) 120.000 0.837 122.500 0.896
No recurrence v local recurrence (including patients 
with local and distant recurrence) 277.500 0.366 266.000 0.254
Distant recurrence v local recurrence (including 
patients with local and distant recurrence) 95.000 0.434 95.500 0.434
p53
Mean values
Table 85 - Recurrence v no recurrence
Group No. of 
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 34.68 37.62 6.76 1.35 1.31 0.23
Recurrence 32 41.24 39.97 6.96 1.63 1.26 0.22
Table 86 - No recurrence v local recurrence v distant recurrence v both local and 
distant
Group
No.
of
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 34.68 37.62 6.76 1.35 1.31 0.23
Local only recurrence 14 51.43 40.97 10.95 1.86 1.23 0.33
Distant only recurrence 11 33.73 42.88 12.93 1.36 1.36 0.41
Local/Distant recurrence 7 38.57 34.36 12.99 1.57 1.27 0.48
Table 87 - No recurrence v local recurrence v distant/both recurrence
Group
No.
of
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 34.68 37.62 6.76 1.35 1.31 0.23
Local only recurrence 14 51.43 40.97 10.95 1.86 1.23 0.33
Distant/both recurrence 18 35.61 38.79 9.14 1.44 1.29 0.30
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Table 88 - No recurrence v local/both recurrence v distant only recurrence
Group
No.
of
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 34.68 37.62 6.76 1.35 1.31 0.23
Local/both recurrence 21 47.14 38.52 8.41 1.76 1.22 0.27
Distant only recurrence 11 33.73 42.88 12.93 1.36 1.36 0.41
Table 89 - Mann-Whitney values
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Recurrence v no recurrence 421.500 0.293 433.500 0.368
No recurrence v local recurrence 157.500 0.134 169.500 0.222
No recurrence v distant recurrence 164.500 0.866 165.500 0.888
No recurrence v both local and distant recurrence 99.500 0.740 98.500 0.713
Local recurrence v distant recurrence 55.000 0.244 62.000 0.434
Local recurrence v both local and distant recurrence 37.000 0.400 42.000 0.636
Distant recurrence v both local and distant recurrence 38.500 1.000 35.500 0.791
No recurrence v distant recurrence (including patients 
with local and distant recurrence) 264.000 0.748 264.000 0.744
Local recurrence v distant recurrence (including 
patients with local and distant recurrence) 92.000 0.206 104.000 0.419
No recurrence v local recurrence (including patients 
with local and distant recurrence) 257.000 0.190 268.000 0.262
Distant recurrence v local recurrence (including 
patients with local and distant recurrence) 93.500 0.389 97.500 0.481
CD44H (Score for total percentage of cells showing any CD44H 
expression)
Mean values
Table 90 - Recurrence v no recurrence
Group No. of 
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 36.26 27.97 5.11 2.03 1.50 0.27
Recurrence 32 20.00 26.88 4.75 1.13 1.45 0.26
Table 91 - No recurrence v local recurrence v distant recurrence v both local and 
distant
Group
No.
of
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 37.26 28.16 5.06 2.10 1.51 0.27
Local only recurrence 14 35.00 29.55 7.90 1.93 1.59 0.43
Distant only recurrence 11 10.91 22.12 6.67 0.64 1.21 0.36
Local/Distant recurrence 7 4.29 7.87 2.97 0.29 0.49 0.18
A -28
Table 92 - No recurrence v local recurrence v distant/both recurrence
Group
No.
o f
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 31 37.26 28.16 5.06 2.10 1.51 0.27
Local only recurrence 14 35.00 29.55 7.90 1.93 1.59 0.43
Distant/both recurrence 18 8.33 17.90 4.22 0.50 0.99 0.23
Table 93 - No recurrence v local/both recurrence v distant only recurrence
Group
No.
o f
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
N o recurrence 31 37.26 28.16 5.06 2.10 1.51 0.27
Local/both recurrence 21 24.76 28.39 6.20 1.38 1.53 0.33
Distant only recurrence 11 10.91 22.12 6.67 0.64 1.21 0.36
Table 94 - Mann-Whitney values
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
Recurrence v no recurrence 310.000 0.009 310.000 0.008
N o recurrence v local recurrence 203.500 0.738 202.500 0.717
N o recurrence v distant recurrence 72.500 0.004 73.500 0.004
N o recurrence v both local and distant recurrence 34.000 0.004 34.000 0.004
Local recurrence v distant recurrence 36.500 0.025 37.500 0.029
Local recurrence v both local and distant 
recurrence 15.000 0.010 16.500 0.012
Distant recurrence v both local and distant 
recurrence 37.500 0.930 37.000 0.930
N o recurrence v distant recurrence (including 
patients with local and distant recurrence) 106.500 0.000 107.500 0.000
Local recurrence v distant recurrence (including 
patients with local and distant recurrence) 51.500 0.004 54.000 0.005
N o recurrence v local recurrence (including 
patients with local and distant recurrence) 237.500 0.096 236.500 0.089
Distant recurrence v local recurrence (including 
patients with local and distant recurrence) 76.000 0.123 77.500 0.133
CD44H (Score weighted for intensity of expression) 
Mean values
Table 95 - Recurrence v no recurrence
Group
No.
o f
Cases
Total % score Ranked score
Mean SD. SE Mean SD. SE
N o recurrence 31 49.68 43.47 7.81 1.42 0.99 0.18
Recurrence 32 33.12 54.62 9.66 0.84 1.05 0.19
A -29
Table 96 - No recurrence v local recurrence v distant recurrence v both local and 
distant
Group
No.
o f
Cases
Total % score Ranked score
Mean SD. SE Mean SD. SE
No recurrence 31 49.68 43.47 7.81 1.42 0.99 0.18
Local only recurrence 14 58.57 68.37 18.27 1.36 1.22 0.32
Distant only recurrence 11 19.09 37.80 11.40 0.55 0.82 0.25
Local/Distant recurrence 7 4.29 7.87 2.97 0.29 0.49 0.18
Table 97 - No recurrence v local recurrence v distant/both recurrence
Group
No.
o f
Cases
Total % score Ranked score
Mean SD. SE Mean SD. SE
N o recurrence 31 49.68 43.47 7.81 1.42 0.99 0.18
Local only recurrence 14 58.57 68.37 18.27 1.36 1.22 0.32
Distant/both recurrence 18 13.33 30.29 7.14 0.44 0.70 0.17
Table 98 - No recurrence v local/both recurrence v distant only recurrence
Group
No.
o f
Cases
Total % score Ranked score
Mean SD SE Mean SD. SE
No recurrence 31 49.68 43.47 7.81 1.42 0.99 0.18
Local/both recurrence 21 40.48 61.19 13.35 1.00 1.14 0.25
Distant only recurrence 11 19.09 37.80 11.40 0.55 0.82 0.25
Table 99 - Mann-Whitney values
Total expression 
score
Ranked score
Mann-
Whitney
U
Sig. Mann-
Whitney
U
Sig.
Recurrence v no recurrence 335.500 0.024 324.000 0.013
N o recurrence v local recurrence 214.500 0.951 199.000 0.644
N o recurrence v distant recurrence 87.500 0.016 87.000 0.016
N o recurrence v both local and distant recurrence 33.500 0.003 38.000 0.006
Local recurrence v distant recurrence 38.000 0.033 44.500 0.075
Local recurrence v both local and distant recurrence 15.000 0.010 20.500 0.031
Distant recurrence v both local and distant recurrence 34.500 0.724 33.500 0.659
No recurrence v distant recurrence (including patients 
with local and distant recurrence) 121.000 0.001 153.000 0.005
Local recurrence v distant recurrence (including 
patients with local and distant recurrence) 53.000 0.005 77.000 0.042
No recurrence v local recurrence (including patients 
with local and distant recurrence) 248.000 0.143 235.000 0.109
Distant recurrence v local recurrence (including 
patients with local and distant recurrence) 80.500 0.168 107.000 0,494
A -30
CD44H staining of different intensities.
Table 100 -  Mean values
Group No.
o f
Cases
CD44 low intensity CD44 medium 
intensity
CD44 high intensity
Mean SD SE Mean SD SE Mean SD SE
N o recurrence 31 27.10 21.48 3.86 7.90 10.15 1.82 2.26 6.17 1.11
Recurrence 32 10.94 11.74 2.08 5.94 10.12 1.79 3.44 10.96 1.94
Distant
recurrence 12 8.33 11.93 3.45 5.83 10.84 3.13 2.50 4.52 1.31
Distant and both 
recurrence 18 5.56 9.22 2.17 2.22 6.47 1.52 1.11 3.23 0.76
Table 101 - Mann-Whitney values
CD44 
low intensity
CD44 
medium intensity
CD44 
high intensity
Mann-
Whitney
U
Sig.
Mann-
Whitney
U
Sig-
Mann-
Whitney
U
Sig.
Recurrence v no recurrence 281.000 0.002 424.500 0.264 483.000 0.786
N o recurrence v distant recurrence 70.000 0.003 124.000 0.191 168.000 0.955
N o recurrence v distant recurrence 
(including patients with local and 
distant recurrence) 107.500 0.000 180.000 0.015 264.000 0.608
A - 31
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Table 102 - Mean values
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
N o recurrence 33 46.06 23.31 4.06 2.58 1.17 0.20
Recurrence 29 39.83 20.64 3.83 2.34 0.94 0.17
Table 103 - Mann-Whitney values
Total % score Ranked score
Mann-Whitney U Sig. Mann-Whitney JJ Sig.
403.500 0.284 438.500 0.556
p53
Table 104 - Mean values
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
N o recurrence 33 45.00 36.91 6.43 2.52 1.97 0.34
Recurrence 29 26.55 34.36 6.38 1.45 1.82 0.34
Table 105 - Mann Whiney values
Total % score Ranked score
Mann-Whitney U Sig- Mann-Whitney U Sig.
331.500 0.031 324.500 0.024
CD44H
Table 106 - Mean values (total expression score)
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
N o recurrence 33 28.79 29.34 5.11 1.73 1.48 0.26
Recurrence 29 19.66 23.37 4.34 1.21 1.29 0.24
A -32
Table 107 - Mann-Whitney values
Total % score Ranked score
Mann-Whitney U Sig. Mann-Whitney U Sig.
379.500 0.153 377.500 0.140
Table 108 - Mean values (expression score weighted for intensity)
Group No. of  
Cases
Tota expression score Ranked expression score
Mean SD SE Mean SD SE
No recurrence 33 45.76 54.09 9.41 1.42 1.17 0.20
Recurrence 29 28.97 37.92 7.04 0.90 0.90 0.17
Table 109 - Mann-Whitney values
Total expression score Ranked expression score
Mann-Whitney U Sig. Mann-Whitney U Sig.
382.500 0.166 357.500 0.072
CD44H intensity scores (total percentage scores) 
Table 110 - Mean values
Group
No. o f  
Cases
Low intensity Medium intensity High intensity
Mean SD SE Mean SD SE Mean SD SE
No recurrence 33 15.45 12.27 2.14 9.09 12.84 2.23 4.24 7.51 1.31
Recurrence 29 12.76 13.06 2.43 4.83 4.85 1.46 2.07 4.12 0.77
Table 111 - Mann-Whitney values
Low intensity Medium intensity High intensity
Mann- 
Whitney U Sig.
Mann- 
Whitney U Sig.
Mann- 
Whitney U Sig.
410.000 0.318 420.000 0.339 423.500 0.309
A - 33
No recurrence, local recurrence and distant recurrence groups 
MIB1
Table 112 - Mean values
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 33 46.06 23.31 4.06 2.58 1.17 0.20
Local recurrence 5 64.00 15.17 6.78 3.40 0.55 0.24
Distant recurrence 24 34.79 18.03 3.68 2.12 0.85 0.17
Table 113 - Mann-Whitney values
Total %score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
No recurrence v local recurrence 44.000 0.102 42.000 0.084
No recurrence v distant recurrence 282.500 0.063 315.500 0.174
Local recurrence v distant recurrence 14.500 0.005 14.500 0.005
p53
Table 114 - Mean values
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 33 45.00 36.91 6.43 2.52 1.97 0.34
Local recurrence 5 14.00 31.30 14.00 0.80 1.79 0.80
Distant recurrence 24 29.17 35.01 7.15 1.58 1.84 0.38
Table 115 - Mann-Whitney values
Total % score Ranked score
Mann- 
Whitney U
Sig- Mann- 
Whitney U
Sig.
No recurrence v local recurrence 38.000 0.056 40.500 0.069
No recurrence v distant recurrence 293.500 0.088 284.000 0.061
Local recurrence v distant recurrence 43.000 0.352 44.500 0.382
A -34
CD44H
Table 116 - Mean values (total % score)
Group No. o f  
Cases
Total % score Ranked score
Mean SD SE Mean SD SE
No recurrence 33 28.79 29.34 5.11 1.73 1.48 0.26
Local recurrence 5 18.00 23.87 10.68 1.20 1.10 0.49
Distant recurrence 24 20.00 23.77 4.85 1.21 1.35 0.28
Table 117 - Mann-Whitney values
Total % score Ranked score
Mann- 
Whitney U
Sig. Mann- 
Whitney U
Sig.
No recurrence v  local recurrence 65.500 0.475 67.500 0.529
No recurrence v distant recurrence 314.000 0.175 310.000 0.151
Local recurrence v  distant recurrence 57.000 0.889 55.500 0.801
Table 118 - Mean values (expression score weighted for intensity)
Group No. o f  
Cases
Total expression score Ranked score
Mean SD SE Mean SD SE
No recurrence 33 45.76 54.09 9.41 1.42 1.17 0.20
Local recurrence 5 26.00 41.59 18.60 1.00 0.71 0.32
Distant recurrence 24 29.58 38.05 7.77 0.88 0.95 0.19
Table 119 - Mann-Whitney values
Total expression score Ranked score
Mann- 
Whitney XJ
Sig. Mann- 
Whitney U
Sig.
No recurrence v local recurrence 65.000 0.475 69.000 0.585
No recurrence v distant recurrence 317.500 0.195 288.500 0.068
Local recurrence v  distant recurrence 58.500 0.933 51.000 0.634
A - 35
CD44H intensity scores
Table 120 - Mean values (total % scores)
Group No.
of
Cases
Low intensity Medium intensity High intensity
Mean SD SE Mean SD SE Mean SD SE
No recurrence 33 15.45 12.27 2.14 9.09 12.84 2.23 4.24 7.51 1.31
Local recurrence 5 12.00 10.95 4.90 4.00 8.94 4.00 2.00 4.47 2.00
Distant Recurrence 24 12.92 13.67 2.79 5.00 7.80 1.59 2.08 4.15 0.85
Table 121 - Mann-Whitney values
Low intensity Medium intensity High intensity
Mann-
Whitney
U
Sig.
Mann-
Whitney
U
Sig.
Mann-
Whitney
U
Sig.
No recurrence v local recurrence 69.000 0.585 65.000 0.475 72.500 0.675
No recurrence v distant recurrence 341.000 0.359 355.000 0.448 351.000 0.344
Local recurrence v distant recurrence 57.500 0.889 52.500 0.674 59.500 0.978
A -36
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